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Abstract 
Prostate cancer (PCa) is one of the most prevalent non-cutaneous cancers in men, and is also one of 
the most lethal oncogenic diseases that accounts for a vast majority of male cancer-related deaths. 
Currently, widespread PCa screening is reliant on the prevailing usage of the FDA-approved blood-
based prostate specific antigen (PSA) biomarker. Yet, landmark clinical trials in recent years have 
indicated that serum PSA screening holds a substantial risk of over-diagnosing low grade indolent 
PCa which are unlikely to result in mortality. Consequently, this paucity of accurate disease risk 
stratification during PCa screening has led to a variety of health burden associated with unnecessary 
biopsies, and over-treatment in a considerable fraction of patient population. Given that the 
screening shortcoming of the PSA test is outweighing its benefit, there is a clear need for better 
strategies to improve PCa risk stratification and accurately detect high-grade aggressive PCa 
molecular subtypes at an early stage for timely personalized treatment.         
 
To address this PCa screening conundrum, the research work described in this thesis primarily 
embodies a bipartite strategy which pairs together the use of next-generation PCa-specific 
molecular biomarkers, and the development of innovative nanodiagnostic technologies to target 
these superior biomarkers. In recent years, massive advances in next-generation sequencing 
techniques have led to the discoveries of novel PCa molecular targets which possess excellent PCa-
specificity (i.e. next-generation PCa biomarkers); and have been shown to improve PCa diagnosis, 
prognosis, and prediction of therapeutic resistance in a multitude of seminal clinical studies. The 
most tantalizing prospect among such next-generation PCa biomarkers is the chromosomal gene 
fusion mutation between the TMPRSS2 and ERG genes (TMPRSS2:ERG). TMPRSS2:ERG is a 
highly-recurrent biomarker in the majority of clinically-detected PCa tumor foci, and its exclusive 
presence in cancer cells facilitates the accurate identification of a major PCa subtype. Through 
combinatorial detection of TMPRSS2:ERG with other next-generation PCa biomarkers, it is 
anticipated that PCa molecular subtyping and better disease risk stratification could be achieved. 
Furthermore, these next-generation biomarkers are detectable in patient urine samples as a form of 
liquid biopsy, thus opening up new avenues of truly non-invasive PCa diagnostics.  
 
Presently, urinary biomarker detection is achieved through conventional laboratory-based methods 
which are not ideal for use in a clinical setting. Hence, to realize the use of PCa diagnostics for 
clinical screening, this thesis also details the use of nanotechnology to design various cutting-edge 
diagnostic platforms for next-generation PCa urinary biomarker screening. It is envisioned that such 
PCa nanodiagnostics which exhibits unique physical properties at the nanoscale; could result in 
accurate early PCa detection with unprecedented detection sensitivity, speed, and reliability. 
   
This thesis first describes the design of miniaturized solution-based biosensing systems which 
coupled rapid isothermal RNA target amplification with innovative detection readouts that are 
enabled by nanoscaled mechanisms. These lab-in-a-drop systems integrated the detection of urinary 
TMPRSS2:ERG transcripts within a fluidic microdroplet, and exhibited single-cell detection 
sensitivity through visual and/or quantitative colorimetric readouts. Next, this thesis reports the 
pioneering use of label-free surface-enhanced Raman scattering (SERS) for RNA detection in 
clinical samples. Label-free SERS is a spectroscopic technique for direct detection of adsorbed 
nucleic acid on metallic nanoparticle surfaces but has prior been limited to detection of short-length 
oligonucleotides. Herein, label-free SERS detection of TMPRSS2:ERG RNA in patient urinary 
specimens was shown using a novel combination of isothermal RNA amplification and/or 
chemometrics.           
 
In addition to the use of isothermal amplification, this thesis also investigated the development of 
enzymatic amplification-free nanobiosensors for detection of various RNA biomarker species. By 
exploiting adenine-bare gold affinity interactions, the detection of different species of next-
generation PCa RNA biomarkers was shown. Further, to attain a more comprehensive screening 
outcome to aid in clinical decision-making, this thesis has also devised new nanobioassays for 
concurrent analysis of multiple next-generation PCa biomarkers.  
 
Lastly, to facilitate clinical translation, clinical evaluation of both biomarkers and nanodiagnostic 
technologies (developed through this thesis) was carried out using a cohort of well-annotated 
patient samples. This represents an effort to progress the developed nanotechnologies from an 
academic research phase to patient usage by assessment of clinical performance metrics.  
 
Today, there is an assortment of PCa treatment options such as active surveillance, radical 
prostatectomy, radiation or hormonal therapies; and each treatment has differing molecular subtype-
dependent effectiveness and necessity. It is envisioned that research in the fusion of powerful new-
age biomarkers and avant-garde detection strategies (as showcased in this thesis) could progress the 
field of PCa subtyping and risk stratification in the clinic, therefore granting a more personalized 
treatment approach that is tailored to the needs of individual patients.            
 
Declaration by author 
This thesis is composed of my original work, and contains no material previously published or 
written by another person except where due reference has been made in the text. I have clearly 
stated the contribution by others to jointly-authored works that I have included in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional editorial 
advice, financial support and any other original research work used or reported in my thesis. The 
content of my thesis is the result of work I have carried out since the commencement of my higher 
degree by research candidature and does not include a substantial part of work that has been 
submitted to qualify for the award of any other degree or diploma in any university or other tertiary 
institution. I have clearly stated which parts of my thesis, if any, have been submitted to qualify for 
another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, 
subject to the policy and procedures of The University of Queensland, the thesis be made available 
for research and study in accordance with the Copyright Act 1968 unless a period of embargo has 
been approved by the Dean of the Graduate School.  
 
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the 
copyright holder to reproduce material in this thesis and have sought permission from co-authors for 
any jointly authored works included in the thesis. 
 
Publications during candidature 
 
Peer-Reviewed Articles 
 Koo, K. M.; Wang, J.; Richards, R. S.; Farrell, A.; Yaxley, J. W.; Samaratunga, H.; Teloken, P. 
E.; Roberts, M. J.; Coughlin, G. D.; Lavin, M. F.; Mainwaring, P. N.; Wang, Y.; Gardiner, R. A. 
& Trau, M. (2018) Design and clinical verification of surface-enhanced Raman spectroscopy 
diagnostic technology for individual cancer risk prediction. ACS Nano 12: 8362-8371. 
 
 Koo, K. M.; Dey, S. & Trau,  M.  (2018) Amplification-free multi-RNA type profiling for 
cancer risk stratification via alternating current electrohydrodynamic nano-mixing. Small 14: 
1704025. 
 
 Koo, K. M.; Carrascosa, L. G. & Trau,  M. (2018) DNA-directed assembly of copper 
nanoblocks with inbuilt fluorescent and electrochemical properties: Application in simultaneous 
amplification-free analysis of multiple RNA species. Nano Res. 11: 940-952.  
 
 Koo, K. M.; Wee, E. J. H.; Wang, Y. & Trau,  M.  (2017) Enabling miniaturised personalised 
diagnostics: From lab-on-a-chip to lab-in-a-drop. Lab Chip 17: 3193-3340. *Featured as Issue 
Front Cover Image 
 
 Wang, J.; Koo, K.M.; Wee, E. J. H.; Wang, Y. & Trau, M. (2017) Nanoplasmonic label-free 
surface-enhanced Raman scattering strategy for non-invasive cancer genetic subtyping in patient 
samples. Nanoscale 9: 3496-3503. (co-first author) 
 
 Koo, K. M.; Wee, E. J. H. & Trau,  M.  (2017) High-speed biosensing strategy for non-invasive 
profiling of multiple cancer fusion genes in urine. Biosens. Bioelectron. 89: 715-720. 
 
 Koo, K. M.; Wee, E. J. H.; Mainwaring, P. N.; Wang, Y. & Trau,  M.  (2016) Toward precision 
medicine: A cancer molecular subtyping nano-strategy for RNA biomarkers in tumor and urine. 
Small 12: 6233-6242. *Featured as Issue Cover Image 
 
 Koo, K. M.; McNamara, B.; Wee, E. J. H.; Wang, Y. & Trau,  M. (2016) Rapid and sensitive 
fusion gene detection in prostate cancer urinary specimens by label-free SERS. J. Biomed. 
Nanotech. 12: 1798-1805. 
 
 Koo, K. M.; Wee, E. J. H.; Mainwaring, P. N. & Trau,  M. (2016) A simple, rapid, low-cost 
technique for naked-eye detection of urine-isolated TMPRSS2:ERG gene fusion RNA. Sci. Rep. 
6: 30722. 
 
 Koo, K. M.; Carrascosa, L. G.;  Shiddiky, M. J. A. & Trau,  M. (2016) Amplification-free 
detection of gene fusions in prostate cancer urinary samples using mRNA-gold affinity 
interactions. Anal. Chem. 88: 6781-6788.  
 
 Koo, K. M.; Wee, E. J. H. & Trau,  M. (2016) Colorimetric TMPRSS2-ERG gene fusion 
detection in prostate cancer urinary samples via recombinase polymerase amplification. 
Theranostics 6: 1415-1424. *Featured in NanoTheranostics Special Issue 
 
 Koo, K. M.; Carrascosa, L. G.; Shiddiky, M. J. A. & Trau,  M. (2016) Poly(A) extensions of 
miRNAs for amplification-free electrochemical detection on screen-printed gold electrodes. 
Anal. Chem. 88: 2000-2005.  
  Koo, K. M.; Sina, A. A. I.; Carrascosa, L. G.; Shiddiky, M. J. A. & Trau,  M. (2015) DNA-bare 
gold affinity interactions: mechanism and applications in biosensing. Anal. Mtds. 7: 7042-7054.  
 
 Koo, K. M.; Sina, A. A. I.; Carrascosa, L. G.; Shiddiky, M. J. A. & Trau,  M. (2014) 
eMethylsorb: rapid quantification of DNA methylation in cancer cells on screen-printed gold 
electrodes. Analyst 139: 6178-6184.  
 
Book Chapters 
 Sina, A. A. I; Koo, K. M.; Ahmed, M.; Carrascosa, L. G. & Trau,  M. (2017) Interfacial 
biosensing: Direct biosensing of biomolecules at the bare metal interface. Encyclopedia of 
Interfacial Chemistry: Surface Science and Electrochemistry: Elsevier (In Press) (co-first 
author) 
 
Conference Abstracts 
 Koo, K. M.; Dey, S. & Trau,  M.  (2018) Amplification-free multi-RNA type profiling for 
cancer risk stratification via alternating current electrohydrodynamic nano-mixing. 9
th
 
International Nanomedicine Conference, Sydney (Oral Presentation - Selected) 
 
 Koo, K. M.; Wee, E. J. H.; Mainwaring, P. N.; Wang, Y. & Trau,  M.  (2017) Towards 
precision medicine: A cancer molecular subtyping nano-strategy for RNA biomarkers in tumor 
and urine. 2017 International Conference on Bio-Nano Innovation (ICBNI 2017), Brisbane 
(Oral Presentation - Selected) 
 
 Koo, K. M.; Wee, E. J. H.; Mainwaring, P. N.; Wang, Y. & Trau,  M.  (2017) Toward precision 
medicine: A cancer molecular subtyping nano-strategy for RNA biomarkers in tumor and urine. 
8
th
 International Nanomedicine Conference, Sydney (Oral Presentation - Selected) 
 
 Koo, K. M.; Wee, E. J. H.; Mainwaring, P. N.; Wang, Y. & Trau,  M.  (2016) Towards 
precision medicine: A cancer molecular subtyping nano-strategy for RNA biomarkers in tumor 
and urine. Eur. J. Cancer 68: S33-S33. EORTC-NCI-AACR Molecular Targets & Cancer 
Therapeutics Symposium 2016, Munich (Poster Presentation) 
 
 Koo, K. M.; Wee, E. J. H.; Mainwaring, P. N.; Wang, Y. & Trau,  M.  (2016) Toward precision 
medicine: A cancer molecular subtyping nano-strategy for RNA biomarkers in tumor and urine. 
18
th
 EMBL PhD Symposium 2016: Life by Numb3rs - Towards Quantitative Biology, 
Heidelberg (Flash talk & Poster Presentation) 
 
 Koo, K. M.; Carrascosa, L. G.; Shiddiky, M. J. A. & Trau,  M. (2016) Poly(A) extensions of 
miRNAs for amplification-free electrochemical detection on screen-printed gold electrodes. 7
th
 
International Postgraduate Symposium in Biomedical Science, Brisbane (Poster Presentation) 
*Best Poster Prize 
 
 Koo, K. M.; Wee, E. J. H.; Mainwaring, P. N.; Wang, Y. & Trau,  M.  (2016) Toward precision 
medicine: A cancer molecular subtyping nano-strategy for RNA biomarkers in tumor and urine. 
The 6
th
 NanoBio Conference and 1
st
 Symposium on Minimally Invasive & Image Guided 
Surgery (NanoBio China 2016), Nanjing (Oral Presentation - Selected) 
 
 Koo, K. M.; Carrascosa, L. G.; Shiddiky, M. J. A. & Trau,  M. (2016) Amplification-free 
detection of gene fusions in prostate cancer urinary samples using mRNA-gold affinity 
interactions. 7
th
 Australia and New Zealand Nano-Microfluidic Symposium (ANZNMF 2016), 
Brisbane (Poster Presentation) *Best Poster Prize 
 
 Koo, K. M.; Carrascosa, L. G.; Shiddiky, M. J. A. & Trau,  M. (2016) Poly(A) extensions of 
miRNAs for amplification-free electrochemical detection on screen-printed gold electrodes. 7
th
 
Australia and New Zealand Nano-Microfluidic Symposium (ANZNMF 2016), Brisbane (Poster 
Presentation) 
 
 Wee, E. J. H.; Koo, K. M.; Mainwaring, P. N. & Trau,  M. (2015) Towards rapid and cost-
effective point-of-care detection of TMPRSS2: ERG fusion transcripts in urine via a novel 
methodology. J. Clin. Oncol. 33: 11063-11063. American Society of Clinical Oncology 
Conference 2015, Chicago (Poster Presentation) 
Publications included in this thesis 
I declared that I have obtained permission from all co-authors to include the following 
publications directly into my thesis. 
 
1. Koo, K. M.; Wee, E. J. H.; Wang, Y. & Trau,  M.  (2017) Enabling miniaturised 
personalised diagnostics: From lab-on-a-chip to lab-in-a-drop. Lab Chip 17: 3193-3340. 
Incorporated as Chapter 3.  
 
Contributor Statement of contribution 
Kevin M Koo (Candidate) Drafting and production (65%) 
Eugene JH Wee Drafting and production (15%) 
Yuling Wang Drafting and production (15%) 
Matt Trau Drafting and production (5%) 
 
2. Koo, K. M.; Wee, E. J. H.; Mainwaring, P. N. & Trau,  M. (2016) A simple, rapid, low-
cost technique for naked-eye detection of urine-isolated TMPRSS2:ERG gene fusion 
RNA. Sci. Rep. 6: 30722. Incorporated as Chapter 3.  
 
Contributor Statement of contribution 
Kevin M Koo (Candidate) Conception and design (75%) 
Analysis and interpretation (80%) 
Drafting and production (80%) 
Eugene JH Wee Conception and design (15%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Paul N Mainwaring Conception and design (5%) 
Drafting and production (5%) 
Matt Trau Conception and design (5%) 
Analysis and interpretation (10%) 
Drafting and production (5%) 
 
 
3. Koo, K. M.; Wee, E. J. H. & Trau,  M. (2016) Colorimetric TMPRSS2-ERG gene fusion 
detection in prostate cancer urinary samples via recombinase polymerase amplification. 
Theranostics 6: 1415-1424.  Incorporated as Chapter 3.  
 
Contributor Statement of contribution 
Kevin M Koo (Candidate) Conception and design (75%) 
Analysis and interpretation (90%) 
Drafting and production (85%) 
Eugene JH Wee Conception and design (25%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Matt Trau Drafting and production (5%) 
 
4. Koo, K. M.; McNamara, B.; Wee, E. J. H.; Wang, Y. & Trau,  M. (2016) Rapid and 
sensitive fusion gene detection in prostate cancer urinary specimens by label-free SERS. 
J. Biomed. Nanotech. 12: 1798-1805.  Incorporated as Chapter 4.  
 
Contributor Statement of contribution 
Kevin M Koo (Candidate) Conception and design (80%) 
Analysis and interpretation (75%) 
Drafting and production (75%) 
Benjamin McNamara Analysis and interpretation (5%) 
Eugene JH Wee Conception and design (10%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Yuling Wang Conception and design (10%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Matt Trau Drafting and production (5%) 
 
 
 
5. Wang, J.; Koo, K. M.; Wee, E. J. H.; Wang, Y. & Trau, M. (2017) Nanoplasmonic label-
free surface-enhanced Raman scattering strategy for non-invasive cancer genetic 
subtyping in patient samples. Nanoscale 9: 3496-3503. (co-first author). Incorporated as 
Chapter 4.  
 
Contributor Statement of contribution 
Jing Wang Conception and design (40%) 
Analysis and interpretation (40%) 
Drafting and production (30%) 
Kevin M Koo (Candidate) Conception and design (40%) 
Analysis and interpretation (40%) 
Drafting and production (45%) 
Eugene JH Wee Conception and design (10%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Yuling Wang Conception and design (10%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Matt Trau Drafting and production (5%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Koo, K. M.; Carrascosa, L. G.;  Shiddiky, M. J. A. & Trau,  M., (2016) Amplification-
free detection of gene fusions in prostate cancer urinary samples using mRNA-gold 
affinity interactions. Anal. Chem. 88: 6781-6788. Incorporated as Chapter 5.  
 
Contributor Statement of contribution 
Kevin M Koo (Candidate) Conception and design (70%) 
Analysis and interpretation (75%) 
Drafting and production (75%) 
Laura G Carrascosa Conception and design (15%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Muhammad JA Shiddiky Conception and design (15%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Matt Trau Analysis and interpretation (5%) 
Drafting and production (5%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Koo, K. M.; Carrascosa, L. G.; Shiddiky, M. J. A. & Trau,  M. (2016) Poly(A) extensions 
of miRNAs for amplification-free electrochemical detection on screen-printed gold 
electrodes. Anal. Chem. 88: 2000-2005. Incorporated as Chapter 5.  
 
Contributor Statement of contribution 
Kevin M Koo (Candidate) Conception and design (70%) 
Analysis and interpretation (75%) 
Drafting and production (75%) 
Laura G Carrascosa Conception and design (15%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Muhammad JA Shiddiky Conception and design (15%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Matt Trau Analysis and interpretation (5%) 
Drafting and production (5%) 
 
8. Koo, K. M.; Carrascosa, L. G. & Trau,  M. (2018) DNA-directed assembly of copper 
nanoblocks with inbuilt fluorescent and electrochemical properties: Application in 
simultaneous amplification-free analysis of multiple RNA species. Nano. Res. 11: 940-
952. Incorporated as Chapter 5.  
 
Contributor Statement of contribution 
Kevin M Koo (Candidate) Conception and design (75%) 
Analysis and interpretation (80%) 
Drafting and production (80%) 
Laura G Carrascosa Conception and design (25%) 
Analysis and interpretation (15%) 
Drafting and production (15%) 
Matt Trau Analysis and interpretation (5%) 
Drafting and production (5%) 
 
9. Koo, K. M.; Wee, E. J. H.; Mainwaring, P. N.; Wang, Y. & Trau,  M.  (2016) Toward 
precision medicine: A cancer molecular subtyping nano-strategy for RNA biomarkers in 
tumor and urine. Small 12: 6233-6242. Incorporated as Chapter 6.  
 
Contributor Statement of contribution 
Kevin M Koo (Candidate) Conception and design (75%) 
Analysis and interpretation (80%) 
Drafting and production (70%) 
Eugene JH Wee Conception and design (10%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Paul N Mainwaring Conception and design (5%) 
Drafting and production (5%) 
Yuling Wang Conception and design (10%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Matt Trau Drafting and production (5%) 
 
10. Koo, K. M.; Wee, E. J. H. & Trau,  M.  (2017) High-speed biosensing strategy for non-
invasive profiling of multiple cancer fusion genes in urine. Biosens. Bioelectron. 89: 715-
720. Incorporated as Chapter 6.  
 
Contributor Statement of contribution 
Kevin M Koo (Candidate) Conception and design (75%) 
Analysis and interpretation (90%) 
Drafting and production (85%) 
Eugene JH Wee Conception and design (25%) 
Analysis and interpretation (10%) 
Drafting and production (10%) 
Matt Trau Drafting and production (5%) 
 
11. Koo, K. M.; Dey, S. & Trau,  M.  (2018) Amplification-free multi-RNA type profiling 
for cancer risk stratification via alternating current electrohydrodynamic nano-mixing. 
Small 14: 1704025. Incorporated as Chapter 6.  
 
Contributor Statement of contribution 
Kevin M Koo (Candidate) Conception and design (70%) 
Analysis and interpretation (55%) 
Drafting and production (75%) 
Shuvashis Dey Conception and design (30%) 
Analysis and interpretation (45%) 
Drafting and production (20%) 
Matt Trau Drafting and production (5%) 
Manuscripts included in this thesis 
I declared that I have obtained permission from all co-authors to include the following 
manuscripts directly into my thesis. 
 
 Koo, K. M.; Mainwaring, P. N.; Tomlins, S. A. & Trau,  M. Merging next-generation 
biomarkers and nanodiagnostic platforms for precision prostate cancer management. Nat. 
Rev. Urol. (Under editorial revision) Incorporated as Chapter 2. 
 
Contributor Statement of contribution 
Kevin M Koo (Candidate) Drafting and production (70%) 
Paul N Mainwaring  Drafting and production (10%) 
Scott A Tomlins Drafting and production (10%) 
Matt Trau Drafting and production (10%) 
 
 Koo, K. M.; Wee, E. J. H.; Richards, R. S.; Lavin, M. F.; Gardiner, R. A.; Mainwaring, 
P. N. & Trau, M. TMPRSS2-ERG status in pre- and post-prostatectomy urine: A novel 
first-line triage nanoassay for non-invasive visual identification of significant prostate 
cancer. Submitted. Incorporated as Chapter 7. 
 
Contributor Statement of contribution 
Kevin M Koo (Candidate) Conception and design (60%) 
Analysis and interpretation (80%) 
Drafting and production (80%) 
Eugene JH Wee Conception and design (10%) 
Renée S Richards Analysis and interpretation (5%) 
Martin F Lavin Analysis and interpretation (5%) 
Robert A Gardiner Conception and design (10%) 
Analysis and interpretation (5%) 
Drafting and production (10%) 
Paul N Mainwaring Conception and design (10%) 
Drafting and production (10%) 
Matt Trau Conception and design (10%) 
Analysis and interpretation (5%) 
Contributions by others to the thesis  
The research work being described in this thesis has led to a succession of 
published/submitted peer-reviewed articles with me named as the lead author. As stated 
under the previous section “Publications included in this thesis”, my fellow contributing 
authors on these publications have contributed in part to the experimental design, data 
analysis, and manuscript preparation processes.    
 
Statement of parts of the thesis submitted to qualify for the award of another degree 
None. 
 
Research involving human or animal subjects  
No animal or human subjects were involved in this research. 
 
Acknowledgements 
This pursuit of my doctorate has been a thrilling ride that has no doubt been made so much 
more enjoyable due to the presence of so many wonderful individuals. With my following 
words in this thesis, I wish to express my heartfelt gratitude and appreciation in 
acknowledgement of your influence in the culmination of my dissertation.  
 
I have been fortunate to benefit from various folks who are the best mentors I could have ever 
asked for. Matt - Thank You for always being so supportive and encouraging in moulding us 
as researchers. The research resources and environment you provided in the Trau group, 
together with your bubbly enthusiasm, give such an enviably unrestricted platform to drive 
my research further. Shiddiky - Thank You for recognizing my suitability for research right 
from the start, and being such a momumental figure in helping me through my formative 
beginnings. It is a pleasure to learn so much off you and I am always grateful of what you 
have spurred me on to achieve. Eugene - Thank You for patiently showing me the ropes of 
fundamental research skills at both the lab bench and the workdesk keyboard. It has been a 
pleasure working with us and I have definitely benefitted a lot from your generous sharing of 
knowledge and experience. Paul - Thank You for opening my eyes to the intriguing world of 
clinical research in the real world. You have encouraged and motivated the purpose of my 
work in this thesis and beyond. I also like to acknowledge so many others (Yuling, Laura, 
and the entire Trau group; 'Frank' and the lovely UQCCR collaborators; Scott and his 
awesome UMich group members) whom I have the joy of working alongside with during the 
course of my doctoral studies - Thank You All, I am humbled by all your positive influence 
and constructive pieces of advice. 
 
I will also like to express my gratitude to the many friends and companions whom I have the 
blessing of knowing over the last few years. To my fellow colleagues in AIBN and UQ - 
Thank You all for being the reason why I wake up every morning and look forward to 
stepping into the lab - It is a joy to learn off everyone and be part of this stimulating research 
environment. To all the amazing mates both past and present - Thank You all for being part 
of my life in Brisbane, our treasured friendships have allowed me to hit a pause button on 
research, and take a breather to create so many great memories to look back upon. 
 
Last but not least, I will like to dedicate this thesis to my loving family. Especially to Dad and 
Mum, your unreserved support has encouraged me to give my absolute best. I know how 
much you all miss having me away from your side, and words cannot express my deepest 
appreciation for your unconditional love in enabling me to pursue my endeavours - I am truly 
blessed and proud to be your son.      
        
Finanacial support 
This research was supported by an Australian Government Research Training Program 
Scholarship/International Postgraduate Research Scholarship, and an Australian Postgraduate 
Award. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords 
prostate cancer, precision medicine, early cancer detection, liquid biopsy, fusion genes, 
TMPRSS2:ERG, nanodiagnostics, electrochemical detection, surface-enhanced Raman 
spectroscopy, clinical translation 
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
ANZSRC code: 100402, Medical Biotechnology Diagnostics (incl. Biosensors), 30% 
ANZSRC code: 100703, Nanobiotechnology, 40% 
ANZSRC code: 111202 Cancer Diagnosis, 30% 
 
Fields of Research (FoR) Classification 
FoR code: 1004, Medical Biotechnology, 30% 
FoR code: 1007, Nanotechnology, 40% 
FoR code: 1112, Oncology and Carcinogenesis, 30% 
 
  
Table of Contents 
 
Chapter 1: Thesis Introduction .............................................................................................. 1 
1.1 Background  ................................................................................................................... 1 
1.2 Research aim and objectives  ......................................................................................... 3 
1.3 Significance of project  .................................................................................................. 4 
1.4 Structure of the thesis..................................................................................................... 4 
1.5 References ...................................................................................................................... 7 
Chapter 2: Thesis Literature Review ..................................................................................... 8 
2.0 Merging Next-Generation Biomarkers and Nanodiagnostic Platforms for Precision 
Prostate Cancer Management ................................................................................................. 9 
Chapter 3: Colorimetric Gene Fusion Diagnostics for Visual Binary Readout ............... 39 
3.1 Enabling miniaturised personalised diagnostics: From lab-on-a-chip to lab-in-a-drop
 .............................................................................................................................................. 40 
3.2 A simple, rapid, low-cost technique for naked-eye detection of urine-isolated 
TMPRSS2:ERG gene fusion RNA  ..................................................................................... 82 
3.3 Colorimetric TMPRSS2:ERG gene fusion detection in prostate cancer urinary 
samples via recombinase polymerase amplification  ........................................................... 96 
Chapter 4: Label –Free Surface-Enhanced Raman Scattering Detection Systems for 
Clinical Biomarker Targets  ............................................................................................... 115 
4.1 Rapid and sensitive fusion gene detection in prostate cancer urinary specimens by 
label-free SERS  ................................................................................................................. 116 
4.2 Nanoplasmonic label-free surface-enhanced Raman scattering strategy for non-
invasive cancer genetic subtyping in patient samples  ....................................................... 132 
Chapter 5: Amplification-Free Electrochemical RNA Biomarker Sensing  .................. 149 
5.1 Amplification-free detection of gene fusions in prostate cancer urinary samples using 
mRNA-gold affinity interactions  ...................................................................................... 150 
5.2 Poly(A) extensions of miRNAs for amplification-free electrochemical detection on 
screen-printed gold electrodes ............................................................................................ 170 
5.3 DNA-directed assembly of copper nanoblocks with inbuilt fluorescent and 
electrochemical properties: Application in simultaneous amplification-free analysis of 
multiple RNA species......................................................................................................... 186 
Chapter 6: Simultaneous Analysis of Multiple Biomarkers via High-Throughput 
Parallel/Multiplexing Assays .............................................................................................. 210 
6.1 Toward precision medicine: A cancer molecular subtyping nano-strategy for RNA 
biomarkers in tumor and urine ........................................................................................... 211 
6.2 High-speed biosensing strategy for non-invasive profiling of multiple cancer fusion 
genes in urine  .................................................................................................................... 238 
6.3 Amplification-free multi-RNA type profiling for cancer risk stratification via 
alternating current electrohydrodynamic nano-mixing ...................................................... 259 
Chapter 7: Clinical Evaluation of Non-Invasive Nanodiagnostics for PCa Risk 
Stratification  ........................................................................................................................ 281 
7.0 TMPRSS2-ERG status in pre- and post-prostatectomy urine: A novel first-line triage 
nanoassay for non-invasive visual identification of significant prostate cancer  ............... 282 
Chapter 8: Conclusions and Future Work  ....................................................................... 292 
 
 
List of Abbreviations used in the thesis 
Prostate cancer       PCa 
Food and Drug Administration     FDA 
Prostate specific antigen      PSA 
Surface-enhanced Raman scattering     SERS 
Transmembrane protease, serine 2      TMPRSS2 
V-ets avian erythroblastosis virus E26 oncogene homolog  ERG 
Gene fusion between TMPRSS2 and ERG     TMPRSS2:ERG 
Ribonucleic Acid       RNA 
Quantitative polymerase chain     qPCR 
Fluorescence in-situ hybridization      FISH  
Chapter 1 
 
1 
 
1 
Thesis Introduction 
 
 
1.1 Background 
A detailed research background of this thesis is given in Chapter 2 “Merging Next-
Generation Biomarkers and Nanodiagnostic Platforms for Precision Prostate Cancer 
Management”. The following is a summary of Chapter 2. 
 
Prostate cancer (PCa) is one of the most commonly diagnosed cancers and a leading cause of 
cancer-related deaths in men with a projected 161, 360 (with 26, 730 deaths) and 16, 665 
(with 3452 deaths) newly-diagnosed cases in the United States and Australia respectively for 
2017.
1
 PCa is a clinically heterogeneous disease which ranges from indolent molecular 
subtypes which are insignificant to patient’s health to fatal metastatic tumor growths. Since 
the introduction of prostate-specific antigen (PSA) as a PCa screening biomarker in the 
1980s, the PSA test has seen widespread usage to become the current standard test for PCa 
early detection. However, the PSA test is one with marked deficiency because of its poor 
PCa-specificity in identifying high-grade clinically-significant PCa.
2,3
 This has resulted in 
high incidences of PCa overdiagnosis and overtreatment of men with low-grade diseases 
which would never have a significant impact on mortality.  Therefore, this highlights the 
importance of precision PCa screening that enables specific detection of aggressive PCa 
subtypes which require immediate treatment (i.e. risk stratification). To this end, this thesis 
seeks to engage a cross-disciplinary approach which combines the clinical evaluation of next-
generation PCa biomarkers of superior PCa-specificity, along with the technological 
development of rapid and accurate nanodiagnostic techniques to detect these biomarkers in 
the clinic. 
 
The rise of next-generation sequencing has led to exciting advances in PCa molecular 
subtyping. Specifically, there have been potential game-changing discoveries of next-
generation PCa biomarkers that are associated with clinically-significant PCa. Among these 
next-generation PCa biomarkers, the gene fusion between transmembrane protease, serine 2 
(TMPRSS2) and v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) genes - 
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TMPRSS2:ERG - is a frequent occurrence found in around half of all clinically-detected PCa 
foci.
4
 The TMPRSS2:ERG gene fusion mutation between two independent genes typically 
results in androgen-regulated overexpression of oncogenic ERG to drive tumorgenesis. This 
led to the hypothesis that TMPRSS2:ERG is an early PCa initiation event that cooperates 
with other genomic mutations for transition into high-grade invasive PCa.
5
 Given that 
TMPRSS2:ERG is generally absent in normal prostate tissue and benign prostatic 
hyperplasia, it can potentially function as a highly PCa-specific diagnostic biomarker to aid in 
accurate PCa risk stratification and reduction of unnecessary biopsies/treatments. The 
prognostic utility of TMPRSS2:ERG has been demonstrated in several reports with 
TMPRSS2:ERG being associated with aggressive PCa.
6-8
 This provides additional 
translational value to TMPRSS2:ERG as a biomarker to predict PCa aggressiveness and 
monitor post-treatment biochemical recurrence. Furthermore, TMPRSS2:ERG is detectable 
in urine, hence offering an attractive biomarker candidate for non-invasive PCa early 
detection.
9
 All in all, TMPRSS2:ERG is strongly implicated in the biology of PCa 
development and serves as an attractive target (along with other promising next-generation 
PCa biomarkers) for designing a new era of  precision PCa diagnostics.   
 
Presently, detection of next-generation PCa biomarkers is primarily limited to conventional 
laboratory techniques such as quantitative polymerase chain reaction (qPCR), microarray-
based methods, fluorescence in-situ hybridization (FISH), and next-generation sequencing.
4,9
 
Whilst these methodologies are generally efficient and reliable, they are limited for use in 
rapid clinical screening due to prolonged sample-to-outcome turnaround time, specialized 
equipment requirement, and need for trained personnel to perform the procedures. 
Nanotechnology is a promising avenue to overcome these limitations and improve patient 
diagnoses through desirable and unique biomarker-detection properties that exist at the 
nanoscale.
10
 Hence, this thesis seeks to harness the exciting possibilities and benefits of 
nanotechnologies for fast, cost-effective, and reliable PCa early detection and risk 
stratification in the clinic.  
 
Overall, in a bid to progress towards a new era of precision PCa, this thesis details a two-
pronged approach which fuses (i) the design of various novel nano-strategies with different 
readout platforms and applications, and (ii) the investigation into the use of next-generation 
PCa biomarkers in patient urine samples. Both analytical and clinical aspects of the approach 
are rigorously evaluated to accelerate laboratory-to-clinic translation.  
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1.2 Research aim and objectives 
This thesis aims to merge the development of innovative nanotechnological approaches and 
the detection of next-generation PCa urinary biomarkers, for better non-invasive PCa risk 
stratification in the clinic. The specific research objectives to achieve this aim are as follows: 
  
1. Development of gene fusion (TMPRSS2:ERG) diagnostics towards non-invasive 
clinical use. The TMPRSS2:ERG gene fusion is one of the most common driver 
mutations in PCa, making it a promising PCa- specific biomarker target for clinical 
diagnostics development. This objective involves the novel design of rapid, simple, 
and low-cost nanobiosensors for non-invasive TMPRSS2:ERG RNA detection in 
patient urine samples by the integration of an isothermal amplification technique. 
 
2.  Design of amplification-free nanobiosensors for universal detection of various 
RNA biomarker species. The direct detection of native nucleic acid biomarkers 
without requiring enzymatic amplification is ideal for avoiding amplification 
bias/artifacts. By using the detection of urinary biomarkers in PCa as a model, this 
objective covers the design of a new amplification-free methodology which is 
amenable for different RNA species. 
 
3. Expansion into simultaneous detection of multiple biomarkers. This objective 
builds upon the outcomes of the previous objectives, and progresses towards 
innovative nanodiagnostics for the simultaneous analysis of various next-generation 
PCa urinary biomarkers (including TMPRSS2:ERG) to further improve clinical PCa 
risk stratification.   
 
4. Clinical evaluation of developed nanotechnological assays. To evaluate the 
translational potential for use in the real-world clinical setting, this objective 
investigates the clinical metrics of developed PCa nanodiagnostics through testing in 
a cohort of well-annotated PCa patient urinary specimens.   
 
5. Investigation of biomarker value via pilot clinical studies. Lateral to the clinical 
evaluation of the nanodiagnostic assays, this objective concurrently probes the clinical 
value of different next-generation PCa biomarkers in disease diagnosis, prognosis, 
and treatment decision-making. 
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1.3 Significance of project  
There is a current unmet need for better strategies in comprehensive early PCa detection, and 
accurate discrimination of aggressive from indolent disease. The achievement of the stated 
research aim and objectives in this thesis could have a significant clinical impact in 
advancing these areas. The development of a suite of novel PCa analytical nanodiagnostics 
targeting next-generation PCa urinary biomarkers may enable different distinct 
methodologies for accurate non-invasive PCa early detection. The further clinical analysis of 
both nanotechnological assays and biomarker targets will aid in translating the thesis 
outcomes from the laboratory into clinical use. Together, the blend of avant-garde detection 
methods and superior biomarkers might reduce unneeded biopsies, overdiagnosis, and 
overtreatment of PCa; and lead to more effective treatment decisions of men with, or at risk 
of developing PCa. Finally, from a research perspective, the studies in this thesis could raise 
awareness to the detection of next-generation PCa biomarkers (especially fusion genes) for 
nanotechnologists; as well as communicate the vast potential of nanodiagnostics to clinicians.    
 
1.4 Structure of the thesis 
This thesis comprises of eight chapters, and is presented as a combination of peer-reviewed 
published articles and submitted manuscripts. 
 
Chapter 1 – Thesis Introduction 
This chapter provides a brief research background; aims and objectives; and significance.   
 
Chapter 2 – Thesis Literature Review 
This chapter provides a detailed literature review of research background that is presented in 
this thesis. Specifically, it will encompass the advent of next-generation PCa biomarkers for 
personalized risk stratification and the role that nanotechnology can play in translating these 
biomarkers for clinical screening usage. 
Chapter 2 is presented as an accepted review manuscript under editorial revision:   
 Koo, K. M.; Mainwaring, P. N.; Tomlins, S. A. & Trau,  M. (2017) Merging next-
generation biomarkers and nanodiagnostic platforms for precision prostate cancer 
management. Nat. Rev. Urol. (Under editorial revision) 
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Chapter 3 – Colorimetric Gene Fusion Diagnostics for Visual Binary Readout 
This chapter will describe the development of a rapid microtube-based assay which exploits 
the binary nature of gene fusion biomarkers for visual cancer detection, and allows 
quantitative detection of gene fusion transcripts for potential PCa staging/monitoring. 
Chapter 3 is presented as one peer-reviewed review article, followed by two published 
research articles in the following order: 
 Koo, K. M.; Wee, E. J. H.; Wang, Y. & Trau,  M.  (2017) Enabling miniaturised 
personalised diagnostics: From lab-on-a-chip to lab-in-a-drop. Lab Chip 17: 3193-3340. 
 Koo, K. M.; Wee, E. J. H.; Mainwaring, P. N. & Trau,  M. (2016) A simple, rapid, low-
cost technique for naked-eye detection of urine-isolated TMPRSS2:ERG gene fusion 
RNA. Sci. Rep. 6: 30722. 
 Koo, K. M.; Wee, E. J. H. & Trau,  M. (2016) Colorimetric TMPRSS2-ERG gene fusion 
detection in prostate cancer urinary samples via recombinase polymerase amplification. 
Theranostics 6: 1415-1424. 
 
Chapter 4 – Label-Free Surface-Enhanced Raman Scattering Detection Systems for Clinical 
Biomarker Targets 
This chapter will describe the integration of isothermal amplification with nanoscaled label-
free surface-enhanced Raman scattering technique for RNA biosensing in PCa patient 
samples.  
Chapter 4 is presented as two published research articles in the following order: 
 Koo, K. M.; McNamara, B.; Wee, E. J. H.; Wang, Y. & Trau,  M. (2016) Rapid and 
sensitive fusion gene detection in prostate cancer urinary specimens by label-free 
SERS. J. Biomed. Nanotech. 12: 1798-1805.  
 Wang, J.; Koo, K. M.; Wee, E. J. H.; Wang, Y. & Trau, M. (2017) Nanoplasmonic 
label-free surface-enhanced Raman scattering strategy for non-invasive cancer genetic 
subtyping in patient samples. Nanoscale 9: 3496-3503. (co-first author) 
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Chapter 5 – Amplification-Free Electrochemical RNA Biomarker Sensing 
This chapter will include a series of amplification-free electrochemical RNA nanobiosensors 
based on adenine-bare gold affinity interactions. 
Chapter 5 is presented as three published research articles in the following order:  
 Koo, K. M.; Carrascosa, L. G.;  Shiddiky, M. J. A. & Trau,  M., (2016) 
Amplification-free detection of gene fusions in prostate cancer urinary samples using 
mRNA-gold affinity interactions. Anal. Chem. 88: 6781-6788. 
 Koo, K. M.; Carrascosa, L. G.; Shiddiky, M. J. A. & Trau,  M. (2016) Poly(A) 
extensions of miRNAs for amplification-free electrochemical detection on screen-
printed gold electrodes. Anal. Chem. 88: 2000-2005.  
 Koo, K. M.; Carrascosa, L. G. & Trau,  M. (2018) DNA-directed assembly of copper 
nanoblocks with inbuilt fluorescent and electrochemical properties: Application in 
simultaneous amplification-free analysis of multiple RNA species. Nano Res. 11: 940-
952. 
 
Chapter 6 – Simultaneous Analysis of Multiple Biomarkers via High-Throughput 
Parallel/Multiplexing Assays 
This chapter will describe the development of novel bioassays which enable simultaneous 
detection of multiple biomarkers for a more comprehensive PCa diagnosis.  
Chapter 6 is presented as three published research articles in the following order:  
 Koo, K. M.; Wee, E. J. H.; Mainwaring, P. N.; Wang, Y. & Trau,  M.  (2016) Toward 
precision medicine: A cancer molecular subtyping nano-strategy for RNA biomarkers 
in tumor and urine. Small 12: 6233-6242. 
 Koo, K. M.; Wee, E. J. H. & Trau,  M.  (2017) High-speed biosensing strategy for 
non-invasive profiling of multiple cancer fusion genes in urine. Biosens. Bioelectron. 
89: 715-720.  
 Koo, K. M.; Dey, S. & Trau,  M.  (2018) Amplification-free multi-RNA type 
profiling for cancer risk stratification via alternating current electrohydrodynamic 
nano-mixing. Small 14: 1704025. 
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Chapter 7 – Clinical Evaluation of Non-Invasive Nanodiagnostics for PCa Risk 
Stratification 
This chapter will describe the clinical evaluations of a nanodiagnostic assay which has been 
developed during candidature and the initial results of investigating gene fusion biomarker at 
different PCa stages. 
Chapter 7 is presented as one submitted research manuscript. 
 Koo, K. M.; Wee, E. J. H.; Richards, R. S.; Lavin, M. F.; Gardiner, R. A.; Mainwaring, 
P. N.; Trau, M. TMPRSS2-ERG status in pre- and post-prostatectomy urine: A novel 
first-line triage nanoassay for non-invasive visual identification of significant prostate 
cancer. Submitted. 
 
Chapter 8 – Conclusions and Future Work 
This chapter summarizes the preceding thesis chapters and outlines recommended future 
work based on the current progress showcased through this thesis.  
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2 
Thesis Literature Review 
 
 
Introduction 
Chapter 2 provides a detailed thesis literature review of the advent of next-generation prostate 
cancer biomarkers for personalized risk stratification, and the role that nanotechnology can 
play in translating these biomarkers for clinical screening usage. Specifically, it firstly 
introduces the biology of prostate cancer, as well the importance of disease risk stratification. 
Next, current prostate cancer screening assays and several promising next-generation prostate 
cancer biomarkers are highlighted. Following that, the use and potential of nanotechnological 
approaches in precision prostate cancer early detection and monitoring are reviewed. Finally, 
insights and future outlook towards the clinical translation of precision prostate cancer 
nanodiagnostics for next-generation biomarker detection are provided.    
 
Chapter 2 is based on one review manuscript under editorial revision in Nature Reviews 
Urology.   
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Merging Next-Generation Biomarkers and Nanodiagnostic 
Platforms for Precision Prostate Cancer Management 
 
Kevin M. Koo, Paul N. Mainwaring, Scott A. Tomlins, Matt Trau
 
 
 
ABSTRACT 
The accurate identification and stratified treatment of clinically-significant early prostate 
cancer (PCa) has been an ongoing concern since the outcomes of large international PCa 
screening trials were reported. The controversy surrounding clinical and cost-benefits of PCa 
screening has highlighted the lack of strategies for discriminating high-risk disease requiring 
treatment as opposed to watchful waiting. To address this conundrum, there have been 
evolving advances in molecular subtyping and multi-omic nanotechnology-based PCa risk 
delineation to enable refinement of PCa molecular taxonomy into clinically meaningful and 
druggable subtypes. Due to inter- and intra-tumoural heterogeneity, there is an urgent need 
for novel rapid, cost-effective, accurate PCa nanodiagnostic technologies that distinguish 
clinically-significant PCa for precision oncology approaches. Herein we review the next 
generation of PCa biomarkers and the latest complementary nano-strategies, as well as 
discuss fundamental clinical translation challenges yet to be overcome. 
 
INTRODUCTION 
Prostate cancer (PCa) is the most commonly-diagnosed solid malignancy in men, and 
aggressive sub-variants account for a significant proportion of male cancer-related deaths
1
. 
PCa typically affects men over 65 years of age, with a higher incidence in men of Caucasian 
or African descent as compared to other races and ethnicities. The majority of PCa is 
predominantly hormone-driven, and men with aggressive PCa will generally progress 
towards hormone-refractory/metastatic castration resistant PCa (CRPC) that is still largely 
influenced initially by androgen receptor activity. In recent years, comprehensive genomic, 
epigenetic, transcriptomic and proteomic analysis of the PCa landscape has revealed the 
extent of heterogeneity within the disease. These efforts have revealed common oncogenic 
drivers, such as point mutations in TP53, SPOP, and FOXA1; amplifications and copy 
number variations in AR (in CRPC); aberrations in DNA repair genes such as BRCA1/2, 
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PIK3CA/B, PTEN, MYC; gene fusions involving the ETS gene family; and germline variants 
in susceptibility loci associated with predisposition to PCa development and metastatic 
progression, including ATM
2-16
. These endeavours have also refined our understanding of the 
PCa aetiology and progression, leading to potential advancements in precision treatment 
strategies
17
. 
 
A significant portion of PCa is made up of localized, low grade, indolent disease that is 
unlikely to result in patient death. Ideally, PCa screening should be able to differentiate 
between these different aggressive and indolent PCa subtypes
18, 19
, in order to avoid over 
diagnosis as well unnecessary and potentially morbid therapy. However, to date, accurate 
definition and treatment of high-grade aggressive PCa remains a challenging and 
controversial conundrum in oncology. The present state of clinical PCa screening and 
management is heavily reliant on a blood-based biomarker-driven approach that measures 
serum prostate specific antigen (PSA) levels. Also known as kallikrein-3 (KLK3), PSA is a 
glycoprotein enzyme produced almost exclusively by the prostate gland but is not PCa-
specific with elevated levels in a variety of non-PCa states such as increased age, benign 
prostatic hyperplasia (BPH), or inflamed/infected prostate (prostatitis)
20
. Since FDA-approval 
in 1986, an elevated serum PSA level has been used for opportunistic PCa screening; and this 
has, arguably, led to a revolution in PCa management by reducing PCa mortality through 
enabling early disease detection and treatment intervention. Yet, the use of PSA as a PCa 
screening biomarker is becoming increasingly controversial, due to its high tendency to 
provide false-positive and –negative diagnoses, as well as conflicting clinical screening trial 
results.  
 
Two major large-scale randomized trials that have assessed the potential benefit of PSA 
screening – the European Randomized Study of Screening for Prostate Cancer (ERSPC) 
trial
21
 and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) trial
22
. The 
ERSPC trial investigated PSA screening in a largely unselected population drawn from seven 
different countries, and reported a 21% decrease in PCa mortality in men aged 55-60 years 
after 11 years of follow-up. The PLCO trial was conducted in the USA, and initially found no 
reduction in PCa mortality as well as no benefit of PSA screening
22-24
. However, a recent 
PLCO data reanalysis has found that PSA screening conferred up to 32% lower PCa mortality 
risk
25
, and suggested that initial conclusions were influenced by PSA testing contamination in 
the PLCO trial control group (approximately 85% of men underwent a PSA test at least 
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once
26, 27
). Importantly, this contamination may have been a major cause for the reduction in 
statistical significance for the initial PLCO finding summary. Nonetheless, a general 
consensus of both trials is that widespread PSA-based PCa screening leads to PCa over-
diagnosis and overtreatment with serious implications on men’s health and well-being28. In 
2012, the United States Preventive Task Force (UPSTF) recommended against population-
wide PSA screening for PCa, regardless of age
29
. This recommendation was associated with a 
significant decline in PCa screening and incidence
30, 31
, thus reducing the harmful widespread 
screening effects, but also simultaneously eliminating the known screening benefits for 
patients with the likelihood of developing advanced-stage PCa. As a result of vigorous 
international debate, UPSTF revised its PCa screening guidelines in 2016 to recommend 
clinicians informing men aged 55 – 69 years about the benefits and harms of PSA screening, 
and allowing for personalized shared decision making. In sum, an alternative approach to 
PCa screening might not be to abandon PSA testing altogether, but to design improved 
screening methodologies with better risk stratification capabilities
32, 33
. 
 
Optimal PCa screening risk stratification calls for molecular subtyping to yield information 
on disease biology, prognosis, and treatment benefits. Yet, the molecular classification of 
PCa into disease subtypes for effective targeted therapies (such as that being currently 
performed for HER2 status-breast cancer subtype classification), is still an ongoing effort
34-41
. 
One notable example is the Stockholm 3 (STHLM3) study
42
 for early PCa screening, the first 
proof-of-concept population-based study of using a combination of plasma protein biomarker 
test panel, genetic polymorphism and clinical information for individualized risk-prediction 
of high-grade PCa. The study enrolled male participants aged 50-69 years without PCa, and 
performed both STHLM3 and PSA screening on each participant. Men with a PSA 
concentration of ≥3 ng/mL or being scored as high-risk on the STHLM3 model were referred 
for PCa examination and biopsies. The STHLM3 study reported superior performance in 
predicting aggressive PCa (GS≥7) with an area-under-the-curve (AUC) of 0.74 as compared 
with 0.56 for PSA levels alone, and resulted in a 32% reduction in prostate biopsies. Using 
the existing data, the STHLM3 model has currently been updated and shown to reduce 
biopsies by 34% when being used as a reflex test for men with PSA ≥3 ng/mL43.  
 
To predict prognosis after prostatectomy, Spratt et al. have recently undertaken the intrinsic 
molecular subtyping study of 4236 primary PCa samples through unbiased high-throughput 
sequencing analyses of 100 genes. Through this study, three novel intrinsic PCa subtypes 
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associated with known PCa drivers such as AR and ERG were described, and validated within 
both retrospective and prospective cohorts. Following radical prostatectomy, 10-year distant 
metastasis-free survival rates are 73.6%, 64.4%, and 57.1% across the three subtypes. This 
study also reported a molecular taxonomy describing patients who would benefit from post-
operative radiotherapy. Hence, it is anticipated other large-scale studies of primary PCa 
molecular subtyping
35-38
 and multi-institutional research collaborations into personalized 
metastatic PCa treatments (eg. Stand Up To Cancer-Prostate Cancer Foundation Dream 
Team) will result in novel discoveries of biomarker-driven precision PCa management 
approaches
44
.  
 
In light of the potential translational value of next-generation PCa biomarkers, there is a need 
for complementary cost-effective as well as easy-to-implement advanced detection 
technologies. At present, PCa biomarkers are being characterized with laboratory-based 
techniques which are fitting within the research setting or individual specialized clinical 
laboratories; but unsuitable for rapid, highly cost-effective, and point-of-care clinical 
diagnostics. The attractive potential of nanotechnology may alleviate the current limitations 
of molecular testing in a single reference laboratory or need for expensive proprietary 
equipment, thence enabling point-of-care development for broad cost-effective cancer 
diagnostics.  Furthermore, the use of nanoparticles for nucleic acid or protein target detection 
has attained single molecule-level detection sensitivity, and are capable for use in the 
promising field of liquid biopsies whereby high analytical sensitivity is required for low 
target copies in circulation. In this Review, we discuss the progress of biomarker-driven PCa 
molecular subtyping and the development of companion nano-strategies to refine clinical 
biomarker detection. We also underscore the existing challenges of merging both aspects for 
precision PCa management, and provide our insights on possible resolutions.  
 
NEXT-GENERATION PCa BIOMARKERS 
In recent years, molecular profiling advances in microarray profiling and next-generation 
sequencing have uncovered novel PCa-specific biomarkers with better disease-informing 
abilities (i.e. next generation PCa biomarkers)
45-53
 (TABLE 1; FIG. 1) that may be rapidly 
translated into the clinic to aid better diagnostic, prognostic and predictive algorithms. To 
feature non-invasive circulating next-generation PCa biomarkers, this section will 
categorically summarize urinary/blood-based biomarkers with potential clinical utility 
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encompassing early diagnosis (TMPRSS2:ETS, PCA3); prognosis (SChLAP1); or targeted 
treatment prediction (PTEN, ARV7) in CRPC.  
 
Table 1 Next-generation PCa biomarkers  
Next-Gen PCa 
Biomarkers 
Description Biological 
Function 
Samplin
g Source 
Potential Clincial Utility and 
Performance 
TMPRSS2:ETS 
fusion genes 
Chromosomal 
rearrangement
s of TMPRSS2 
gene and ETS 
transcription 
factors 
Drives the 
overexpression 
of oncogenic 
ERG protein 
under androgen 
control in 
tumorigenesis 
Tissue, 
Blood, 
Urine 
Diagnosis and potentially 
prognosis based on transcript 
levels. 
AUC = 0.75-0.77 
(TMPRSS2:ERG+PCA3+PCP
T risk calculator)
172
 
PCA3 Long non-
coding RNA 
exclusively 
expressed in 
prostate tissue, 
and 
overexpressed 
in PCa. 
Postulated to be 
involved in PCa 
cell survival, in 
part through 
modulating AR 
signalling 
Tissue, 
Blood, 
Urine 
Diagnosis. 
AUC = 0.750.77 
(TMPRSS2:ERG+PCA3+PCP
T risk calculator)
172
 
SChLAP1 Long non-
coding RNA 
highly 
overexpressed 
in a subset of 
aggressive 
PCa patients 
and solely 
expressed in 
PCa 
Associated with 
cancer cell 
invasiveness 
and metastasis 
by antagonizing 
the functions of 
the SW1/SNF 
chromatin-
modifying 
complex 
Tissue, 
Urine 
Prognosis. 
AUC = 0.68 for metastatic PCa 
prediction
100 
PTEN  Most 
frequently 
mutated and 
deleted 
suppressor 
gene 
Activates the 
phosphoinositid
e-3-kinase 
(PI3K) pathway 
to promote 
tumor initiation 
and growth. 
Tissue, 
Blood 
Prognosis. 
ARV7 Splice variant 
of androgen 
receptor 
lacking ligand-
binding 
domain 
Maintain 
androgen 
receptor-
regulated 
transcription in 
treatment-
resistant PCa 
models 
Blood 
(CTCs) 
Predictive of treatment 
efficacy. 
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Figure 1 Molecular biomarkers for precision PCa management. Progressive next-
generation sequencing and bioinformatic analysis has yielded a suite of next-generation 
biomarkers and assays for PCa molecular subtyping from blood, urine, and tissue samples. 
 
TMPRSS2:ETS fusion genes 
Chromosomal rearrangements have been found to be common aberrations in PCa, and 
through the carcinogenic processes of kaetegis and chromothripsis, lead to fusions of distant 
genes
54-57
. In 2005, by using a novel bioinformatics analysis, recurrent fusions between the 5’ 
promoter sequence of the androgen-regulated TMPRSS2 gene and ETS transcription factors 
(in particularly the coding sequence of the ERG gene) were described to be commonly 
present in PCa.
58
 TMPRSS2 encodes for a membrane-bound serine protease
59
 found 
expressed on prostate cells; and involved in a signal transduction pathway associated with 
PCa metastasis and invasion
60
. ERG translates into an oncogenic protein which is 
overexpressed in PCa to drive PIN to carcinoma transition
61
. TMPRSS2:ERG (T2:ERG) 
fusion genes are a result of chromosomal translocations or interstitial deletions between the 
two genes which are about 3 Mb apart on chromosome 21
62-66
. As TMPRSS2 contains 
androgen-sensitive elements, it was originally conceptualized that the fusion event puts ERG 
expression under androgen control, and drives the overexpression of oncogenic ERG protein 
in tumorigenesis
67
. However, breakthrough studies of late have revealed that that there are 
additional layers of complexities to this process
68-74
. 
 
Altogether, T2:ERG is present  approximately 50% (ranging from about 10% in Chinese
75
 to 
about 70% in northern European populations) of clinically-detected PCa cases, with rarer 
occurrences of fusions involving other ETS family members such as ETV1 or ETV5
58
. Several 
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T2:ERG isoforms may exist through alternate splicing and differing fusion junctions between 
the two genes, with the most common (>90%) isoform  being the  T1E4 gene fusion between 
exon 1 of TMPRSS2 and exon 4 of ERG
76, 77
. T2:ERG has displayed superior PCa specificity 
with general absence in non-PCa conditions, and largely detected in the precursor high-grade 
prostate intraepithelial neoplasia (HGPIN) in close proximity to malignant carcinoma. Hence, 
as one of the most PCa-specific biomarkers currently available, T2:ERG is highly attractive 
as a target for next-generation PCa diagnostic development. Recent studies have also 
suggested that T2:ERG-positive PCa is a distinct subtype which could be targeted by 
T2:ERG- or ERG-based therapeutics
78-84
. 
 
Since the original T2:ERG description, numerous international studies
85
 have investigated the 
clinical utility of urinary T2:ERG detection. The prognostic potential of urinary T2:ERG is a 
source of debate, with some studies associating T2:ERG to aggressive PCa
86-88
 with other 
studies showing conflicting outcomes
89
. However, as T2:ERG is specifically expressed by 
tumor cells only; higher detected urinary T2:ERG levels could be linked to increased tumor 
volume which is indicative of high-grade PCa
90
. To further increase the performance of 
T2:ERG for non-invasive PCa stratification, a strategy utilizing a combination of next-
generation urinary PCa biomarkers such as: T2:ERG and PCA3 for the Mi Prostate Score 
(MiPS) test, or ERG with PCA3 for the ExoDx Prostate IntelliScore assay, may be explored.  
 
PCA3 
PCA3 is a highly PCa-specific long non-coding RNA biomarker which is exclusively 
overexpressed in cancerous prostate tissues and HGPIN
91
, and has been postulated to be 
involved in PCa cell survival, in part through modulating AR signalling
92
. PCA3 was first 
described in 1999
93
, and is one of the pioneering next-generation PCa screening biomarkers 
being incorporated into strategies to improve the diagnostic accuracy of PSA-based PCa 
screening. PCA3 is found to be detectable in urine and prostatic fluid as a non-invasive PCa 
biomarker, and numerous subsequent studies have investigated the clinical utility of urinary 
PCA3
94-96
. The clinical sensitivity and specificity of urinary PCA3 for PCa detection is 
around 65% and 90% respectively. PCA3’s first major clinical contribution was through 
combination with serum PSA, resulting in a PCa detection improvement with an AUC of 
0.75. This eventually led to an FDA-approved PCa diagnostic assay in 2012 for men with a 
previous negative prostate biopsy, and subsequently the assay was further refined upon 
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through the incorporation of T2:ERG. This diagnostic evolutionary approach of combinations 
of next-generation PCa biomarkers is clearly improving PCa screening accuracy
97
.  
 
SChLAP1 
SChLAP1 is a lncRNA biomarker which is first discovered through bioinformatics analysis of 
a subset of cancers to identify selectively-upregulated lncRNAs associated with PCa 
recurrence and progression
98
. It has been found to be highly overexpressed in a subset of 
aggressive PCa patients and solely expressed in PCa
99
, and rarely in normal tissues or other 
cancer types. SChLAP1 is associated with cancer cell invasiveness and metastasis by 
antagonizing the tumor-suppressive functions of the SW1/SNF chromatin-modifying 
complex
98
. Separately, a large unbiased multi-institution analysis of genes related to 
metastasis and mortality after primary PCa radical prostatectomy, has revealed and validated 
SChLAP1 to be the top-ranked prognostic biomarker for metastasis development
100
. In this 
study, SChLAP1 was detectable non-invasively in PCa urine sediments and found to be a 
viable urinary biomarker candidate for discriminating high-risk aggressive PCa. The potential 
utility of SChLAP1 has been further shown in latter studies which associated SChLAP1 
dysregulation as an aggressive feature in unfavorable intraductal and cribriform 
subpathologies
101
, and a demonstration of non-invasive SChLAP1 detection in PCa patient 
circulating tumor cells (CTCs)
102
.  
 
PTEN 
Phosphatase and tensin homolog (PTEN) is the most frequently mutated and deleted (~30-
60%) tumor suppressor gene
103-106
  in high-grade PCa. PTEN loss is commonly used as a 
tissue biomarker in immunohistochemical detection, and is associated with poorer prognosis 
and aggressive metastatic PCa, as well as rapid development of hormonal treatment 
resistance. Recently, PTEN loss in CTCs and matched tumor tissue samples has shown strong 
correlation
107
, thus illustrating the potential use of liquid biopsies for detecting PTEN loss. 
Inactivation of PTEN, a tumour suppressor, in turn permits downstream signalling of the 
phosphoinositide-3-kinase (PI3K) pathway to cause increased phosphorylated AKT levels; 
promoting cancerous cell growth, proliferation, survival, and migration via multiple 
downstream promoters
108
. PTEN deletion has also been found to co-exist with T2:ERG 
presence to drive carcinogenesis in late-stage PCa
109-114
, and are considered to reflect 
particularly aggressive PCa phenotypes.  
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ARV7 
Androgen receptor splice variants lack the ligand-binding domain, and have been shown to be 
capable of maintaining androgen receptor-regulated transcription in treatment-resistant PCa 
models
115-119
. Androgen receptor splice variant 7 (ARV7), which has a deletion of exon 7
120-
122
, has been implicated in the development of castrate-resistant PCa
123
. A recent seminal 
study has suggested ARV7 transcript presence in CTCs of castrate-resistant PCa patients is 
associated with lower rate of PSA decline, as well as reduced progression-free and overall 
survival with androgen-mediated pathway targeted therapies such as  enzalutamide and 
abiraterone
124
. Lately, in keeping with previous reports, a correlative study has found that 
patients with positive CTC nuclear ARV7 protein expression have superior overall survival 
with taxane therapy over enzalutamide and abiraterone
125
. Thus, ARV7 and other splice 
variants are being refined for their role as biomarkers for predicting treatment sensitivity in 
PCa patients. More recently, AR aberrations in circulating cell-free nucleic acids have been 
linked to enzalutamide and abiraterone resistance
126-129
, thus offering another minimally 
invasive approach for predicting therapeutic resistance in metastatic PCa. With promising 
data from the ongoing SPARTAN
130
, PROSPER
131
, STAMPEDE
132
, and LATITUDE
133
 
trials investigating different therapeutic options for metastasis-free survival; studies into 
biomarkers (such as ARV7) associated with treatment-prediction will be invaluable and 
potentially practice-changing for high-risk PCa management. 
 
EXISTING AND EMERGING BIOMARKER-DIRECTED PCa 
SCREENING DIAGNOSTICS 
Apart from the above prominent examples, there also exist several other promising 
biomarkers: other gene fusion variants involving other ETS genes such as ETV1, ETV4, 
ETV5; GSTP1- and EZH2- associated epigenetic changes; SPINK1; AMACR; and different 
variations of PSA proteins. A multi-omic approach which combines these different next-
generation PCa biomarkers may provide information needed to define PCa therapy after 
initial diagnosis, and/or help define patient-specific characteristics that are important when 
determining therapy. As evident of the promise of biomarkers, there are presently several 
biomarker-based diagnostics (TABLE 2) clinically available to support PSA screening 
outcomes
134, 135
. 
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Table 2 Biomarker-driven PCa assays for use on human clinical samples to support PSA 
testing 
Commercial 
Molecular 
PCa Tests 
Clinical 
Utility 
Biomarkers Sampling 
Source 
Provider Certification Performance 
PHI  Improves 
prediction of 
aggressive 
disease and 
risk of 
progression 
during active 
surveillance 
Levels of 
total PSA, 
free PSA 
(fPSA), and 
p2PSA (a 
PCa-specific 
fPSA 
isoform) 
Blood Beckman 
Coulter, Inc 
(CA, USA) 
FDA AUC = 0.69-
0.77 
4Kscore® Discriminates 
aggressive 
disease, and 
predict long-
term risk of 
cancer 
metastasis 
before biopsy 
or after 
negative 
biopsy 
Levels of 
total PSA, 
free PSA, 
intact PSA, 
human 
kallikrein 2 
(KLK2) 
Blood OPKO 
Laboratory 
(FL, USA) 
CLIA AUC = 0.81-
0.82 
ConfirmMDx Advises 
repeat biopsy 
decisions 
Methylation 
levels of 
GSTP1, APC, 
and RASSF1 
Tissue MDxHealth, 
Inc. (CA, 
USA) 
 
CLIA Sensitivity  = 
0.68 
Specificity =  
0.64 
Oncotype Dx Advises 
appropriate 
treatment 
such as active 
surveillance 
or invasive 
treatment 
during early 
diagnosis 
Expression of 
12 cancer-
associated 
genes(and 
five reference 
genes) 
representative 
of four 
different 
biological 
pathways  
Tissue Genomic 
Health, Inc. 
(CA, USA) 
CLIA NA 
Prolaris Provides 
disease 
progression 
risk in biopsy 
tissues  
Expression 
levels of 31 
(and 15 
housekeeping 
genes) cell 
cycle 
progression 
genes  
Tissue Myraid 
Genetics, 
Inc. (UT, 
USA) 
CLIA NA 
Decipher® Predicts the 
metastatic 
risk of 
metastatic 
disease within 
five years 
after radical 
Analysis of 
22 aggressive 
PCa-
associated 
RNA markers 
Tissue GenomeDx 
Biosciences, 
Inc. (CA, 
USA) 
CLIA AUC = 0.82 
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prostatectomy  
MiPS Provides 
additional 
information 
for repeat 
biopsy 
decision, and 
predicts risk 
of high-grade 
disease 
Levels of 
PCA3, 
T2:ERG, 
KLK3 
Urine MLabs (MI, 
USA) 
CLIA AUC = 0.75-
0.77 
SelectMDx  Predicts high-
grade disease, 
and aids in 
biopsy 
selection 
decisions 
Levels of 
HOXC6, 
DLX1, KLK3 
Urine MDxHealth, 
Inc. (CA, 
USA) 
CLIA AUC = 0.71-
0.77 
ExoDx 
Prostate 
IntelliScore 
Improves 
discrimination 
of GS≥7, 
GS=6, and 
benign tumors 
Levels of 
PCA3 and 
T2:ERG  
Urinary 
exosomes 
Exosome 
Diagnostics, 
Inc. (MA, 
USA) 
CLIA AUC = 0.73-
0.77 
 
PHI and 4Kscore® 
In view of the poor sensitivity of total PSA alone, commercially available PCa screening 
blood tests such as the prostate health index (PHI) assay (Beckman Coulter, Inc) and four-
kallikrein (4Kscore®) test (OPKO Laboratory) have been developed. Both tests utilize 
combinations of different serum PSA isoforms and/or related proteins for increased PCa-
specific sensitivity.  
 
PHI is a FDA-approved blood serum assay that combines the levels of total PSA, free PSA 
(fPSA), and p2PSA (a PCa-specific fPSA isoform). By using the formula: 
(p2PSA/fPSA)*PSA
0.5
, PHI has been shown to significantly outperform the use of total PSA 
and fPSA alone, with test outcomes demonstrating improved prediction of  aggressive disease 
as well as the likelihood of progression during active surveillance
136-138
.  
Similar to PHI, the 4Kscore® test is a Clinical Laboratory Improvement Amendments 
(CLIA)-certified blood test which combines the levels of total PSA, free PSA, intact PSA, 
human kallikrein 2 (KLK2), and clinical information. The test can be administered before 
biopsy or after negative biopsy for better individualized PCa risk stratification. Several 
European and American studies have indicated that test outcomes could discriminate 
aggressive disease (GS ≥7), as well as predict long-term risk of cancer metastasis139-142. 
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ConfirmMDx 
The ConfirmMDx test (MDxHealth, Inc.) is a CLIA-certified tissue-based assay which 
interrogates the methylation levels of a multi-gene panel (GSTP1, APC, and RASSF1) from 
biopsy samples
143-145
. The underlying biological concept behind the ConfirmMDx test lies in 
the occurrence of an epigenetic field effect whereby cells adjacent to cancer foci display 
DNA methylation changes which can be detected by the assay but undetectable by 
histopathology
146-149
. As there is a tendency for tumors to be missed by an initial round of 
transrectal ultrasound-guided biopsies, patients may often be subjected to multiple further 
biopsies. Through DNA methylation analysis, the ConfirmMDx test can advise repeat biopsy 
decisions to separate patients who have a true negative biopsy from those who may have 
occult cancer
150-153
. ConfirmMDx has an excellent 90% Negative Predictive Value (NPV), 
but a Positive Predictive Value (PPV) of only 28%. 
 
Oncotype Dx 
The Oncotype Dx assay (Genomic Health, Inc.) is a CLIA-certified multi-gene early PCa 
detection assay based on a comparison between the individual’s tumor and healthy tissue at 
biopsy. The assay detects the expression of 12 cancer-associated genes representative of four 
different biological pathways, five reference genes and uses an algorithm to calculate a 
Genomic Prostate Score (GPS)
154-156
. For men recently diagnosed with early-stage PCa, the 
GPS have been demonstrated to risk stratify via prediction of probability of pathological 
characteristics, and advise the selection of appropriate treatment such as active surveillance 
or invasive treatment
157
.    
 
Prolaris 
The Prolaris Score assay (Myraid) is CLIA-certified and directly measures cancer cell growth 
characteristics in biopsy tissues for disease prognosis and risk stratification.  By utilizing the 
combined measured expression levels of 31 cell cycle progression and 15 housekeeping 
genes, the Prolaris Score assay is aimed at using proliferation to discriminate disease 
progression risk (i.e. low expression signature is correlated with low disease progression 
risk)
158-160
. 
 
Decipher® 
The Decipher® test (GenomeDx) is a CLIA-certified tissue-based assay which aims to 
predict the risk of metastatic disease (independent of Gleason scoring or PSA test results) 
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within five years after radical prostatectomy surgery
161-164
. This is achieved through the 
analysis of 22 aggressive PCa-associated RNA markers which were discovered from 
genome-wide search algorithms of more than a million markers, and has been extensively 
validated in collaboration with leading academic medical institutions. These 22 markers are 
associated with cell proliferation, migration, tumor motility, androgen signalling and immune 
system evasion. 
 
Progensa and MiPS 
The Progensa test (Hologic) is the first FDA-approved urine-based molecular assay which 
quantifies the ratio of PCA3 to PSA mRNA levels non-invasively from urinary samples to 
assist in decisions for repeat-biopsies
165-170
. PCA3 is a unique non-PSA long non-coding 
RNA biomarker which has been found to be overexpressed in more than 95% of primary and 
metastatic PCa tissues, but not in normal or non-PCa tissues.
93
 Although the Progensa test has 
been shown for use in detecting PCa of higher-grade
171
, a lack of an optimal signal cutoff has 
thus far limited its prognostic ability. 
 
PCA3 has also been combined with T2:ERG in a CLIA-certified urinary PCa early detection 
test called the MiPS that also incorporates serum PSA. MiPS provides additional information 
on whether a biopsy is needed by providing a risk estimate of PCa detection upon biopsy. 
Additionally, the combination of highly PCa-specific PCA3 and T2:ERG biomarkers in MiPs 
also predicts a patient’s risk of developing high-grade PCa172-177 and validation of alternative 
formulas combining T2:ERG and PCA3 has also been conducted
178
.   
 
SelectMDx  
SelectMDx (MDx Health, Inc) is a CLIA-certified urinary PCa early detection assay which 
was first demonstrated in a Dutch study in 2015 to aid in selecting men for biopsy
179
. 
SelectMDx consists of the RT-PCR analysis of a three gene panel (HOXC6 and DLX1 
overexpression, with KLK3 as an internal control) in combination with risk factors like PSA, 
PSA density, DRE, age and family history of prostate cancer. The HOXC6 and DLX1 
biomarkers were selected from a biomarker discovery study based on gene expression 
profiling of tissue and urinary sediment samples
179
, and have been reported to be good 
predictors for high-grade PCa detection.
180
 SelectMDx has a reported NPV of 98% for 
aggressive PCa, and an AUC of 0.89. 
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ExoDx Prostate IntelliScore 
Exosomes are nm-sized double-lipid membrane vesicles which are secreted from cells, and 
can be found in different biofluids such as blood or urine. A study in 2009 first reported that 
PCa cell-derived exosomes in urine contain both PCA3 and T2:ERG mRNA
181
. Using 
advances in exosomal RNA purification, this original discovery has subsequently been 
developed into the CLIA-certified ExoDx Prostate IntelliScore assay (Exosome Diagnostics). 
The assay assesses exosomal RNA levels of PCA3, ERG, and SPDEF genes by RT-PCR to 
derive an overall score for improved discrimination of GS≥7, GS=6, and benign PCa: AUC = 
0.74 (95% CI 0.68-0.80) in 774 men. Given the increased research into the biomarker cargo 
in PCa cell-derived urinary exosomes, exosomes may potentially be a viable resource for PCa 
diagnosis and clinical management
182, 183
.   
 
Multiparametric magnetic resonance imaging 
Advanced tissue imaging is currently surfacing as a pathological biomarker to 
supplement/enhance molecular biomarker testing in distinguishing aggressive tumor foci. 
Explicitly, multiparametric magnetic resonance imaging (mpMRI) is emerging as a 
promising biomarker for PCa screening, localization, staging, and risk stratification. A 
mpMRI combines three separate parameters (i.e. imaging techniques): T2-weighted (T2W) 
imaging, diffusion-weighted imaging (DWI), and dynamic contrast enhancement (DCE) 
imaging to provide detailed anatomical and functional prostate imaging.  
 
In recent years, studies have indicated that mpMRI offers a biomarker for better 
discrimination between high- and low-risk PCa
184-186
, as well as more accurate mpMRI-
guided biopsies to target tumors
187-189
. In the latest multicentre randomized PRECISION trial 
consisting of 500 men in total
190
, it was found that the use of mpMRI for pre-biopsy risk 
assessment and targeted biopsy was superior to standard transrectal ultrasonography-guided 
biopsy (TRUSGB). 95 (38%) men who underwent mpMRI-targeted biopsy were diagnosed 
with clinically-significant PCa, as compared to 64 men (26%) who went through TRUSGB. 
Concurrently, it was also observed that there is less overdetection of clinically-insignificant 
PC (9% vs. 22%), and fewer biopsy cores being required in mpMRI group than in the 
TRUSGB group. Together with molecular biomarker-driven approaches, mpMRI could aid in 
minimizing the over-diagnosis and –treatment of clinically insignificant PCa (thus reducing 
the number of unnecessary prostate biopsies). 
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NANO-STRATEGIES FOR NEXT-GENERATION PCa BIOMARKER 
DETECTION  
The foregoing discussion provides an overview of biomarker-driven efforts in PCa molecular 
subtyping. To augment these advances in PCa biology, modern cancer nanotechnology 
research may yield next-generation PCa biomarker detection nano-strategies to revolutionize 
precision PCa management.      
 
Nanotechnology applications in the field of cancer require cross-disciplinary research 
interfacing biology, chemistry, physics, engineering, and medicine
191, 192
. The basic rationale 
for utilizing nm-sized materials is to exploit the unique physical (eg. optical, magnetic, 
electronic, or structural) properties which transpire within nanoscale-sized range
193
. A 
familiar example of cancer nanotechnology application is the use of synthetic nanovectors 
such as liposome for therapeutic drug delivery into target cancerous tissues (e.g. liposomal 
doxorubicin). Beside cancer drug delivery applications, the advantage of a nanotechnological 
approach in being of similar dimensions to molecular biomarker targets is also beneficial for 
cancer diagnostics development.  
 
Table 3 Examples of nanomaterials and nanoparticles used in the detection of different 
PCa biomarkers with enhanced limits-of-detection   
Nanotechnology PCa Biomarker  Detection Limit Detection Medium 
Silicon nanowires  PSA protein 0.8 pg/mL
196
 Serum 
Carbon nanotubes  PSA protein 4 pg/mL
197
 Serum, Tissue 
Graphene PSA protein 8 pg/mL
198
 Serum 
Iron oxide 
paramagnetic 
nanoparticles 
Whole PCa tumor cell; 
various isoforms of 
PSA protein; T2:ERG, 
PCA3, SChLAP1 
mRNA  
0.1 ng/mL (protein)204 
1000 copies (RNA)
208
 
Urine 
Quantum dots PSA protein 0.5 ng/mL
213
  
Surface-enhanced 
Raman Scattering 
nanoparticles 
Various isoforms of 
PSA protein; T2:ERG 
variants, PCA3, ARV7 
mRNA 
12 pg/mL (protein)
215
 
100 copies (RNA)
217
 
Serum, Urine 
 
The emergence of nanotechnology-based approaches for PCa screening (TABLE 3) is 
extremely promising due to highly sensitive analytical detection features, easy clinical utility, 
and affordability. Essentially serving as general nucleic acid/protein/metabolite biomarker 
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sensors, such nano-strategies impart remarkable detection capabilities without any specialized 
sample processing techniques. Increasingly, we have seen many instances of miniaturized 
platforms (eg. integrated diagnostics, wearables, implantables enabled by nano-components) 
for disease biomarker panel analysis after comprehensive genetic screening by next–
generation sequencers (FIG. 2). This section will review the background and performance of 
nano-strategies (nanostructured materials, nanoparticles, and miniaturized integrated systems) 
that have been demonstrated for PCa biomarker detection.  
 
 
Figure 2 A futuristic view of diagnostic miniaturization. Continuous innovations in the 
nanotechnology field have seen the evolution of clinical diagnostics from next-generation 
sequencers with massive genetic screening capabilities to miniaturized technologies for 
targeted biomarker analysis. We are currently on the cusp of witnessing the advent of 
nanoscaled diagnostics that could fundamentally change clinical practice though enhanced 
disease detection, treatment, and monitoring. Adapted from ref.
219
 with permission from the 
Royal Society of Chemistry.     
 
Nanostructured materials 
Generally, nanostructured materials refer to constructions of nanoscaled dimensions and 
properties. Particularly, the aforementioned physical properties of such nanoscaled 
approaches are able to impart significant breakthroughs in detection speed and sensitivity. 
With regards to PCa nanodiagnostics which stemmed from nanostructured materials over the 
past decade, there have been developments that largely focus on PSA as a target for detection 
in clinical specimens
194
. A historical footnote is the first nanotechnology assay which used 
microcantilevers for PSA protein detection at low clinically-relevant detection limits
195
. This 
was followed by silicon-nanowire field-effect sensors which incorporated nanowires and 
surface PSA receptors into arrays for highly-sensitive PSA protein detection in undiluted 
serum samples
196
. In recent years, the rise of carbon nanotubes
197
 and graphene
198
 as new 
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forms of super-conductive nanomaterials has also been reported for electrochemical PSA 
protein detection in human tissue and serum samples. Whilst such nanostructured materials 
have been demonstrated for breakthroughs in PSA detection sensitivity, there is a lack of 
successful clinical translation; likely due to the restricted academic research expertise in 
fabricating novel nanomaterials and a scarcity in progressing towards clinical studies from 
shortage of funding and/or diagnostic commercialization knowledge.     
 
Nanoparticles  
The most commonly used nanoparticles for molecular diagnostic applications are metallic 
substrates of various shapes and transpire within the nm range. After a couple of decades of 
widespread research, the production and use of conventional nanoparticles are established 
and commercially available. Due to their high surface-to-volume ratio, nanoparticles serve as 
an ideal substrate for maximal loading of intended biological molecules onto the nanoparticle 
surface. In addition, as electron behaviours are constrained differently within nanostructures, 
this imbues the nanoscaled substrates with unique size-dependent magnetic, electronic, and 
optical properties which are useful for diagnostic applications. In terms of in vitro 
diagnostics, nanoparticles have been widely utilized in PCa nanodiagnostic applications
199-
201
.  Iron oxide-core paramagnetic magnetic nanoparticles have mostly been used for isolation 
and purification of specific molecular targets prior to detection
202
. This has been 
demonstrated for the detection of different PSA protein isoforms and even whole PCa tumor 
cells
203, 204
. Aside from PSA detection, there has been progress in the last couple of years with 
the use of magnetic particles for detection of next-generation PCa RNA biomarkers such as 
T2:ERG, PCA3, and SChLAP1
205-210
. In particular, magnetic particle-based purification has 
enabled amplification-free electrochemical detection of these biomarkers at a fraction of PCR 
assay cost, and with improved sensitivity and speed. Lately, magnetic particles have also 
been showcased for dual functions in both the isolation and visual detection of next-
generation PCa RNA biomarker (T2:ERG) non-invasively from urine samples
211
.  
 
Quantum dots are nm-sized semiconducting particles with better enhanced fluorescence 
emissions
212
 than conventional organic fluorophores due to a quantum confinement effect of 
electron energy bands. With tunable size-dependent emission wavelengths and better 
photostability, quantum dots have mainly found applications in PSA protein detection
213, 214
. 
Although quantum dots are excellent for nucleic acid detection, the nature of multiple 
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overlapping fluorescence emission spectra does limit their ability in multiplexed biomarker 
detection.   
 
In this multiplexing regard, the use of surface-enhanced Raman scattering (SERS) 
nanoparticles might be more optimal. SERS nanoparticles generally consist of nanostructured 
metallic surfaces to greatly enhance the Raman scattering signals of surface-adsorbed 
biomolecules. Importantly, Raman spectra widths are much narrower than those of 
fluorescence, thus making SERS more suitable for multiplexed biomarker detection. SERS 
has been utilized in many studies for multiplexed detection of PCa biomarkers such as 
various PSA forms with excellent detection sensitivity
215
. Of late, SERS nanoparticles have 
also been employed in the detection of next-generation PCa biomarkers for potential 
molecular subtyping purposes
216-218
. A drawback of SERS nanoparticles is the degree of 
batch variability during bulk nanoparticle synthesis which could impact detection 
performance and accuracy. Thus, further research efforts into large-scale SERS nanoparticles 
with high reproducibility and stability are required to realize clinical SERS nanodiagnostics.     
 
Miniaturized integrated systems 
Besides the synthesis of novel nanomaterials and nanoparticles, nanotechnology has also 
initiated the design of miniaturized device-based lab-on-a-chip or solution-based lab-in-a-
drop systems. Such systems seek to downscale and integrate different aspects of biomarker 
analysis workflow (i.e patient sample preparation, target copy amplification, and target 
detection readout) onto a singular platform; thus minimizing patient sample requirement and 
sample-to-outcome turnaround time. A limitation of lab-on-a-chip systems is that a need for 
sophisticated and complex engineering is hampering the translation into widespread clinical 
use. Thence, the development of miniaturized systems which could similarly perform 
integrated biomarker analysis in absence of specialized fabrication is a potentially attractive 
alternative. Pointedly, the main conceived advantage of lab-in-a-drop diagnostics (FIG. 3)
219
 
in avoiding the need for costly and specialized precise engineering; may be beneficial in the 
translation to practical commercial products for personalized disease applications.  
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Figure 3 Lab-in-a-drop. A nanodiagnostic platform which miniaturizes an entire laboratory-
based biomarker analysis workflow (crude sample preparation, target copy amplification, and 
biomarker detection readout) within a singular fluid droplet
219
. The above scheme illustrates a 
system in which different barcoded nanoparticles are used for multiplex quantification of 
various PCa biomarkers in patient urinary samples
217
. Lab-in-a drop nanodiagnostics could be 
a rapid and cost-effective tool for interrogating cancer biomarkers from liquid biopsies with 
high sensitivity and reliability at point-of-care. 
 
CHALLENGES IN CLINICAL TRANSLATION OF NOVEL 
BIOMARKERS AND NANO-STRATEGIES 
The above-mentioned nano-sized technology solutions represent the field’s work towards the 
nano-optimization of PCa screening. However, it is worth noting that PCa nanodiagnostics is 
presently at an early stage of promise, and there are necessary steps to be taken for successful 
translation into viable precision clinical screening tools. This section covers our perspectives 
on the challenges and potential solutions for the clinical translation of both next-generation 
biomarkers and nanodiagnostic technologies within the next decade. 
 
Validation of biomarker panel  
With the availability of high-throughput next-generation sequencing technologies today for 
whole-exome and transcriptomic sequencing of cancer specimens, the discovery of new and 
better biomarkers in PCa and other cancer types has progressed at an exponential rate but 
may be nearing saturation
220
. Given the heterogeneity of PCa, it is unlikely that a single 
Chapter 2 
 
28 
 
biomarker is sufficient for disease risk stratification. It is more probable that a panel of 
several biomarkers is required, and the main challenge would be the assembly of such a 
molecular target panel for precision PCa management
221
. For PCa, the ideal biomarker-driven 
screening test needs to show superior clinical sensitivity and specificity, and demonstrate 
significant improvement to the ROC curve in comparison to the PSA test and routinely-
available clinicopathological variables. To ensure maximal efficacy for clinical use, proper 
and in-depth biomarker validation needs to be performed through well-designed and -
conducted biomarker clinical trials with validation across different institutions. Moreover, 
from a clinical perspective, a PCa diagnostic biomarker panel may need to be modified for 
patients of different germline heritage, especially in underrepresented populations (eg. 
different PCa drivers in men of African descent as compared to Caucasian descent)
222
. For 
treatment biomarkers, smarter trial designs such as adaptive enrichment approaches
223, 224
 
may effectively help identify predictive PCa biomarkers to benefit from specific treatments.   
 
Clinical verification of nanodiagnostics 
To date, the translation success of nanodiagnostics from research concept to clinical use has 
been limited. The foremost issue is that nanodiagnostics are presently being evaluated mostly 
based on their analytical performance in research laboratories, with lack of continued 
evaluation in a clinical setting. While the establishment of analytical detection sensitivity, 
selectivity, and repeatability is no doubt crucial; the subsequent clinical evaluation of these 
nanodiagnostics to test robustness, reproducibility, standardization, and applicability for 
actual patient use is generally being overlooked, thereby impeding most promising 
nanotechnologies from progressing towards clinical translation use. Thus, this is a significant 
obstacle to be overcome for promising PCa nanodiagnostic technologies to be adopted for 
clinical use. Clinical evaluation involves the testing of novel nanotechnologies on a cohort of 
patient samples (of appropriate size and context) to establish clinical sensitivity, specificity, 
PPV, NPV, and AUC. Lately, progress on this front has been made by employing a relevant 
and proven MiPS PCa clinical biomarker model to comprehensively verify the clinical 
performance of SERS nanodiagnostic technology
225
. The evaluation of these clinical 
parameters will enable the generation of clinically-relevant biomarker detection limits, which 
is notably different from its analytical counterparts. For instance, analytical detection limit of 
single-molecule level is an outstanding limit-of-detection analytically, however, might not be 
of great clinical utility if there is no disease implication (i.e. no clinical action required) when 
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an oncogenic biomarker is present at a single copy. This may especially be of significance in 
PCa, where indolent disease is extremely common and there is a need to avoid overtreatment.  
 
Acceleration of biomarker and nano-strategy validation process 
Comprehensive clinical validation and translation of novel PCa biomarkers and new 
biomarker-based nanotechnologies needs to be effectively accelerated (typically 5-10 years 
for each) to provide faster patient benefit. A feasible way to streamline this process might be 
the simultaneous combined evaluation of new nanodiagnostic technologies on novel 
biomarkers to investigate potential clinical benefits, thus leading to a shorter overall 
timeframe. This move may be realized by carefully-designed clinical studies with well-
established pre-study research objectives regarding the choice of nano-strategy and biomarker 
panel, and relevant patient cohorts and samples.    
 
Standardization of protocols 
It is of a paramount concern that protocols related to PCa biomarker analysis and 
nanodiagnostic development are now varied across different research institutions. Under the 
circumstances of collaborative biomarker studies within larger consortia, care must be taken 
to minimize systematic as well as random variation with proper control conditions to allow 
proper head-to-head comparisons and cross-validation of related studies. Particularly, the 
standardization of patient sample processing and molecular testing processes in biomarker 
analysis are pivotal. Recently, a combination of standardized whole urine sample collection 
protocol, automated urinary RNA extraction and PCR platform has been demonstrated to 
enhance the overall analytical performance of urinary RNA assays such as SelectMDx
226
. For 
nanodiagnostic development, there needs to be standardization of manufacturing and 
synthesis processes and storage conditions to minimize batch-to-batch variability and ensure 
optimal functions during applications. 
  
Multidisciplinary collaboration 
The successful realization of a novel clinical PCa diagnostic test involving next-generation 
PCa biomarker detection requires complementary cutting-edge detection approaches. In this 
regard, the role of nanotechnology in enabling rapid, highly sensitive, accurate, and 
affordable biomolecular target sensing is greatly encouraging. Due to relatively poor 
awareness of next-generation PCa biomarkers in the nanotechnology research field, we have 
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seen the emergence of many innovative nanotechnology-based biosensing techniques from 
research groups around the world which have only focused on improving PSA detection as a 
PCa diagnosis model. This calls for more frequent interactions between the fields of clinical 
and nanodiagnostic research in the form of multidisplinary conferences and forums, so that 
nanotechnologists could be kept up to date with the most relevant clinical information on 
biomarker discovery and advances (and clinicians, in turn, with nanodiagnostic revolutions). 
This will allow state-of-the-art diagnostic nanotechnologies to be designed for the most 
promising and exciting cancer biomarkers available, thus directing efforts to address the most 
relevant and pressing need in clinics. 
 
CONCLUSIONS AND FUTURE OUTLOOK 
In conclusion, to allow accurate PCa risk stratification, a single biomarker is unlikely to be 
sufficient to achieve the required diagnostic sensitivity and specificity. Emerging evidence 
from panels of various next-generation PCa biomarkers shows effective PCa classification 
into different molecular subtypes that are potentially amenable for personalized treatment 
strategies. Besides early detection purposes, the use of PCa molecular subtyping could extend 
to the guidance of PCa treatment decisions. It is anticipated that research efforts in the next 
decade will focus on the clinical evaluation and translation of different combinations of next-
generation PCa biomarkers, in order to elucidate a multi-omic comprehensive panel which 
possess high discrimination ability for clinically-significant PCa subtypes.  
 
Besides the translation of next-generation PCa biomarkers, the importance of developing 
superior detection technologies to target these biomarkers in human specimens is equally 
essential to justify changing clinical as well as regulatory screening paradigms. In this aspect, 
the unique benefits of nanotechnological approaches could be exploited for higher detection 
sensitivity, accuracy, and speed at a reduced cost. The urinary detection of PCa biomarkers 
could offer a truly non-invasive form of PCa liquid biopsy which may yet overcome the 
challenges of tumor heterogeneity associated with surgical tissue biopsies
227
. While 
preliminary results have been promising with the introduction of several urine-based PCa 
tests in the clinic, the possibility of more powerful urine-based diagnostics which could 
provide an accurate overall disease molecular snapshot, demands for further clinical 
evaluation before clinical translation. With the many innovative nanodiagnostic 
developments internationally, the potential of cancer nanotechnology in improving current 
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PCa standard-of-care is optimistic. To translate these nanotechnologies for clinical use in the 
near future, researchers must properly evaluate their developed methodologies in relevant 
patient cohorts, established clinically-relevant detection limits, and comprehensively evaluate 
clinical performance parameters.  
 
Lastly, it is of our view that optimal outcomes for PCa patients will be derived from the 
synergy of ideas and knowledge integrated from different fields brought together under the 
umbrella of cross-platform meetings. We hope that this review can serve to bridge the gap in 
knowledge between the PCa biological/clinical and nanodiagnostic fields: by informing 
urologic clinicians about future possibilities and benefits of PCa nanotechnology-based 
screening, and alerting nanotechnologists to the availability of next-generation PCa 
biomarkers for integration into their nanodiagnostic research. 
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3 
Colorimetric Gene Fusion Diagnostics for Visual Binary Readout 
 
 
Introduction 
The TMPRSS2:ERG is a highly-specific prostate cancer biomarker which has been found to 
occur in around half of all prostate cancer cases, potentially representing a major prostate 
cancer subtype for tailored treatment approaches. The binary nature of the TMPRSS2:ERG 
biomarker which renders it present in prostate cancer and absent in benign conditions, makes 
it an extremely attractive target for clinical diagnostics development. In this chapter, a new 
solution-based biosensing system is described for the non-invasive detection of 
TMPRSS2:ERG RNA in prostate cancer urine samples. This biosensing system aims to 
integrate an entire nucleic acid detection workflow within a miniscule fluid droplet (i.e. lab-
in-a-drop (LID)) for point-of-care (POC) usage. Specifically, a combination of reverse-
transcription recombinase polymerase amplification (RT-RPA) and different colorimetric 
readout methodologies within a downscaled fluid volume, has enabled the rapid convenient 
detection of urine-purified TMPRSS2:ERG RNA. Chapter 3.1 showcases the LID concept for 
POC nucleic acid biomarker detection with a comprehensive review of integrated 
miniaturized diagnostics. Chapter 3.2 introduces a novel coupling of isothermal RT-RPA 
with a flocculation-based visual readout, which exploits the binary nature of TMPRSS2:ERG 
for simplistic (yes/no), inexpensive, and non-invasive detection of urinary TMPRSS2:ERG 
RNA within a microdroplet. Chapter 3.3 describes the development of “FusBLU”, a 
microtube-based quantitative assay which coupled RT-RPA with an enzymatic substrate 
oxidation for flexible colorimetric, spectrophotometric or electrochemical TMPRSS2:ERG 
RNA detection. 
 
Chapter 3 is based on three published articles in Lab on a Chip (2017) [Chapter 3.1], 
Scientific Reports (2016) [Chapter 3.2], and Theranostics (2016) [Chapter 3.3]. 
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Enabling Miniaturised Personalised Diagnostics: From Lab-on-a-
Chip to Lab-in-a-Drop 
 
Kevin M. Koo, Eugene J. H. Wee, Yuling Wang and Matt Trau
 
 
 
ABSTRACT 
The concept of personalised diagnostics is to direct accurate clinical decisions based on an 
individual’s unique disease molecular profile. Lab-on-a-chip (LOC) systems are prime 
personalised diagnostics examples which seek to perform an entire sample-to-outcome 
detection of disease nucleic acid (NA) biomarkers on a single miniaturised platform with 
minimal user handling. Despite the great potential of LOC devices in providing rapid, 
portable, and inexpensive personalised diagnosis at the point-of-care (POC), the translation of 
this technology for widespread use has still been hampered by the need for sophisticated and 
complex engineering. As an alternative miniaturised diagnostics platform free of precision 
fabrication, there have been recent developments towards a solution-based lab-in-a-drop 
(LID) system; by which an entire laboratory-based diagnostics workflow could be 
downscaled and integrated within a singular fluid droplet for POC detection of NA 
biomarkers. Contrary to existing excellent reviews on miniaturised LOC fabrication and 
individual steps of NA biomarker sensing, we herein focus on miniaturised solution-based 
NA biosensing strategies suited for integrated LID personalised diagnostics development. In 
this review, we first evaluate the three fundamental bioassay steps for miniaturised NA 
biomarker detection: crude sample preparation, isothermal target amplification, and detection 
readout of amplicons. Then, we provide insights on research advancements towards a 
functional LID system which integrates all three of the above-mentioned fundamental steps. 
Finally, we discuss perspectives and future directions of LID diagnostic platforms in 
personalised medicine applications. 
    
1 INTRODUCTION 
Personalised diagnostics refers to the detection of biological disease markers in individual 
patients in order to guide decisions for patient-specific diagnosis, therapy, and monitoring.
11-
14
 With the advent of sequencing technologies which enable a comprehensive outlook of a 
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person’s genetic makeup, it is now possible to innovatively tailor specific 
diagnoses/treatments accordingly to the individual’s genetic profile. Hence, instead of a one-
size-fits-all treatment approach, this stratification of disease subtypes can improve clinical 
outcomes in a variety of human diseases. While personalised diagnostics is applicable for 
many diseases, the field of cancer is one which is in great need for personalised diagnostics to 
have a significant impact. The complex and heterogeneous nature of cancer-driving 
mechanisms often lead to patients exhibiting tumour genetic variabilities that differ from 
patient-to-patient and/or tumour-to-tumour within the same patient.
15,16
 Thus, molecular 
diagnostic technologies for simple and rapid analysis of cancer biomarkers from clinical 
patient samples such as tissue or biological fluids are particularly in demand. With the current 
emphasis on quick disease diagnosis and early treatment intervention, diagnostics are being 
preferably developed for clinician-orientated
17
 or patient-orientated
18
 point-of-care (POC) use 
within hospital or home settings respectively. An ideal vision for personalised cancer 
diagnostics is one which incorporates several workflows (from patient sample preparation to 
assay readout) onto a singular platform that could conveniently be performed at POC with a 
rapid and accurate analysis result.   
 
A prime example of a single-platform POC personalised diagnostic system is the concept of 
lab-on-a-chip (LOC) devices. A LOC generally utilizes microfluidics and nanotechnology to 
perform one or several typical laboratory processes on a single device.
19-21
 The main benefits 
of integrating different laboratory functions on a small-scaled LOC are: (i) use of miniscule 
amount of fluid volumes which reduces required sample/reagent amount and costs; (ii) 
shorter sample-to-answer turnaround time due to smaller diffusion distances, higher surface-
to-volume ratios, and faster heating (i.e. smaller heating capacities); (iii) potential for low-
cost mass production. The exciting potential of LOC technologies for POC personalised 
diagnostics is highly promising but since their emergence decades ago, majority of LOC 
systems have faced difficulties in progressing to real-world products for practical 
applications. Currently, the constraints which impede LOC commercialization include high 
fabrication costs, complex precision engineering, and difficulties in controlling sophisticated 
on-chip fluid movement/biochemical reactions.
22
 Thus, in order to meet the pressing need for 
personalised diagnostics in the real-world, it is worthy to explore alternatives to LOC which 
are similarly able to combine different conventional laboratory workflows onto a smaller-
scaled platform. 
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Fig. 1 Precision fabrication-free lab-in-a-drop (LID) point-of-care diagnostics for combining 
different laboratory-based nucleic analysis steps onto a singular miniaturised platform. 
Adapted from ref. 76 with permission from Royal Society of Chemistry.  
 
A feasible solution to current LOC limitations is a miniaturised microtube-based biosensing 
system which enables miniaturised analysis of disease biomarkers from a single µL- input 
volume of biological sample. As such, apart from circumventing the need for specialised chip 
fabrication and complicated microfluidic flow manipulation, such a solution-based system is 
attractive in allowing rapid and low-cost personalised diagnostics for diseases as traditional 
bioassays could essentially be downsized into a droplet - lab-in-a-drop (LID) - and be 
programmed for detection within a microtube conveniently with minimal instrumentation 
(Fig. 1).  
 
Nucleic acids (NAs) such as DNA and RNA play vital roles in disease 
initiation/progression,
23,24
 and are key biomarkers for developing POC personalised 
diagnostics. Additionally, the target-specific isolation of NA biomarkers is easily achievable 
through well-designed oligonucleotide probes that are relatively cheap to manufacture, while 
sensitive detection of trace target amount is feasible through a range of NA amplification 
techniques. These factors are advantages over the detection of other biomarker classes such 
as proteins or metabolites, which are typically limited by the availabilities of specific 
antibodies and target amplification methods. In this review, we focus on miniaturised 
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biosensors which target NAs as an important and ubiquitous class of biomarkers. The 
traditional biosensing of NA biomarkers from biological samples consists of 3 fundamental 
steps: (i) Sample preparation (i.e. NA biomarker isolation/purification) from raw biological 
samples such as blood, urine or saliva; (ii) Amplification of NA targets to increase detection 
sensitivity; (iii) Transduction of target levels into a readable qualitative or quantitative signal. 
The miniaturisation of these fundamental steps into simplistic and convenient downscaled 
fluid droplets could allow us to achieve a practical LID biosensor that is readily available for 
personalised diagnostics applications. Moreover, the successful miniaturisation of NA target 
extraction, amplification, and detection as demonstrated on many LOC platforms in literature 
are also applicable as model concepts for LID diagnostics development. 
 
Whilst numerous reviews relating to each of these three individual aspects of NA biosensing 
have been written,
25-30
 an extensive review that considers all three aspects for the 
development of miniaturised personalised diagnostics is lacking. We acknowledge that 
extensive research and advances have been achieved at the individual aspects of NA 
diagnostics. However, more often than not, miniaturised diagnostics development neglect to 
consider sample preparation strategies for compatible use with downstream amplification and 
readout processes, thus overlooking the foremost biosensing aspect. Without a suitable 
upstream sample preparation strategy to isolate relevant biomarkers to begin the biosensing 
process, the emphasis on state-of-the-art downstream biosensing aspects may be ineffectual. 
Furthermore, vital factors of combining individual biosensing aspects, such as reagents of an 
upstream process inhibiting/affecting the performance of the next downstream process, are 
likely to be missed when integration is not considered.            
 
In this review, we summarise the recent advancements of suitable techniques/technologies in 
the three fundamental biosensing aspects for miniaturised patient diagnostics. We also 
describe our own research group’s efforts in achieving a miniaturised LID system through 
consolidation of all these three aspects. Lastly, we discuss perspectives and future directions 
of LID diagnostic platforms in personalised medicine applications.  
 
2 DOWNSCALED SAMPLE PREPARATION  
High-quality NA isolation from primary samples is crucial as the performance of any 
DNA/RNA molecular assay is dependent on the quality of the NA input.
28
 For POC 
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personalised diagnostics applications, NA sample preparation is further complicated due to 
restrictions in availability of on-site resources. The first of two main steps during NA sample 
preparation is cellular lysis, where cell structures can be disrupted by mechanical, chemical, 
thermal, electrical, enzymatic or a combination of strategies to release genetic material for 
analysis. The second step is NA extraction which can be broadly classified into chemical or 
physical methods to concentrate and enrich for NA targets.
31
 Depending on the desired 
diagnostics application, an appropriate sampling approach must be considered as part of its 
design. The following section will discuss the three most practised strategies in laboratories 
and how they have or could be applied in miniaturised LOC/LID systems for POC 
personalised diagnostics applications.  
 
2.1 Phenol:chloroform methods 
A classical chemical/physical sample preparation technique is the phenol:chloroform 
method.
32
 The advantages of this approach are combined sample lysis and NA extraction that 
has both high yield and purity. For improved efficiency, macerated tissue or crude lysate in a 
neutral aqueous buffer is mixed with the phenol:chloroform mixture and allowed to settle 
(centrifuge) into organic and aqueous phases. NA (and contaminating carbohydrates) is 
preferentially found in the aqueous phase while proteins and lipids are found in the organic 
phase. The aqueous phase is carefully removed and can be subjected to further rounds of 
phenol:cholorform extraction to improve NA purity. Next, NA is further purified by 
precipitation using a high salt and alcohol washes to remove the carbohydrates. RNases can 
be added at this point to degrade RNA and thus yielding relatively pure DNA.  
 
Alternatively, by adjusting acidic conditions (pH 4-6) and with the addition of a chaotropic 
agent such as guanidinium thiocynade, the phenol:chloroform method can be modified to 
specifically partition RNA into the aqueous phase.
33,34
 Commercially, this mixture is 
marketed as TRIzol or TRI-reagent. RNA is finally recovered using alcohol precipitation 
similar to the classical phenol:chloroform methods. DNA and proteins can also be purified 
subsequently from the organic phase if desired, further underscoring the versatility of the 
method.  
 
Notwithstanding the benefits, phenol:chloroform methods are relatively long and tedious 
(multiple centrifuge and wash steps) to perform as compared to other contemporary strategies 
and generates hazardous waste products that may not be suitable for POC diagnostics. 
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Fig. 2 Schematic of the RNA purification process using the liquid-phase nucleic acid 
purification chip. (a) An aqueous phase containing DNA, RNA, and protein in the 
microwells. (b) Organic phase of pH 4.6 was introduced into the headspace channel with 
continuous forward and reverse flow. In the case of on-chip DNA extraction, an organic 
phase with a pH of 8.0 was introduced into the headspace channel instead. (c) Protein and 
DNA were transferred from the aqueous phase into the organic phase, while RNA was 
retained in the aqueous phase. (d) The organic phase was expelled and evaporated under 
vacuum while purified RNA in the microwell was concurrently dried (e, f). Residual organic 
phase was further decontaminated by repetitive washing and vacuum evaporating with 70% 
ethanol. (g) q-RT-PCR reaction mixture was loaded into the microwells. (h) Microwells were 
covered with mineral oil followed by on-chip q-RT-PCR amplification. Adapted from ref. 26 
with permission from American Chemical Society. 
 
Morales and Zahn first showed that microscaled droplet-based phenol extraction of bacterial 
DNA could be carried out on a microfluidic device.
35
 To resolve the issue of residual organic 
phase interference with downstream PCR amplification, Zhang et al. recently demonstrated a 
microfluidic liquid-phase nucleic acid purification chip to selectively isolate NA targets from 
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single bacterial cells in nL sample volume for on-chip quantitative PCR in the same 
microwells (Fig. 2).
36
 While these miniaturised strategies have been developed for 
phenol:chloroform extraction within microfluidics-based systems, it will be challenging for 
translation into POC diagnostics due to poor compatibility of hazardous waste with routine 
disposable plastics.  
 
Very recently, a spin column method (commercially known as DirectZol from Zymo 
Research) based on solid phase extraction (SPE) was developed to simplify and reduce 
extraction time to as little as 5 minutes. While in the right direction of enabling the methods 
for miniaturisation, its dependence on phenol, chloroform, and combined RNA/DNA 
isolation are its major limitations. In addition, due to its incompatibility with enzymes, 
phenol:chloroform methods are very unlikely to be used in direct POC sample-to-answer 
detection. A more likely strategy for enabling POC might be through miniaturised 
pneumatics (either manual or automated compressed air-driven) to enable SPE approaches, 
such as the SPE integration into a pipette tip that we will be reviewing in the ensuing section.  
 
2.2 Solid phase extraction (SPE) 
Currently, most routine lab-based NA isolation protocols typically require the use of 
centrifuges (for example, silica spin column-based methods
37,38
) that are based on SPE or 
popularly known as the Boom method.
38
 Here, samples are first lysed enzymatically (usually 
sodium dodecyl sulphate with proteinase K method) or with guanidium-based buffers. Then, 
negative charges of the NA are manipulated in solution with positively charged salts (eg. 
sodium, magnesium, ammonium, guanidine, etc) to promote precipitation onto surfaces. 
After a wash step, highly pure NA is recovered at high yields by elution with a pH 7-8 buffer. 
However, access to centrifuges may not always be possible especially for POC or home-
based personalised medicine. For this reason, numerous microfluidic LOC strategies
39
 have 
been proposed to implement SPE for POC. 
 
One extension of SPE that avoids the need for centrifuges and has gained recent popularity is 
solid phase reversible immobilization (SPRI).
40-44
 SPRI typically precipitates NA onto 
magnetic microparticles and with the aid of a magnetic field, facilitates buffer solution 
changes, washes and elution in a single sample holder. Therefore, SPRI potentially requires 
simpler equipment and is more suited for miniaturised POC bioassays. In some iterations of 
SPRI, various microparticle surface modifications have been explored to improve extraction 
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yield. These include carboxylic acid,
40
 cellulose,
43,44
 and chitosan.
42
 However, conventional 
SPRI, like classical methods, are limited by the need for multiple sample/liquid 
manipulations. Various strategies have since been developed to automate SPRI
45
 but most 
POC-tailored approaches still require some form of micro-equipment
42,46-48
 that may be 
miniaturised onto LOC platforms but may not be suitable for low resource settings.  
 
Fig. 3 The TruTip nucleic acid extraction process, whereby a porous, monolithic binding 
matrix is inserted into a pipette tip. Adapted from ref. 39 with permission from MyJove 
Corporation. 
 
A recent development in convenient SPE-based sample prep is the TruTip® system by 
Akonni Biosystems. The method involves engineering a highly porous silica frit within a 
pipette tip that function as the SPE platform (Fig. 3).
49
 This approach essentially avoids the 
laborious liquid handling and centrifuging to just a few pipetting steps, and significantly 
reducing preparation times.
24,25 The TruTip® system is automatable, and also has comparable 
NA extraction performance with other market-leading spin column brands.
50,51
  
 
In-built SPE platforms have been adopted numerous times for miniaturised LOC applications 
in literature.
52,53
 Hong et al. carried out mRNA purification on a single microfluidic chip in 
nL volumes by using functionalised magnetic beads and Akutsu et al. have developed an 
integrated system for automated NA extraction and purification using magnetic beads within 
a disposable pipette tip. Yet, these miniaturised platforms require specialised manufacturing 
which is not readily available to the community. Perhaps an SPE approach that is able to 
retrofit with existing common labware, such as manual pipettes, could be a more viable and 
cost-effective/affordable LID alternative for POC personalised diagnostics. 
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2.3 Direct sampling  
The ideal POC personalised diagnostics test would be one that involves direct addition of 
crude samples to the NA detection reaction, and avoids prior lysis and extraction steps. 
However, achieving this goal has multiple challenges: For instance, the sample matrix (e.g. 
blood, mucus, saliva, urine, biofilm, etc.) may not be compatible with downstream bioassays 
due to the presence of inhibitors, hence needing purification approaches such as those 
discussed in the previous sections. In addition, without some form of cellular disruption (i.e. 
lysis), there may not be sufficient genetic material available for detection if raw sample is 
used, thus affecting assay analytical sensitivity. 
 
The simplest direct sampling and detection approach is thermal disruption of samples during 
the initial 95°C phase of PCR. Directed-evolution techniques have now resulted in DNA 
polymerases that are tolerant of sample-derived inhibitors.
54
 
55
 While useful for a variety of 
applications, direct thermal disruption is not compatible with a variety of isothermal NA 
amplification methods that typically rely on thermophobic enzymes. The subsequent addition 
of thermophillic enzymes for isothermal amplification, or the bioengineering of novel 
thermostable enzymes, may be feasible for thermal sample preparation.   
 
Direct sampling on miniaturised devices via electrical cell lysis has been shown in literature. 
Lam and co-workers demonstrated integrated on-chip bacterial lysis with an applied electric 
field and direct sensing of bacterial NA pathogens with nanostructured microsensors.
56
 
Besant et al. also present an integrated device that leveraged electrochemistry-driven lysis in 
close proximity to a microelectrode for rapid analysis of bacteria mRNA at clinically relevant 
levels.
57
 For electrical lysis of mammalian cells, Lu et al. have showcased a micro-
electroporation device for electrolysis of human carcinoma cells to release subcellular 
materials.
58
 Despite these successful demonstrations of downscaled electrical lysis and 
detection, it is challenging to apply the electrical lysis mechanism for clinical POC 
personalised diagnostics due to the need for careful voltage control and precise 
microelectrode fabrication. With advances in nanofabrication techniques and nanomaterial 
synthesis, electrical cell lysis may perhaps be applicable for eventual widespread sample 
preparation.   
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Fig. 4 Schematic of a microdevice architecture highlighting the EA1 enzyme-containing 
ZyGEM solution and swab chambers. Also highlighted is the hydro-phobic valve that allows 
proper loading of the ZyGEM solution prior to rotation, and the two vents, which allow 
proper airflow for correct fluidic movement. Adapted from ref. 50 with permission from 
Royal Society of Chemistry. 
 
Recently, a newly-characterised enzyme called EA1
59
 has been used for closed-tube and 
microfluidic sample preparation in miniaturised PCR-based genetic assays (Fig. 4).
60-62
 While 
its mechanism of action is not well understood, it is likely similar to that of proteinase K-
based lysis for NA isolation but with better thermostability and efficiency
62,63
 and thus more 
suited for trace NA applications. However, with EA1 being a proteinase, it is likely 
incompatible with downstream enzymatic processes without first performing a heat 
inactivation step. This thus effectively rules out its use in isothermal NA amplification 
techniques which are ideal for designing miniaturised personalised diagnostics (detailed 
review in the next section). Perhaps as new designer enzymes are being created through 
directed-evolution bioengineering techniques, it may be possible in the future to formulate 
isothermal assays with proteinase-resistant enzymes for POC personalised diagnostics.  
 
3 MINIATURISED ISOTHERMAL AMPLIFICATION  
To enable small-scaled formats of traditional bioassays, high analytical sensitivity is needed 
to detect trace biomarker amounts in minuscule sample volumes. A way to increase low NA 
target copies to a detectable level from minute amounts of biological sample input is the 
employment of amplification techniques. Specifically, isothermal amplification methods are 
attractive due to the elimination of complex thermal cycling associated with tradition PCR. 
Isothermal amplification allows for rapid and efficient amplification at a constant temperature 
that is achievable with a simple heating element, thus rendering it ideal for integration onto 
miniaturised diagnostics systems. In addition, isothermal amplification is suited for use in 
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POC settings in which constant NA amplification temperature is more easily achievable than 
more complicated temperature cycling protocol. The alternative working principles of 
different isothermal amplification techniques also typically render them more robust (less 
inhibitory) for use in biologically-complex matrix than traditional PCR; this is advantageous 
for use on patient samples which contain many non-target biological molecules. Many 
isothermal amplification techniques have emerged in recent years, and this section will 
summarise several promising isothermal techniques which have been shown to be functional 
in small-volume reactions on miniaturised systems.
64,65
 
 
3.1 Loop-mediated isothermal amplification (LAMP) 
 
 
Fig. 5 (A) Principle of LAMP method. (a) Primer design of the LAMP reaction. (b) Starting 
structure producing step. (c) Cycling amplification step. Adapted from ref. 57 with 
permission from Nature Publishing Group. (B) Schematic illustration of singleplex iμLAMP. 
Adapted from ref. 58 with permission from Royal Society of Chemistry. (C) Principle of 
HDA method. Adapted from ref. 64 with permission from EMBO Press. (D)  Schematic 
layout of the microreactors and the reagent loading network for real-time isothermal helicase-
dependent amplification. Adapted from ref. 65 with permission from Springer Publisher. 
 
LAMP is an exponential amplification method
66
 which utilizes four target-specific primers: 
one forward inner primer (FIP), one backward inner primer (BIP), and two outer primers (F3 
and B3), for hybridisation to six primer binding sites flanking the sequence region for 
amplification (Fig. 5A). The FIP and BIP both carry sequences which are essential for self-
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priming and creating fundamental LAMP dumbbell structures for a successful LAMP 
reaction.  
 
The LAMP process firstly starts with FIP binding to template and extension, followed by F3 
binding to displace the newly-synthesized strands.
67
 The newly-synthesized strands function 
as templates for BIP and B3 binding and extension, resulting in LAMP dumbbell structures. 
The cycling amplification proceeds on with priming and extension of FIP and BIP alternately 
on the dumbbell structures, and the resultant LAMP products consist of singular dumbbell 
and multi-looped cauliflower-like structures. With the inclusion of reverse transcriptase, 
reverse transcription LAMP (RT-LAMP) can be performed on RNA targets. LAMP can 
provide up to 10
9
-fold amplification in approximately 60 min and at a constant temperature of 
60-65 °C. The use of four primers for targeting six different sites aids in increasing 
amplification specificity but also results in constraints and complexity during primer design 
and multiplexing capability.  
 
To date, the suitability of LAMP for integration into miniaturised diagnostics has been 
demonstrated for numerous bacterial and viral targets. Fang et al. have successfully reduced a 
LAMP reaction volume to 5 µL in an eight-channel microfluidic chip (µ-LAMP) for nucleic 
acid target detection (Fig. 5B).
68
 Oh et al. have reported the use of LAMP on a centrifugal 
microfluidic device for the detection of S. typhimurium and E. coli.
69
 The centrifugal device 
allows for simple reagents distribution to achieve 25 parallel LAMP assays on a single 
miniaturised platform. The end-point colourimetric readout provided a detection sensitivity of 
within 60 min. Lee et al. also reported the development of an integrated LAMP device for 
amplification and detection of hepatitis B virus (HBV) DNA.
70
 The key innovation of this 
work is the real-time visual detection of turbidity changes due to the precipitation of 
magnesium pyrophosphate, a by-product of the down-scaled isothermal LAMP reaction. The 
device was tested on clinical serum samples with 2 copies/µL detection sensitivity within 60 
min. More recently, Song and co-workers also employed LAMP on miniaturised devices for 
the detection of Zika virus RNA in oral samples.
71
 By using leuco crystal violet dye, the 
LAMP products could be detected visually with a sensitivity of five plaque-forming units in 
under 40 min. 
 
Besides visual detection, on-chip LAMP could also be suitably combined with more sensitive 
and quantitative electrochemical or fluorescent platforms. More recently, further 
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miniaturisation of LAMP has been achieved through digital LAMP (dLAMP). These dLAMP 
assays involve the further partition of individual LAMP into minuscule droplets for absolute 
quantification of targets after isothermal amplification. Rane and co-workers introduced an 
integrated microfluidic device platform for LAMP amplification of N. gonorrhoeae DNA 
within droplets (~10 pL).
72
 Rodriguez-Manzano et al. have also achieved 5 nL-droplet LAMP 
reactions for hepatitis C virus RNA detection with a mobile phone camera-readout.
73
  
 
3.2 Helicase-dependent amplification (HDA) 
Similar to many amplification methodologies, HDA is inspired by nature with a working 
principle which mimics the biological DNA replication process (Fig. 5C). Instead of using 
heat to separate DNA strands during amplification, HDA first uses a thermostable DNA 
helicase for strand separation.
74
 Next, single-stranded binding proteins maintain the opened 
DNA structure and allow conventional primer hybridisation and extension. This DNA 
helicase-dependent strand separation enables the HDA to occur at a uniform temperature of 
around 65°C for 30-90 min, and is particularly advantageous for amplifying kilobase-long 
target sequences. In a similar fashion to traditional PCR, a single HDA process consists of a 
pair of forward and reverse primers, and is capable of RNA amplification with the inclusion 
of reverse transcriptase. The simplistic workflow of HDA makes it amenable for down-
scaling for performance at small volumes.  
 
There are several reports in literature of miniaturised platforms with integrated HDA for 
nucleic acid target detection. Ramalingam and co-workers designed a simple microfluidic 
system without complex pumps or valves (Fig. 5D).
75
 All solution flow was manipulated by 
capillary action and HDA primers were surface-bound in individual nL-microchambers to 
allow multiple biomarker analysis from a single sample. This miniaturised platform was 
shown to enable real-time HDA quantification of SARS cDNA at a constant 62 °C.       
 
There are also several microfluidic devices that combined target extraction, isothermal HDA, 
and detection readout on a single platform. Mahalanabis et al. used micro-solid phase 
extraction to isolate DNA from bacteria cells for isothermal HDA at 65 °C.
76
 Using 
fluorescent reporters, real-time fluorescence readout of the HDA amplicons was achieved 
within 50 min. Zhang et al. utilised a droplet sample-to-answer microfluidic platform for the 
detection of disease biomarkers from crude biosamples.
77
 The platform made use of silica 
superparamagnetic particles and unique surface topographic features for cellular DNA 
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purification, droplet HDA and real-time fluorescence readout. The detection of promising 
ovarian cancer biomarker Rsf-1 from human whole blood samples was achieved in 160 min.    
 
 
3.3 Rolling circle amplification (RCA) 
 
 
Fig. 6 (A) Principle of RCA method. Adapted from ref. 69 with permission from Nature 
Publishing Group. (B) Schematic illustration of working mechanism for amplified single-
molecule detection by converting nanometer-scale specific molecular recognition events 
mediated by RCA to fluorescent micrometer-sized DNA molecules amenable to discrete 
optical detection. Adapted from ref. 71 with permission from Nature Publishing Group. (C) 
Principle of RPA method. Adapted from ref. 73 with permission from PLOS. (D)  Schematic 
layout of a thermoformed lab-on-a-chip cartridge for fully automated analysis of nucleic 
acids based on isothermal RPA. Adapted from ref. 75 with permission from Royal Society of 
Chemistry. 
 
RCA is an isothermal amplification technique which uses circular DNA templates to generate 
lengthy single-stranded DNA products that comprises of repeated sequences.
78
 In order to 
generate circular templates from target sequences, padlock probes bind specifically to DNA 
target sequences before being ligated, sealed and circularised. After primer hybridisation to a 
circular template, Φ29-DNA polymerase serves to extend the primer and the polymerase’s 
strand-displacing activity ensures continuous rolling amplification (Fig. 6A). 
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RCA can provide linear 10
3
-fold amplification at about 37 °C in 60 min. Although the low 
amplification temperature of RCA is attractive for integration into miniaturised platforms, it 
can also lead to non-specific amplification in addition to the need to generate circularised 
padlock probes from initial nucleic acid targets at different temperatures. The relatively low 
amplification efficiency of linear RCA can be improved by single-stranded DNA binding 
proteins addition. Another RCA modification to increase amplification efficiency to 10
9
-fold 
is through the addition of a second primer (complementary to first-round amplification 
product) for exponential hyperbranched RCA (HRCA).
79
 HRCA generally uses Bst DNA 
polymerase at 60 °C for 90 min.  
 
RCA has been integrated into many miniaturised diagnostics for detection of circular DNA 
that exist in plasmids and virus. Mahmoudian et al. reported a microchip platform which 
performed RCA in µL-level wells for the detection of V. cholerae from clinical samples.
80
 
The on-chip amplification of padlock probes occurred at 37 °C and amplicons were 
immediately detected on the same platform via micro-electrophoresis in <65 min. 
 
Single target molecule detection by miniaturised digital RCA has first been shown by Jarvius 
et al. (Fig. 6B).
81
 On this platform, nm-sized circular padlock probes are formed in target 
presence and amplified into µm-sized RCA amplicons. The amplicons are subsequently 
tagged with fluorescence probes and individually detected under a microscope for absolute 
enumeration. Multiplexed target detection is demonstrated by using different fluorescence 
probes for the detection of V. cholera and V. fisheri. Juul et al. have also shown a pL-droplet 
platform called rolling-circle enhanced enzyme activity detection (REEAD) for highly 
sensitive (< 1 parasite/µL) and non-invasive detection of all Plasmodium parasite species in 
crude patient saliva samples.
82
 This approach relies on the specific circularization of a RCA 
template by the endogenous Plasmodium enzyme topoimerase I prior to small-volume RCA.  
 
However, despite these recent developments miniaturised RCA diagnostics, there is still 
room for improvement due to a current lack of RCA-based singular platforms which 
integrates the full sample extraction to target detection readout workflow. 
 
3.4 Recombinase polymerase amplification (RPA) 
RPA is an isothermal exponential amplification technique which uses recombinase enzymes 
for strand separation, thereby removing the use of thermal cyclers (Fig. 6C).
83
 The 
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recombinase enzymes form complexes with primers to locate complementary sequences on 
targets for primer hybridisation. Similar to HDA, single-stranded DNA binding proteins are 
used to maintain opened DNA structures during extension by DNA polymerase in RPA. RT-
RPA is the modified RPA version for RNA templates by inclusion of reverse transcriptase 
enzyme to generate cDNA before amplification. RPA enables very rapid (~10-20 min) 
amplification at a constant temperature of 37-42 °C without compromising sensitivity and 
specificity, thus making it ideal for at point-of-care. Furthermore, RPA is commercially-
available (TwistDx) in the form of preserved freeze-dried pellets, making the reaction stable 
for use outside of the laboratory environment. The simplicity, robustness, and versatility of 
RPA has recently been demonstrated in the design of a cutting-edge Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR)-based NA detection platform;
84
 and used to 
detect specific viral strains, distinguish pathogenic bacteria, genotype human DNA, and 
identify circulating tumour DNA mutations with attomolar sensitivity.  
 
Lutz et al. introduced the first miniaturised on-chip RPA with pre-stored RPA reagents on the 
chip (Fig. 6D).
85
 Each chip can performed up to 30 RPA assays concurrently in individual 
microchambers (10 µL each) by on-chip centrifugal force control. The successful detection of 
the antibiotic resistant gene mecA of S. aureus is achieved with less than < 10 copies 
detection sensitivity within 20 min. This chip-based RPA platform shows that downscaling of 
RPA reagent volume is possible and further developments in target multiplexing could enable 
analysis of several targets from a single patient sample.  
 
Wee and Lau et al. have developed a miniaturised (µL-scale) tube-based RPA assays termed 
as Single Drop Genomics (SDG) in which a singular 1 µL-droplet of extracted NA sample is 
introduced into a downscaled RPA assay (12.5 µL each) for rapid (~15 min) isothermal target 
amplification. A drop of the resultant amplified products is then utilised to initiate a 
colourimetric bridging flocculation-based readout. SDG has been successfully demonstrated 
for a wide variety of pathogen and cancer biomarkers and consolidates the usual workflow of 
a centralised laboratory into a single miniaturised drop for rapid detection.
86-89
           
 
Despite the high viscosity of the RPA buffer which complicates droplet formation, RPA has 
been successfully downscaled into droplet reactions as digital RPA. Shen et al. and Tsaloglou 
et al. have demonstrated a SlipChip device that confines miniaturised nL-scale RPA reactions 
onto a single platform.
90,91
 The RPA reactions on the SlipChip offer quantitative fluorescence 
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detection of bacterial nucleic acid biomarkers down to a few hundred copies/mL in < 30 min. 
More recently, Li et al. showcased the downsizing of RPA reaction into thousands of pL-
sized wells on an array chip.
92
 Within each well, RPA of DNA targets is completed rapidly 
within 30 min. 
 
3.5 Nucleic acid sequence-based amplification (NASBA)/Transcription-mediated 
amplification (TMA)        
 
 
Fig. 7 (A) Principle of NASBA method. Adapted from ref. 84 with permission from United 
States National Academy of Sciences. (B) Schematic illustration of a single device 
architecture showing the distinct functional microfluidic modules: RNA purification and real-
time NASBA chambers. Adapted from ref. 86 with permission from Royal Society of 
Chemistry. (C) Principle of SDA method. For clarity, the initial SDA process is shown only 
in the forward direction. Adapted from ref. 90 with permission from United States National 
Academy of Sciences. (D)  Strategy to realize cleavage-based RNA amplification. Adapted 
from ref. 93 with permission from Nature Publishing Group. 
 
NASBA is an exponential amplification method which has been designed for RNA 
amplification at a constant temperature (Fig. 7A).
93,94
 In a NASBA reaction, reverse 
transcriptase firstly extends a target-bound forward primer (contains an overhang sequence 
complementary to T7 promoter) and synthesizes complementary DNA on the initial RNA 
target. Next, RNAse H degrades the initial RNA target before a reverse primer binds 
specifically to the remaining single-stranded DNA strand. Then, reverse transcriptase extends 
the reverse primer to form a double-stranded DNA template that contains both target and T7 
promoter sequences. Using the double-stranded DNA template, T7 RNA polymerase 
transcribes many RNA strands (complementary to initial RNA target) that once again become 
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templates for reverse transcriptase to form more double-stranded DNA templates. This 
continuous cycling of reverse transcription, degradation, and transcription results in 
exponential 10
9
-fold amplification in 90-120 min at 41°C. TMA has an identical working 
principle to NASBA except for the use of an enzyme with dual reverse transcriptase and 
RNase H activities. Although the amplification process of NASBA/TMA proceeds at a 
constant temperature, it is worthy to note that pre-amplification steps at different 
temperatures are required to remove secondary RNA structures. The compatibility of 
NASBA with POC NA diagnostics has been shown by Pardee et al. recently through the 
development of a programmable diagnostic platform for low-cost femtomolar detection of 
Zika virus.
95
   
 
Gulliksen et al. have shown the miniaturisation of NASBA on a microfluidic chip platform 
with real-time detection of human papillomavirus (HPV) in microchambers (Fig. 7B).
96
 The 
nL-scale reaction volume demonstrates the feasibility and performance of downscaled 
NASBA assays. To overcome the adsorption issue of NASBA reaction molecules on the 
surface of the microfluidic chip, a pre-surface treatment step is necessary.   
 
The successful integration of NASBA with sample RNA extraction and real-time detection 
readout on a single miniaturised platform was first shown by Dimov et al.
97
 In this work, 
solid-phase RNA extraction was performed on chip using silica beads and fluorescence-
tagged molecular beacons were used to quantitatively detect amplicons after NASBA in real-
time. The whole sample-to-answer process was completed within 30 minutes in µL-
chambers. Reinholt et al. also integrated target extraction and NASBA on a miniaturised 
device for the detection of C. parvum.
98
 The µL-scale NASBA reaction was completed within 
90 min at 41 °C before the NASBA amplicons were detected off-chip. More recently, Chung 
et al. showcased the integration of Norovirus RNA target extraction via microbeads, small-
volume NASBA, and fluorescence detection on a miniaturised device.
99
    
 
3.6 Strand displacement amplification (SDA) 
SDA is an isothermal exponential amplification strategy for DNA targets (Fig. 7C).
100
 The 
first step involves thermal separation of the double-stranded T1 and T2 DNA templates, 
followed by hybridisation and extension of S1 forward and S2 reverse primer pair (carrying 
an overhang restriction enzyme site sequences). During S1 and S2 extension, B1 and B2 
bumper primers (each located a few bases upstream from S1 and S2 respectively) extend 
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enzymatically at the same time. These bumper primer extensions displace S1- and S2-primer 
extended products (S1-ext and S2- ext) from T1 and T2 templates. The displaced S1-ext and 
S2-ext serve as templates for S2 and S1 primers respectively to form double-stranded 
products containing active restriction enzyme sites. The restriction enzymes then create gaps 
on these active sites, and polymerase-catalysed extensions from these gaps displace 
downstream sequences. The displaced strands then once again serve as templates for S1 and 
S2 primers, and repeated cycling of this process result in approximately 10
7
-fold exponential 
amplification in 120 min at 37 °C.     
 
There are several reports of miniaturised SDA assays for NA detection. Burns and co-
workers have successfully shown nL-volume SDA reactions and electrophoresis detection of 
resultant products on a device platform.
101
 The SDA reaction was completed within 17 min at 
50 °C. Yang et al. integrated miniaturised dielectrophoretic extraction of DNA targets from 
E. coli cells, µL-scale SDA, and fluorescence readout on a single platform.
102
  The whole 
sample-to-answer process is completed within 2.5 hours at a constant SDA temperature of 60 
°C. Zhao and co-workers created a µL-volume strategy named “cleavage-based RNA 
amplification” to simultaneously amplify and detect RNA within microtubes (Fig. 7D). The 
assay linked three SDA reactions together to achieve highly efficient signal amplification, 
and on-site detection can be realized by the DNAzyme-based colourimetric readout.
103
 A 
commercially-available SDA system (Becton Dickinson ProbeTec
TM
 ET System, USA) has 
also shown successful detection of C. trachomatis and N. gonorrhoeae in miniaturised 
microchambers.
104
 
 
More recently, Giuffrida et al. demonstrated nL-volume droplet SDA on a microfluidic 
platform for miRNA detection.
105
 The method was established to detect as little as 10
-18
 mol 
of microRNA target sequences that were compartmentalised in 20 nL droplets, and the ability 
to discriminate between full-matched, single-mismatched, and unrelated sequences was also 
investigated. Furthermore, the suitability of the method for biological samples was also tested 
by detecting microRNA-210 from transfected K562 cells. 
 
 
 
 
 
Chapter 3.1 
 
70 
 
3.7 Overview of miniaturised isothermal amplification 
 
Table 1 Overview of miniaturisable isothermal amplification techniques 
Technique Minimal 
primer 
quantity 
Reaction 
enzymes 
Customary 
amplification 
temperature 
(°C) 
Approximate 
amplification 
duration (min) 
Estimated 
size of 
amplicons 
(bp) 
Limit of 
detection 
Miniaturised 
reaction 
volume 
Refs. 
LAMP 4 DNA 
polymerase 
60-65 60 Range 
from 
hundreds 
to 
thousands 
 
 
 
5 DNA/ 
RNA 
copies 
pL 56, 
57, 62 
HDA 2 Helicase and 
DNA 
polymerase 
 
65 30-90 ≤200 
 
 
 
 
 
1 DNA/ 
RNA 
copy 
nL 
 
64, 65 
RCA 1 Ligase and 
DNA 
polymerase 
 
95 (optional 
initial heating), 
followed by 37 
60 Range 
from 
hundreds 
to 
thousands 
 
 
 
10 DNA/ 
RNA 
copies 
pL 68, 72 
RPA 2 Recombinase 
and DNA 
polymerase 
 
37-42 10-20 ≤500 1 DNA/ 
RNA 
copy 
pL 73, 82 
NASBA/ 
TMA 
2 Reverse 
transcriptase, 
RNase H, 
and RNA 
polymerase 
65/95 (initial 
heating), 
followed by 41 
90-120 ≤250 1 RNA 
copy 
nL 
 
83, 
84, 86 
SDA 2  DNA 
polymerase; 
restriction 
enzyme 
95 (initial 
heating), 
followed by 37 
120 Range 
from 
hundreds 
to 
thousands 
10 DNA/ 
RNA 
copies 
nL 90, 91 
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As reviewed in this section, there have been many works of miniaturisable isothermal NA 
amplification techniques in literature. It is anticipated that as the mechanisms of more 
biological processes are being unravelled by continuing research efforts, the field of 
isothermal NA amplification will continue its progress towards more cutting-edge techniques. 
Each reviewed technique in this section has its own working mechanism for amplification 
without thermal cycling; thus leading to differing reaction requirements (eg. primers, enzyme, 
temperature) and product size (Table 1). Hence, an isothermal amplification technique if 
suitable characteristics can be employed in accordance with different designs and 
applications of a diagnostics test. The compatibility of these reviewed techniques with 
downsized reaction volumes, as generally demonstrated on LOC platforms, may similarly be 
utilised in miniaturised LID diagnostics. Yet, it is worthwhile to note the lack of integrated 
systems as sample preparation is commonly being performed independently of the isothermal 
amplification platform. Therefore, it would be helpful to focus future investigations on more 
successful integrations of miniaturised sample preparation methodologies with isothermal 
target amplification. On the other hand, integrated detection readout of amplification products 
on the same platform has been routinely shown over past years. The next section will review 
these different miniaturised detection readouts.         
 
4 MICROSCALED DETECTION READOUT  
The design of a miniaturised readout system that could detect biomarker targets in a simple, 
effective and rapid way is essential towards designing POC personalised diagnostics. In line 
with the discussion on advancements in miniaturised sample preparation and isothermal 
amplification earlier in this review; compatible readout strategies become increasingly 
important as the final step to an integrated personalised diagnostics platform with high 
sensitivity, specificity, user-friendliness and cost-effectiveness. Over past years, various 
innovative detection readout systems have been reported for miniaturised LOC platforms, and 
this section will summarise these advances with a targeted focus on relevant detection 
technologies for solution-based LID platforms.         
 
4.1 Microfluidics platforms 
A couple of decades ago, lateral flow devices were first developed as simple and low-cost 
bioassays for use in POC settings. The principle of such devices is generally based on the 
specific capture of amplified NA targets by surface-functionalised probes for a simplistic 
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visual readout.
106,107
 The biggest limitation of lateral flow devices is the lack of multiplexing 
as it is difficult to analyse more than one target concurrently. To resolve this issue, a 
microfluidic approach is thus developed to offer advantages in (i) high-throughput parallel 
detection, (ii) small sample volume manipulation, (iii) portability; and (iv) high capacity 
workflow integration. These benefits offered by the combination of microfluidics and lateral 
flow assays are very attractive for personalised diagnostics.
12
 One recent example of such an 
assay is the development of a microfluidic single-molecule spectroscopy technique which 
allows one-step analysis and quantification of circulating DNA in serum volumes smaller 
than 1 pL without additional DNA isolation or enzymatic amplification steps.
108
 Several 
paper-based microfluidic approaches have also been shown to enable the simultaneous 
parallel detection of multiple analytes
109-111
 on a low-cost platform. As such paper 
microfluidic approaches are generally designed for POC testing in resource-poor settings, 
their quantitative performance might not be suited for accurate biomarker analysis within a 
clinical setting. Therefore, this has led to the emergence of more sophisticated microfluidic 
LOC devices for integrated NA biosensing. To date, both fluorescence and electrochemical-
based detection readout have been integrated with microfluidic devices to provide a sample-
to-answer format on a single platform.  
 
Traditionally, the fluorescence-based readout has been commonly-employed for NA 
detection due to its high level of sensitivity and low background noise.
112,113
 Successful 
examples include the commercially-available GeneXpert platform (Cepheid) which integrates 
sample processing and PCR in a disposable plastic microfluidics cartridge which contains 
reagents for cell lysis, nucleic acid extraction, amplification and fluorescent amplicon 
detection. The DxN VERIS MDx system (Beckman Coulter) also uses a cartridge system for 
automated magnetic bead-based sample preparation, followed by PCR of NA targets with 
real-time fluorescence readout.
114
 Another commercial example is the cobas® Liat® PCR 
System (Roche) which utilises uniquely-engineered assay tubes for miniaturised POC “lab-
in-a-tube” NA testing. This automated system is able to perform multiplexed NA biomarker 
detection with quantitative fluorescence readout, and consolidates single platform (samples 
preparation and qPCR) within 20 min.
115
 Despite these commercialised state-of-the-art 
technologies, there are still existing limitations (such as ionisation hazards of GeneXpert 
platform due to sonication; bulky and costly equipment of DxN VERIS MDx system) to be 
resolved in order to deploy these technologies for optimal use in POC diagnostics. The 
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miniaturisation of fluorescence readout systems may aid in increasing the portability and 
affordability of such technologies for ideal POC diagnostics.  
 
In the direction of miniaturised fluorescent NA detection readouts, there have been recent 
advancements in smartphone optical systems
116,117
 and portable fluorometers. The adaptation 
of smartphones into handheld fluorescence detectors offers the advantage of NA analysis on a 
widely-available platform in POC settings. Likewise, the Twista® (TwistDx) portable 
fluorometer has been shown by Teoh and co-workers for convenient and low-cost detection 
of dengue virus RNA with comparable outcomes to conventional laboratory qPCR technique. 
The good detection sensitivity of such portable fluorometers is useful for high-throughput 
small-volume assays for parallel detection of multiple NA targets, such as the miRPA 
developed by Wee and Trau.
118
 Additionally, Koo et al. have developed a simple and rapid 
gene fusion strategy which exploits the specificity of DNA ligase and the speed of isothermal 
amplification to simultaneously detect multiple fusion gene RNAs within a short sample-to-
answer time frame of 60 min by using real-time fluorescent detection.
119
 These techniques are 
all suitable for downscaled NA target detection on miniaturised fluorescence readout systems.  
 
 
Fig. 8 Droplet platform that incorporates sample extraction, washing, cell lysis and RT-PCR 
into a free-standing droplet into a flexible virtual laboratory with (sub)microliter volumes. 
Adapted from ref. 111 with permission from John Wiley & Sons. 
 
The increased miniaturisation of fluorescence NA detection has been further enabled by the 
advent of droplet microfluidics. Droplet microfluidics is a recently-developed powerful NA 
assay which integrates sample preparation and genetic analysis within discrete droplets; 
including steps of cell lysis, DNA binding, washing, elution, amplification and detection (Fig. 
8). As all reagents are stored in droplets, it eliminates the need for fluidic coupling to external 
reagent reservoirs.
77,120,121
 The successful demonstration of droplet microfluidics also serves 
to highlight the feasibility of LID systems which similarly aim to achieve miniaturised 
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bioassays within small-volume fluid droplets. Integrated droplet NA assays have also allowed 
precise digital analysis of NA biomarker copy number but multiplexed target detection has so 
far been limited; largely due to the long-standing issue of multiple fluorescent spectral 
overlapping, and the challenging analysis of so many different droplets (i.e. fluidic bodies) 
within the solution. Hence, a LID platform such as the SDG assay, which integrates and 
miniaturises traditional biosensing into a singular droplet to maintain a single fluidic body 
(without need for droplet partitioning of a single reaction), might be more suited for high-
throughput multiple biomarker analysis. 
 
Electrochemical-based microfluidics have also displayed immense potential for POC 
personalised diagnostics due to its compatibility with low-cost, portable, and miniaturised 
analysis.
122-124
 Particularly, the development of nanostructured electrodes has made the 
electrochemical platform more powerful for ultrasensitive NA detection. As reported, chip-
based nanostructured microelectrodes (NMEs) have been developed with a low 10 aM 
detection limit.
57,125-128
 Ölcer et al. developed a microfluidics- and nanoparticle-based 
amperometric biochip for cyanobacteria NA detection and all steps of the assay were 
performed during the reagent flow for  fast and sensitive DNA detection.
129 Electrode 
miniaturisation is a significant step towards integration of electrochemical detection with 
complementary upstream biosensing processes for personalised diagnostics.   
 
Miniaturised electrochemical detection has also been incorporated with on-chip isothermal 
NA amplification such as LAMP to detect S. typhimurium with a detection limit of 16 copies 
of genomic DNA.
130
 To this end, Ng et al. recently demonstrated a portable electrochemical 
biosensor platform by combining with isothermal RPA of DNA targets, gold nanoparticles, 
and screen-printed electrodes for sensitive and rapid detection of M. tuberculosis DNA.
88,131
 
The downscaled electrochemical analysis enabled an overall sample-to-answer timeframe of 
90 min with a cost of under USD 10 for each test. The introduction of mass-produced screen-
printed electrodes in electrochemical biosensing has led to new possibilities in miniaturised 
POC personalised diagnostics.
132
 Explicitly, the electrochemical detection of NA targets
133,134
 
on inexpensive and disposable screen-printed electrodes could allow for rapid and cost-
effective screening of multiple NA biomarkers in the clinic.  Moreover, screen-printed 
electrodes are also readily suitable for existing POC instruments, such as personal 
glucometers. There are recent reports which exploit commercially-available glucometers for 
pM-level NA biosensing.
135,136
 Typically, the DNA targets are first bound to magnetic beads 
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via covalently-attached capture strands, followed by the binding of secondary invertase-
conjugated DNA strands to form a sandwich assay. Then, invertase enzymatically catalyzed 
the hydrolysis of sucrose to glucose and fructose, which can be subsequently detected using 
screen-printed electrodes on a personal glucometer. However, such methods have yet to 
undergo clinical evaluation, and future clinical trials with a relevant disease model will be 
useful to test the feasibility for widespread POC usage.   
 
There are excellent reviews on microscaled detection readouts that have been successfully 
coupled to microfluidics devices for potential POC diagnostics use.
137,138
 Yet, widespread use 
of these devices is largely limited by high device manufacturing cost and reproducibility 
difficulties at massive production levels. Thus, there is a need for the development of 
alternative miniaturised technologies, such as LID systems, that could overcome these 
challenges.  
 
4.2 Miniaturised lab-in-a drop (LID)-compatible readouts 
In this section, with a targeted focus on LID systems, we will summarise and overview 
miniaturised readouts approaches that are appropriate for solution-based LID personalized 
diagnostics. Specifically, we will highlight colourimetric as well as surface-enhanced Raman 
spectroscopy (SERS) readouts which are suitable for visual and multiplexed NA biomarker 
detection respectively.  
 
4.2.1 Visual colourimetric readout  
Colourimetric detection is a very appealing for POC diagnostics development as it does not 
require the use of expensive and complex sensing equipment. One typical and widely-used 
colourimetric approach is based on enzymatic catalysis of substrate oxidation, such as 
horseradish peroxidase (HRP) for 3,3',5,5'-Tetramethylbenzidine (TMB).
87,139,140
 By 
combining isothermal NA amplification with colourimetric approaches, a quick turnaround 
time (including sample preparation) could be achieved. For instance, Koo and co-workers 
recently report a novel rapid (75 min), cost-efficient and minimal-equipment assay named 
“FusBLU”. The microtube-based FusBLU assay coupled isothermal target amplification with 
a HRP-based colourimetric readout to detect a prostate cancer fusion gene RNA 
biomarker.
139
 Despite the convenient and rapid nature of enzyme-catalysed colourimetric 
readouts, poor enzyme stability by denaturation, and costly enzyme purification are limiting 
factors for POC usage.
141 Perhaps ongoing research into mass engineering and production of 
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stable enzymes or enzyme storage strategies may enable the convenient use of enzyme-based 
colourimetric assays outside of research settings in the future.  
 
 
Fig. 9 (A) Colourimetric assay that uses gold nanoparticles aggregation for DNA sensing. 
Adapted from ref. 132 with permission from Elsevier. (B) A combination of rolling circle 
amplification and nicking endonuclease-assisted nanoparticle amplification for rapid, 
colourimetric detection of DNA.  Adapted from ref. 135 with permission from John Wiley & 
Sons. 
 
Mirkin and colleagues pioneered the use of gold nanoparticles (AuNPs) for hybridisation-
based DNA colourimetric detection (Fig. 9A).
142-144
 In presence of DNA targets, covalently-
bound probes on AuNPs are cross-linked through hybridisation at each end of their DNA 
targets, thus produce cross-linked AuNPs aggregates to result in a reaction mixture colour 
change from red to blue. Recently, Xu et al. have further enhanced the AuNPs-based 
colourimetric approach for ultrasensitive DNA detection (1 pM) by combination with 
isothermal RCA of DNA targets (Fig. 9B).
145
 To date, the challenges for using AuNPs-based 
assays in clinical diagnostics include low AuNPs stability and need for specialised AuNPs 
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preparation. The design of alternative nanomaterials and synthesis process could resolve 
these shortcomings and further the use of nanoparticle-based colourmetric detection.  
 
 
Fig. 10 Single Drop Genomics assay that uses bridging flocculation of magnetic particles for 
rapid nucleic acid target detection. Adapted from ref. 76 with permission from Royal Society 
of Chemistry. 
 
Recently, Trau and colleagues have developed the SDG assay, a novel bridging flocculation-
based colourimetric approach for qualitative evaluation of isothermally amplified NA targets 
(Fig. 10).
86
 A key unique feature of the bridging flocculation mechanism (previously used in 
water purification for decades),
146
, is that the NA flocculation event is entirely sequence-
independent and only relies on the presence/absence of amplicons (i.e. biomarker target). 
Hence, this renders SDG as an exceedingly simple and convenient way of detecting amplified 
targets with minimal conventional equipment. Wee and Lau et al. have demonstrated SDG on 
an isothermal RPA to generate double-stranded amplicons from plant pathogen targets, which 
in turn, induces flocculation of SPRI magnetic beads for simple naked-eye readout. In 
accordance to an ideal LID system, the entire SDG workflow is miniaturised for performance 
within microdroplets. The pivotal benefit of SDG is its simplistic and elegant detection of NA 
biomarkers, coupled with straightforward visual yes/no detection evaluation. The versatile 
nature of SDG has been shown for detection of a broad range of disease biomarkers including 
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DNA methylation
87
; M . tuberculosis DNA;
88
 cancer gene fusion RNA;
89
 as well as different 
pathogenic NA biomarkers across the plant and animal kingdom.
86
 Thus, SDG shows great 
potential for further advancements into a true POC personalised LID diagnostics; enabling 
rapid, sensitive, and relatively inexpensive colourimetric NA biomarker detection in a 
resource-limited area. Yet, SDG is not yet a finished product with several areas for further 
improvement. Section 5 of this review will provide a detailed discussion of the required 
future advancements for SDG to realise an ideal LID platform.    
 
4.2.2 Multiplexed surface-enhanced Raman spectroscopy (SERS) readout  
The high demand for comprehensive POC disease diagnosis call for a miniaturised “one-pot” 
multiplexed assay that can simultaneously detect and readout multiple biomarkers.
147,148
 
Whilst colourimetric detection is an ideal diagnostics approach for qualitative yes/no readout 
(for a single biomarker), rapid and quantitative multiplexed biomarker detection is highly 
desired in diseases which require screening of a biomarker panel. Fluorescence-based 
detection is most commonly associated with multiplexed NA detection, and generally 
accomplished by hybridising each NA target with a different fluorescent dye molecule. Even 
though being largely reliable and effective, multiplexed fluorescence detection is constrained 
by its broad emission spectral peaks. This makes the interpretation of multiple overlapping 
spectral peaks (i.e. multiple biomarkers) a difficult task. Hence, surface-enhanced Raman 
spectroscopy (SERS), with its narrow and well-defined spectral peaks, could be an attractive 
option for multiplexed biomarker detection in personalised diagnostics applications.      
 
SERS is an optical technique that utilises nanostructured metallic surfaces to enhance the 
Raman scattering of surface-adsorbed analytes.
149,150
 SERS has enabled the detection of 
various disease biomarkers with extremely low limit-of-detection, and even down to single 
molecule detection.
151,152
 SERS provides several notable benefits for “one-pot” multiplexed  
NA biomarker sensing, including: (i) the widths of Raman spectra are 10-100 times narrower 
than those of fluorescence, thus making it more suitable for extensive multiplexing; (ii) 
sensitivity with only one single laser excitation; and (iii) photostability to ensure signal 
reproducibility.  
 
SERS has been utilised in various miniaturised multiplexed NA detection platforms involving 
designed nanostructures. Cao et al. have reported the use of microchip for DNA detection 
with a sandwich format by SERS, which was possible to detect six different target DNA 
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sequences.
153
 Irudayaraj et al further developed the multiplexed assay by using the non-
fluorescent Raman reporter molecules which were directly conjugated on the surface of the 
AuNPs. A low fmol-level detection limit was achieved to monitor gene expression in cancer 
cell lines.
154,155
 These platforms are spatial multiplexed approaches, which involve the 
physical separation of each NA target onto different spots on the microchip. The rationale for 
this spatial approach is to minimise nonspecific binding for rapid SERS scanning of 
individual spot. By using a solution-based LID detection platform, the spatial separation of 
targets can be avoided by “one-pot” SERS detection of a small-volume target mixture,156-158 
thus enabling quicker analysis of multiple targets.  
 
 
Fig. 11 “One-pot” surface-enhanced Raman scattering platform for simultaneous five-plexed 
detection of prostate cancer RNA biomarkers within 80 min. Adapted from ref. 147 with 
permission from John Wiley & Sons. 
 
To enhance detection sensitivity, SERS detection readout can be augmented with a prior PCR 
amplification step to increase NA target copies.
156,159,160
 As reviewed earlier, isothermal 
amplification techniques are attractive for designing POC diagnostics. In order to achieve 
multiplexed SERS NA biomarker detection for POC use, it will be ideal to integrate sample 
preparation and isothermal amplification protocols prior to “one-pot” SERS readout. To 
realise this aim, our research group has designed a sensor platform based on isothermal RPA 
and SERS detection readout. Lau et al. recently demonstrated an integrated one-tube assay 
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(combining sample preparation, target amplification, and detection readout) for simultaneous 
on-site (outside of a laboratory setting) detection of three different plant pathogen DNA 
within a 40 min sample-to-answer timeframe.
158
 For future POC personalised diagnostics, 
this miniaturised and integrated biosensing assay is currently being adapted for human 
clinical samples such as blood or urine.  Additionally, the multiplexing capability of the RPA 
and SERS combination has been further investigated. Koo et al. have presented a five-plexed 
molecular subtyping assay for simultaneously detection of prostate cancer RNA biomarkers 
using multiplexed isothermal RPA prior to SERS readout of the different target amplicons 
(Fig. 11).
157
 This work  shows distinct advantages for personalised diagnostics development, 
including (i) rapid detection owing to the isothermal RT-RPA with “one-pot” SERS readout; 
(ii) easy interpretation of detection outcomes from well-resolved SERS spectral peaks 
without the need for further data processing; (iii) applicable to NA targets in clinical samples 
such as tissue biopsy specimens and urine samples. As with SDG, this RPA and SERS 
combination strategy has been performed in small-volume reactions, making it amenable for 
future development into a LID personalised diagnostics platform for multiplexed NA 
biomarker screening. Despite the suitability of SERS for multiplexed biomarker detection in 
LID systems, the design of SERS-associated readout equipment and labels are not applicable 
for POC usage so far. Section 5 of this review will discuss these factors in detail and how 
current research directions enable SERS for LID personalised diagnostics.    
 
5 TOWARDS TRUE LAB-IN-A-DROP (LID) SYSTEMS 
To meet the urgent need for POC personalised diagnostics, LID systems could harness 
similar advantages of rapid and miniaturised NA detection as offered by LOC platforms. 
Additionally, the main conceived benefit of LID systems is the downscaled integration of an 
entire diagnostics workflow into a droplet within a microtube and thus avoiding the need for 
costly precise device engineering. Although the fabrication of  paper-based microfluidics or 
even   more complex (such as the SlipChip)
161
 LOC platforms are becoming relatively 
simpler as compared to the past, it is inevitable that specialised skills and considerable costs 
are still required. LID could address these issues by miniaturising biosensing for 
compatibility with a mass-produced standard microtube format, without any form of 
fabrication. The ideal LID system would combine and integrate the 3 main aspects of NA 
diagnostics as reviewed in previous sections: sample preparation, target amplification and 
detection readout. In this section, we will discuss and offer insights on how to advance (with 
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the SDG assay highlighted in section 4.2.1 as an example) towards a truly integrated LID 
system for POC use.  
 
The SDG assay which currently utilizes a magnetic beads flocculation mechanism to produce 
a colourimetric change in presence of NA target. SDG has shown potential for development 
into simple, rapid and affordable LID diagnostics for use in homes by personnel with 
minimal training. In its present form, SDG has incorporated miniaturised isothermal RPA and 
flocculation-based colourimetric readout into droplet-sized reactions in a microtube for 
clinical sample testing. However, SDG is lacking a compatible upstream sample preparation 
workflow which could be downscaled and seamlessly integrated. A miniaturised microtube-
based SPE technique could be a feasible sample preparation methodology for SDG. SPRI 
beads could be used for isolating NA from clinical samples before transferring a droplet of 
the extracted NA for isothermal amplification and subsequent naked-eye detection. Another 
plausible way is to functionalize the inner surface of the microtube with probes for NA 
targets capture from clinical samples and then performed a downscaled RPA and detection 
readout on the captured targets within the same microtube.
162
 Additionally, an ideal 
miniaturised sample preparation technique for SDG should be capable of shortening the 
current total assay time, and simplistic enough for self-testing by non-trained personnel. 
 
Whilst the qualitative colourimetric readout of SDG is suited for providing a quick POC 
yes/no readout for a single NA target, it may not be suitable for immediate quantification of 
disease biomarker levels that are of interest to clinicians in hospitals. In this case, a 
quantitative readout could be achieved by changing the detection of RPA-amplified targets to 
an alternative colour change readout which could be measured spectrometrically or 
electrochemically from minimal liquid volume by trained personnel. Moreover, simultaneous 
quantitative analysis of several biomarkers from minuscule sample input via multiplexed 
SERS is also a viable alternative readout for SDG. At present, the biggest limitation of SERS 
for POC diagnostics is the high cost of portable/handheld Raman spectrometers. It is 
anticipated that the situation would change with the advancements in optical instruments 
miniaturisation into portable systems or mobile phone platforms. Additionally, the bulk 
synthesis of SERS labels with minimal batch variation and maximal stability is still 
challenging, and research in large-scale production of SERS labels for reproducible usage is 
highly desired. We anticipate that SDG could be coupled with such developments for 
quantitative and multiplexed NA biosensing at the POC. 
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Hence, with further improvements by integrated miniaturised sample preparation and 
superior quantitative multiplexed readout, we envision that SDG has significant potential for 
evolving into a complete LID personalised diagnostics system with extensive applications.  
 
6 SUMMARY AND PERSPECTIVES 
In summary, we have reviewed the three essential aspects of miniaturised biosensing, 
namely: downscaled sample preparation, miniaturised isothermal amplification, and 
microscaled detection readout. Additionally, we put forward the concept of a “lab-in-a-drop 
(LID)” detection platform, which integrates the three above-mentioned fundamental 
biosensing aspects within a miniaturised fluid droplet to achieve simple and rapid 
personalised diagnostics at POC.  
 
We evaluated several different sample preparation methods using phenol:chloroform, SPE, 
and direct sampling. SPE is currently considered to be a suitable sample preparation 
technique for miniaturised diagnostics due to its simplicity, low cost of operation, and lack of 
hazardous waste. However, direct sampling from biological samples without any prior lysis 
and extraction would be most ideal and advancements in this area would be significant 
progress towards the translation of LID/LOC technologies for clinical use.  
 
To detect trace amounts of NA targets from biological samples, a target amplification 
strategy is required to enhance the resultant readout signal to a detectable level. An 
isothermal amplification technique is extremely compatible for POC personalised diagnostics 
without the need for conventional PCR thermal cycling. We appraised several isothermal 
amplification methods which are compatible for use in miniaturised diagnostics. Each 
different method carries its own unique benefits and disadvantages; and the choice of which 
for use in LID/LOC platforms would be dependent on assay features assay such as nature of 
biomarker targets (i.e. DNA or RNA), required length of resultant amplicons, or 
amplification time.  
 
As for types of detection readouts, we underlined various miniaturised fluorescence and 
electrochemical readouts which have been successfully demonstrated on microfluidic LOC 
systems. With a focus on the development of LID systems, we also provided a more in-depth 
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review of colourimetric and SERS readouts which are compatible for providing rapid yes/no 
outcome of biomarker presence or measurements of several different biomarker targets from 
a single tube respectively. 
 
Overall, we believe that the numerous recent displays of LID system innovations; which have 
now allow the possibility of integrating traditionally laboratory-based NA analysis 
procedures (preparation, amplification, detection) into a miniaturised fluid droplet, is 
currently resulting in a suite of highly-disruptive POC diagnostics technologies.  LID systems 
could thus play a significantly useful role in personalised disease diagnosis. In this new era of 
precision medicine, rapid and affordable personalised diagnosis could pave the way for early 
detection and regular monitoring of disease for individual patients, thus allowing timely and 
highly-effective medical interventions. Through miniaturisation of typical NA detection 
assays into an integrated microtube-based platform, LID systems may allow for simple, 
convenient, and inexpensive NA biomarker detection. In essence, a LID assay could be 
employed for POC use in the clinic for quick clinical diagnoses; in homes for frequent 
individualised testing; or out in the field for community healthcare.       
 
There still exist several hurdles towards the realisation of a LID system which could be 
performed at POC for personalised disease diagnosis. The main challenge is the integration of 
a suitable sample preparation technique into the current format of LID system (i.e. SDG 
assay). We envisage that increasing research effort into rapid and simple techniques for 
isolating NA from crude biological samples could resolve this conundrum in the near future. 
Another issue is the realisation of a detection readout which could be performed at POC to 
quantitatively analyse several NA biomarkers at the same time. We identify impending 
improvements to portable SERS instruments to be a possible answer to this problem.      
 
Nonetheless, miniaturised biosensors are highly promising for the next generation of 
personalised diagnostics, and we anticipate that further research into the development of LID 
systems could play a role in the translation of personalised diagnostics into commercial use. 
Lastly, we hope that this review will provide readers with the crucial role of personalised 
diagnostics in this new era of precision disease diagnosis and treatment, as well as pique 
interest in the concept and potential of miniaturised LID systems.   
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A Simple, Rapid, Low-Cost Technique for Naked-Eye Detection 
of Urine-Isolated TMPRSS2:ERG Gene Fusion RNA 
 
Kevin M. Koo, Eugene J. H. Wee, Paul N. Mainwaring, Matt Trau
 
 
 
ABSTRACT  
The TMPRSS2:ERG gene fusion is one of a series of highly promising prostate cancer (PCa) 
biomarker alternatives to the controversial serum PSA. Current methods for detecting 
TMPRSS2:ERG are limited in terms of long processing time, high cost and the need for 
specialized equipment. Thus, there is an unmet need for less complex, faster, and cheaper 
methods to enable gene fusion detection in the clinic. We describe herein a simple, rapid and 
inexpensive assay which combines robust isothermal amplification technique with a novel 
visualization method for evaluating urinary TMPRSS2:ERG status at less than USD 5 and 
with minimal equipment. The assay is sensitive, and rapidly detects as low as 10
5 
copies of 
TMPRSS2:ERG transcripts while maintaining high levels of specificity.  
 
INTRODUCTION 
Current prostate cancer (PCa) screening relies mainly on measuring serum prostate-specific 
antigen (PSA) levels which has clearly demonstrated improvements in patient survival
163-165
. 
Although PSA screening has been utilized widely for several decades, its value as a 
biomarker is controversial due to its poor sensitivity and specificity. As a consequence, this 
has frequently led to over diagnosis and unnecessary medical expenses
163,166,167
. Therefore, 
this has encouraged researchers to develop a new generation of more accurate PCa screening 
biomarkers. In 2005, the gene fusion between transmembrane protease, serine 2 (TMPRSS2) 
and v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) was reported as a 
recurring event in PCa
4
. Further studies have confirmed TMPRSS2:ERG to be a highly-
specific PCa biomarker that is present in at least 50% of PCa cases
168
 and is associated with 
PCa progression through inducing androgen-regulated ERG overexpression as well as 
partnering with other oncogenic events such as PTEN loss
169
. The prognostic potential of the 
TMPRSS2:ERG biomarker has been demonstrated in several studies in which 
TMPRSS2:ERG presence was associated with more aggressive forms of PCa and poorer 
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clinical prognosis (higher PSA level, Gleason score and/or tumour stage)
6,170
. Additionally, 
TMPRSS2:ERG transcripts are also detectable in urine as a potential non-invasive and 
convenient biomarker for early PCa-detection. Most importantly, TMPRSS2:ERG is a binary 
biomarker which is commonly associated with premalignant PCa but not benign conditions, 
thus making it the most specific PCa biomarker to date
171
. For treatment purposes, recent 
studies have shown TMPRSS2:ERG to be a potential drug target for impeding tumor growth 
and metastasis
172,173
. Therefore, the detection of TMPRSS2:ERG presents as an unique 
opportunity for developing novel binary (positive/negative) strategies for PCa screening or 
treatment. 
 
Reverse transcription-polymerase chain reaction (RT-PCR), and fluorescence in situ 
hybridization (FISH) are the most commonly-used techniques for TMPRSS2:ERG detection 
in clinical PCa specimens. While FISH assays are useful for detecting gene fusions on both 
DNA and RNA in tissue cells
174
, they have limited sensitivity due to high background 
fluorescence. As a consequence, FISH may be unsuitable for detecting trace amounts of 
TMPRSS2:ERG transcripts in clinical samples such as urine specimens. In contrast, RT-PCR 
is a sensitive assay which is routinely used in many studies for detecting low levels of 
TMPRSS2:ERG transcripts in PCa urine specimens
9,147,175
. However, PCR techniques are 
constrained to laboratory settings by the high number of thermal cycles needed to detect low 
TMPRSS2:ERG levels (typically requiring ≥120 min); need for highly trained personnel; and 
required specialized equipment. Recently, an isothermal transcription-mediated amplification 
(TMA)-based assay
176
 was developed to resolve issues faced by RT-PCR methods but the 
chemiluminescence readout of this assay still has limitations such as high reagent cost, 
prolonged experimental procedures as well as the need for specialized instrumentation. 
Hence, it is still of interest to the community to develop a rapid yet inexpensive novel point-
of-care assay to address the shortcomings of current methodologies for routine 
TMPRSS2:ERG screening.  
 
Colorimetric assays based on gold nanoparticles aggregation have been developed for 
sensitive and rapid detection of polynucleotide sequences
177
. However, the subtle colour 
changes of these assays frequently require the use of spectrophotometry for readout. 
Therefore, an opportunity presents itself to enable easier visual detection by naked-eye 
interpretation; and one such possibility could be polymer (eg. DNA)-mediated flocculation 
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assays
86,88,178
 which typically possess a binary threshold for flocculation output and 
interpretation
179-181
. This sort of binary evaluation system would also complement the binary 
nature of the TMPRSS2:ERG biomarker. 
 
Herein, we present a novel TMPRSS2:ERG detection technique by combining a robust 
isothermal amplification method with a flocculation-based visual readout. The assay is a 
relatively simple, rapid, and inexpensive methodology for evaluating urinary TMPRSS2:ERG 
status with good sensitivity and specificity. 
 
MATERIALS 
RNA extraction from cell lines 
The cell lines DuCap and LnCap were generously donated by Matthias Nees (VTT, Finland); 
Gregor Tevz (APCRC, Australia); and Michelle Hill (UQDI, Australia). The cells were 
cultured in RPMI-1640 growth media (Life Technologies, Australia) supplemented with 10% 
fetal bovine serum (Life Technologies, Australia) in a humidified incubator containing 5% 
CO2 at 37 ºC. RNA was extracted using Trizol reagent (Life Technologies, Australia) and 
RNA integrity and purity were checked using a NanoDrop Spectrophotometer (Thermo 
Scientific, USA). 
 
RNA extraction from clinical urinary specimens 
Ethics approval was obtained from The University of Queensland Institutional Human 
Research Ethics Committee (Approval No. 2004000047). Methods pertaining to clinical 
samples were carried out in accordance with approved guidelines and informed consent was 
obtained from all subjects prior to sample collection.  
 
Voided urine specimens were collected from 10 men undergoing treatment for CRPCa and 5 
healthy men with no clinical history of PCa. Urine specimens (30–50 ml) were centrifuged at 
700 g for 10 min and urinary sediments were washed with ice-cold PBS buffer before being 
centrifuged again at the same conditions. 25 µl of lysis buffer (150 mM Tris-HCI pH 8.0, 4.5 
M guanidium-HCI, 3% v/v Triton-X and 1.5 mM EDTA) was added to 50 µl of PBS-
suspended urinary sediments with vigorous mixing to release total RNA. Next, total RNA 
was purifed from 25 µl of cell lysate using the Agencourt AMPure XP kit (Beckman Coulter, 
USA). Briefly, two volumes SPRI reagent was first incubated with the cell lysate for 10 
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minutes. The RNA-bound magnetic beads were then separated from the lysate using a magnet 
and washed once with 100% isopropanol and twice more with 80% ethanol. Finally, total 
RNA was eluted in 25 µl of RNase-free water. 
 
cDNA synthesis and nucleic acid amplification 
For cell line experiments, the TwistAmp Basic RPA kit (Twist-DX, UK) was used with slight 
modifications to manufacturer’s instructions. Briefly, 1 µl of extracted RNA, 50 units of 
MMuLV reverse transcriptase (New England Biolabs, UK) and 500 nM of each primer 
(Table 1) were added to make a 12.5 µl reaction volume prior to incubation at 39°C for 20 
min. For all other experiments, the TwistAmp Basic RT-RPA kit (Twist-DX, UK) was used 
with slight modifications to manufacturer’s instructions to simultaneously generate cDNA 
and rapidly amplify the cDNA templates in a single tube reaction. Briefly, 2 µl of extracted 
RNA and 500 nM of each primer (Table 1) were added to make a 12.5 µl reaction volume 
prior to incubation at 41°C for 30 min. 
 
Table 1 Oligonucleotide sequences 
Oligonucletotides Sequence (5’ to 3’) 
RT-RPA Forward, RT-PCR Forward CCTGGAGCGCGGCAGGAAGCCTTATCAGTTG 
RT-RPA Reverse GCTAGGGTTACATTCCATTTTGATGGTGAC 
RT-PCR Reverse TCCTGCTGAGGGACGCGTGGGCTCATCTTG 
Oligonucleotides were purchased from Integrated DNA Technologies, USA 
 
Bridging flocculation colorimetric readout   
RPA amplicons was similarly purified using SPRI as previously described but with only one 
ethanol wash step. After purification, 5 µl of purified RPA amplicons was incubated with 2 
volumes of SPRI magnetic beads for 5 min before bead separation by magnet. Then, 20 µL of 
flocculation buffer (200 mM sodium acetate, pH 4.4) was added to the beads. After 1 min of 
incubation, the mixture was gently agitated using a magnet and observed for colour change.   
 
RT-PCR 
RT-PCR was performed on extracted total RNA from clinical urine specimens to validate 
results from our assay. The KAPA SYBR FAST One-Step qRT-PCR kit (KAPA 
BIOSYSTEMS, USA) was used to set up a single reaction volume of 10 µl for each sample. 
Each reaction volume consist of 1X KAPA SYBR FAST qPCR Master Mix, 200 nM of each 
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primer (Table 1), 1X KAPA RT Mix and 3 µl of extracted RNA. The tubes were incubated at 
42°C for 10 min to synthesize cDNA, followed by 95°C for 5 min to deactivate RT before 
cycling 35 times (95°C for 30 s, 70°C for 30 s and 72°C for 1 min) and finished with 72°C 
for 10 min. Lastly, the RT-PCR products were visualized on 1.5% agarose gel to verify 
amplification. 
 
RESULTS 
Assay principle 
Figure 1 depicts the working principle of our assay. This assay first employed magnetic beads 
to isolate and purify total RNA from urinary sediments by the Solid Phase Reversible 
Immobilization (SPRI) technique
182
. Next, isothermal reverse transcriptase-recombinase 
polymerase amplification
83
 (RT-RPA) was utilized to rapidly amplify TMPRSS2:ERG 
transcripts within 30 min. Lastly, amplified DNA (i.e. positive for TMPRSS2:ERG) were 
detected using a DNA-mediated bridging flocculation phenomenon whereby only amplicons 
of sufficient length (i.e., ≥200 bp)88 and amounts could initiate flocculation of magnetic beads 
to maintain a colourless solution. 
 
 
Figure 1. Schematic representation of rapid and simple assay for TMPRSS2:ERG gene 
fusion detection in prostate cancer urine specimens. Total RNA which potentially include 
TMPRSS2:ERG transcripts is first isolated from the urine specimen of a screening candidate. 
Isothermal reverse transcriptase-recombinase polymerase amplification is used to generate 
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cDNA amplicons exclusively in the presence of TMPRSS2:ERG fusion transcripts. This is 
followed by adding SPRI magnetic beads to spontaneously bind post-amplification 
sequences. Successful amplicons (i.e. TMPRSS2:ERG-positive) induces bridging 
flocculation of magnetic beads to produce a colourless solution. Specimens without 
TMPRSS2:ERG transcripts result in no amplification and beads bound with only primer 
sequences are of insufficient length to mediate flocculation, thereby producing a brown-
coloured solution indicative of a negative TMPRSS2:ERG reading. 
 
Assay specificity for TMPRSS2:ERG 
As a proof-of-concept, we applied our method to detect the most common TMPRSS2:ERG 
fusion transcript (TMPRSS2 exon1 to ERG exon 4) in cultured DuCap (TMPRSS2:ERG-
positive) and LnCap (TMPRSS2:ERG-negative) human PCa cells
4
. The RT-RPA primers 
spanned the fusion junction of TMPRSS2 and ERG (Fig. 1), thus reducing the likelihood of 
amplifying wild type transcripts. As expected, DuCap cells were tested positive (colourless) 
for TMPRSS2:ERG while LnCap were negative (brown-coloured)  (Fig. 2A). The RPA 
products were verified by agarose gel electrophoresis which only showed a 216 bp product 
band for the DuCap cell line but not for the LnCap cell line. When cell line RNA (NoT 
control) and reverse transcriptase (no RT control) were omitted from the RPA reaction, no 
products were detected to affirm that products were TMPRSS2:ERG RNA-dependent. To 
control for RNA loading,  the housekeeping transcript, RN7SL1
183
, was used. We also 
confirmed the identity of the RPA amplicons through sequencing (Supplementary Fig. 1). 
The successful detection of TMPRSS2:ERG in DuCap cells demonstrated the specificity of 
our assay to detect TMPRSS2:ERG transcripts from total RNA. In addition, the colorimetric 
readout of the assay clearly showed the distinct colour changes between TMPRSS2:ERG 
states, thus potentially allowing a rapid and convenient binary evaluation of gene fusion 
status by the naked eye with minimal equipment.  
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Figure 2. Detection of TMPRSS2:ERG transcripts in prostate cancer cell lines and clinical 
urine specimens. (a) TMPRSS2:ERG detection in DuCap and LnCap cell lines. (b) Titration 
assay of spiking different concentrations of synthetic TMPRSS2:ERG RNA into LnCap RNA 
background. (c) Two separate runs of TMPRSS2:ERG detection in urine specimens of 10 
castrate-resistant prostate cancer patients and 5 healthy males with no prior prostate cancer 
history; 1st run (Left): PC1-PC10 & H1; 2nd run (Right): H2-H5. No RT and NoT refers to 
no-reverse transcriptase and no-template controls respectively. Top row: Images of 
flocculation assays for RT-RPA reactions. Bottom: Gel electrophoresis images corresponding 
to the RT-RPA reactions. Note: Gel electrophoresis experiments were all performed under 
similar experimental conditions (200V, 30 min) and images have been cropped for clarity of 
presentation, full-length blots/gels are presented in Supplementary Fig. 4. 
 
Assay limit-of-detection 
We then tested the sensitivity of our assay by titrating known amounts of synthetic 
TMPRSS2:ERG RNA into a 10 ng of LnCap total RNA background. As little as 10
5
 copies 
of TMPRSS2:ERG RNA (Fig. 2B) could be detected and this number of fusion transcripts 
was approximately equivalent to that of a single-cell
184
.  
 
Urine TMPRSS2:ERG in PCa patients 
To demonstrate clinical utility, we then applied our assay to analyze TMPRSS2:ERG status 
in clinical urine specimens from 10 metastatic castration-resistant PCa (CRPCa) patients and 
5 healthy control patients. Using RN7SL1 housekeeping transcripts as input control, we 
detected TMPRSS2:ERG transcripts from urine specimens in 7 out of 10 metastatic CRPC 
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patients (70%) but not in the healthy patient and no-template (NoT) controls (Fig. 2C). These 
outcomes were further validated by the current gold standard RT-PCR assay (Supplementary 
Fig. 2) with a different pair of primers (Table 1). Both our assay and RT-PCR gave identical 
results, thus supporting our TMPRSS2:ERG assay as a feasible  faster alternative to RT-PCR.  
 
DISCUSSION 
The current use of PSA levels for PCa diagnosis has led to incidences of false-
positive/negative results
185
. Gene fusions are one of the new generation of promising PCa 
biomarkers which could replace or supplement the PSA test as it is highly PCa-specific and 
absent in benign conditions
6,168
. Thus, we hypothesized that an assay which is able to reliably 
and rapidly detect gene fusion presence at a low-cost, could be a useful tool for diagnosing 
PCa in the point-of-care setting. Here we report a novel urine-based gene fusion assay by 
detecting the common TMPRSS2 (exon 1):ERG (exon 4)
4
 in PCa patients. This assay differs 
from previous reports of gene fusion detection methodologies in the literature as it is able to 
give a positive/negative flocculation-based outcome detectable by naked eye within 90 
minutes with minimal equipment. 
 
The bridging flocculation phenomenon in our assay refers to the ability of RT-RPA 
amplicons to initiate cross-linking of magnetic beads and flocculate out of an aqueous 
dispersion, thus rendering the solution colourless (Fig. 1). The length of the amplicons limits 
this flocculation mechanism as short-length primers (in the event of unsuccessful 
amplification) are unable to induce bridging of magnetic beads. Bridging flocculation of 
magnetic beads is particularly useful for visual detection of a variety of nucleic acid-based 
pathogens after successful amplification
86,88
. Whilst various lines of research have reported 
visual DNA detection through magnetic particles aggregation
186-188
, our assay is unique in 
requiring only a conventional magnetic plate (i.e. static magnetic field) after a rapid 30 min 
isothermal amplification.   
 
Importantly, the sensitivity (10
5
 TMPRSS2:ERG transcript copies) and specificity of this 
approach (Fig. 2A & B) could be useful for detecting low TMPRSS2:ERG amount in a 
complex clinical sample such as urine. Furthermore, the colorimetric readout of the assay 
clearly demonstrated the distinct colour changes between TMPRSS2:ERG states, thus 
potentially allowing a rapid and convenient binary evaluation of gene fusion status. Unlike 
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RT-PCR/FISH assays which require time-consuming preparation, long assay times, and 
costly fluorescence readouts; our assay is able to avoid these complications. Firstly, the RT-
RPA technique is readily-available commercially in pellet form and preparation steps are 
simple, quick and minimal. Secondly, the amplification process is isothermal and rapid to 
facilitate shorter assay turn-around-time. In contrast to the traditional fluorescence readouts 
of RT-PCR/FISH; our novel flocculation-based colorimetric readout is simpler and quicker to 
prepare, more cost-effective without need for specialized instruments, and free from 
conventional fluorescence bleaching issues.  
 
To demonstrate potential clinical utility, we used our assay to investigate the TMPRSS2:ERG 
status in urine samples from 10 CRPCa patients and 5 healthy controls (Fig. 2C). The results 
were subsequently verified with gold standard RT-PCR with 100% concordance 
(Supplementary Fig. 2). Furthermore, our assay findings were also consistent with literature 
reports describing the presence of TMPRSS2:ERG in late-stage metastatic CRPCa 
patients
189
. It is also worth highlighting that the assay results were obtained in approximately 
90 minutes, and we have also been able to detect TMPRSS2:ERG transcripts from whole 
urine specimens without any need for ultracentrifugation to concentrate urinary sediments 
(Supplementary Fig. 3). However, we found that detection from whole urine is only possible 
if the assay is performed immediately (within 2 hours) after specimen collection. We 
hypothesized that RNA from whole urine most likely degraded with time, therefore 
decreasing RT-RPA efficiency. In contrast, sediment RNA remained stable for extraction 
even after 12 hrs (Supplementary Fig. 3). While using whole urine may be convenient, due to 
logistic limitations and assay reproducibility, urinary sediments are the more viable RNA 
source for this study. Nonetheless, if the assay could be done immediately on-site, detecting 
TMPRSS2:ERG from whole urine may still be a possibility and thus further simplifying the 
method.  
 
There are several aspects of our assay which could be further developed and improved upon 
in order to realize its full potential as a clinical tool. First, the flocculation colorimetric 
readout is not quantitative and only offers a discrete yes/no result in its current format. 
However, this could be overcome by designing softwares to measure the intensity and size of 
cross-linked magnetic beads. As more transcripts could lead to higher flocculation, the 
intensity and size of the flocculated magnetic beads could be quantitative for TMPRSS2:ERG 
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transcripts. Furthermore, our assay could be modified as a chip-based assay in the future as 
isothermal amplification, magnetic beads, and visual readout are components which are ideal 
for chip-based assay development. By integrating our assay onto a chip, we could potentially 
increase assay throughput and multiplexibility, improve portability through assay 
miniaturization, and eventually automate the whole assay process. Nonetheless, the current 
assay is still an attractive low resource alternative as compared to RT-PCR or FISH. 
 
In conclusion, we describe a novel coupling of isothermal RT-RPA with a flocculation 
readout to enable a rapid, convenient, inexpensive and non-invasive method for detecting 
PCa gene fusion RNA. To our knowledge, our colorimetric readout method is the first display 
of using the RT-RPA technique and bridging flocculation phenomena to evaluate urinary 
gene fusion transcripts such as TMPRSS2:ERG. This positive/negative readout is easily 
evaluated by the naked eye and also complements binary biomarkers such as gene fusions. 
We envisage that our assay may have wide application potential in detecting different gene 
fusion occurrences in other forms of cancers or diseases by simply tailoring primer 
sequences. 
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SUPPORTING INFORMATION 
 
 
Supplementary Figure 1. DNA sequencing of DuCap RNA amplicons after RT-RPA. RT-
RPA amplicons of extracted DuCap RNA was purified using SPRI magnetic beads and 
sequenced to verify amplification of target TMPRSS2:ERG region. *The ERG sequence 
bases are underlined to indicate the TMPRSS2:ERG fusion junction. 
 
 
Supplementary Figure 2. RT-PCR of extracted RNA from patient urine specimens. 
Extracted RNA from urine specimens of 10 metastatic castrate-resistant prostate cancer 
patients and 5 healthy patients were amplified using RT-PCR for TMPRSS2:ERG detection. 
The RT-PCR amplicons were visualized on agarose gel and used to validate the screening 
results of our assay on the same group of patients (Figure 2C).  
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Supplementary Figure 3. Comparison of RNA stability in whole urine and urinary 
sediments. RT-RPA of patient whole urine and urinary sediment RNA extracted at 0, 2 and 
12 hrs after specimen collection.  
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Supplementary Figure 4. Full-length gel images of Figure 2 results. Dotted outlines 
represent cropping lines of images shown in Figure 2A, B, and C.
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Colorimetric TMPRSS2-ERG Gene Fusion Detection in Prostate 
Cancer Urinary Samples via Recombinase Polymerase 
Amplification 
 
Kevin M. Koo, Eugene J. H. Wee, Matt Trau
 
 
 
ABSTRACT 
TMPRSS2 (Exon 1)-ERG (Exon 4) is the most frequent gene fusion event in prostate cancer 
(PC), and is highly PC-specific unlike the current serum prostate specific antigen (PSA) 
biomarker. However, TMPRSS2-ERG levels are currently measured with quantitative 
reverse-transcription PCR (RT-qPCR) which is time-consuming and requires costly 
equipment, thus limiting its use in clinical diagnostics. Herein, we report a novel rapid, cost-
efficient and minimal-equipment assay named “FusBLU” for detecting TMPRSS2-ERG gene 
fusions from urine. TMPRSS2-ERG mRNA was amplified by isothermal reverse 
transcription-recombinase polymerase amplification (RT-RPA), magnetically-isolated, and 
detected through horseradish peroxidase (HRP)-catalyzed colorimetric reaction. FusBLU was 
specific for TMPRSS2-ERG mRNA with a low visual detection limit of 10
5
 copies. We also 
demonstrated assay readout versatility on 3 potentially useful platforms. The colorimetric 
readout was detectable by naked eye for a quick yes/no evaluation of gene fusion presence. 
On the other hand, a more quantitative TMPRSS2-ERG detection was achievable by 
absorbance/electrochemical measurements. FusBLU was successfully applied to 12 urinary 
samples and results were validated by gold-standard RT-qPCR. We also showed that 
sediment RNA was likely the main source of TMPRSS2-ERG mRNA in urinary samples. We 
believe that our assay is a potential clinical screening tool for PC and could also have wide 
applications for other disease-related fusion genes.       
 
INTRODUCTION 
Prostate cancer (PC) is the most common form of cancer and the second leading cause of 
cancer death in males of developed countries 
190
. The customary screening approach for 
prostate biopsies is mainly based on high serum prostate specific antigen (PSA) levels and/or 
abnormal digital rectal examination (DRE). PSA is the primary PC biomarker used by 
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clinical practitioners and has led to a significant increase in PC diagnosis since its 
introduction 
191
. However, due to its low PC-specificity, the majority of PSA-diagnosed cases 
are actually benign and do not require medical intervention. This has in turn led to redundant 
medical expenses as well as negative effects on patients’ overall well-being 192. Thus, there is 
a pressing need for better PC diagnostic biomarkers, particularly one with high PC-specificity 
for discriminating benign cases from aggressive PC cases. 
 
In 2005, Tomlins and co-workers identified recurrent PC fusion genes between the promoter 
of transmembrane protease, serine 2 (TMPRSS2) and the coding sequence of erythroblastosis 
virus E26 (ETS) family members 
4
. These fusions were a result of chromosomal 
rearrangements-induced androgen-dependent overexpression of oncogenic ETS transcription 
factors  
193
. The fusion of TMPRSS2 exon 1 to ERG exon 4 (TMPRSS2-ERG) is the most 
frequent subtype of these gene fusions, appearing in about 50% of PC patients and 90% of all 
PC gene fusions 
194
. More importantly, TMPRSS2-ERG is highly PC-specific and absent in 
non-PC samples. Furthermore, TMPRSS2-ERG may correlate with PC aggression and 
metastatic potential 
168,176,195
; potentially making them more attractive as diagnostic and 
prognostic biomarkers than serum PSA.  
 
TMPRSS2-ERG mRNA is commonly detected from the cell sediment fraction of urine 
9,175
. 
Recently, Nilsson and co-workers had reported TMPRSS2-ERG detection in urinary 
exosomes 
196
. Additionally, it is also highly plausible that TMPRSS2-ERG mRNA is freely 
circulating within the urine sample. Given that TMPRSS2-ERG is detectable from multiple 
sources within urine 
197
, it could be worth  investigating  the primary source (circulating free 
mRNA in whole urine, cellular RNA or exosomal RNA) of the fusion mRNA. This could 
potentially lead to a more in-depth understanding of the cancer biology and aid in future 
assay development.    
 
Currently, quantitative reverse transcription PCR (RT-qPCR) is mainly used to measure 
TMPRSS2-ERG mRNA levels in urinary samples 
4,6,175
. However, this approach is too time-
consuming and laborious for use in a clinical setting. Therefore, the development of newer, 
faster and convenient assays for quantifying TMPRSS2-ERG mRNA in clinical samples may 
aid in improved PC screening and treatment monitoring. 
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Colorimetric assays have been developed for a wide range of target analytes and offer 
benefits such as low cost, short assay time, visual readout, and quantitative detection via 
absorbance measurements 
198
. In particular, the reaction between tetramethyl benzidine 
(TMB) and horseradish peroxidase (HRP) in presence of hydrogen peroxide (H2O2) to 
produce a blue-colored product 
87
 has been employed in many colorimetric assays, with 
ELISA as a well-known example. Additionally, it has been demonstrated by previous studies 
87,140,199
 that TMB could serve as an electrochemical substrate. Given the excellent simplicity, 
sensitivity and speed of electrochemical biosensors 
200-202
, it may be ideal to adapt TMB-
based colorimetric assays for alternative electrochemical readouts to exploit such advantages. 
Therefore, we hypothesized that a TMB-based assay which displays a quantitative 
colorimetric/electrochemical signal change in TMPRSS2-ERG presence could be potentially 
useful for diagnostic purposes. 
 
Herein, we describe the FusBLU assay, a novel approach to detect and quantify TMPRSS2-
ERG fusion mRNA. By the innovative merger of isothermal reverse-transcription 
recombinase polymerase reaction (RT-RPA) and HRP-catalyzed colorimetric readout, 
TMPRSS2-ERG mRNA in urine could be specifically amplified and detected by naked-eye or 
by quantitative absorbance measurements. The versatility of the assay readout was further 
shown by conveniently performing FusBLU on a portable potentiostat for electrochemical 
detection. The practical application of our assay was demonstrated using PC cell lines and 
patient urinary samples. We also applied our assay to detect TMPRSS2-ERG mRNA in whole 
urine, urinary sediments and exosomes of PC urinary specimens in order to investigate the 
primary source of the mRNA. 
 
MATERIALS AND METHODS 
RNA extraction from cell lines 
DuCap and LnCap cells were kindly donated by Matthias Nees (VTT, Finland); Gregor Tevz 
(APCRC, Australia); and Michelle Hill (UQDI, Australia). DuCap and LnCap cells were 
cultured in RPMI-1640 growth media (Life Technologies, Australia) supplemented with 10% 
fetal bovine serum (Life Technologies, Australia) in a humidified incubator (Sanyo MCO-
19AIC, Japan)  containing 5% CO2 at 37 ºC. Total RNA was extracted by lysing cells with 
Trizol® reagent (Life Technologies, Australia) before adding chloroform to separate RNA 
into a clear upper aqueous layer. Then, RNA was precipitated from the aqueous layer and 
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resuspended in 50 µL of RNase-free water. RNA purity and integrity were checked using a 
NanoDrop Spectrophotometer (Thermo Fisher Scientific, Australia) 
 
RNA extraction from clinical urinary samples 
Ethics approval was obtained from The University of Queensland Institutional Human 
Research Ethics Committee (Approval No. 2004000047). Informed consent was obtained 
from all subjects prior to sample collection and methods pertaining to clinical samples were 
carried out in accordance with approved guidelines. 
 
For whole urine RNA extraction, 1 mL of fresh urine sample was briefly mixed with 500 µL 
of lysis buffer 
86
 (150 mM Tris-HCI pH 8.0, 4.5 M guanidium-HCI, 3% v/v Triton-X and 1.5 
mM EDTA). Total RNA was purified from 25 µL of cell lysate using the Agencourt AMPure 
XP kit (Beckman Coulter, Australia). Briefly, two volumes of Solid Phase Reversible 
Immobilization (SPRI) reagent was incubated with the cell lysate for 10 minutes. The RNA-
bound magnetic beads were then separated from the lysate using a magnet and washed twice 
with 80% ethanol. Finally, total RNA was eluted in 25 µL of RNase-free water.  
 
For urinary cell sediment RNA extraction, urinary samples (30–50 mL) were centrifuged 
(Beckman Coulter Allegra
TM
 X-22R, Australia) at 700 g, 4ºC for 10 min and urinary 
sediments (supernatant was kept for exosomal RNA extraction) were washed with ice-cold 10 
mM PBS buffer before being centrifuged again at the same conditions. Then, 25 µL of lysis 
buffer was added to a 50 µL fraction of PBS-suspended urinary sediments with vigorous 
mixing to release total RNA. Next, total RNA was purified from 25 µL of cell lysate using 
the procedure as described for whole urine RNA extraction. 
 
For urinary exosomal RNA extraction, microvesicles in the supernatant (after urinary 
sediment centrifugation) was firstly pelleted by ultracentrifugation (Beckman Coulter 
Optima
TM
 XL-100 K, Australia) at 100 000 g, 4ºC for 90 min and resuspended in 200 µL of 
10 mM PBS buffer. Then, the Exo-spin
TM
 kit (Cell Guidance Systems, USA) was used 
accordingly to manufacturer’s instructions to isolate exosomes from the pellet. To ensure that 
extracted RNA was of exosomal origin, the isolated urinary exosomes were treated with 
RNase A (New England Biolabs, Australia) to degrade all non-exosomal RNA before RNA 
extraction. Exosomal total RNA was extracted by Trizol® reagent (Life Technologies, 
Australia) using the procedure as described for RNA extraction from cells.         
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Colorimetric FusBLU assay 
Synthetic oligonucleotide and primer sequences used in our experiments were obtained 
commercially (IDT, Singapore). RT-RPA primer sequences were designed based on the 
fusion junction of the most common TMPRSS2 (Exon 1):ERG (Exon 4) mRNA isoform 
reported in literature 
4
. The RT-qPCR primers were also designed to amplify the same target 
TMPRSS2:ERG isoform. 
 
For cell line experiments, the TwistAmp Basic RPA kit (Twist-DX, UK) was used with slight 
modifications to manufacturer’s instructions. Briefly, 1 µL of extracted RNA, 50 units of 
MMuLV reverse transcriptase (New England Biolabs, Australia), 375 nM of each primer 
(Table 1) and 20 nM of biotinylated dUTPs (Thermo Fisher Scientific, Australia) were added 
to make a 12.5 µL reaction volume prior to incubation at 43°C for 20 min. For all other 
experiments, the TwistAmp Basic RT-RPA kit (Twist-DX, UK) with pre-included reverse 
transcriptase was used with the same modifications to manufacturer’s instructions. The 43ºC 
amplification temperature, which is above the manufacturer’s recommended optimum 
temperature, was required for higher amplification specificity.  
 
Table 1. Oligonucleotide sequences used in experiments.  
Oligos 5'-Sequence-3' 
RT-RPA TMPRSS2-
ERG Fwd Primer 
Sequence 
CCTGGAGCGCGGCAGGAAGCCTTATCAGTTG 
RT-RPA TMPRSS2-
ERG Rev Primer 
Sequence 
GCTAGGGTTACATTCCATTTTGATGGTGAC 
RT-RPA 
Housekeeping Fwd 
Primer Sequence 
GCTATGCCGATCGGGTGTCCGCACTAAGTT 
RT-RPA 
Housekeeping Rev 
GACGGGGTCTCGCTATGTTGCCCAGGCTGG 
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Primer Sequence 
RT-qPCR Fwd Primer 
Sequence 
CCTGGAGCGCGGCAGGAAGCCTTATCAGTTG 
RT-qPCR Rev Primer 
Sequence TCCTGCTGAGGGACGCGTGGGCTCATCTTG 
 
For colorimetric detection of RT-RPA products, 2 µL of RT-RPA products was incubated 
with 1 µL of 1:1000 diluted streptavidin (SA)-HRP (BD Biosciences, Australia), 1 µL of SA-
magnetic beads (New England Biolabs, Australia) and 10 µL of wash buffer (10 mM PBS 
buffer, 0.5% triton-X) for 5 min. Then, a magnet was used to separate the beads and beads 
were washed three times with wash buffer (10 mM PBS buffer, 0.1% Tween20). Lastly, 25 
µL of 1-Step™ TMB substrate solution (Thermo Fisher Scientific, Australia) was added to 
the beads and the mixture was observed for color change after 5 min. For each sample, two 
separate RT-RPA assays were performed for independent detection of TMPRSS2-ERG and 
housekeeping (RN7SL1) RNA. For quantitative measurements of color change, absorbance 
readings were recorded at 650 nm with a NanoDrop Spectrophotometer (Thermo Fisher 
Scientific, Australia). For each sample, relative TMPRSS2-ERG level was calculated by 
normalizing the absorbance value of TMPRSS2-ERG to the respective housekeeping RN7SL1 
as follows: 
 
Relative TMPRSS2-ERG Level = XTmprss2-ERG / XRN7SL1     (1) 
 
where XTmprss2:ERG and XRN7SL1 are the average absorbance readings at 650 nm for 
TMPRSS2-ERG and housekeeping RN7SL1 RNA respectively. 
 
Alternative electrochemical readout 
For electrochemical detection of RT-RPA products, total RNA was isolated from patient 
urinary sediments and after which, the same steps as described previously for colorimetric 
FusBLU assay were performed. At 5 min after TMB-H2O2 addition, 500 mM H2SO4 was 
added to stop the reaction and activate TMB for electrochemical detection. The electrodes 
used in our experiments were screen-printed electrodes (DRP110, Dropsens, Spain) with 
carbon as working and counter electrodes, and silver as reference electrode. Briefly, 45 µL of 
the resulting mixture after H2SO4 addition was pipetted onto the electrode surface, and 
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ensured that the solution was in contact with all three electrode types (i.e. working, counter, 
and reference). Amperometry measurements were carried out using a portable µSTAT 400 
bipotentiostat/galvanostat (Dropsens, Spain) at 150 mV, 30 s. Each sample’s electrochemical 
measurement was scored for relative TMPRSS2-ERG level in the same manner as described 
previously for absorbance readings. All measurements were performed at room temperature. 
 
RT-qPCR 
The KAPA SYBR
®
 FAST One-Step qRT-PCR kit (KAPA Biosystems, Australia) was used 
to set up a single reaction volume of 10 µl for each sample. Each reaction volume consist of 
1X KAPA SYBR
®
 FAST qPCR Master Mix, 200 nM of each forward and reverse primer 
(Table 1), 1X KAPA RT Mix, 50 nM ROX dye and 30 ng of cell line total RNA template. 
RT-qPCR was performed using the Applied Biosystems® 7500 Real-Time PCR System 
(Thermo Fisher Scientific, Australia). The cycling protocol was: 42°C for 10 min to 
synthesize cDNA, followed by 95°C for 5 min to deactivate RT before cycling 35 times 
(95°C for 30 s, 50°C for 30 s and 72°C for 1 min) and finished with 72°C for 10 min.  
 
RESULTS    
FusBLU assay for TMPRSS2-ERG detection 
As illustrated in Fig. 1, our colorimetric assay utilized a combination of isothermal RT-RPA 
and TMB-based colorimetric readout for detecting TMPRSS2-ERG mRNA. Total RNA was 
firstly isolated from various sources used in our study and specific primers were used to 
amplify the TMPRSS2-ERG mRNA region at a constant temperature of 43ºC. During the 
isothermal RT-RPA, biotinylated dUTPs were randomly incorporated into the newly-
synthesized strands. Then, SA-magnetic beads and SA-HRP were added to select for and 
label biotinylated RT-RPA products through biotin-streptavidin interactions. Lastly, TMB-
H2O2 was added for color change reaction to test for the presence of HRP which in turn 
signifies the presence of RT-RPA products (i.e. TMPRSS2-ERG positive).  
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Fig. 1. FusBLU assay for rapid TMPRSS2-ERG detection. Total RNA is isolated from urine 
and TMPRSS2-ERG mRNA is specifically amplified by RT-RPA isothermally. During strand 
polymerization, biotinylated dUTP bases are randomly incorporated and subsequently, SA-
magnetic beads and SA-HRP are added to RT-RPA products for coupling through biotin-SA 
interactions. After magnetic isolation of RT-RPA products, TMB is added and a blue color 
change indicates the presence of TMPRSS2-ERG.  
 
Assay specificity 
To demonstrate the specificity of FusBLU in detecting TMPRSS2-ERG, we applied our assay 
to total RNA from two different PC cell lines. DuCap and LnCap are well-studied cell lines 
with the presence and absence of TMPRSS2-ERG respectively 
4
. As shown in Fig. 2A, our 
assay was able to specifically amplify TMPRSS2-ERG mRNA from DuCap RNA and 
subsequently generated a blue color change. On the other hand, when the assay was 
performed on LnCap RNA, RT-RPA products were not generated at a detectable level 
colorimetrically (Fig. 2A). The specific colorimetric detection of TMPRSS2-ERG could be 
followed by naked-eye observation of color change or more quantitatively by absorbance 
measurements (Fig. 2B). Furthermore, gel electrophoresis was also used to verify that the 
RT-RPA primers used in our experiments were specific and generated 216 bp products only 
in TMPRSS2-ERG positive DuCap samples. RN7SL1 housekeeping RNA was used as a 
loading control to validate successful RNA isolation from the cell lines (Fig. 2A). In addition, 
control experiments without the reverse transcriptase did not generate any RPA products, 
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thus demonstrating that amplification was dependent on TMPRSS2-ERG mRNA, not DNA 
targets (Fig. 2).     
 
 
Fig. 2. Specificity of FusBLU assay. (A) HRP-catalyzed colorimetric results for DuCap 
(fusion positive) and LnCap (fusion negative) cell lines with corresponding gel 
electrophoresis images after RT-RPA. Top panel: TMPRSS2-ERG. Bottom panel: RN7SL1. 
No reverse transcriptase (No RT) and no-template control (NTC) were included. (B) 
TMPRSS2-ERG levels normalized to RN7SL1. Error bars represent standard deviation of 
three independent experiments. 
 
Assay sensitivity 
To evaluate assay sensitivity, we prepared a titration of synthetic TMPRSS2-ERG mRNA 
(10
2
-10
8 
copies) into a background of LnCap total RNA to test the limit of detection (LOD). 
As expected, the color change intensity increased with increasing amounts of input targets 
(Fig. 3A). By visual detection, the assay LOD was 10
5
 copies of TMPRSS2-ERG mRNA at 
which a blue color change in solution was still observable. The determination of assay 
sensitivity could also be followed quantitatively by absorbance measurements and assay LOD 
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was further improved by 10-fold to 10
4
 TMPRSS2-ERG mRNA copies with a linear range of 
10
4
-10
8
 copies (Fig. 3B). However, it is worthy to note that the LOD of 10
5
 copies by visual 
detection is approximately equivalent to single cell level of detection 
184
 and thus may 
potentially be adequate for TMPRSS2-ERG screening purpose in a clinical setting.  FusBLU 
also showed good assay reproducibility with intra- and inter-assay variability of 12.5% and 
10.5% respectively (n = 3). 
      
 
Fig. 3. Sensitivity of FusBLU assay. (A) HRP-catalyzed colorimetric change generated from 
10
2 
- 10
8
 copies of synthetic TMPRSS2-ERG mRNA, and corresponding gel electrophoresis 
images after RT-RPA. (B) Calibration plot of the average absorbance measurements
 
at 
different initial RT-RPA input amounts. Inset shows the analogous linear calibration plot. (C) 
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HRP-catalyzed current change generated from 10
3
 - 10
7
 copies of synthetic TMPRSS2-ERG 
mRNA.  Inset shows the analogous linear calibration plot. Error bars represent standard 
deviation of three independent experiments.  
 
Colorimetric assay performance on clinical specimens 
After establishing assay specificity and sensitivity, we challenged FusBLU with urine 
specimens to demonstrate potential clinical utility. To this end, we isolated sediment RNA 
from the urinary samples of 12 men and applied FusBLU for TMPRSS2-ERG detection. The 
magnetic SPRI method provided a minimal yield of 15 ng total RNA; an amount which was 
sufficient for our analysis using FusBLU. Of the 12 clinical urinary samples used in our 
experiments: 5 (P1-P5) were metastatic hormone-refractory PC patients undergoing 
treatment; 5 (P6-P10) were diagnosed with PC after biopsies; and the remaining 2 (H1 and 
H2) were healthy controls. As shown on Fig. 4A, we could visually detect TMPRSS2-ERG in 
8 of the patient samples (P1, P3, P4, P5, P7, P8, P9, and P10), while the remaining samples 
(P2, P6, H1, and H2) showed no observable color change as similar to the no-target control 
(NTC). For quantitative detection, the relative absorbance measurements (Eqn. 1) provided 
additional information of TMPRSS2-ERG levels in different patients (Fig. 4B). In addition, 
we also performed RT-qPCR, the current gold standard gene fusion detection approach on the 
same 12 urinary samples as a benchmark comparison. The RT-qPCR threshold cycle (Ct) 
values (Fig. 4D) showed that higher Ct values (i.e. lower amount of targets in samples) were 
generated for samples with low FusBLU-detected TMPRSS2-ERG levels. We found that our 
FusBLU results were in excellent agreement with the RT-qPCR results, thus validating the 
TMPRSS2-ERG status of the patient samples. 
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Fig. 4. FusBlu assay on clinical urinary samples. (A) HRP-catalyzed colorimetric results of 
12 urinary samples over two different assay runs (1
st
 run (Left): P1-P5; 2
nd
 run (Right): P6-
H2). Top panel: TMPRSS2-ERG. Bottom panel: RN7SL1. (B) TMPRSS2-ERG levels 
normalized to RN7SL1. (C) TMB-derived currents of 12 urinary samples compared to no 
template-control (NTC). (D) RT-qPCR threshold cycle (Ct) values for each sample as 
validation for FusBLU results. Error bars represent standard deviation of three independent 
experiments. 
 
Alternative electrochemical readout 
Since TMB was electrochemically active and considering the multiple advantages of an 
electrochemical biosensor 
201,203,204
, we integrated the use of a portable potentiostat as an 
alternative FusBLU readout strategy to further demonstrate the potential for clinical 
screening applications. We firstly established the LOD of the electrochemical readout by a 
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titration assay, and observed that 10
3
 TMPRSS2-ERG copies were detectable with a linear 
range of 10
3
-10
7
 copies (Fig. 3C). 
 
We next used the same collection of 12 urinary samples to demonstrate the electrochemical 
readout. Fig. 4C showed the TMPRSS2-ERG levels detected electrochemically were similar 
to that of spectrophotometry (Fig. 4B) and RT-qPCR (Fig. 4D). Taken together, these results 
indicated that FusBLU was a robust method for detecting TMPRSS2-ERG levels in urine and 
could be readily adapted for naked-eye, spectrophotometrical or electrochemical readout 
platforms.  
 
Investigating TMPRSS2-ERG source in urine 
After demonstrating FusBLU’s potential for clinical applications, we used our assay to 
investigate the primary source of TMPRSS2-ERG mRNA in urine. The potential sources 
included cell-free circulating RNA, cell sediment RNA and exosomal RNA. To this end, 3 
TMPRSS2-ERG-positive PC patients (P1, P3, and P4) were first selected (Fig. 4) and total 
RNA was then isolated from the three candidate sources and assayed with FusBLU. As 
shown on Fig. 5A, the sediment fraction gave the strongest color intensity change (i.e. highest 
amount of TMPRSS2-ERG mRNA), followed by circulating free fraction, while the exosomal 
fraction contain the least amount of TMPRSS2-ERG mRNA. In addition, quantitative 
absorbance measurements showed that TMPRSS2-ERG mRNA in the sediment fraction was 
2-fold and 12-fold higher than in the circulating free and exosomal fractions respectively 
(Fig. 5B). Absorbance results were also validated by gel electrophoresis following RT-RPA 
of the isolated total RNA from the various candidate sources (Fig. 5A). Our results therefore 
suggested that the sediment fraction is likely the main source of TMPRSS2-ERG mRNA in 
urine. 
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Fig. 5. Source of TMPRSS2-ERG mRNA in urine. Total RNA isolated from circulating free, 
sediment, and exosomal fractions of 3 patient urine samples were studied (A) HRP-catalyzed 
colorimetric changes and corresponding gel electrophoresis images after RT-RPA. Top panel: 
for TMPRSS2-ERG. Bottom panel: RN7SL1. (B) TMPRSS2-ERG levels normalized to 
RN7SL1. Error bars represent standard deviation of three independent experiments. 
 
DISCUSSION 
Recurrent gene fusions between TMPRSS2 exon 1 and ERG exon 4 is one of the emerging PC 
biomarker alternative to serum PSA. TMPRSS2-ERG offers higher PC specificity, potential 
prognostic value and is detectable in urine as a non-invasive biomarker 
9,175
. However, the 
conventional RT-qPCR approach for measuring TMPRSS2-ERG levels is not ideal for routine 
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clinical screening due to long assay time and the need for specialized instrument 
4,6
. 
Therefore, we have developed FusBLU, an assay (Fig. 1) which combined isothermal RT-
RPA and HRP-based colorimetric readout for quick and quantitative TMPRSS2-ERG 
detection in 90 min without requiring expensive readout instruments. With FusBLU, we 
demonstrated (i) potential TMPRSS2-ERG detection in clinical urinary samples with a quick 
and convenient visual readout; (ii) quantitative TMPRSS2-ERG detection by alternative 
absorbance/electrochemical readout platforms; (iii) cell sediment RNA as potentially the 
main source of TMPRSS2-ERG mRNA in patient urinary samples.  
 
In order for the assay to be used for TMPRSS2-ERG detection in real biological samples such 
as urine specimens, assay specificity and sensitivity are of paramount importance. High assay 
specificity is required to avoid false-positive/negative results due to detection of non-target 
mRNA  and high assay sensitivity is required to detect trace amounts of TMPRSS2-ERG 
mRNA from a complex background of other biological molecules. FusBLU was highly 
specific for TMPRSS2-ERG mRNA in fusion-positive DuCap cells but not fusion-negative 
LnCap cells (Fig. 2). This high assay specificity was largely enabled by designing RT-RPA 
forward primer across the fusion junction to selectively amplify only gene fusion events. In 
future, this flexibility of primer design may also allow specific detection of other TMPRSS2-
ERG isoforms for multiplexed FusBLU gene fusion detection. Our assay visual detection 
limit of 10
5
 copies of TMPRSS2-ERG mRNA (Fig. 3A); which was approximately single-cell 
level 
205
, may be especially useful for non-invasively detecting the low levels of TMPRSS2-
ERG in urine. Furthermore, this visual LOD could be further improved up to 100-fold with 
easily-adaptable absorbance/electrochemical readouts. In comparison to other standard 
urinary TMPRSS2-ERG detection methodologies such as RT-qPCR, FusBLU required lower 
sample input  (10 ng total RNA vs. 50 ng total RNA for RT-qPCR in our experiments) and 
was able to produce results within a shorter timeframe (75 min vs. 150 min for RT-qPCR in 
our experiments).  
 
To demonstrate the potential clinical utility of FusBLU, we applied our assay to 12 urinary 
samples (Fig. 4) and found excellent agreement between our assay results and current gold-
standard RT-qPCR results (Fig. 4D). Importantly, the healthy and NTC samples generated 
negligible background signals, and varying TMPRSS2-ERG levels were detected for the other 
samples with good reproducibility over independent runs. These data therefore suggested the 
reliability and functional applicability of our assay for routine diagnostics. Furthermore, the 
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presence of TMPRSS2-ERG in the urine samples of the late-stage metastatic, hormone 
refractory samples was consistent with previous reports in literature 
206,207
. Hence, our results 
suggested that FusBLU may be a useful screening tool for the TMPRSS2-ERG positive 
metastatic subtype of aggressive PC. Considering the good assay sensitivity as well as speed 
and simple naked-eye evaluation of color change detection; FusBLU may also be a rapid and 
convenient preliminary PC screening tool for guiding clinical decisions. In addition, 
quantitative absorbance measurements of the color intensity can also provide additional 
information that could be beneficial for tracking patient response to treatment or for relapse 
monitoring. Lastly, electrochemical approaches have high potential for rapid, sensitive, 
inexpensive and portable biosensing 
130,208,209
 and thus have attracted great interest for clinical 
diagnostic developments. To this end, we exploited TMB’s compatibility as an 
electrochemical substrate and adapted FusBLU into an electrochemical assay with a portable 
potentiostat to highlight the versatility of the method (Fig. 4C). Despite the use of a portable 
potentiostat, the FusBLU electrochemical readout provided the highest detection sensitivity 
(10
3 
copies) out of the three different readout platforms. In short, FusBLU is potentially a 
flexible methodology that could be tailored to specific diagnostic needs. 
 
While it is known that TMPRSS2-ERG mRNA is present in urine, it is not previously clear 
where the fusion mRNA originated from. Hence, identifying the primary source of 
TMPRSS2-ERG mRNA in urine might be useful for future assay development and may help 
better understand the cancer biology of TMPRSS2-ERG subtypes. Using FusBLU, we found 
that TMPRSS2-ERG mRNA was most abundant in the sediment fraction of urine (Fig. 5). 
TMPRSS2-ERG mRNA in circulating free fraction was the second most abundant source 
while minimal fusion mRNA was detected in the exosomal fraction. A possible explanation 
for our observation could be the shedding of tumor cells from the primary (and metastastic) 
tumors in the prostate into the urine through the prostatic urethra 
210,211
. It could also be from 
ingested tumor cells that are present in urine within white blood cells of the immune system 
212
. The presence of the TMPRSS2-ERG mRNA in circulating free fraction was likely from 
the spontaneous lysis of cells since minimal RNA was detected in the exosomal fraction. 
Nevertheless, the data is still preliminary and warrants further investigation. Notwithstanding, 
the data did suggested that although TMPRSS2-ERG was detectable in whole urine, the 
sediment fraction is most likely the best choice for sampling TMPRSS2-ERG mRNA due to 
ease of preparation and high abundance. Additionally, the use of our assay as a rapid and 
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convenient research tool for biological studies was also demonstrated through this set of 
successful experiments to investigate the source of TMPRSS2-ERG mRNA in urine. 
 
FusBLU shows promise as a faster, simpler, and more cost-effective solution for gene fusion 
biomarkers detection as compared to current techniques. Nevertheless, there remain some 
aspects of the assay which could be further investigated in future studies. Firstly, our main 
aim in this report is to demonstrate FusBLU as a successful proof-of-concept technology 
which could be applied to real patient samples. While FusBLU detected TMPRSS2-ERG 
levels in 12 clinical urinary samples as a demonstration, it would be ideal to apply the method 
to a larger pool of patients and also of samples at various stages of PC. This would allow a 
better evaluation of the clinical utility of the assay for PC diagnosis. Secondly, we envisaged 
an improved version of FusBLU assay with multiplexing capabilities to detection multiple 
biomarkers. It has been suggested that detecting a combination of gene fusion isoforms or 
other PC biomarkers could improve PC diagnostic and predictive accuracy 
6
. In this regard, 
we feel that an electrochemical readout would be better suited for this purpose as performing 
the assay on an array of miniaturized electrodes could greatly increase throughput.  
 
In summary, we have developed FusBLU; a quantitative TMPRSS2-ERG assay with single-
cell level detection sensitivity and highly specific for the most common gene fusion isoform 
in PC. This assay was achieved by the novel combination of isothermal RT-RPA and HRP-
catalyzed colorimetric readout of RT-RPA products. Our assay was successfully applied to 
cell lines and patient urine samples with minimal equipment and at a low cost in 
approximately 75 minutes. Through the use of this assay, we also determined that total RNA 
isolated from urinary sediments as the main source for TMPRSS2-ERG mRNA detection 
from urinary samples. We believe that our colorimetric assay is potentially useful for POC 
detection of TMPRSS2-ERG, or other oncogenic fusion genes.  
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4 
Label-Free Surface-Enhanced Raman Scattering Detection Systems for 
Clinical Biomarker Targets 
 
 
Introduction 
Label-free surface-enhanced Raman Scattering (SERS) is a surface spectroscopic technique 
which directly detects adsorbed molecules on nanostructured metallic surfaces. Label-free 
SERS is an extremely attractive technique for simple and rapid detection of nucleic acid 
targets due to 1) direct target analysis without the need for detection readout labelling; 2) 
sensitive and rapid target detection due to SERS effect; 3) ability to provide chemical 
component and structure information of nucleic acid targets. Despite these benefits, label-free 
SERS has rarely, if any, been described for biomarker detection in real patient samples due to 
several severe limiting factors. In this chapter, prostate cancer RNA biomarker detection in 
patient urine samples was used as a model to showcase efforts in using isothermal reverse-
transcription recombinase polymerase amplification (RT-RPA) to enable label-free SERS for 
clinical applications. Chapter 4.1 describes a new label-free SERS strategy for detecting gene 
fusion RNA in clinical samples via double-stranded-DNA/gold nanoparticles aggregation 
mechanism. Chapter 4.2 showcases a non-invasive prostate cancer subtyping technique based 
on multiplexed RT-RPA, label-free SERS via self-synthesized positively charged silver 
nanoparticles, and multivariate analysis to detect long nucleic acid biomarker amplicons.    
 
Chapter 4 is based on two published articles in the Journal of Biomedical Nanotechnology 
(2016) [Chapter 4.1], and Nanoscale (2017) [Chapter 4.2]. 
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ABSTRACT 
Recurrent chromosomal rearrangements such as fusion genes are associated with cancer 
initiation and progression. Prostate cancer (PCa) is a leading cause of cancer-related deaths in 
men and the TMPRSS2-ERG gene fusion is a recurrent biomarker in about 50% of all 
prostate cancers. However, current screening tools for TMPRSS2-ERG are generally 
confined to research settings and hence, the development of a rapid, sensitive and accurate 
assay for TMPRSS2-ERG detection may aid in clinical PCa diagnosis and treatment. Herein, 
we described a new strategy for non-invasive TMPRSS2-ERG detection in patient urinary 
samples by coupling the isothermal reverse transcription-recombinase polymerization 
amplification (RT-RPA) to amplify TMPRSS2-ERG transcripts and directly detect the 
amplicons using surface-enhanced Raman scattering (SERS). This novel coupling of both 
techniques allows rapid and quantitative TMPRSS2-ERG detection. Our assay can 
specifically detect as low as 10
3 
copies input of TMPRSS2-ERG transcripts and was 
successfully applied to clinical PCa urinary samples. Hence, we believe our assay is a 
potential clinical screening tool for TMPRSS2-ERG in PCa and may have broad applications 
in detecting other gene fusion transcripts in other diseases. 
 
INTRODUCTION   
In recent years, oncogenic gene fusion events have emerged as a promising new source of 
cancer biomarkers.
1-3
 Fusion genes have key roles in cancer progression and can serve as 
promising drug targets for cancer treatment. Of particular interest, the TMPRSS2-ERG gene 
fusion is the most common gene fusion occurrence amongst all solid tumor cancers and is 
found in approximately half of all prostate cancer (PCa) cases.
4-6
 In contrast to the traditional 
prostate-specific antigen (PSA), TMPRSS2-ERG is not only more specific for PCa but also 
associated with aggressive PCa and thus may be more informative as a biomarker.
7, 8
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Furthermore, TMPRSS2-ERG transcripts are also present in patient urine samples,
9, 10
 thus 
offering its potential as an attractive non-invasive PCa biomarker. 
 
Classical methodologies, such as reverse transcription (RT)-PCR and fluorescence in situ 
hybridization (FISH), are commonly used to detect gene fusions including TMPRSS2-ERG.
9, 
11
 Whilst these methods offer good detection sensitivity, they are laborious, time-consuming 
and prone to artifacts. Hence, the development of a simpler, rapid and accurate assay to detect 
the low TMPRSS2-ERG transcript copies in urine is very much sought after. An 
advancement in such a detection methodology could improve the clinical utility of the 
TMPRSS2-ERG biomarker for point-of-care (POC) applications. 
 
Due to the relatively low TMPRSS2-ERG target copies in limited clinical biopsies, nucleic 
acid amplification methods are usually required to increase copy numbers to a sufficient level 
for detection. The recombinase polymerase amplification (RPA) is an isothermal 
amplification technique which offers advantages over conventional amplification methods 
such as PCR.
12
 These benefits include low constant operational temperature; therefore 
avoiding the need for expensive themocyclers and short amplification times (10-15 min) 
while achieving equivalent sensitivities to PCR. The applications of RPA has been 
demonstrated in the detection of a wide range of pathogens
13, 14
 and we hypothesized that 
RPA is an attractive option for POC gene fusion detection if readily coupled to a similarly 
convenient and sensitive readout platform.    
 
Surface-enhanced Raman scattering (SERS) is an emerging analytical technique for highly 
sensitive (down to single molecule)
15, 16
 and specific detection of nucleic acids
17, 18
 based on 
electromagnetic field enhancement effect of molecules, e.g. DNA, near noble metal surfaces. 
With recent advancements in handheld portable SERS systems
19
, SERS-based assay may 
potentially be adopted for rapid, sensitive and portable POC applications. SERS-based assays 
typically use labels such as Raman reporter molecules-coated gold nanoparticles (AuNPs), to 
generate a distinctive Raman signal for detection, which requires additional 
modifications/hybridization on AuNPs. Nonetheless, label-free and direct SERS platform 
offers great opportunity for simple and rapid detection of nucleic acids by using AuNPs or 
silver nanoparticles (AgNPs) aggregates as an enhancement substrate.
20, 21
 However, since the 
duplex structure of double-stranded DNA (dsDNA), in conjunction with the strong 
electrostatic repulsion between negatively-charged dsDNA and AuNPs/AgNPs; prevent the 
bases from being exposed to the metal surface, direct SERS detection of dsDNA bases 
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remains challenging.
20
 As such, most of these approaches typically require single-stranded 
DNA (ssDNA) detection by exploiting the strong affinity between ssDNA and AuNPs. While 
useful, ssDNA are inherently susceptible to rapid degradation and thus may limit its 
applications. To address this, Graham and co-workers recently reported the use of spermine-
modified AgNPs to create stable dsDNA-AgNPs aggregates, thus allowing direct SERS 
detection of dsDNA bases.
22
 Nonetheless, we propose an alternate strategy whereby 
streptavidin-modified AuNPs (SA-AuNPs) may be used to bind biotinylated dsDNA analytes 
instead. This, therefore allows for better control over the dsDNA/AuNPs aggregation and in 
turn, enables a label-free and quantitative SERS assay for dsDNA detection.  
  
Herein, we describe, to the best of our knowledge, the first assay to merge isothermal RT-
RPA with dsDNA/AuNPs-mediated SERS to detect TMPRSS2-ERG transcripts in a fast, 
sensitive and specific fashion. Using this strategy, we were able to detect as little as 10
3 
copies input of synthetic TMPRSS2-ERG transcripts and show specific TMPRSS2-ERG 
detection in different PCa cell lines. To demonstrate clinical feasibility, the method was also 
successfully extended to PCa urine samples where fusion gene status was determined 
accurately in 75 mins.                                     
 
EXPERIMENTAL 
Reagents 
All reagents were purchased from Sigma Aldrich and used as is unless otherwise stated. DNA 
oligonucleotides (Integrated DNA Technologies, USA) were purchased and sequences are 
shown in Table 1.  
 
Table 1. Oligonucleotide sequences used in experiments.  
Oligos 5'-Sequence-3' 
Synthetic TMPRSS2-ERG 
Sequence 
GAGTAGGCGCGAGCTAAGCAGGAGGCGGAGGCGGAG
GCGGAGGGCGAGGGGCGGGGAGCGCCGCCTGGAGCG
CGGCAGGAAGCCTTATCAGTTGTGAGTGAGGACCAGT
CGTTGTTTGAGTGTGCCTACGGAACGCCACACCTGGCT
AAGACAGAGATGACCGCGTCCTCCTCCAGCGACTATG
GACAGACTTCCAAGATGAGCCCACGCGTCCCTCAGCA
GGATTGGCTGTCTCAACCCCCAGCCAGGGTCACCATC
AAAATGGAATGTAACCCTAGCCAGGTGAATGGCTCAA
G 
RT-RPA TMPRSS2-ERG CCTGGAGCGCGGCAGGAAGCCTTATCAGTTG 
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Fwd Primer Sequence 
RT-RPA TMPRSS2-ERG 
Rev Primer Sequence GCTAGGGTTACATTCCATTTTGATGGTGAC 
RT-RPA Housekeeping 
Fwd Primer Sequence 
GCTATGCCGATCGGGTGTCCGCACTAAGTT 
RT-RPA Housekeeping 
Rev Primer Sequence 
GACGGGGTCTCGCTATGTTGCCCAGGCTGG 
RT-PCR Fwd Primer 
Sequence 
CCTGGAGCGCGGCAGGAAGCCTTATCAGTTG 
RT-PCR Rev Primer 
Sequence TCCTGCTGAGGGACGCGTGGGCTCATCTTG 
 
Preparation of SA-AuNPs for SERS detection  
AuNPs with ~60 nm diameter were synthesized by aqueous reduction of HAuCl4 with 
sodium citrate according to Frens’s method.23 SA-AuNPs were prepared as previously 
reported.
24
 Briefly, 1 mL of 60 nm AuNPs was adjusted to pH 9.0-9.5 with 1 M NaHCO3 
aqueous solution. Then, 25 µL of 1 mg/mL streptavidin was added to AuNPs under shaking 
for 1 hr at RT. Next, 10 µL of 2% PEG was added and incubated for 12 hrs at 4°C to stabilize 
the SA-AuNPs. Following that, the resultant mixture was centrifuged at 4°C for 15 min (7600 
rpm) and the pellet was resuspended in 200 µL of 1M PBS for further use.  
 
RNA extraction from cell lines 
DuCap and LnCap cells were kindly donated by Matthias Nees (VTT, Finland); Gregor Tevz 
(APCRC, Australia); and Michelle Hill (UQDI, Australia). The cells were cultured in RPMI-
1640 growth media (Life Technologies, Australia) supplemented with 10% fetal bovine 
serum (Life Technologies, Australia) in a humidified incubator containing 5% CO2 at 37 ºC. 
RNA was extracted using Trizol® reagent (Life Technologies, Australia). RNA purity and 
integrity were checked using a NanoDrop Spectrophotometer (Thermo Scientific, USA). 
 
RNA extraction from clinical urinary samples 
Urinary samples (30–50 mL) were centrifuged at 700 g for 10 min and urinary sediments 
were washed with ice-cold PBS buffer before being centrifuged again at the same condition. 
25 µL of lysis buffer (150 mM Tris-HCI pH 8.0, 4.5 M guanidium-HCI, 3% v/v Triton-X and 
1.5 mM EDTA) was added to 50 µL of PBS-suspended urinary sediments with vigorous 
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mixing to release total RNA. Next, total RNA was purified from 25 µL of cell lysate using 
the Agencourt AMPure XP SPRI kit (Beckman Coulter, USA). Briefly, two volumes SPRI 
reagent was first incubated with the cell lysate for 10 min. The RNA-bound magnetic beads 
were then separated from the lysate using a magnet and washed twice with 80% ethanol. 
Finally, total RNA was eluted in 25 µL of RNase-free water. 
 
RT-RPA 
For cell line experiments, the TwistAmp Basic RPA kit (Twist-DX, UK) was used with slight 
modifications to manufacturer’s instructions. Briefly, 1 µL of extracted RNA, 50 units of 
MMuLV reverse transcriptase (New England Biolabs, UK), 250 nM of each primer (Table 1) 
and 20 nM of biotinylated dUTPs (ThermoFisher, Australia) were added to make a 12.5 µL 
reaction volume prior to incubation at 41°C for 20 min. For all other experiments, the 
TwistAmp Basic RT-RPA kit (Twist-DX, UK) was used with slight modifications to 
manufacturer’s instructions. Briefly, 1 µL of extracted RNA and 250 nM of each primer 
(Table 1) were added to make a 12.5 µL reaction volume prior to incubation at 41°C for 20 
min. RT-RPA amplicons were visualized on 1.5% agarose gel to verify amplification and 
validate SERS results.  
 
RT-PCR 
RT-PCR was performed to validate results of clinical urinary samples. The KAPA SYBR
®
 
FAST One-Step qRT-PCR kit (Kapa Biosystems, USA) was used to set up a single reaction 
volume of 10 µL for each sample. Each reaction volume consisted of 1X KAPA SYBR
®
 
FAST qPCR Master Mix, 200 nM of each primer (Table 1), 1X KAPA RT Mix and 3 µL of 
extracted RNA. The tubes were incubated at 42°C for 10 min to synthesize cDNA, followed 
by 95°C for 5 min to deactivate RT before cycling 35 times (95°C for 30 s, 69°C for 30 s and 
72°C for 1 min) and finished with 72°C for 10 min. Lastly, the RT-PCR amplicons were 
visualized on 1.5% agarose gel to verify amplification. 
 
SERS detection 
1 uL of RT-RPA amplicons were incubated with 10 µL of synthesized SA-AuNPs for 10 min 
at room temperature to allow coating of biotin-dsDNA onto AuNPs based on biotin-
streptavidin binding.  SERS spectra were recorded with a portable IM-52 Raman microscope 
(Snowy Range Instruments, USA). The 785 nm laser was used for excitation of Raman 
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scattering, and SERS spectra were obtained at 1 sec integration with laser power (70 mW) 
under a long distance objective (40 x, NA = 0.60). 
 
For quantitative TMPRSS2-ERG measurements, the average Raman intensity at 795 cm
-1
 
(wavenumber for uracil)
25
 on the SERS spectra of the sample of interest was normalized with 
the same point on the SERS spectra of the RN7SL1 housekeeping RNA. The normalization 
was calculated as follows: 
 
Relative TMPRSS2:ERG Level = XSample / XHousekeeping  
 
where XSample and XHousekeeping are the average Raman intensity at 795 cm
-1
 for sample of 
interest and housekeeping RNA respectively. 
  
For convenient stratification of patients’ fusion gene status, a relative TMPRSS2:ERG value 
of 1.0 was established as the cut-off for differentiating patients who were positive or negative 
for TMPRSS2:ERG respectively. This value was obtained through DuCap and LnCap cell 
line studies (Fig. 3D) which showed that the relative TMPRSS2:ERG level for LnCap 
(negative for TMPRSS2:ERG) did not exceed the value of 1.0.    
  
RESULTS AND DISCUSSION 
Principle of SERS assay for gene fusion detection 
Fig.1 depicts the schematic representation of our approach for gene fusion detection by RT-
RPA and SERS. After total RNA purification from cells, a short region spanning across 
TMPRSS2-ERG fusion junction is amplified isothermally by RT-RPA. During the 
amplification process, biotinylated dUTPs are randomly incorporated in place of T into 
growing strands to generate biotin-dsDNA polymers. These biotin-dsDNA polymers then 
serve as binding substrates for SA-AuNPs and can result in a AuNPs-dsDNA network 
structure as shown in Fig. 1. Upon laser excitation, SERS signals from individual nucleic acid 
bases are generated. The SERS signal level is proportional to the amount of RT-RPA 
amplicons, which in turn, reflect the amount of TMPRSS2-ERG transcripts in the sample. In 
contrast, no biotin-dsDNA polymers are generated in the absence of fusion transcripts for 
SA-AuNPs binding and thus, no distinct SERS signal is observed.  
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Fig. 1. Schematic representation of combining RT-RPA and SERS for rapid TMPRSS2-ERG 
detection. Total RNA is isolated from sample source and TMPRSS2-ERG transcripts are 
specifically amplified by RT-RPA isothermally. During strand polymerization, biotinylated 
dUTP bases are randomly incorporated and subsequently serve as binding sites for SA-
AuNPs. Upon laser excitation, AuNPs enhance DNA-mediated SERS to signal positive 
amplification, which in turn, represents TMPRSS2-ERG presence. No amplification and 
therefore no SERS signal is generated if the fusion gene is not present.  
 
Sensitive detection of TMPRSS2-ERG transcripts 
To evaluate the sensitivity of our assay, we titrated synthetic TMPRSS2-ERG RNA 
transcripts at known concentrations (0-10
8
 input copies) and measured the resulting SERS 
signal. The SERS spectra shown in Fig. 2A clearly indicated the distinct signals of different 
bases in the RT-RPA amplicons. Signal peaks at 795 cm
-1
, 1240 cm
-1
 and 1385 cm
-1
 
corresponded to uracil while the peak at 1560 cm
-1
 was that of guanine.
25
 As expected, the 
average SERS signal also increased proportionally with increasing input templates (Fig. 2A). 
The corresponding gel electrophoresis analysis of the RT-RPA amplicons, which showed 
increasing band intensities in an input-dependent manner, was also in good agreement with 
our SERS data (Fig. 2B). Although we observed low level of SERS signal peaks in the no-
template control (NTC) (Fig. 2A), we attributed this to minimal amounts of non-specific 
amplification which could not be observed by gel electrophoresis (Fig. 2B) but detectable by 
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more sensitive SERS technique. Using 795 cm
-1
 as the reference wavenumber for uracil 
bases, the detection limit of our assay was about 10
3 
copies of TMPRSS2-ERG RNA input, at 
which the average SERS signal was approximately 1.5-fold higher (t-test P<0.05) above the 
background signal of the NTC (Fig. 2C). This low detection limit of our assay was 
approximately the amount of TMPRSS2-ERG transcripts present within a single cell.
26
 In 
addition, SERS signal from dsDNA (10
8
 copies) only without AuNPs; AuNPs; and SA-
AuNPs controls showed very weak intensity with no well-defined peaks presented, thus 
demonstrating that SERS signals in our assay were mainly generated from amplified nucleic 
acid bases using AuNPs for SERS enhancement. Considering the presented data, the low 
detection limit (10
3
 input copies) and RSD (10.8%) demonstrated the high sensitivity and 
reproducibility of our TMPRSS2-ERG assay.  
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Fig. 2. Sensitivity of assay. (A) Average SERS spectra generated using 0 - 10
8
 copies of 
synthetic TMPRSS2-ERG transcripts as initial RT-RPA inputs.  (B) Gel electrophoresis 
image generated using 0 - 10
8
 copies of synthetic TMPRSS2-ERG transcripts as initial RT-
RPA targets. (C)  Average Raman intensity (at 795 cm
-1
)
 
of different initial RT-RPA input 
amount. Error bars represent standard deviation of three independent experiment. 
 
Specific TMPRSS2-ERG detection in DuCap cell line 
To test the specificity of our assay, we assayed the DuCap and LnCap model cell lines which 
were positive and negative for TMPRSS2-ERG transcripts respectively
4
. As expected, the 
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average SERS signal generated from DuCap-derived RNA was distinctly higher than that of 
LnCap (Fig. 3A). In contrast, the average SERS signal of LnCap-derived RNA was low and 
close to the background signal of the no template (NTC). We also performed our assay on the 
RN7SL1 housekeeping gene
27
 as a loading control and observed consistent average SERS 
spectra (Fig. 3B) thus demonstrating that the difference in SERS signal was indeed due to the 
difference in TMPRSS2-ERG status. We further validated our results with gel electrophoresis 
(Fig. 3C) and similar to the SERS data, amplification was observed only with DuCap-derived 
RNA. By normalizing TMPRSS2-ERG signals to RN7SL1’s at 795 cm-1, the SERS signal for 
DuCapwas about 2.5 fold higher than that of LnCap (Fig. 3D). Furthermore, no amplification 
was detected when reverse transcriptase was removed from the RPA reaction, thus indicating 
that amplification was TMPRSS2-ERG transcript (RNA) dependent (Fig. 3E). We also 
observed that the average SERS signals for housekeeping RN7SL1-derived RNA were lower 
than that of DuCap (Fig. 3A & 3B); despite both having similar band intensities on gel (i.e. 
same amount of amplicons) (Fig. 3C). One possible explanation could be that the RN7SL1 
amplicon sequence (45 adenine bases) contained eight lesser adenine bases and therefore 
lesser biotinylated dUTPs as compared to the TMPRSS2-ERG amplicons (53 adenine bases). 
This may, in turn, lead to lower amounts of SA-AuNPs binding and subsequently lower 
SERS signal for RN7SL1 amplicons.  
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Fig. 3. Specificity of assay. (A) Average SERS spectra generated by our assay on cell lines 
which are positive (DuCap) and negative (LnCap) for TMPRSS2-ERG. (B) Corresponding 
average SERS spectra of housekeeping RN7SL1 RNA for DuCap and LnCap cell lines. (C) 
Gel electrophoresis image generated using RT-RPA on cell lines which are positive (DuCap) 
and negative (LnCap) for TMPRSS2-ERG. (D) Housekeeping RN7SL1-normalized relative 
TMPRSS2-ERG levels of DuCap, LnCap and no-template control (NTC). Error bars 
represent standard deviation of three independent experiments. (E) Gel electrophoresis image 
generated using RT-RPA on DuCap and LnCap RNA with/without reverse transcriptase.  
 
Assay performance on clinical urinary specimens  
To demonstrate potential clinical utility, we applied our assay to urinary samples from 3 
metastatic PCa patients (Fig 4). Each individual’s TMPRSS2-ERG- and RN7SL1-derived 
Chapter 4.1 
 
139 
 
SERS spectra are shown in Fig. 4A and 4B respectively. To allow for convenient 
stratification of patients’ fusion gene status, a relative TMPRSS2:ERG level higher than the 
value of 1.0 was scored “TMPRSS2-ERG positive” as established from cell line experiments 
(Fig 3D). Using this approach, we found that Patient #1 was scored negative, while Patients 
#2 and #3 were positive for TMPRSS2-ERG. These SERS results were also in good 
agreement via standard gel electrophoresis analysis of the corresponding RT-RPA amplicons 
(Fig. 4D). An additional RT-PCR (Fig. 4E) using a different set of primers (Table 1) was also 
performed to validate our results.  
 
Finally, considering all the data presented, our proposed SERS-based assay has demonstrated 
good sensitivity, specificity and reproducibility, as well as a practical application with clinical 
patient samples. Our entire assay can be completed within 75 mins and is, to the best of our 
knowledge, one of the fastest assays for the detection of TMPRSS2-ERG. The assay may be 
useful as a diagnostic screening tool and for monitoring changes in TMPRSS2-ERG 
transcript levels, for example, over the course of cancer treatment. The assay’s simplicity and 
rapid turnover can potentially enable physicians to make timely clinical decisions especially 
in aggressive PCa cases.          
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Fig. 4. Assay performance on prostate cancer urinary samples. (A) Average TMPRSS2-ERG 
SERS spectra generated for 3 clinical urinary samples. (B) Average RN7SL1 SERS spectra 
for 3 clinical urinary samples. (C) Housekeeping RN7SL1-normalized relative TMPRSS2-
ERG levels of 3 clinical urinary samples and no-template control (NTC) control. Error bars 
represent standard deviation of three independent experiments. (D) Gel electrophoresis image 
generated using RT-RPA to detect TMPRSS2-ERG transcripts in the 3 clinical urinary 
samples. (E) Gel electrophoresis image generated using RT-PCR on 3 PCa urinary samples. 
 
CONCLUSIONS  
To conclude, we have developed a novel strategy for rapid TMPRSS2-ERG detection in PCa 
by combining RT-RPA with a direct and label-free SERS readout for the first time. Our assay 
is sensitive to 10
3 
input copies of TMPRSS2-ERG RNA transcripts (approximately single-cell 
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levels). Assay specificity was demonstrated by accurately differentiating between TMPRSS2-
ERG positive and negative cells. Our method could also be applied to PCa clinical urinary 
samples as a potential non-invasive approach for TMPRSS2-ERG detection. Finally, this 
approach is easily adaptable for the detection of other fusion genes in cancer by simply 
redesigning the RT-RPA primers. We believe that our proposed assay has potential in both 
cancer diagnostics and research as a simple yet rapid method for evaluating gene fusion 
transcripts.  
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ABSTRACT 
Simple nucleic acid detection methods could facilitate the progress of disease diagnostics for 
clinical uses. An attractive strategy is label-free surface-enhanced Raman scattering (SERS) 
due to its sensitivity and capability of providing structural fingerprinting of analytes that are 
close to or on nanomaterial surfaces. However, current label-free SERS approaches for 
DNA/RNA biomarker detection are limited to short and synthetic nucleic acid targets and 
have not been fully realized in clinical samples due to two possible reasons: i) low target 
copies in limited patient samples and ii) poor capability in identifying specific biomarkers 
from complex samples. To resolve these limitations and enable label-free SERS for clinical 
applications, we herein present a novel strategy based on a combination of multiplex reverse 
transcription-recombinase polymerase amplification (RT-RPA) to enrich for multiple RNA 
biomarkers, followed by label-free SERS aided by multivariate statistical analysis to directly 
detect, identify and distinguish between these long amplicons (~200 bp). As a proof-of-
concept clinical demonstration, we employed the strategy for non-invasive subtyping of 
prostate cancer (PCa). In a training cohort of 43 patient urinary samples, we achieved 93.0% 
specificity, 95.3% sensitivity, and 94.2% accuracy. We believe that our proposed assay could 
pave the way for simple and direct label-free SERS detection of multiple long nucleic acid 
sequences in patient samples and thus facilitate rapid cancer molecular subtyping for 
personalized therapies. 
 
INTRODUCTION 
The analysis of RNA biomarkers in cancer could inform on disease pathogenesis, medical 
diagnosis, disease staging, and therapeutic monitoring.
1
 For example, in prostate cancer 
(PCa), the molecular subtyping of patients based on their highly PCa-specific gene fusion 
mutation - TMPRSS2 exon 1 and ERG exon 4 (T1E4) - RNA status could potentially inform 
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clinical decision-making and aid in directing precision therapies.
2, 3
 However, current 
commonly employed RNA detection strategies (e.g. reverse transcription-polymerase chain 
reaction (RT-PCR), next generation sequencing (NGS), NanoString, and Forster resonance 
energy transfer (FRET)-based biosensors, etc.) suffer from limitations such as costly 
fluorescence labelling and complex experimental procedures.
1, 4-6
 While other contemporary 
methods employing isothermal amplification have been proposed to shorten assay time and 
cost,
7, 8
 most still require some form of expensive reagents. Simpler and low-cost strategies 
are therefore urgently needed to facilitate the use of RNA biomarkers in clinic. 
 
Label-free surface-enhanced Raman scattering (SERS), an approach to directly detect 
molecules absorbed onto nanostructure surfaces, is an attractive and powerful tool for nucleic 
acid detection. Compared to other technologies or SERS sensors that require auxiliary 
labelling modification/hybridization chemistry, label-free SERS sensors have the competitive 
characteristics in rapid, simple, cost-efficient and direct detection as well as providing the 
chemical component information for the target. However, most of current label-free SERS 
detection of nucleic acids are limited to short synthetic sequences, mainly focusing on 
characterizing chemical and structural differences within a single DNA/RNA sequence,
9-14
 
and have rarely, if any, been translated into clinical applications. This could be due in part to 
the poor spectral reproducibility and/or limited sensitivity.
10
 Notwithstanding, applying label-
free SERS technology to DNA/RNA biomarker detection in clinical samples has additional 
major challenges including: i) trace levels of target RNA biomarkers in limited, complex 
clinical samples; ii) poor capability to detect multiple DNA/RNA biomarkers simultaneously. 
Novel strategies are therefore needed to implement label-free SERS-based DNA/RNA 
bioassays for subtyping cancer. 
 
To overcome limitations of label-free SERS for clinical applications, we herein present a 
novel DNA/RNA detection strategy consisting of multiplex reverse transcription-
recombinase polymerase amplification (RT-RPA) to enrich for target sequences followed by 
sequence identification with label-free SERS. As previous works distinguish multiple 
sequences based on subtle SERS spectral differences,
10, 12
 they are unavoidably subject to 
subjectivity and poor spectral reproducibility. To address these issues, multivariate statistical 
analysis was used to distinguish between two > 200 bp long sequences and to predict for the 
presence of a particular sequence. As a proof-of-concept clinical demonstration, we applied 
the method in the risk stratification of PCa in 43 urinary samples based on a highly-promising 
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PCa RNA biomarker - T1E4 fusion gene, as well as an endogenously-expressed 
housekeeping RNA (RN7SL1)
15
 that is used as a loading control to verify the presence of 
input RNA (i.e. rule out false-negative T1E4 results).
15
 With 93.0% specificity, 95.3% 
sensitivity, and 94.2% accuracy, we believe that the proposed assay could pave the way for 
simple and direct label-free SERS detection of long nucleic acid sequences in complex 
samples. 
 
MATERIALS AND METHODS 
Materials  
All reagents were purchased from Sigma Aldrich, unless otherwise stated. Synthetic 
oligonucleotide and primer sequences used in our experiments were purchased from 
Integrated DNA Technologies (Singapore), and sequences are shown in Table 1.  
 
Table 1. Oligonucleotide sequences 
Oligos 5'-Sequence-3' 
T1E4 RT-RPA Fwd Primer  CCTGGAGCGCGGCAGGAAGCCTTATCAGTTG 
T1E4 RT-RPA Rev Primer  GCTAGGGTTACATTCCATTTTGATGGTGAC 
RN7SL1 RT-RPA Fwd Primer  GCTATGCCGATCGGGTGTCCGCACTAAGTT 
RN7SL1 RT-RPA Rev Primer  GACGGGGTCTCGCTATGTTGCCCAGGCTGG 
T1E4 RT-RPA amplicon  
CCTGGAGCGCGGCAGGAAGCCTTATCAGTTGTGAG
TGAGGACCAGTCGTTGTTTGAGTGTGCCTACGGAA
CGCCACACCTGGCTAAGACAGAGATGACCGCGTCC
TCCTCCAGCGACTATGGACAGACTTCCAAGATGAG
CCCACGCGTCCCTCAGCAGGATTGGCTGTCTCAACC
CCCAGCCAGGGTCACCATCAAAATGGAATGTAACC
CTAGC 
RN7SL1 RT-RPA amplicon  
GCTATGCCGATCGGGTGTCCGCACTAAGTTCGGCAT
CAATATGGTGACCTCCCGGGAGCGGGGGACCACCA
GGTTGCCTAAGGAGGGGTGAACCGGCCCAGGTCGG
AAACGGAGCAGGTCAAAACTCCCGTGCTGATCAGT
AGTGGGATCGCGCCTGTGAATAGCCACTGCACTCC
AGCCTGGGCAACATAGCGAGACCCCGTC 
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RNA extraction from cell line  
DuCap cell line was kindly donated by Matthias Nees (VTT, Finland) and Gregor Tevz 
(APCRC, Australia). The cells were cultured in RPMI-1640 growth media (Life 
Technologies, Australia) supplemented with 10% fetal bovine serum (Life Technologies, 
Australia), 2 mM Glutamax (Gibco, Australia) and 1% PenStrep (Invitrogen, Australia) in a 
humidified incubator containing 5% CO2 at 37 ºC. RNA was extracted using Trizol® reagent 
(Life Technologies, Australia). RNA purity was checked using a NanoDrop 1000 
Spectrophotometer (Thermo Scientific, USA). 
 
RNA extraction from urinary samples  
For clinical samples, ethics approval was obtained from The University of Queensland 
Institutional Human Research Ethics Committee (Approval No. 2004000047) and informed 
consent was obtained from all subjects prior to sample collection. Methods pertaining to 
clinical samples were carried out in accordance with approved guidelines. Voided urinary 
samples were collected from male patients undergoing treatment for PCa and healthy men 
with no PCa history. Total RNA was extracted from urinary samples using the commercially-
available ZR urine RNA isolation Kit
TM
 (Zymo Research, USA). For each sample, 30 mL of 
urine was passed through the supplied ZRC GF
TM
 Filter to retain urinary cells. Then, 700 µL 
of supplied urine RNA buffer was passed through the filter and the filtered cells were 
collected in the flow-through. Next, as per manufacturer’s instructions, cells from the flow-
through were lysed, washed and eluted in 10 µL of RNase-free water. 
 
RT-RPA of RNA biomarkers  
The TwistAmp Basic RT kit (Twist-DX, UK) was used with slight modifications to 
manufacturer’s instructions to simultaneously generate complementary DNA (cDNA) and 
rapidly amplify cDNA templates in a single tube reaction. Briefly, 1 µl of extracted total 
RNA and 250 nM of each primer (Table 1) were added to the supplied reagents to make a 
12.5 µl reaction volume prior to incubation at 41°C for 15 min. Amplicons were then purified 
using the Agencourt AMPure XP SPRI kit (Beckman Coulter, USA) and then eluted in 
RNase-free water for the following SERS measurement. 
 
Preparation of AgNPs  
Silver nanoparticles of positive surface charges (AgNPs) were prepared as previously 
reported.
16
 Briefly, 100 µL 0.5 M AgNO3 was added to 50 mL of distilled water, followed by 
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the addition of 35 µL 0.1 M spermine. The mixture was under vigorous stirring for 20 min 
before the addition of 1.25 mL 0.01 M NaBH4. The reaction was kept under gentle stirring 
for 20 min until the colloid colour turned into grey. The ζ potential of the AgNPs (diluted in 
water) is +19.2 ± 0.4 mV, measured by Zetasizer NANO Series using standard settings 
(viscosity = 0.89, temperature = 25 
◦
C). TEM (JEM-1010) and UV-vis spectra (NanoDrop 
1000 spectrophotometer) detection were also performed to characterize AgNPs (Fig. S1). The 
maximum absorption peak for the AgNPs locates at 397 nm. 
 
Label-free SERS measurements  
1 µL of RT-RPA amplicons was mixed with 60 µl of AgNPs for 2 h. Next, SERS spectra in 
the range of 400-1800 cm
-1
 were collected from the sample mixture using a portable IM-52 
Raman Microscope with a 785 nm wavelength laser as the excitation source. 70 mW of 
incident laser power in 1 s of illumination was used for the detection. Each sample was 
represented with the average spectrum calculated from 5 measurements. 
 
Multivariate statistical analysis for biomarker prediction model  
The raw SERS spectra were firstly baseline-corrected to remove background noise using the 
Vancouver Raman Algorithm (a five-order polynomial fitting algorithm).
17
 In order to 
compensate for gross differences in the spectral response due to physical effects, area 
normalization of the spectroscopic data was performed by Origin 8 software (OriginLab Inc., 
USA).  
 
A combination of principal component analysis (PCA) and linear discriminant analysis 
(LDA) - termed as PCA-LDA was applied in multivariate statistical analysis. As each SERS 
spectrum in the range of 400-1800 cm
-1
 possessed 1401 variables, PCA was therefore 
introduced to capture main variables for expression in different linear combinations of 
significant principal components (PCs). Spectrum i is in the form as:  
       
 
       
where    represents spectrum i and is a combination of parameters,      values are PC scores 
and   is the residual. The data     is highly correlated in a multi-dimensional space.   
 
Independent T-test of PC scores was used to examine ability in discriminating two data sets 
that were composed of separate T1E4 and RN7SL1 SERS spectra. Selected PC scores from 
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significantly different PCs (p < 0.05) were used to build the LDA training model in an 
unbiased manner with the leave-one-out and cross-validation method. In this method, one 
sample (i.e., one spectrum) was left out from the data set, and the remaining samples were 
used for redeveloping the LDA model to classify the withheld sample. This process was 
repeated until all samples were classified. A receiver operating characteristic (ROC) curve 
which was generated by successively changing discrimination thresholds to determine 
discrimination sensitivity and specificity of the LDA model, was introduced to illustrate the 
discrimination ability of PCA-LDA model in predicting the different RNA biomarkers.  
 
SPSS 19.0 software package (SPSS Inc., Chicago, Illinois) was used for Independent T-test, 
PCA, LDA, and ROC analysis. 
 
RESULTS AND DISCUSSION 
Principle of target RNA biomarker detection using RT-RPA coupled with label-free 
SERS 
Fig.  1 depicts the RT-RPA coupled with label-free SERS strategy for cancer subtyping via 
RNA biomarkers in PCa patient samples. After total RNA extraction from urinary samples, 
target RNA biomarkers are amplified by isothermal RT-RPA and stabilized in the form of 
dsDNA amplicons. We believe this homogeneous mixture of highly-concentrated and stable 
DNA aids in achieving reproducible SERS signals. Following the amplification and 
purification, dsDNA amplicons are mixed with positively-charged AgNPs that function as 
SERS substrates. The AgNPs’ surfaces are covered with spermine to generate stable colloids 
in aqueous solution and enable formation of long-term (> 24 h) stable particle clusters after 
DNA addition.
10, 16
 When DNA adhesion reached its equilibrium (2 h), SERS spectra are 
collected in colloidal suspensions with a long working distance objective to represent a 
statistically-averaged result of a large ensemble of nanoparticle/DNA clusters in continuous 
Brownian motions within the scattering volume. This offers SERS spectra reproducibility that 
could represent molecular information of dsDNA amplicons such as base components and 
phosphate backbone structures. As such molecular information is distinct for different RNA 
biomarkers, it is therefore expected that the resulting SERS spectra will enable discrimination 
between different RNA biomarker sequences. 
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Fig. 1. Schematic representation of label-free SERS detection for RNA biomarkers. The total 
RNA was firstly extracted from urinary samples. RT-RPA was then used to amplify the target 
RNA into dsDNA sequences. Purification of amplicons was performed prior to incubation 
with positively-charged AgNPs and subsequent SERS measurements. 
 
Assay demonstration using DuCap cell line RNA  
To test the capability of our assay for clinical applications, we first used cultured RN7SL1- 
and T1E4-positive DuCap cell line as a preliminary model to individually detect T1E4 and 
RN7SL1RNA biomarkers. After performing the assay, we successfully acquired two unique 
SERS spectra for each target (Fig. 2A, curves a-b), which were also easily-discriminated 
from background signals of the RT-RPA no-template control (NTC) and AgNPs alone (Fig. 
2A, curves c-d). The major vibrational peak assignments for SERS spectra of targets have 
been listed on Table 2. The peaks assigned to phosphate backbone (913 cm
-1
), purines (560, 
742 and 1334 cm
-1
), and pyrimidines (1632 cm
-1
) could readily be observed on the SERS 
spectral profiles of both T1E4 and RN7SL1 target amplicons. In contrast, these peaks were 
absent on both SERS spectra of the no-template and AgNPs controls, and could therefore be 
used to specifically detect the presence of target amplicons.  
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Fig. 2. (A) Typical average SERS spectra of (a) RN7SL1 and (b) T1E4 RNA from DuCap 
cell line sample, (c) no-template control (NTC), and (d) background signal of AgNPs. (B) 
Gel electrophoresis image of RT-RPA amplicons from DuCap cell line-derived total RNA.  
 
Table 2. Typical vibrational assignments of major peaks in the observed SERS spectra of 
RNA transcripts 
Peak positions (cm
-1
) Major assignments 
560 A
18
 
742 Ring breathing of A,
18, 19
 T
20
 
788 C, T
21
  
913 Deoxyribose and backbone,
20, 22
 phosphate
18
,  
1035 dT, dG, dC, deoxyribose,
22
 A,
18
   
1180 T
21
 
1247/1263 C, G
21
 
1334 Ring breathing of A
18, 19
  
1457 A,
18
 deoxyribose and backbone 
20
 
1539 Ring stretching of dA and dG
22
 
1632 C=C stretching of C
23
 
Abbreviations: A - adenine; T - thymine; C - cytosine; G - guanine. dA - deoxyadenosine; dG 
- deoxyguanosine; dC - deoxycytidine; dT - deoxythymidine; 
 
Gel electrophoresis analysis was used to validate the successful amplification and sizes of 
T1E4 and RN7SL1 RT-RPA amplicons from the DuCap cell line (Fig. 2B). As expected, 
T1E4 and RN7SL1 amplicons were 216 bp and 204 bp respectively, thus indicating specific 
RT-RPA amplification.  
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Assay sensitivity  
Sensitive assays are very beneficial as availability of clinical specimens and target abundance 
are typically limited in quantity. To this end, we tested assay sensitivity by titrating synthetic 
T1E4 RNA (0-10
6 
copies) in a background of total RNA isolated from a T1E4-negative cell 
line. In Fig. 3A, we observed that peak intensities at 742 and 1334 cm
-1
 (purines) increased 
with higher synthetic T1E4 input copies, and therefore the two peaks were utilized as 
candidates for assay sensitivity evaluation. As shown in Fig. 3B and 3C, the peaks at 742 and 
1334 cm
-1
 for a low amount of synthetic T1E4 input copies (10
2
) were significantly higher (p 
< 0.05) than no-input signals, and 10
2 
T1E4
 
input copies was thus determined as our assay 
detection limit. RT-RPA amplification of target RNA biomarkers was fundamental in 
exponentially increasing low RNA target copies in the starting sample and stabilizing the 
amplicons in dsDNA form, thus leading to a sensitive and robust label-free SERS detection 
strategy for trace amounts of RNA biomarkers. 
 
Gel electrophoresis analysis of the corresponding RT-RPA amplicons (for different T1E4 
input copies) was further employed to verify RT-RPA products (Fig. 3D). As consistent with 
SERS, we observed a positive association between gel band intensities and T1E4 input 
copies. However, the detection sensitivity of gel electrophoresis was lower at 10
4
 input 
copies, at which an amplicon band was still visible. It is worthy to note that recently 
described colorimetric RT-RPA assays for T1E4 detection also have poorer analytical 
sensitivity as compared to label-free SERS assay.
24, 25
 This 100-fold improvement in 
sensitivity further underscores a potential advantage of combining label-free SERS with RT-
RPA. We attributed this increase in T1E4 detection sensitivity to the signal amplification 
conferred by SERS. Meanwhile, compared to other label-free SERS-based technologies,
9, 11, 
26
 our methodology is unique in detecting longer sequences and at lower starting RNA 
concentration through the combination use of positively-charged AgNPs and RT-RPA. 
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Fig. 3. Assay sensitivity evaluation. (A) Typical average SERS spectra after baseline-
correction generated using various amounts of input synthetic T1E4 sequences. (B) Typical 
comparison of 742 and 1334 cm
-1
 peaks in the average SERS spectra of T1E4 after baseline-
correction generated with no input and using 10
2 
and 10
3
 copies of input synthetic T1E4 
sequences. (C) Average SERS intensities (at 742 and 1334 cm
-1
) using different amounts of 
input synthetic T1E4 sequences. Error bars represent standard deviations (SDs) of three 
independent experiments. (D) Gel electrophoresis image generated using various amounts of 
input synthetic T1E4 sequences.  
 
Assay application to patient samples  
After establishing the feasibility of our assay for RNA biomarker detection in cultured cells, 
we proceeded to apply our method to clinical PCa samples. In this regard, we performed our 
assay for the detection of T1E4 and RN7SL1 RNA biomarkers from a T1E4-positive, a 
T1E4-negative, and a healthy control urinary samples. As shown in Fig. 4A, SERS spectra of 
RN7SL1 (curve a) and T1E4 (curve b) RNA biomarkers from a T1E4-positive urinary 
sample were similar to those of same biomarkers detected from DuCap cell line. In contrast, 
SERS spectra of T1E4-negative (curve c) and healthy (curve d) controls showed no peaks at 
positions for purines, pyrimidines and phosphate backbone (Table 2). Instead, SERS spectra 
from T1E4-negative and healthy samples resembled the background signal from AgNPs (Fig. 
2A, curve d). As the presence of T1E4 biomarker in these three urinary samples was pre-
verified via RT-RPA and gel electrophoresis analysis (Fig. 4A insert), we demonstrated the 
successful detection of PCa biomarkers in urinary samples using our assay combination of 
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RT-RPA and AgNPs-based label-free SERS. Given that negligible signals were obtained for 
the control samples, our assay also exhibited accurate and selective target detection.  
 
Most importantly, our assay offers several advantages over current RNA detection 
methodologies in clinical samples: i) relatively short assay time (~ 2 hr) and low cost; ii) no 
need for any labelling procedures for detection readout; iii) molecular information achieved 
from SERS spectra could be potentially useful for further cancer subtyping analysis.  
 
We further investigated our assay reproducibility for detecting PCa urine-derived RNA 
biomarkers by including more T1E4-positive patient samples (n = 43). Fig. 4B showed that 
distinct T1E4 and RN7SL1 SERS spectra could be reproducibly detected in this larger cohort 
of patient samples. This data further suggested the clinical potential of our assay for non-
invasive RNA biomarker detection in urinary samples.  
 
 
Fig. 4. Typical average SERS spectra of RNA biomarkers from urinary samples. (A) Typical 
average SERS spectra of (a) internal control RN7SL1- and (b) T1E4-amplified from a T1E4-
positive urinary sample, (c) a T1E4-negative urinary sample, and (d) a healthy control. The 
inset is the gel electrophoresis image of T1E4 and RN7SL1 RT-RPA amplicons from the 
T1E4-positive, T1E4-negative, healthy urinary samples. (B) Normalized average SERS 
spectra of RN7SL1 and T1E4 amplicons from 43 T1E4-positive urinary samples, with the 
shaded areas representing the SDs of the means.  
 
Statistical analysis for prostate cancer subtyping  
We envisaged one potentially significant clinical application of our assay is for biomarker-
based cancer subtyping. By sensitive and specific detection of cancer subtype-specific 
biomarkers, we could potentially classify patients for more precise and effective therapies 
with the proposed assay.  
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In order to differentiate and predict T1E4-positive PCa with greater discrimination, we 
employed PCA-LDA-based multivariate statistical method to deconvolute the different SERS 
spectra. PCA identified key components (i.e. PCs) for differentiating SERS spectra of T1E4 
and RN7SL1 amplicons. Using Independent T-test, we found that PC1, 3 and 4 have p values 
of < 0.001 but PC2 has a p value of > 0.05. This indicated that PC2 included less information 
in differentiating RN7SL1 and T1E4 and was therefore omitted. To further discuss the 
difference contributions of PC1, 3 & 4 towards discriminating between T1E4 and RN7SL1 
RNA biomarkers, we used the individual PC correlation coefficient profiles (Fig. S2). We 
observed that PC1, 3 & 4 contributed peaks at 487 cm
-1 
(background AgNPs signal), 560 cm
-1 
(adenine), 742 cm
-1 
(adenine and thymine), 788 cm
-1 
(cytosine and thymine), 913-1035 cm
-1 
(adenine, deoxythymidine, deoxyguanosine, deoxycytidine, deoxyribose, backbone, and 
phosphate), 1180 cm
-1 
(thymine), 1247/1263 cm
-1 
(cytosine and guanine), 1457 cm
-1 
(deoxyribose, backbone, and adenine), 1539 cm
-1  
(adenine and guanine) and 1605-1684 cm
-1 
(cytosine and thymine) cm
-1
.
18, 20-22
  Consequently, PC1, PC3 and PC4 scores were selected 
for discriminating SERS spectra of T1E4 and RN7SL1 amplicons (Figs. 5A-C) and used as 
axes in three-dimensional mapping of T1E4 and RN7SL1 SERS signals (Fig. 5D).   
 
In Fig. 5D, T1E4 and RN7SL1 SERS signals (n = 43 for each) were clustered into two 
separate groups on the basis of their PC scores, thus indicating that the combination of (PC1, 
PC3, and PC4) was significant in differentiating T1E4 and RN7SL1 RNA biomarkers in PCa 
urinary samples. These three PCs were then incorporated to build a biomarker-discriminating 
training model and this training model is demonstrated to be able to predict SERS signals of 
T1E4 and RN7SL1 with the specificity of 93.0%, sensitivity of 95.3%, and accuracy of 
94.2% (Fig. 5E).  
 
In order to demonstrate our assay as a potential PCa subtype screening tool, we performed 
duplexed RT-RPA amplification and label-free SERS detection of both T1E4 and RN7SL1 
biomarkers from each of 11 T1E4-positive urinary samples. As the presence of both 
biomarkers within a single sample after duplexed amplification led to different SERS spectral 
signatures from our well-differentiated individual T1E4 and RN7SL1 SERS signals, our 
developed PCA-LDA training model could accurately discriminate these 11 ‘mixed’ samples, 
as shown in Fig. 5E. The distribution of discriminant scores in Fig. 5E showed that the 
‘mixed’ samples were located between individual T1E4 and RN7SL1 clusters with an area 
under ROC curve (AUC) of 0.978 (Fig. 5F). This indicated that our model was capable of 
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identifying samples which were positive for both PCa biomarker T1E4 and internal control 
RN7SL1, thus suggesting a valuable first-line clinical screening tool for identifying T1E4-
positive PCa patients (via non-invasive detection from urine) for effective subtype-specific 
treatment.  
 
 
 
Fig. 5. Box plots of PC1 (A), PC3 (B), and PC4 (C) scores for RN7SL1, T1E4, and ‘mixed’ 
amplicons. The line within each notch box represents the median, and the lower and upper 
boundaries of the box indicate first and third quartiles respectively. Error bars (whiskers) 
represent the 1.5-fold interquartile range. Independent T-test yields *p < 0.001 for all three 
PCs, indicating these three PCs are diagnostically significant in differentiating RN7SL1 and 
T1E4. (D) A three-dimensional mapping of the PCA result for the RN7SL1 (black circle) and 
T1E4 (red triangle). (E) Box plots of the discriminant scores belonging to spectra of 43 
RN7SL1, 43 T1E4 and 11 ‘mixed’ amplicons from urinary samples. (F) The receiver 
operating characteristic (ROC) curve for discriminating T1E4, RN7SL1 and ‘mixed’ 
amplicons from urinary samples. 
 
The use of label-free SERS for multiplexed DNA/RNA detection is inherently difficult due to 
similar chemical structures of targets and poor spectral reproducibility.
10, 12
 To date, label-
free SERS has been limited to classification of synthetic short sequences as longer nucleic 
acid sequences have more complicated interactions with SERS substrates.
10, 12
 To 
demonstrate our methodology is applicable for various RNA targets, we successfully showed 
detection of four other RNA biomarkers isolated from three patient urine samples (Fig. S3A). 
We performed Raman difference spectra analysis for all pairing combinations of RNA target 
signals (Figs. S3B-D) and the resultant spectral peaks display spectral differences between 
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two different RNA targets. For example, in Fig. S3B, the analysis shows that T1E2 and 
RN7SL1 have spectral differences at 560 cm
-1
, 1035 cm
-1
, and 1334 cm
-1
, which could be 
assigned to adenine (560 cm
-1
, 1035 cm
-1
, and 1334 cm
-1
); and deoxythymidine, 
deoxyguanosine, deoxycytidine, and deoxyribose (1035 cm
-1
). 
 
Taken together, while we have demonstrated a duplexed assay for two long sequences (i.e. 
RT-RPA amplicons of target RNA biomarkers) from clinical samples as well as the 
applicability of our method for detecting various RNA biomarker targets (Fig. S3), future 
work could improve on aspects such as nucleic acid-NPs interactions and data processing to 
increase multiplexing capabilities. Nonetheless, a duplexed system presented here is a step 
towards this direction and is potentially useful as a diagnostic tool for multiple RNA 
biomarkers detection. 
 
CONCLUSIONS 
In this work, we presented a label-free SERS assay which incorporated RT-RPA and 
multivariate statistical analysis for detecting RNA biomarkers in clinical samples and further 
enabling PCa subtyping. Our assay overcame limitations with traditional RNA detection 
techniques and expanded label-free SERS detection to long-length nucleic acid sequences in 
clinical samples by: (1) enriching low amount of target RNA biomarkers in patient samples to 
enhance subsequent label-free SERS signals; and (2) introducing multivariate statistical 
analysis to differentiate SERS spectra of different RNA biomarkers.  
 
Our assay was shown to be sensitive to 100 copies of input RNA, and multivariate statistical 
analysis was used to differentiate two different biomarkers with excellent discrimination 
accuracy. The detection of T1E4 PCa biomarker in PCa urinary samples demonstrated the 
clinical value of our assay for non-invasive molecular classification of a potentially 
aggressive PCa subtype to enable targeted treatments.  
 
We envision that the novel combination of experimental and statistical techniques described 
in our proposed assay could be a viable way for simpler cancer subtyping (via nucleic acid 
biomarkers detection) in clinical patient samples. 
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SUPPLEMENTARY INFORMATION 
 
 
Fig. S1. UV-Vis absorption spectrum of AgNPs. The maximum absorption locates at 397 nm. 
The insert is the corresponding TEM image.  
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Fig. S2. Calculated correlation coefficient profiles of three diagnostically significant principal 
components (PCs) from a data set composed by 43 T1E4 and 43 RN7SL1 SERS spectra. 
Each PC revealed diagnostically significant spectral features (p < 0.001) for the 
discrimination between T1E4 and RN7SL1 RNA biomarkers. 
 
 
Fig. S3. (A) SERS spectra of various target RNA biomarkers isolated from patient unary 
samples (n = 3), including ARV7, SChLAP1, fusion genes between TMPRSS2 exon 1 and 
ERG exon 5 (T1E5), TMPRSS2 exon 1 and ERG exon 2 (T1E2), TMPRSS2 exon 1 and 
ERG exon 4 (T1E4), and RN7SL1. Dotted lines indicate spectral positions for differentiating 
the distinct SERS signatures of each individual target. (B-D) Difference spectra obtained by 
digital subtraction between each combination pairs of target RNA signals.  
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     5 
Amplification-Free Electrochemical RNA Biomarker Sensing 
 
 
Introduction 
Chapters 3 and 4 have explored the use of isothermal RNA amplification for detection of 
urinary prostate cancer biomarkers. However, to avoid potential complications such as 
amplification bias/artifacts, primer design for the amplification process must be carefully 
considered and further optimized experimentally. Additionally, shorter-length RNA species 
such as microRNAs require customized amplification protocols due to their short primer-
sized lengths. Thus, an amplification-free RNA biosensing system could be a viable 
alternative to detect different RNA biomarker species in their native forms directly. To this 
end, an electrochemical readout could provide the necessary analytical sensitivity for RNA 
detection without enzymatic amplification. In this chapter, a series of amplification-free 
electrochemical RNA nanobiosensors explored the novel concept of using affinity 
interactions between adenine bases and gold (Koo et al., Analytical Methods, 2015) to adsorb 
RNA targets onto electrode surfaces for amplification-free electrochemical detection. Chapter 
5.1 and 5.2 demonstrate the amplification-free detection of messenger RNA and microRNA 
respectively, and Chapter 5.3 reports the combination of DNA-templated copper nanoparticle 
synthesis and adenine-gold adsorption for amplification-free detection of all common RNA 
biomarker species.      
 
Chapter 5 is based on three published articles in Analytical Chemistry (2016) [Chapter 5.1], 
Analytical Chemistry (2016) [Chapter 5.2], and Nano Research (2017) [Chapter 5.3]. 
 
Chapter 5.1 
 
162 
 
Amplification-free Detection of Gene Fusions in Prostate Cancer 
Urinary Samples using mRNA-Gold Affinity Interactions 
 
Kevin M. Koo, Laura G. Carrascosa, Muhammad J. A. Shiddiky,
 
and Matt Trau 
 
 
ABSTRACT 
A crucial issue in present-day prostate cancer (PCa) detection is the lack of specific 
biomarkers for accurately distinguishing between benign and malignant cancer forms. This is 
causing high degree of overdiagnosis and overtreatment of otherwise clinically insignificant 
cases. As around half of all malignant PCa cases display a gene fusion mutation between the 
TMPRSS2 promoter sequence and the ERG coding sequence (TMPRSS2:ERG) detectable in 
urine; non-invasive screening of TMPRSS2:ERG mRNA in patient urine samples could 
improve specificity of current PCa diagnosis. However, current gene fusion detection 
methodologies are largely dependent on RNA enzymatic amplification, which requires 
extensive sample manipulation, costly labels for detection, and it is prone to bias/artifacts. 
Herein we introduce the first successful amplification-free electrochemical assay for direct 
detection of TMPRSS2:ERG mRNA in PCa urinary samples by selectively isolating and 
adsorbing TMPRSS2:ERG mRNA onto bare gold electrodes without requiring any surface 
modification. We demonstrated excellent limit-of-detection (10 cells) and specificity using 
PCa cell line models; and showcased clinical utility by accurately detecting TMPRSS2:ERG 
in a collection of 17 urinary samples obtained from PCa patients. Furthermore, these results 
were validated with current gold standard reverse transcription (RT)-PCR approach with 
100% concordance.  
 
INTRODUCTION 
As cancer care is increasingly moving towards personalized treatment,
1-4
 the clinical 
applications of cancer detection assays are ultimately decided by novel biomarkers which 
could stratify cancer subtypes; for instance, to clearly distinguish malignant cancer forms 
from other benign conditions. This is particularly required for prostate cancer (PCa) diagnosis 
because the current use of prostate specific antigen (PSA) biomarker is associated with over 
diagnosis and overtreatment.
5,6
 Recurrent gene fusions are an emerging class of biomarkers 
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which have been found to be widespread in different cancers such as prostate,
7
 breast,
8
 and 
lung
9
 cancers. These fusions result from chromosomal rearrangements events such as 
translocations, deletions, or inversions; and are associated with cancer initiation and 
progression by oncogene overexpression.
10,11
  
 
Among all gene fusion cancer variants, the fusion between the exon 1 promoter sequence of 
TMPRSS2 gene and the exon 4 coding sequence of ERG gene (TMPRSS2:ERG) is 
especially common in PCa. In 2005, Tomlins et al. discovered TMPRSS2:ERG to be present 
in 50% of all malignant PCa cases and further work has related it to aggressive PCa 
subtypes.
12-15
 More importantly, TMPRSS2:ERG is absent in benign conditions which do not 
require treatment.
7,12,16,17
 Furthermore, it has been shown that TMPRSS2:ERG mRNA could 
be detected non-invasively through the urine samples of PCa patients, thereby providing a 
convenient way of diagnosing PCa without invasive tissue biopsy procedures.
17,18
 This has 
allowed TMPRSS2:ERG to be an exceptionally promising biomarker for predicting 
malignant PCa during early diagnosis and for stratifying PCa risk in individual patient to 
enable precision medicine.
15,19-22
  
 
Current detection methodologies for TMPRSS2:ERG or any other gene fusion mRNA have 
largely been limited to amplification techniques such as reverse transcription-PCR (RT-
PCR)
18,19,23
 or isothermal transcription mediation amplification (TMA).
20,24,25
 In particular, 
the detection of limited TMPRSS2:ERG mRNA copies from urinary samples requires 
enzymatic reverse transcription and amplification in order to achieve suitable detection 
sensitivity limit. Although RT-PCR and TMA are useful for sensitive and specific detection 
of TMPRSS2:ERG, they involve extensive sample manipulation during enzymatic RNA 
amplification. The use of enzymes will increase assay cost and require cold storage to prevent 
enzyme degradation. The amplification process might also cause amplification bias/artifacts 
to affect assay reliability. In addition, both these techniques require a level of technical 
expertise to perform and the subsequent gel electrophoresis or fluorescence readouts involves 
time-consuming preparation steps and costly reagents/probes. Hence, the development of an 
amplification-free technique with superior urinary TMPRSS2:ERG mRNA detection 
sensitivity could avoid all these issues and would be a major breakthrough towards better and 
more robust PCa diagnosis. 
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In this report, we described a new approach for simple, sensitive, and amplification-free 
detection of TMPRSS2:ERG mRNA from cultured cells or clinical urinary samples. The 
underlying mechanism is based on poly adenine (polyA)-mediated mRNA-gold adsorption. 
Previous studies have shown that nucleic acid can spontaneously adsorb onto a bare gold 
surface by physisorption and chemisorption mechanisms.
26
 The adsorption affinity between 
nucleic acid bases and gold was found to be highly sequence-dependent and largely follows 
the trend A > C ≥ G > T27 with adenine bases displaying highest affinity interaction with gold 
over the other bases. This sequence affinity trend has been exploited in many applications
26
 
such as self-attachment of DNA sequences on gold surfaces;
28,29
 electrochemical
30,31
 or 
optical
32
 detection of changes in DNA composition (e.g., base changes due to bisulfite-treated 
methylated DNA); and more recently, detection of miRNAs.
33
 However, to the best of our 
knowledge, the use of sequence-dependent adsorption has not been demonstrated for the 
detection of long-length RNA biomarkers such as TMPRSS2:ERG mRNA. Since all mRNA 
naturally comprise of 3’ polyA tail sequences, we exploited the strong affinity interaction 
between polyA-containing mRNA and gold for adsorbing TMPRSS2:ERG mRNA onto bare 
gold electrode surfaces with high efficiency. To this end, we performed magnetic isolation of 
target TMPRSS2:ERG mRNA using probes complementary to the gene fusion junction, 
followed by polyA-mediated TMPRSS2:ERG mRNA-gold adsorption onto a bare electrode 
surface for electrochemical detection. The adsorbed mRNA was then electrochemically 
quantified in the presence of the [Fe(CN)6]
3-/4- 
redox system. Conventionally, this redox 
systems is coupled to the [Ru(NH3)6]
2+/3+ 
to improve detection sensitivity (i.e., 
electrocatalytic enhancement of the signal) of mRNA detection.
35-37
 However, we
26,30,31
 and 
Zhang et al.
34
 have previously demonstrated that this system alone can be used for 
quantification of surface-bound oligonucleotides at bare gold electrodes. In this report, for the 
first time, we rationalized that a similar system could work for rapid electrochemical 
quantification of mRNA.  
 
With our assay, the three main issues associated with conventional TMPRSS2:ERG detection 
techniques were resolved. Firstly, the direct adsorption of isolated TMPRSS2:ERG mRNA 
through their polyA tail maximized mRNA loading onto the electrode surface. This is crucial 
for highly-sensitive TMPRSS2:ERG detection without enzymatic reverse transcription and 
amplification steps. Furthermore, this adsorption mechanism is a rapid, simple, and cost-
efficient process as compared to the conventional approach of using recognition and 
transduction layers in RNA biosensors; and does not require any tedious functionalization 
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protocols underlying each step of the sensor fabrication or expensive reagents/labels. 
Secondly, the use of complementary capture probes to the gene fusion-junction ensured direct 
TMPRSS2:ERG isolation with high specificity, thus circumventing amplification 
bias/artefacts observed in conventional methods. Lastly, the use of magnetic beads for 
isolating captured TMPRSS2:ERG mRNA is an inexpensive, convenient and easily-
automated procedure. Through this approach, we achieved TMPRSS2:ERG detection from as 
little as 10 PCa cells without any amplification or electrode surface modification. To 
demonstrate clinical utility, we have also successfully extended the application of our assay 
to urinary samples of PCa patients and our assay outcomes were consistent with the gold 
standard RT-PCR method. 
 
EXPERIMENTAL SECTION 
Cell Culture  
DuCap and LnCap cells were kindly provided by Matthias Nees (VTT, Finland); Gregor 
Tevz (APCRC, Australia); and Michelle Hill (UQDI, Australia). The cell lines DuCap and 
LnCap were cultured in RPMI-1640 growth media (Life Technologies) supplemented with 
10% fetal bovine serum (Life Technologies) in a humidified incubator containing 5% CO2 at 
37ºC. Cell quantification was performed by first mixing an equal volume of 0.4% Trypan 
Blue (Sigma-Aldrich) to trypsinized cell suspension. Then, a sample mixture was loaded onto 
a haemocytometer for cell counting under an inverted phase contrast microscope. Cell 
number was diluted to the required amount for experiments accordingly and total RNA was 
extracted using Trizol® reagent (Life Technologies). RNA integrity and purity were checked 
using a NanoDrop Spectrophotometer (Thermo Scientific). 
 
RNA Extraction from Clinical Urinary Specimens  
Ethics approval was obtained from The University of Queensland Institutional Human 
Research Ethics Committee (Approval No. 201400012) and informed consent was obtained 
from all subjects prior to sample collection. Methods pertaining to clinical samples were 
carried out in accordance with approved guidelines.  
  
Voided urinary samples were collected from 17 men undergoing treatment for PCa and 4 
healthy men with no clinical history of PCa at the Royal Brisbane and Women’s Hospital. 
Total RNA was extracted from the urine samples using the commercially-available ZR urine 
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RNA isolation Kit
TM
 (Zymo Research). For each sample, 30 mL of urine was passed through 
the supplied ZRC GF
TM
 Filter to retain urinary cells. Then, 700 µL of supplied urine RNA 
buffer was passed through the filter and the filtered cells were collected in the flow-through. 
Next, as per manufacturer’s instructions, the cells from the flow-through were lysed, washed 
and eluted in 10 µL of RNase-free water. 
 
Probe Hybridization and Magnetic Isolation 
For probe hybridization, extracted total RNA from cell lines/ urinary samples were adjusted 
to required concentration (as required) in 5 µL of RNase-free water before mixing with 10 µL 
of 5x SSC buffer (pH 7) and 10 µL of 10 µM biotinylated capture probes (5’- 
CAACTGATAAGGCTTCCTGCCGCGCTCCAGG-Biotin -3’). *Underlined and bold are 
complementary to ERG and TMPRSS2 sequences respectively. The mixture was heated to 65 
ºC for 2 min before being placed on a mixer for 60 min at room temperature to allow capture 
probe hybridization to TMPRSS2:ERG mRNA. 
 
For magnetic isolation of TMPRSS2:ERG mRNA, 20 µL of streptavidin-labeled Dynabeads
®
 
MyOne
TM
 Streptavidin C1 (Invitrogen) magnetic beads was firstly washed with 2x washing 
and binding (B&W) buffer (10 mM Tris-HCl, pH 7.5; 1 mM EDTA ; 2 M NaCl) and 
resuspended in 25 µL of 2x B&W buffer. Then, the resuspended magnetic beads were added 
to the prepared capture probes-TMPRSS2:ERG mRNA (as described above), mixed 
thoroughly, and incubated on a mixer for 30 min at room temperature to allow magnetic 
beads-labeling of capture probes. After which, the magnetic beads with attached capture 
probes-TMPRSS2:ERG mRNA were isolated with a magnet, washed twice with 2x B&W 
buffer and resuspended in 10 µL of RNase-free water.   
 
Adsorption of Isolated mRNA on Gold Electrode Surface 
To release the captured TMPRSS2:ERG mRNA from the magnetic beads and capture probes, 
the magnetically-isolated TMPRSS2:ERG mRNA was heated for 2 min at 95°C, immediately 
placed on a magnet, and the supernatant containing the released TMPRSS2:ERG mRNA was 
collected. Then, 5 µL of this released mRNA was diluted to 30 µL in 5X SSC buffer (pH 7.0) 
(unless otherwise stated) and directly dropped onto the working electrode surface of a screen-
printed gold electrode (Dropsens) and allowed to adsorb for 20 min (unless otherwise stated) 
with gentle shaking at room temperature. The electrodes were then washed with 10 mM 
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phosphate buffer (137 mM sodium chloride, 2 mM potassium chloride, pH 7.4) before 
electrochemical measurements.   
 
Electrochemical Detection 
All electrochemical measurements were performed on a CH1040C potentiostat (CH 
Instruments) with the three-electrode system (gold working and counter electrodes, silver 
reference electrode) on each screen-printed gold electrode. The electrolyte buffer consisted of 
10 mM phosphate buffer solution (pH 7) containing 2.5 mM [Fe(CN)6]
3-
/[Fe(CN)6]
4-
 (1:1) 
and 0.1 M KCl. Differential pulse voltammetry (DPV) signals were recorded from -0.1 V- 0.5 
V with a pulse amplitude of 50 mV and a pulse width of 50 ms. The % current response 
change was calculated as follows: 
 
% Current Response Change = [(iBare – iAdsorbed) / iBare] x 100 (1) 
 
where iBare and iAdsorbed are current densities for bare electrode and electrode after 
sample adsorption respectively. 
 
RT-PCR 
The KAPA SYBR
®
 FAST One-Step qRT-PCR kit (KAPA BIOSYSTEMS) was used to set 
up a single reaction volume of 10 µl for each sample. Each reaction volume consist of 1X 
KAPA SYBR
®
 FAST qPCR Master Mix, 200 nM of each forward (5’-
CCTGGAGCGCGGCAGGAAGCCTTATCAGTTG-3’) and reverse (5’-
GCTAGGGTTACATTCCATTTTGATGGTGAC-3’) primer, 1X KAPA RT Mix and 3 µl of 
input RNA target. The tubes were incubated at 42°C for 10 min to synthesize cDNA, 
followed by 95°C for 5 min to deactivate RT before cycling 35 times (95°C for 30 s, 69°C for 
30 s and 72°C for 1 min) and finished with 72°C for 10 min. Lastly, the RT-PCR products 
were visualized on 1.5% agarose gel to verify amplification. 
 
RESULTS AND DISCUSSION 
Principle of Amplification-free TMPRSS2:ERG Electrochemical assay 
The detection of the most common TMPRSS2:ERG fusion gene variant in approximately 
50% of PCa cases,
7,35
 is rapidly gaining attention as a way to improve diagnosis and 
prognosis of early PCa.
15,21,36
 However, current methodologies such as amplification-based 
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techniques are limited by the need for thermal cycling and enzymatic amplification to attain 
sufficient copy number level for detection.
15,37
 Therefore, by using the most frequent fusion 
between TMPRSS2 exon 1 and ERG exon 4 in PCa as a model to maximize clinical utility; 
we were motivated to design an amplification-free assay for detecting gene fusion mRNA 
from clinical urinary specimens with high detection sensitivity and specificity. 
 
Our assay is made up of three crucial steps in order to realize electrochemical detection of 
TMPRSS2:ERG mRNA without enzymatic amplification: specific capture of 
TMPRSS2:ERG mRNA from sample using magnetic isolation followed by heat release of 
captured mRNA, and adsorption of isolated mRNA onto a bare gold electrode surface by 
mRNA-gold affinity interaction for electrochemical readout (Fig. 1). Firstly, we used 
biotinylated capture probes which are complementary to the unique TMPRSS2:ERG gene-
fusion junction (Fig. 1a) for specific hybridization to TMPRSS2:ERG mRNA targets (Fig. 
1b). Next, the hybridized mRNA targets are isolated from total RNA background and 
sequestered on the surface of streptavidin-coated magnetic beads through biotin-streptavidin 
interactions. Then, the TMPRSS2:ERG mRNA are magnetically purified and released from 
the capture probes through subsequent heating. Finally, the released TMPRSS2:ERG mRNA 
are allowed to adsorb onto the bare gold surface of screen-printed electrodes for 20 min (Fig. 
1c). The adsorption process is facilitated by the high affinity between adenines of the 
TMPRSS2:ERG mRNA polyA tails and gold. For quantification of adsorbed 
TMMPRSS2:ERG mRNA, we optimized conditions for mRNA coverage on the electrode 
surface to be adequately low (i.e., partial blocking of electrode surface) for bulk ferricyanide 
ions to overcome coulombic repulsion (with negatively-charged mRNA); and approach the 
electrode surface to generate a detectable Faradaic current signal
34
. In the presence of 
adsorbed TMMPRSS2:ERG mRNA onto the electrode surface, coulombic repulsion of 
ferricyanide ions away from the surface resulted in a significantly lower signal as compared 
to a bare electrode
30,31
. This decrease in Faradaic current with respect to the baseline bare 
electrode current (% current response change) is also inversely proportional to the amount of 
adsorbed mRNA, thus allowing for quantitative TMPRSS2:ERG detection. 
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Figure 1. Schematic representation of assay. (A) TMPRSS2:ERG mRNA resulted from the 
fusion between TMPRSS2 promoter sequence and ERG coding sequence. (B) Total RNA is 
firstly purified from urinary samples before specific capture of TMPRSS2:ERG mRNA 
transcripts by biotinylated capture probes and magnetic isolation with streptavidin-coated 
magnetic beads. (C) After magnetic purification, TMPRSS2:ERG mRNA are released from 
magnetic beads and allowed to adsorb onto the gold surface of screen-printed electrodes for 
electrochemical detection. The presence of adsorbed TMPRSS2:ERG mRNA will lead to 
higher coulombic repulsion of similarly-charged ferricyanide ions away from the electrode 
surface and lead to a decrease in electrochemical signal. 
 
Assay Optimization 
The electrochemical signal level of our assay is dependent on the amount of mRNA being 
adsorbed on the electrode surface. The electrochemical signal of an electrode with low 
mRNA surface coverage is similar to that of a bare electrode as ferricyanide ions has easy 
access to the electrode surface (i.e., less coulombic repulsion) to generate a Faradaic current. 
Thus, to achieve excellent assay sensitivity and speed, it is ideal to maximize the amount of 
adsorbed mRNA on the electrode surface in the shortest timeframe possible. To this end, we 
optimized parameters such as adsorption time and pH, which are known to affect mRNA-
gold adsorption kinetics.
30-32
 In these experiments, we used 3 ng (100 cells) of starting total 
RNA, an amount which we approximated to be within a urine sample. The starting total RNA 
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was isolated from DuCap cells, a PCa cell line which carries the TMPRSS2:ERG fusion 
gene. 
 
We firstly tested different adsorption times (5, 10, 15, 20, and 30 min) for the mRNA-gold 
adsorption process to take place before electrochemical readout. By using a clinically 
relevant amount of isolated total RNA from 100 cells, we found that a maximal current 
response change of approximately 50% was observed at 20 min and no significant increase (t-
test P=0.098) in current response change was observed thereafter (Fig. 2a). This was 
probably due to maximal adsorption of TMPRSS2:ERG mRNA on the gold electrode surface 
at 20 min, thus leading to no signal improvement beyond this timepoint. Hence, we used a 20 
min adsorption time for all further experiments. 
 
Next, we optimized the adsorption buffer pH for the maximal current response change. Using 
5 different buffer pH (pH 3, 5, 7, 9, and 11), we found that the optimal pH for generating 
maximal signal occurred at neutral pH 7 (Fig. 2b). The signal change level being generated 
improved with increasingly acidic pH up to pH 7 but subsequently decreased at even higher 
basic pH. We believe that the highest signal change was obtained at neutral pH because of 
electrode surface damage during electrochemical measurements at lower acidic pH, and on 
the other hand, mRNA is prone to degradation at higher basic pH.
38
 Therefore, the adsorption 
buffer pH was optimized at pH 7 for further experiments. 
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Figure 2. Optimization of mRNA-gold adsorption. (A) Mean % current response change 
after 5, 10, 15, 20, 25, and 30 min of mRNA-gold adsorption time. (B) Mean % current 
response change using different buffer pH (3, 5, 7, 9, and 11) for mRNA-gold adsorption. 
Error bars represent standard deviation of three independent experiments. 
 
Detection Sensitivity and Specificity 
To evaluate assay sensitivity, we performed detection on different amounts of total RNA 
isolated from known number of DuCap cells (0, 10, 100, 1000 and, 10 000 cells). 
Electrochemical measurements were taken following TMPRSS2:ERG mRNA capture, 
isolation, adsorption onto electrode surface. We observed that TMPRSS2:ERG mRNA (i.e. 
number of DuCap cells) was linearly correlated with % current response change (Fig. 3a) 
over the range of 0-10 000 cells, and the limit of detection (LOD) was established to be ~10 
cells (300 pg of total RNA) (Fig. 3b). The observed electrochemical signal change using 10 
DuCap cells is 15% and 25% higher (t-test P=0.030) than signals from no-template control 
(NoT) and bare electrode respectively. This LOD is achieved without amplification and 
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highlights the high sensitivity of the electrochemical detection after rapid adsorption (20 min) 
of captured mRNA onto screen-printed gold electrode surface. Since tumor cells in the 
prostate tend to be shedded into the urine of PCa patients, this limit of detection of 10 cells 
(300 pg of total RNA) is adequate for the detection of TMPRSS2:ERG mRNA in patient 
urine samples. Our assay detection sensitivity is, to our knowledge, the highest for an 
electrochemical gene fusion assay. In literature, an electrochemical assay
39
 for 
TMPRSS2:ERG detection has previously demonstrated a detection sensitivity of 10 ng 
mRNA, a level which is readily available in tumor tissue but unlikely in urinary samples. 
 
 
Figure 3. Sensitive of assay. (A) Differential pulse voltammograms corresponding to input 
total RNA from different numbers of DuCap cells. (B) Mean % current response change 
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using input total RNA from different numbers of DuCap cells. Inset show the analogous 
linear calibration plot. Error bars represent standard deviation of three independent 
experiments.  
 
To test for assay specificity, we targeted total RNA from LnCap, a negative control cell line 
which does not carry the TMPRSS2:ERG fusion gene. The resulting measurements showed a 
significant decrease in electrochemical response for RNA derived from 1000 DuCap cells, 
whilst RNA derived from a similar number of LnCap cells gave a level of electrochemical 
response similar to NoT (Fig. 4a). In quantitative terms, the electrochemical response change 
using DuCap RNA is 50% higher than that of NoT RNA (t-test P=0.001), but LnCap RNA is 
not significantly different from NoT background signals (t-test P=0.070) (Fig. 4b). This 
indicated that hybridization of capture probes to non-specific mRNA targets was negligible. 
Furthermore, we also verified the specific capturing and isolation of TMPRSS2:ERG mRNA 
by reverse-transcription amplification whereby specific TMPRSS2:ERG primers were used 
to amplify the isolated TMPRSS2:ERG mRNA after heat release from magnetic beads, and 
amplicons were later visualized by gel electrophoresis (Fig. 4c). The included NoT and no 
reverse transcriptase (No RT) controls verified that the amplification was dependent on RNA-
based targets, whilst no capture probes and no heat release controls showed that the 
TMPRSS2:ERG mRNA targets were isolated by use of capture probes and released after heat 
treatment. This high specificity is largely due to the capture probe which was designed to 
hybridize across the fusion junction of TMPRSS2:ERG and helps minimize the likelihood of 
non-specific hybridization. The specific capture and release of mRNA targets is also essential 
for avoiding non-specific adsorption of non-target molecules (i.e. false-positive signals). Our 
assay clearly demonstrates specific TMPRSS2:ERG detection on cell lines, suggesting this 
assay could also be implemented in detection from complex biological specimens such as 
clinical urinary samples. 
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Figure 4. Specificity of assay. (A) Differential pulse voltammograms corresponding to input 
total RNA from DuCap (TMPRSS2:ERG-positive) and LnCap (TMPRSS2:ERG-negative) 
cell lines.  (B) Mean % current response change using input total RNA from DuCap and 
LnCap cell lines. Error bars represent standard deviation of three independent experiments. 
(C) RT-PCR of isolated TMPRSS2:ERG mRNA after heat release from beads with no-
template (NoT), no reverse transcriptase (No RT), no capture probes, and no heat release 
controls.  
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TMPRSS2:ERG Detection in Clinical Urinary Specimens 
To investigate the clinical application of our assay, we challenged our amplification-free 
electrochemical assay with the analysis of TMPRSS2:ERG levels in total RNA isolated from 
the clinical urinary samples of 12 metastatic castrate-resistant PCa patients (Patient 1-12), 5 
PCa patients (Patient 13-17) with localized disease, and 4 healthy patient controls. Our assay 
found 12 of the samples to be TMPRSS2:ERG positive (Fig. 5a), and representative 
voltammograms of differing TMPRSS2:ERG levels from the clinical samples are shown in 
Fig. 5b. The 12 TMPRSS2:ERG-positive samples showed about 20-50% current response 
change as compared to bare electrodes, and the 5 TMPRSS2:ERG-negative samples (Patient 
2, 11, 12, 15, 16 ) displayed <20% current response change (Fig. 5a).  
 
 
Figure 5: Clinical applications of assay. (A) Mean % current responses corresponding to 
TMPRSS2:ERG detection in urinary samples (n = 21). Error bars represent standard 
deviation of three independent experiments. (B) Representative differential pulse 
voltammograms of TMPRSS2:ERG-positive and -negative patients, as well as healthy patient 
and NoT controls. 
 
These results were also verified by current standard RT-PCR approach which showed the 
same 12 patients to be TMPRSS2:ERG-positive (Fig. 6). This is indicative that the 
electrochemical signals generated by our assay could discriminate TMPRSS2:ERG 
presence/absence in PCa urinary samples. With the healthy control samples, the 
electrochemical signals were equivalent to the background signal at <10% current response 
change, thus confirming assay specificity. The successful application of our assay to real 
clinical PCa samples (Fig. 5 and Fig. S1); and the subsequent validation of our assay results 
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with RT-PCR (Fig. 6) as well as sequencing of RT-PCR amplicons (Fig. S2), suggested the 
viability of this technique for clinical use.  
 
 
Figure 6. RT-PCR validation of TMPRSS2:ERG detection from urinary samples. RT-PCR 
validation of TMPRSS2:ERG status in urinary samples (n = 21). RT-PCR of housekeeping 
RN7SL1 transcripts were included as loading controls. 
 
Nonetheless, we are aware that our current assay format is a promising technology 
demonstration, and application to a larger pool of patient samples is required to prove clinical 
utility. To our knowledge, our assay is the first amplification-free technique for non-invasive 
TMPRSS2:ERG detection. The clinical significance of our assay is broad as it is readily 
adaptable for detecting different gene fusion mRNA or any other RNA-based biomarkers by 
changing the capture probe sequences. As it has been indicated that a combination of 
TMPRSS2:ERG and other different PCa biomarkers could allow a diagnosis with better 
sensitivity and prognosis accuracy,
12
 the multiplexed detection of different PCa gene fusion 
biomarkers from an individual PCa patient could provide a more comprehensive diagnosis 
and personalized treatment plan. 
 
Our developed assay is an inexpensive and amplification-free alternative to current 
amplification-based techniques for gene fusion detection (Fig. 1). Current RT-qPCR 
techniques mainly employ fluorescence readout for quantitative TMPRSS2:ERG 
detection.
18,19
 Fluorescence readout approaches are limited by higher assay cost, need for 
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specialized instrument, and likelihood of high background fluorescence. Our data clearly 
demonstrates that our electrochemical readout could avoid these limitations as it provides 
rapid and quantitative electrochemical signals, and simply requires a potentiostat for 
measurements. Additionally, the mRNA-gold electrode surface adsorption mechanism prior 
to electrochemical detection made use of the natural strong affinity of adenine bases (i.e., 
polyA tails of captured mRNA) towards gold to bind isolated TMPRSS2:ERG mRNA onto 
the electrode surface. This simplistic approach is a convenient and rapid way for binding 
target mRNA sequences to gold electrode surface for electrochemical detection and has been 
previously demonstrated for DNA biosensing.
26,30,31
 Moreover, we performed our assay using 
screen-printed gold electrodes which are commercially-available and ensure highly 
reproducible results. On top of that, the low cost of these electrodes also enable one-time 
usage without need for time-consuming electrode cleaning. With this cost-effective electrode 
platform and without the need for tedious electrode surface modification and electrocatalytic 
labelling; our proposed approach is ideal for developing a clinically-friendly TMPRSS2:ERG 
assay. 
 
CONCLUSIONS 
In conclusion, we have presented the first amplification-free electrochemical assay for gene 
fusion detection in PCa urinary samples. Our assay combines the use of magnetic 
TMPRSS2:ERG mRNA isolation, adsorption of isolated mRNA onto electrode surface by 
natural high binding affinity between adenine bases on mRNA polyA tails and gold, and 
rapid electrochemical detection of adsorbed mRNA using a ferricyanide system. Our 
proposed assay offers numerous advantages over existing methodologies. Most notably, it 
removes the need for enzymatic amplification, tedious experimental protocols and expensive 
fluorescence readout instruments; while also ensuring highly sensitive, specific, and non-
invasive detection of TMPRSS2:ERG gene fusion, a more PCa-specific and potentially more 
superior alternative to current serum PSA biomarker. Furthermore, the clinical utility of this 
assay was demonstrated through successful TMPRSS2:ERG detection from PCa clinical 
urine samples. The analysis of urinary TMPRSS2:ERG in this assay offers a convenient and 
less invasive alternative to tissue biopsies, and could also be potentially used for monitoring 
drug responses and treatment effectiveness. Our assay is currently a proof-of-principle 
demonstration of TMPRSS2:ERG detection in PCa patients. For future work, we envisage it 
as a platform technology which, with slight modifications, could enable detection of other 
Chapter 5.1 
 
178 
 
oncogenic gene fusion biomarkers. Furthermore, our assay could also be readily customised 
for detecting many other RNA-based cancer biomarkers such as microRNAs, splice variants, 
or non-coding RNAs detection. Finally, the simple workflow of our assay could allow for 
integration into many device-based biosensing applications such as microfluidic platforms. 
This may firstly reduce required sample volume, which could lead to faster hybridization 
kinetics (i.e., shorter assay time) within a smaller volume, could also enable high throughput 
and multiplexed detection of a selected panel of cancer biomarkers to characterize molecular 
subtypes. 
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SUPPLEMENTARY INFORMATION 
 
 
Figure S1. Representative Sanger sequencing of RT-PCR products from a TMPRSS2:ERG-
positive urinary sample. *The TMPRSS2 sequence bases are underlined to indicate the 
TMPRSS2:ERG fusion junction.  
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ABSTRACT 
Current amplification-based microRNA (miRNA) detection approaches are limited by the 
small sizes of miRNAs as well as amplification bias/artifacts. Herein, we report on an 
amplification-free miRNA assay based on elevated affinity interaction between poly-
adenylated miRNA and bare gold electrode. The poly(A) extension on 3’ ends of 
magnetically-isolated miRNA targets facilitated high adsorption efficiency onto gold 
electrode surfaces for electrochemical detection without any cumbersome electrode surface 
functionalization procedures. The assay showed excellent detection sensitivity (10 fM) and 
specificity, and was demonstrated for quantitative miR-107 detection in human cancer cell 
lines and clinical urine samples. We believe our assay could be useful as an amplification-
free alternative for miRNA detection.     
 
INTRODUCTION 
MicroRNAs (miRNAs) are short (~22 nucleotides) non-coding RNA molecules which are 
rapidly gaining interest as cancer biomarkers due to the crucial roles they play in cancer 
initiation and progression.
1-3
 In recent years, research has shown that miRNAs post-
transcriptionally regulate gene expression mainly by binding to the 3’ untranslated region of 
targeted messenger RNAs (mRNAs) to inhibit translation, functioning as oncogenes and 
tumor suppressors.
4
 Besides showing promise as diagnostic and prognostic biomarkers in 
cancer, miRNAs are also attractive as non-invasive biomarkers with high stability in bodily 
fluids such as blood, urine, or saliva.
5, 6
 Thus, in order to implement miRNA biomarkers for 
use in clinical practice, it is essential to develop methodologies for quantitative miRNA 
detection with high sensitivity and specificity. 
 
Quantitative reverse-transcription polymerase chain reaction (RT-qPCR) is the current gold 
standard for miRNA quantification.
7, 8
 The amplification-based RT-qPCR technique offers 
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good sensitivity and specificity for miRNA detection. Yet, miRNAs still pose some 
challenging issues for amplification-based techniques due to their short lengths which is 
about the same size of conventional PCR primers. Furthermore, amplification-based methods 
have drawbacks such as errors due to amplification bias/artifacts; and the fluorescence 
readout also requires costly instruments, fluorescent labels, and is susceptible to background 
fluorescence interference. Therefore, an amplification-free miRNA detection methodology 
could represent an appealing alternative to alleviate these issues. 
 
Electrochemical assays have been shown to offer excellent sensitivity and specificity for 
miRNA detection without any prior amplification process.
9-12
 Additionally, electrochemical 
assays provide rapid readout, and the required detection equipment and reagents are 
inexpensive. Typically, to enable electrochemical detection of miRNAs, gold electrode 
surfaces are functionalized with probes for specific hybridization with target miRNAs. To 
remove this tedious functionalizing process, different research groups have exploited the 
highly sequence-dependent nucleic acid-bare gold adsorption affinity trend of A > C ≥ G > T 
(i.e., adenine bases adsorb to gold most strongly and quickly)
13, 14
 for direct and efficient 
adsorption of poly-adenylated nucleic acid probes onto bare gold electrode surface.
15
 We 
therefore hypothesized that by modifying target miRNAs (i.e. nucleic acid sequences) with 
poly(A) sequence extensions, we could facilitate rapid and high miRNA-gold electrode 
surface adsorption for subsequent detection. This methodology would allow for 
electrochemical miRNA detection without any prior miRNA amplification or cumbersome 
electrode surface functionalization steps involved in fabricating recognition and transduction 
layers in conventional electrochemical miRNA biosensors. The adsorbed miRNAs could then 
be electrochemically detected with a [Fe(CN)6]
3-/4-
 redox system.
16, 17
 Unlike conventional 
redox system (e.g., [Ru(NH3)6]
3+
/[Fe(CN)6]
3-
)
11, 18
, this system alone is sufficient for 
quantifying surface-bound nucleic acid sequences reliably.
14, 16, 17, 19
 As outlined by Zhang 
and co-workers
19
, it follows an electron transfer kinetics-based mechanism, where density of 
the adsorbed nucleic acid sequences at the electrode surface should be sufficiently low (i.e., 
partial blocking).   
 
Herein we describe a novel approach for direct amplification-free detection of miRNA by 
firstly magnetically isolating target miRNAs, then conveniently extending target miRNAs 
with poly(A) sequences to enable rapid adsorption onto a gold electrode surface for 
electrochemical quantification. The practical application of the assay was showcased through 
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the quantitative detection of a specific miRNA sequence in different breast and prostate 
cancer cell lines and assay results were validated with gold-standard RT-qPCR method. We 
also successfully detected target miRNAs in prostate cancer urine samples. 
 
EXPERIMENTAL SECTION 
Isolation of Target miRNAs 
Total RNA was extracted from cancer cell lines (MDA-MB-231, MCF7, and 22Rv1 using 
Direct-zol
TM
 kit (Zymo Research, USA), and target miRNAs were subsequently hybridized 
onto complementary capture probes-functionalized magnetic beads. Then, hybridized targets 
were washed, heat-released, and resuspended in RNA-free water. (See Supplementary 
Information for more details) 
 
Electrochemical Detection of Target miRNAs 
Isolated target miRNAs were extended with poly(A) sequences separately within a tube 
before adsorption on screen-printed gold electrode surface. The adsorbed miRNAs were then 
detected by differential pulse voltammetry (DPV). (See Supplementary Information for more 
details)       
 
RESULTS AND DISCUSSION 
Assay Principle 
Our novel assay for amplification-free electrochemical detection of miRNA is schematically 
depicted in Figure 1. miRNA targets are firstly specifically hybridized to complementary 
capture probes which have been functionalized onto the surfaces of streptavidin-coated 
magnetic beads through biotin-streptavidin interactions. Next, hybridized miRNA targets are 
magnetically purified and released from the capture probes through heating. The miRNA 
targets are then subjected to poly(A) extension on 3’ ends using polymerase A enzyme in 
order to increase miRNA-gold adsorption efficiency. After poly(A) extension, the miRNA 
targets are able to adsorb on the gold surface of screen-printed electrodes effectively due to 
high affinity between adenines of the polyA sequences and gold. Under optimized conditions, 
the coulombic repulsion between negatively-charged ferricyanide ions in the buffer and 
negatively-charged miRNA phosphate groups on the electrode surface will be sufficiently 
low for ferricyanide ions to overcome and diffuse on the electrode surface to generate a 
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detectable Faradaic current signal which is significantly lower than the signal on a bare 
electrode.
16, 17, 19
 
 
Figure 1. Schematic representation of assay. Magnetic beads-coupled capture probe 
sequences were firstly used for specific hybridization to miRNA targets. After hybridization, 
the miRNA targets were purified by magnetic separation before being released from capture 
probes through heating. Next, poly(A) extension was performed on the 3’ ends of released 
miRNA targets using polymerase A enzyme prior to adsorption onto the gold surface of 
screen-printed electrodes. The presence of adsorbed miRNAs leads to coulombic repulsion of 
ferricyanide ions away from the electrode surface, thus leading to a lower Faradaic current 
relative to a bare electrode. Quantitative miRNA detection is achieved as higher/lower 
amount of starting miRNA targets will lead to increased/decreased miRNA adsorption on 
electrode surface and in turn, lower/higher electrochemical signal.  
 
Gold Surface Characterization Before and After miRNA Adsorption 
We used Fourier transform infrared spectroscopy (FTIR) to characterize the miRNA- and 
poly(A) extended miRNA-modified gold electrode surfaces. After miRNA adsorption, we 
observed FTIR spectra band changes generated from a bare gold surface (Figure S1). These 
strong bands (1418, 1655 cm
-1
)
20
 were characteristic signatures of C-H; C=O; C=N; N-H 
bonds in nucleic acids. In addition, poly(A) extended-miRNA adsorption resulted in 
enhanced absorbance at band positions (1553, 1603, 1639 cm
-1
)
13
 characteristic of adenine 
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bases. The results showed the successful adsorption of both unmodified and poly(A) miRNAs 
on a bare gold surface. 
 
Detection Sensitivity Before and After miRNA Poly(A) Extension 
To evaluate the effect of poly(A) extension on miRNA adsorption efficiency, we determined 
the detection sensitivity of our assay before and after poly(A) extension of isolated targeted 
miRNA. The sequence of miR-107 (Table S1) was used as a model target miRNA in our 
experiments. In previous studies, miR-107 overexpression has been associated with increased 
tumor growth and metastatic potential in cancer cells by regulating gene expression.
21-23
 
Moreover, higher miR-107 expression level has also been detected in the urine and blood 
serum samples of cancer patients,
24, 25
 and has been suggested as a potential marker for 
cancer diagnosis and staging. 
 
To test for assay detection sensitivity, a series of synthetic target miR-107 of different 
concentrations was detected. We observed an increasing relative DPV signal change (% i) 
with higher starting concentration of target miRNA (Figure 2) after 10 min adsorption time. 
This was attributed to the higher amount of target miRNA being isolated and subsequently 
adsorbed into the electrode surface. A higher amount of adsorbed miRNA caused higher 
coulombic repulsion of [Fe(CN)6]
3-
 ions from approaching the electrode surface, and resulted 
in a lower Faradaic current. Detection sensitivities were determined to be 1 pM (% i = 10%) 
(Figure 2A) and 10 fM (% i = 12%) (Figure 2B) before and after miRNA poly(A) extension 
respectively. The 100-fold improvement in detection sensitivity was attained due to poly(A) 
extension conferring higher adsorption affinity interaction between miRNA and gold surface 
as adenines have highest affinity interactions with gold amongst all nucleic acid bases.
13
 
Thus, this resulted in an increased amount of adsorbed miRNA in the same amount of time as 
compared to miRNA without poly(A) extension. In addition, the negligible signal response 
from the no-template (NoT) control (% i = 3%) showed that electrochemical signals were 
mainly from adsorption of isolated miR-107 targets and unaffected by other molecules 
present in the adsorption mixture. Our detection limit of 10 fM with a linear range of 5 fM-5 
pM is also superior or comparable with those of existing amplification-free miRNA 
electrochemical assays described in literature.
11, 26-28
 Most electrochemical miRNA sensing 
strategies
29
 developed in recent years achieved a fM detection sensitivity which is similar to 
our proposed assay. However, it is worthy to highlight the advantage of enhanced simplicity 
of our assay as compared to these assays. Our miRNA detection methodology does not 
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require any tedious electrode surface functionalization; and utilized commercially-available 
screen printed electrodes which are inexpensive, disposable and provided good assay 
reproducibility with a RSD of 4.8% (n = 3). 
 
 
Figure 2. Improved assay sensitivity after poly(A) extension. Differential pulse 
voltammetry (DPV) showing signal changes to different concentrations of starting miR-107 
targets before (A1) and after (B1) poly(A) extension of isolated miRNA targets. % i (Relative 
DPV signal change) corresponding to different starting miR-107 target concentrations before 
(A2) and after (B2) poly(A) extension of isolated miRNA targets. Insets show the analogous 
linear calibration plots. Error bars represent standard deviation of three independent 
experiments. 
 
Detection Specificity 
To evaluate the specificity of the capture probes in our assay for selectively isolating miR-
107 targets, we performed our assay on two unrelated and non-complementary miRNAs 
(miR-429 and miR-200c) and compared the obtained signals to that of miR-107 at the same 
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assay starting miRNA concentration. We used an excessive starting miRNA concentration of 
10 pM in order to test the capture probe specificity under saturating target condition. We 
found that electrochemical signals from experiments involving miR-429 (% i = 4.5%) and 
miR-200c (% i = 3.5%) were similar to the NoT control (Figure 3A). In contrast, 
electrochemical signal from the detection of miR-107 was about 10-fold higher (% i = 50%) 
than the signals of these non-complementary miRNA sequences (Figure 3B). These 
experiments demonstrated the high specificity of our capture probes in isolating miR-107 
targets for miRNA-gold adsorption and subsequent electrochemical detection.  
 
 
Figure 3. Assay specificity. (A) DPV showing signal changes after assay was performed on 
different starting miRNA sequences (miR-107; miR-429; miR-200c, 10 pM). (B) % i 
(Relative DPV signal change) corresponding to the different starting miRNA sequences. 
Error bars represent standard deviation of three independent experiments. 
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Detection of miR-107 Levels in Cancer Cell Lines and Patient Samples 
After establishing the assay sensitivity and specificity towards miR-107 targets, we then 
challenged the assay with total RNA extracted from cultured human breast (MDA-MB-231 
and MCF-7) and prostate cancer (22Rv1) cells to investigate assay performance with more 
complex biological samples. According to our assay results, miR-107 levels were expressed 
at varying levels in the different cell lines (Figure 4A). With the same amount of starting total 
RNA, our assay detected miR-107 to be lower-expressed in MCF7 cells, and 1.5-fold and 
3.5-fold higher in MDA-MB-231 and 22Rv1 cells respectively (Figure 4B). Our assay results 
were in good agreement with previous findings in literature which also observed similar miR-
107 expression level patterns in these cell lines.
21, 23
 RT-qPCR was also performed as gold-
standard assay validation and the miR-107 levels in all three cell lines were observed to be 
concordant with results of our assay (Figure 4C). In addition, we also quantitatively detected 
miR-107 levels in extracted total RNA from three clinical prostate cancer urine samples. As 
shown in Figures 4D and S2, the DPV signals from these patient samples were significantly 
higher than the NoT control sample. These results clearly indicated that our proposed assay 
could be applied for miR-107 detection in clinical samples. As miR-107 overexpression is 
linked to increased metastatic potential of cancer cells and tumor progression
21, 23
, our assay 
may aid in detecting miR-107 expression levels in cancer patients for diagnostic purpose or 
monitoring the treatment response of drugs targeting miR-107.   
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Figure 4. Assay performance on human cancer cell lines and patient samples. (A) DPV 
showing signal changes for detection of different miR-107 expression levels in breast (MDA-
MB-231; MCF7) and prostate (22Rv1) cancer cell lines. (B) % i (Relative DPV signal 
change) corresponding to miR-107 levels in the three different human cancer cell lines. (C) 
RT-qPCR validation of miR-107 expression levels in the three different human cancer cell 
lines. (D) % i (Relative DPV signal change) corresponding to miR-107 levels in three 
prostate cancer urinary samples. Error bars represent standard deviation of three independent 
experiments.  
 
CONCLUSIONS 
In conclusion, the electrochemical assay described herein displayed excellent sensitivity and 
specificity for quantitative miRNA detection. We detected miR-107 levels in human cancer 
cells and urine samples without any amplification process, electrode surface 
functionalization, and costly specialized equipment. The high sensitivity (10 fM) was enabled 
by poly(A) extension of specifically-isolated miR-107 targets for better miRNA-gold 
adsorption efficiency. The electrochemical readout which was performed using screen-
printed gold electrodes; paves the way for a rapid, quantitative, and inexpensive miR-107 
detection that could be ideal for clinical diagnostics. We envisaged that the assay could also 
be readily extended to other miRNA markers through adaptation of capture probe sequences. 
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SUPPLEMENTARY INFORMATION 
 
DETAILED EXPERIMENTAL SECTION 
Reagents and Materials 
All reagents were of analytical grade and purchased from Sigma Aldrich (Australia). 
UltraPureTM DNase/RNase-free distilled water (Invitrogen, Australia) was used throughout 
the experiments. Oligonucleotides were purchased from Integrated DNA Technologies 
(USA) and sequences are shown in Table S1. Screen-printed gold electrodes, DRP-C220BT 
(diameter ¼ 4mm), were acquired from Dropsens (Spain). 
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Fourier Transform Infrared Spectroscopy (FTIR) for Surface Characterization 
FTIR experiments were performed on the Nicolet 5700 FTIR instrument (Thermo Fisher 
Scientific, USA). Spectra were collected from 50 scans in the 1400-1800 cm
-1
 region at 2 cm
-
1
 resolution. The measurements were done on a bare gold surface, and gold surfaces after 
adsorption of unmodified and poly(A)-extended synthetic miRNA (miR-107) sequences 
(Table S1).    
 
RNA Extraction from Cell Lines 
MDA-MB-231 and MCF7 breast cancer cell lines were purchased from ATCC (USA), and 
22Rv1 prostate cancer cell line was kindly donated by Colleen Nelson (APCRC, Australia). 
The cell lines were cultured in RPMI-1640 growth media (Life Technologies, Australia) 
supplemented with 10% fetal bovine serum (Life Technologies, Australia) in a humidified 
incubator containing 5% CO2 at 37ºC. RNA was extracted using Direct-zol
TM
 kit (Zymo 
Research, USA) and RNA integrity and purity were checked using a NanoDrop 
Spectrophotometer (Thermo Scientific, Australia). 
 
RNA Extraction from Clinical Urine Samples 
For clinical samples, ethics approval was obtained from The University of Queensland 
Institutional Human Research Ethics Committee (Approval No. 201400012) and informed 
consent was obtained from all subjects prior to sample collection. Methods pertaining to 
clinical samples were carried out in accordance with approved guidelines. Voided urinary 
samples were collected from 3 men patients undergoing treatment for prostate cancer. Total 
RNA was extracted from the urine samples using the commercially-available ZR urine RNA 
isolation Kit
TM
 (Zymo Research, USA). For each sample, 30 mL of urine was passed through 
the supplied ZRC GF
TM
 Filter to retain urinary cells. Then, 700 µL of supplied urine RNA 
buffer was passed through the filter and the filtered cells were collected in the flow-through. 
Next, as per manufacturer’s instructions, the cells from the flow-through were lysed, washed 
and eluted in 10 µL of RNase-free water. 
 
miRNA Capture and Magnetic Isolation 
Firstly, 20 µL of streptavidin-labeled Dynabeads
®
 MyOne
TM
 Streptavidin C1 (Invitrogen, 
Australia) magnetic beads was washed with 2x washing and binding (B&W) buffer (10 mM 
Tris-HCl, pH 7.5; 1 mM EDTA ; 2 M NaCl) and resuspended in 25 µL of 2x B&W buffer. 
Next, an equal volume of 10 µM biotinylated capture probes (Table S1) was added and the 
Chapter 5.2 
 
194 
 
resultant mixture was incubated on a mixer for 15 min at room temperature to generate 
capture probes-functionalized magnetic beads. The functionalized magnetic beads were 
washed thrice with 2x B&W buffer and resuspended in 10 µL of 5x SSC buffer (pH 7) before 
use.  
 
For specific miRNA capture, 50 ng of extracted total RNA from cell lines or synthetic miR-
107 sequences (Table S1) of various concentrations were adjusted to 10 µL with RNase-free 
water before mixing with 10 µL of capture probes-functionalized magnetic beads. The 
mixture was placed on a mixer for 20 min at room temperature to allow capture probe 
hybridization to miRNA targets. After this step, the magnetic beads with attached miRNA 
targets were isolated with a magnet, washed twice with 2x B&W buffer and resuspended in 
7.5 µL of RNase-free water.   
 
Table S1. Oligonucleotide sequences used in experiments.  
Oligos 5'-Sequence-3' 
Biotinylated 
miR-107 
Capture Probe  
TGATAGCCCTGTACAATGCTGCT-Biotin 
Synthetic 
miR-107 
Sequence 
AGCAGCAUUGUACAGGGCUAUCA 
RT-qRCR 
Forward 
Primer  
AGCAGCATTGTACAG 
RT-qRCR 
Reverse 
Primer 
TTTTTTTTTTTTTTTTTG 
 
Poly(A) Extension and Adsorption of Isolated miRNA on Gold Electrode Surface 
To release the captured miRNA targets from the magnetic beads and capture probes, the 
resuspended miRNA target mixture was heated for 2 min at 95°C, immediately placed on a 
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magnet, and the supernatant containing the released miRNA targets was collected. Then, to 
extend poly(A) sequences on the released miRNA targets, 7.5 µL of released miRNA was 
added to 1 µL of 10x E. Coli Poly(A) polymerase reaction buffer (250 mM NaCl, 50 mM 
Tris-HCl, 10 mM MgCl2, pH 7.9), 1 mM ATP, and 5 U E. Coli Poly(A) polymerase (New 
England BioLabs, Australia) to make up a 10 µL reaction mixture. The reaction mixture was 
incubated at 37°C for 15 min before being diluted to 30 µL in 5X SSC buffer (pH 7.0) and 
then directly dropped onto the working electrode surface of a screen-printed gold electrode 
(Dropsens, Spain) for 20 min of miRNA-gold adsorption with gentle shaking at room 
temperature. The electrodes were then washed with 10 mM phosphate buffer (137 mM 
sodium chloride, 2 mM potassium chloride, pH 7.4) before electrochemical measurements.   
 
Electrochemical Detection 
All electrochemical measurements were performed on a CH1040C potentiostat (CH 
Instruments, USA) with the three-electrode system (gold working and counter electrodes, 
silver reference electrode) on each screen-printed gold electrode. The electrolyte buffer 
consisted of 10 mM phosphate buffer solution (pH 7) containing 2.5 mM [Fe(CN)6]
3-
/[Fe(CN)6]
4-
 (1:1) and 0.1 M KCl. Differential pulse voltammetry (DPV) signals were 
recorded from -0.1 V- 0.5 V with a pulse amplitude of 50 mV and a pulse width of 50 ms. 
The % current response change was obtained by calculated as follows: 
 
(% i) = [(iBare – iAdsorbed) / iBare] x 100  
 
where iBare and iAdsorbed are current densities for bare electrode and electrode after 
sample adsorption respectively. 
 
RT-qPCR 
The KAPA SYBR
®
 FAST One-Step qRT-PCR kit (KAPA BIOSYSTEMS, Australia) was 
used to set up a single reaction volume of 10 µl for each sample. Each reaction volume 
consist of 1X KAPA SYBR
®
 FAST qPCR Master Mix, 200 nM of each forward and reverse 
primer (Table S1), 1X KAPA RT Mix, 50 nM ROX dye and 30 ng of cell line total RNA 
template. RT-qPCR was performed using the Applied Biosystems® 7500 Real-Time PCR 
System (Thermo Scientific, Australia). The cycling protocol was: 42°C for 10 min to 
synthesize cDNA, followed by 95°C for 5 min to deactivate RT before cycling 35 times 
(95°C for 30 s, 50°C for 30 s and 72°C for 1 min) and finished with 72°C for 10 min.  
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Figure S1. Representative FTIR spectra of bare gold surface (Black), and gold surfaces after 
adsorption of unmodified (Red) and poly(A)-extended (Blue) synthetic miRNA sequences. 
Band positions in grey and blue are chracteristic of nucleic acid bases (A, U, G, C)
1
 and 
adenine bases (A)
2
 respectively.  
 
Figure S2. Representative DPV signals for detection of miR-107 levels in three prostate 
cancer urinary samples. 
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DNA-Directed Assembly of Copper Nanoblocks with Inbuilt 
Fluorescent and Electrochemical Properties: Application in 
Simultaneous Amplification-Free Analysis of Multiple RNA 
Species  
 
Kevin M. Koo, Laura G. Carrascosa, and Matt Trau 
 
 
ABSTRACT 
The intrinsic affinity of DNA molecules towards metallic ions can drive specific formation of 
copper nanostructures within the nucleic acid helix structure in a sequence-dependent 
manner. The resultant nanostructures have interesting fluorescent and electrochemical 
properties which are attractive for novel biosensing applications. However, the potential of 
DNA-templated nanostructures for precision disease diagnosis remains unexplored. 
Particularly, DNA-templated nanostructures may have outstanding clinical diagnostics 
prospect in the universal amplification-free detection of different RNA biomarker species. 
Due to low cellular levels and differing species-dependent length and sequence features, 
simultaneous detection of different messenger RNAs (mRNAs), microRNAs (miRNAs) and 
long non-coding RNAs (lncRNAs) species with a single technique is a challenging task. 
Herein, we report a contemporary technique for facile in-situ assembly of DNA-templated 
copper nanoblocks (CuNBs) on various RNA species targets after hybridization-based 
magnetic isolation. Our approach circumvents typical drawbacks associated with 
amplification and labelling procedures of current RNA assays; and the synthesized CuNBs 
impart amplification-free fM-level detection limit with flexible fluorescence or 
electrochemical readouts. Furthermore, our nanosensing technique displays clinical 
application promise as demonstrated by non-invasive analysis of three diagnostic RNA 
biomarkers from a cohort of 10 prostate cancer patient urinary samples with 100%-
concordance (qRT-PCR validation). We envision that the good analytical performance and 
versatility of our methodology could be of widespread use in both diagnostics and research 
fields. 
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INTRODUCTION 
DNA molecules can exhibit intrinsic affinity towards a wide range of metallic ions and give 
rise to a variety of nanostrutures within the nucleic acid helix structure. In particular, silver 
(Ag) [1, 2] or copper (Cu) [3-5] nanostructures (CuNs) with interesting fluorescent and/or 
electrochemical properties can be created via DNA-directed assembly. CuNs are particularly 
attractive over other DNA-templated metal nanostructures due to a faster and more stable 
synthesis process as Cu
2+
 ions are less likely to form insoluble precipitate with common 
anions in biosensing environments. The synthesis process is also shown to be sequence-
dependent and mostly favourable towards thymine (T)-rich sequences in either the single-
stranded [6-8] or double-stranded [9-11] forms. This is a very attractive feature for nucleic 
acid detection as fluorescence signals can be effortlessly generated on specific DNA regions, 
thus avoiding complex target-labelling chemistry. The large Stokes shift difference between 
excitation and emission wavelength of fluorescent CuNs [9, 12] is also favourable for 
eliminating background signals in complex biological environments. Despite these appealing 
advantages of facile, rapid and low-cost DNA-directed CuNs synthesis; the biosensing 
potential of DNA-templated CuNs for precision diagnostic purposes has remained scarcely 
exploited. In this work we focused on developing a universal amplification-free nanosensor 
of multiple RNA species for cancer diagnosis using DNA-templated CuNs.  
  
The detection of different RNA species targets such as messenger RNAs (mRNAs) [13], 
microRNAs (miRNAs) [14], and long non-coding RNAs (lncRNAs) [15, 16], is useful for 
developing cancer diagnostics and guiding treatment decisions [17, 18]. Taking prostate 
cancer (PCa) as an example, recent studies [19-22] have indicated that a suite of different 
RNA biomarker species could serve to improve current PCa diagnosis [23]. Explicitly, the 
gene fusion TMPRSS2:ERG (T1E4) mRNA biomarker has been found to be highly PCa-
specific and rarely occurred in benign conditions [24, 25], whilst overexpression of miR-107 
miRNA [26-28] and SChLAP1 lncRNA [29] biomarker is associated with increased risk for 
developing PCa metastasis and aggressive subtypes. These three different RNA biomarker 
species have also been readily detected in urine samples, and could allow early identification 
of malignant PCa cases without invasive biopsy procedures [30, 31]. However, the universal 
detection of multiple RNA biomarker species is complex with current tools. 
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The universal analysis of different RNA species is challenging due to the widely-differing 
length or sequence (i.e. presence of poly-A tails) characteristics of individual RNA species. 
Presently, different variations of reverse transcription polymerase chain reaction coupled with 
fluorescence readout (qRT-PCR) are most commonly-used for quantitative RNA detection 
[32, 33]. Despite the good reliability of these qRT-PCR variations for sensitive and specific 
RNA detection, they are limited by the need for enzymatic amplification and use of 
fluorescent labels. Enzymatic amplification requires extensive sample manipulation and 
could lead to amplification artifacts/bias; and miRNA amplification is also especially 
challenging due to their short primer-sized lengths. Moreover, traditional qRT-PCR 
fluorescent organic dye labels are costly, complex and time-consuming to synthesize; 
unstable at ambient conditions; and requires cumbersome target-hybridization procedures. 
 
Our nanosensing technique demonstrates, for the first time, DNA-directed assembly of Cu 
nanoblocks (CuNBs) on different RNA species for simultaneous amplification-free detection 
of multiple RNA biomarker species relevant to PCa detection. By enabling poly(A-T)-
templated CuNBs synthesis on magnetically-purified RNA targets, our proposed technique 
exhibited high specificity, fM-level sensitivity, and flexible fluorescence/electrochemical 
RNA detection. We also showed the clinical translation promise by parallel analysis of 
various promising RNA biomarker (T1E4, miR-107, SChLAP1) species in PCa patient 
urinary samples. 
 
EXPERIMENTAL 
Materials and Reagents  
All reagents were of analytical grade and purchased from Sigma Aldrich (Australia). 
UltraPureTM DNase/RNase-free distilled water (Invitrogen, Australia) was used throughout 
the experiments. Oligonucleotides were purchased from Integrated DNA Technologies 
(Singapore) and sequences are shown in Table 1. 
 
RNA extraction from cultured PCa cells  
DuCap and 22Rv1 cells were cultured in RPMI-1640 growth media (Life Technologies, 
Australia) supplemented with 10% fetal bovine serum (Life Technologies, Australia) in a 
humidified incubator containing 5% CO2 at 37ºC. RNA was extracted using Direct-zol
TM
 kit 
(Zymo Research, USA) according to the manufacturer’s instructions. Total RNA integrity 
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and purity were checked using a NanoDrop Spectrophotometer (Thermo Scientific, 
Australia). 
 
RNA extraction from PCa urinary samples  
Ethics approval was obtained from The University of Queensland Institutional Human 
Research Ethics Committee (Approval No. 2004000047) and informed consent was obtained 
from all subjects prior to sample collection. Methods pertaining to clinical samples were 
carried out in accordance with approved guidelines. 
 
Voided urinary samples were collected from men undergoing treatment for PCa at the Royal 
Brisbane and Women’s Hospital. Total RNA was extracted from the urine samples using the 
commercially-available ZR urine RNA isolation Kit
TM
 (Zymo Research, USA). For each 
sample, 30 mL of urine was passed through the supplied ZRC GF
TM
 Filter to retain urinary 
cells. Then, 700 µL of supplied urine RNA buffer was passed through the filter and the 
filtered cells were collected in the flow-through. Next, as per manufacturer’s instructions, the 
cells from the flow-through were lysed, washed and eluted in 10 µL of RNase-free water. 
Total RNA concentration for each sample was assayed using Qubit® RNA HS Assay Kit 
(Thermo Scientific, Australia) and total RNA input for each single assay run was 
standardized to 30 ng for non-biased comparisons of target biomarker expression levels.  
 
Magnetic isolation of RNA targets  
Extracted total RNA from cell lines/urinary samples were adjusted to 30 ng in 5 µL of 
RNase-free water prior to mixing with 10 µL of 5x saline-sodium citrate (SSC) buffer (pH 7). 
RNA targets T1E4, miR-107 and SChLAP1 in samples were hybridized with 10 µL addition 
of 10 µM biotinylated complementary capture probes in individual tubes. For mRNA (T1E4) 
and lncRNA (SChLAP1) samples, the capture probes-targets mixture was heated to 90 ºC for 
2 min before being incubated at 70 ºC for 60 min to facilitate hybridization. For miRNA 
(miR-107), the resultant mixture was incubated at 60 ºC for 30 min at room temperature. 
 
For magnetic isolation of RNA targets, 20 µL of streptavidin-labelled Dynabeads
®
 MyOne
TM
 
Streptavidin C1 (Invitrogen, Australia) magnetic beads was firstly washed with 2x washing 
and binding (B&W) buffer (10 mM Tris-HCl, pH 7.5; 1 mM EDTA ; 2 M NaCl) and 
resuspended in 25 µL of 2x B&W buffer. Then, the resuspended magnetic beads were added 
to each of the prepared capture probes-targets tubes, mixed thoroughly, and incubated on a 
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mixer for 30 min at room temperature to allow magnetic beads binding to capture probes. 
After that, the magnetic beads with attached RNA targets were isolated with a magnet, 
washed twice with 2x B&W buffer and resuspended in 10 µL (for mRNA) or 7.5 µL (for 
miRNA and lncRNA) of RNase-free water.   
 
PolyA tails synthesis on miRNA and lncRNA targets  
For miRNA and lncRNA targets, 3’-polyA tails were extended on the targets by mixing 7.5 
µL of resuspended magnetic beads-miRNA/lncRNA targets- with 1 µL of 10x E. Coli 
Poly(A) polymerase reaction buffer (250 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, pH 
7.9), 1 mM ATP, and 5 U E. Coli Poly(A) polymerase (New England BioLabs, Australia) to 
make up a 10 µL reaction mixture. Each reaction mixture was incubated at 37°C for 30 min 
(unless otherwise stated) and Poly(A) polymerase was inactivated by addition of 10 mM 
EDTA. 
 
Next, 10 µL of 10 µM polyT sequences was added separately to each RNA target tube and 
incubated at ambient temperature for 20 min on a mixer to allow hybridization to polyA tails. 
After hybridization, RNA targets were magnetically purified as previously described and 
resuspended in 10 µL of RNase-free water. To release the captured RNA targets from the 
magnetic beads, each solution of resuspended RNA targets was heated for 2 min at 95°C, 
immediately placed on a magnet, and the supernatant containing the released RNA targets 
was collected.  
 
DNA-templated CuNBs synthesis for fluorescence/electrochemical readout 
To synthesize CuNBs on polyA-T sequences, 10 µL released RNA targets was mixed with 
MOPS buffer (10mM MOPS, 150 mM NaCl, pH 7.6), 200 µM CuSO4 (unless otherwise 
stated) and 2 mM sodium ascorbate (unless otherwise stated). The mixture was allowed to 
react for 10 min at ambient temperature for DNA-templated CuNBs synthesis.  
 
For fluorescence readout, the incubated mixture was immediately subjected to fluorescence 
detection of RNA targets. The fluorescence measurements were performed on a Tecan 
Infinite® M200 PRO fluorescence plate reader (Tecan, Switzerland) with an excitation 
wavelength of 340 nm and an emission wavelength range of 500 nm-650 nm (max λem = 580 
nm).  
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For electrochemical readout, the incubated mixture was diluted to 30 µL in 5x SSC buffer 
(pH 7.0) and directly dropped onto the gold working electrode surface of a DRP-C223BT 
screen-printed electrode (Dropsens, Spain) and allowed to adsorb for 20 min with gentle 
agitation at ambient temperature. Subsequently, 1 mM 6 mercapto-1-hexanol in 50 mM PBS 
buffer (685 mM sodium chloride, 100 mM potassium chloride, 2.5% glycerol, pH 7.4) was 
added onto electrode surface for 15 min to block the remaining bare surface. The electrodes 
were then washed with 10 mM PBS buffer (pH 7.4) before amperometry measurements in the 
presence of 100 mM PBS buffer pH 7.4) containing 10 mM H2O2. The measurements were 
performed on a CH1040C potentiostat (CH Instruments, USA) at -0.3 V for 30 s.    
 
qRT-PCR validation  
The KAPA SYBR
®
 FAST One-Step qRT-PCR kit (KAPA BIOSYSTEMS, Australia) was 
used to set up a single reaction volume of 10 µl for each sample. Each reaction volume 
consisted of 1X KAPA SYBR
®
 FAST qPCR Master Mix, 200 nM of each forward and 
reverse primer (Table S1), 1X KAPA RT Mix, 50 nM ROX dye and 30 ng of sample total 
RNA template. RT-qPCR was performed using the Applied Biosystems® 7500 Real-Time 
PCR System (Thermo Fisher Scientific, Australia). The cycling protocol was: 42°C for 10 
min to synthesize cDNA, followed by 95°C for 5 min to deactivate RT before cycling 35 
times (95°C for 30 s, 50°C for 30 s and 72°C for 1 min) and finished with 72°C for 10 min. 
The cycle threshold (Ct) value of each qPCR reaction was determined for comparison and 
validation with our assay results. 
 
RESULTS AND DISCUSSION 
Mechanism of RNA detection using DNA-templated CuNBs  
The underlying mechanism of our proposed RNA detection method (Fig. 1) involves the 
coupling of parallel magnetic isolation of individual RNA targets and in-situ poly(A-T)-
templated CuNBs synthesis for convenient fluorescence or electrochemical target detection. 
During initial magnetic target isolation, different RNA species (i.e. mRNA, miRNA, and 
lncRNA) are first complementarily bound to respective biotinylated capture probes in parallel 
reactions. Then, the captured targets are magnetically purified by streptavidin-magnetic 
beads, and 3’-polyA tails are enzymatically-synthesized [34] for miRNA and lncRNA targets 
(without natural polyA tails) exclusively. All targets are then hybridized to polyT sequences 
through their naturally-occurring (for mRNA targets)/enzymatically-synthesized polyA tails. 
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After hybridization, RNA targets are magnetically purified again to remove unhybridized 
polyT sequences. The poly(A-T) sequences (on purified RNA targets) served as templates for 
fluorescent CuNBs synthesis and subsequent fluorescence measurements of corresponding 
RNA target levels. As fluorescence is spontaneously generated upon successful poly(A-T)-
templated CuNBs synthesis, our approach does not require additional fluorescent dye 
labelling. 
 
Figure 1. Schematic of assay using DNA-templated CuNBs synthesis for versatile detection 
of different RNA species. Total RNA is first isolated from sample before capture probes are 
used to capture RNA biomarker targets separately in individual assays for magnetic isolation. 
After magnetic enrichment of targets, poly A polymerase is used to enzymatically extend 
poly(A) tails on miRNA and lncRNA targets prior to target release from magnetic beads. 
Poly(T) sequences are then introduced for complementary hybridization to poly(A) tails of all 
RNA targets and resulting poly(A-T) served as templates for CuNBs synthesis on RNA 
targets. The presence of CuNBs allowed for RNA targets detection by either direct 
fluorescence readout or electrochemical readout after target adsorption onto gold electrode 
surface.   
 
To improve detection sensitivity, we flexibly adapted the fluorescence readout for an 
alternative electrochemical readout (via CuNBs-induced reduction of hydrogen peroxide). 
We have previously shown that isolated RNA target sequences could be quickly adsorbed 
onto gold electrode surfaces based on nucleic acid bases-gold affinity interactions [34, 35]. 
Based on this mechanism, RNA targets-poly(A-T)-CuNBs (i.e. RNA targets after poly(A-T)-
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templated CuNBs synthesis) are conveniently dispensed onto a bare gold electrode surface 
for adsorption. The electrode surface-adsorbed CuNBs are then induced to catalyze hydrogen 
peroxide (H2O2) reduction, generating an electrochemical current response that is measurable 
by amperometry to directly reflect RNA target amount.   
 
In this report, we used three different model PCa-related RNA targets to evaluate the 
versatility of detecting different RNA species for cancer diagnosis. The three targets 
comprised of mRNA (T1E4), miRNA (miR-107), and lncRNA (SChLAP1) biomarkers. 
 
Synthesis of CuNBs on Poly(A-T) sequences  
We first evaluated the successful synthesis of fluorescent CuNBs on poly(A-T) sequences by 
performing our proposed detection methodology with miR-107 (1 pM) as a model target. As 
miR-107 targets do not naturally contain polyA tails, polyT complementary hybridization is 
only possible in the event of enzymatic 3’-polyA tails synthesis. Hence, miR-107 is an ideal 
target for showing that pre-assembly of poly(A-T) sequences on RNA targets was necessary 
for CuNBs synthesis upon CuSO4 and sodium ascorbate addition. Fig. 2 showed that 
fluorescence was emitted (Tube 1) under UV light source when all necessary procedures 
were performed. Control experiments with the omission of miR-107 target (i.e. no-template 
control (NTC)) (Tube 2); polyT sequences (Tube 3); enzymatic polyA tails extension (Tube 
4); sodium ascorbate (Tube 5); and CuSO4 (Tube 6) demonstrated that fluorescence was only 
generated in the event of efficient CuNBs synthesis on poly(A-T) sequences (Fig. 2 inset). 
This is in good agreement with a previous report [9] which demonstrated that double-
stranded poly(A-T) sequences could serve as templates for fluorescent CuNBs synthesis. 
TEM imaging also showed the successful synthesis of poly(A-T)-templated CuNBs with 
spherical shapes of 20 nm in average size (Fig. 2 inset).  
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Figure 2. Synthesis of Poly(A-T)-templated CuNBs. Combined fluorescence spectra for 
(Tube 1); and control experiments with the omission of miR-107 target (i.e. no-template 
control (NTC) (Tube 2); polyT sequences (Tube 3); enzymatic polyA tails extension (Tube 
4); sodium ascorbate (Tube 5); and CuSO4 (Tube 6). Inset shows the corresponding tubes 
under UV light source and TEM image of poly(A-T)-templated CuNBs (as indicated by 
arrows). Scale bar represents 100 nm. 
 
Although single-stranded polyT sequences are also excellent templates for CuNBs synthesis 
[6], we did not observe any fluorescence with the addition of polyT sequences in absence of 
polyA tails (Tube 4). We reasoned that the second round of magnetic RNA target enrichment 
was effective in removing any unhybridized polyT sequences, thus resulting in the absence of 
background fluorescence signal. We also did not observe any fluorescence signal when 
CuNBs synthesis was attempted on only miR-107 templates with (Tube 3) or without (Tube 
4) polyA tails, thus indicating highly-selective CuNBs synthesis on poly(A-T) templates 
solely. This observation of non-CuNBs growth on single-stranded RNA is consistent with 
previous findings that single-stranded polyA sequences [6] and random DNA [6, 9] are 
unable to support CuNBs synthesis. Thus, our results reinforced the concept that double-
stranded nucleic acid templates are generally more stable and ideal for CuNBs synthesis in 
biosensing applications [36, 37]. Moreover, the use of poly(A-T)-templated CuNBs synthesis 
in our experiments provided advantages such as more effective CuNBs synthesis [9], lower 
required target concentration (i.e. no need for enzymatic amplification), as well as non-biased 
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and reproducible fluorescence detection of different RNA targets since CuNBs synthesis was 
not sequence-dependent (i.e. solely poly(A-T)-dependent).  
 
Optimization of Poly(A-T)-Templated CuNBs Synthesis  
Using miR-107 (1 pM) as a model target, we also optimized the polyA extension time as well 
as CuSO4 and sodium ascorbate concentrations to maximize the generated fluorescence 
signals (Fig. S1). First, we used various enzymatic polyA extension times (5, 15, 30, 45, 60 
min) to test the minimal time for generating a significant fluorescence signal. We found that 
fluorescence signal saturated at 30 min with no significant increased beyond this timepoint 
(Fig. S1(a)). It is likely that the process of enzymatic polyA extension on miR-107 targets 
had reached its maximal at 30 min, and a longer extension time would not result in 
significantly longer polyA tails (i.e. longer poly(A-T)) for higher CuNBs-fluorescence. 
Hence, we used a polyA extension time of 30 min for all further experiments. 
 
Next, we investigated the effect of different CuSO4 concentrations (50, 100, 200, 400, and 
800 µM), followed by different sodium ascorbate concentrations (0.5, 1, 2, 4 and 8 mM) for 
CuNBs synthesis. We observed signal saturation at 200 µM CuSO4 (Fig. S1(b)) and 2 mM 
sodium ascorbate (Fig. S1(c)), thereby indicating that synthesis of CuNBs was most 
favourable under these conditions to generate the highest fluorescence signal. Therefore, 
CuNBs synthesis conditions were performed with 200 µM CuSO4 and 2 mM sodium 
ascorbate for further experiments.    
 
Sensitivity for detecting different RNA target species  
To investigate the sensitivity of our proposed method in detecting different RNA target 
species, we prepared different concentrations of T1E4 (0-500 pM), miR-107 (0-100 pM), and 
SChLAP1 (0-500 pM) target sequences for detection. We observed increasing fluorescence 
intensities with higher concentrations of all RNA targets (Figs. 3(a), 3(d), and 3(g)), thus 
indicating increased synthesis of poly(A-T)-templated fluorescent CuNBs synthesis. Using 
the fluorescence readout, the limit-of-detection (LOD) was 500 fM (1.5 x 10
4
 copies); 100 fM 
(3 x 10
5
 copies); 500 fM (1.6 x 10
4
 copies) for T1E4, miR-107, and SChLAP1 respectively 
(Figs. 3(b), 3(e), and 3(h)). By titrating different target concentrations (Fig. S2), we 
established working curves with good linear correlations between fluorescence intensities and 
target concentrations (Figs. 3(c), 3(f), and 3(i)). Amongst the three different RNA species, 
our data illustrated the highest assay sensitivity for miRNA detection. We conjectured that 
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the shorter lengths of miRNAs allow for more efficient hybridization to similar-length 
capture probes and increased poly(A) extensions to result in higher signal generation.     
 
 Figure 3. Sensitivity of assay via fluorescence readout. Fluorescence signals generated using 
various concentrations of (a) T1E4 mRNA; (d) miR-107 miRNA; and (e) SChLAP1 lncRNA 
targets within the 500-640 nm wavelength range. The respective (580 nm) limit-of-detection 
(b, e, h) and linear calibration plot (c, f, g) for each of T1E4, miR-107, and SChLAP1 are 
shown. Error bars represent standard deviation of three independent experiments. 
 
Next, we investigated if detection sensitivity could be further improved by using an 
alternative readout technique. As such, electrochemical readouts would be appealing because 
of their excellent sensitivity, simplicity, and inexpensive instrumentation. Dai et al. have 
previously showcased the electrocatalysis of DNA-RNA heteroduplex-templated Cu 
nanoclusters for high fM-target detection sensitivity [37]. Hence, we hypothesized that 
poly(A-T)-templated CuNBs might provide similar properties for enhanced electrochemical 
detection sensitivity. To enable electrochemical readout, we adsorbed RNA targets-poly(A-
T)-CuNBs on a bare gold electrode surface [34], and utilized CuNBs-induced reduction of 
H2O2 to generate an amperometric signal which directly correlated to biomarker quantity 
(Figs. 4(a), 4(d), and 4(g)). Using this alternative electrochemical readout, we achieved lower 
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limits-of-detection as compared to the fluorescence readout (up to 10-fold improvement) 
(Figs. 4(b), 4(e), and 4(h)) : 100 fM (3 x 10
3
 copies); 10 fM (3 x 10
4
 copies); 100 fM (3.24 x 
10
3
 copies) for T1E4, miR-107, and SChLAP1 respectively. By titrating different target 
concentrations (Fig. S3), we established working curves with good linear relationships 
between current levels and target concentrations (Figs. 4(c), 4(f), and 4(i)) for all three RNA 
target species. The high sensitivity of electrochemical assays have been well-studied [38]; 
and the versatile adaptation of our assay for electrochemical readout provided additional 
benefits such as rapid analysis, ability for high-throughput parallel assays, and possibility for 
point-of-care testing with a portable potentiostat.  
 
 
Figure 4. Sensitivity of assay via electrochemical readout. Electrochemical signals generated 
using various concentrations of (a) T1E4 mRNA; (d) miR-107 miRNA; and (e) SChLAP1 
lncRNA targets. The respective limit-of-detection (b, e, h) and linear calibration plot (c, f, g) 
for each of T1E4, miR-107, and SChLAP1 are shown. Error bars represent standard deviation 
of three independent experiments. 
 
As mRNAs, miRNAs, and lncRNAs are commonly used as disease diagnostic biomarkers in 
the clinic or for biological studies, the fM-level detection sensitivity of our methodology is 
capable of analyzing low amounts of different RNA biomarker species in clinical samples. 
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This fM-level of sensitivity is also similar or superior to recently-developed detection 
techniques of a particular RNA species [37, 39-41]. Moreover, it is worthy to highlight that 
our developed methodology is novel in the detection of different RNA species via a single 
technique without any need for enzymatic amplification or conventional fluorescent labelling.  
 
Selectivity of detecting RNA target  
To test the selectivity of the capture probes used in our proposed method for specific isolation 
and subsequent detection of RNA target, we utilized a single capture probe at a time in 
various presence of different targets (T1E4, miR-107, and SChLAP1). The capture probes 
used in our experiments were shown to be selective for respective T1E4 mRNA, miR-107 
miRNA, and SChLAP1 lncRNA targets (Figs. 5(a), 5(b), and 5(c)), with approximately 8–
fold decrease in fluorescence intensity (Fig. 5(d)) for non-specific targets. As the mixture of 
different RNA species is similar to the environment of isolated total RNA from cell, the high 
target selectivity of our methodology would be applicable for accurate RNA biomarker 
detection in the biologically-complex blood or urine samples. 
 
 
Figure 5. Selectivity of assay. Fluorescence signals generated using different RNA targets 
and a single (a) T1E4 mRNA; (b) miR-107 miRNA; and (c) SChLAP1 lncRNA target capture 
probe within the 500-640 nm wavelength range. The fluorescence signal differences at 580 
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nm (d) for specific detection of T1E4, miR-107, and SChLAP1 are shown. Error bars 
represent standard deviation of three independent experiments. 
 
Analysis of RNA biomarker signatures using PCa cell line models  
After establishing the assay sensitivity and selectivity on synthetic RNA sequences, we 
continued the evaluation of our methodology on biologically-complex cell line models. To 
this end, we challenged our technique with total RNA extracts from PCa cell lines (DuCap 
and 22Rv1) to detect different RNA species (T1E4 mRNA, miR107 miRNA, and SChLAP1 
lncRNA) by both fluorescence (Figs. 6(a) and 6(b)) and electrochemical readouts (Figs. 6(d) 
and 6(e)). It was observed that both fluorescence and electrochemical readouts produced 
similar cell line biomarker expression trends: DuCap showed T1E4 expression, whilst 22Rv1 
overexpressed both miR-107 and SChLAP1 (Figs. 6(c) and 6(f)). These findings were in 
concordance with reports in literature [25, 26, 28, 29] which detected similar RNA biomarker 
expression trends in these cell lines. Furthermore, the successful selective RNA target 
detection in total RNA isolation from cultured cells also showed high resilience against 
interference from non-target molecules of our methodology; a parameter greatly required for 
clinical sample application. Although there have been developed assays for detecting RNA 
biomarkers from cultured cells, the simultaneous detection of different RNA species has 
rarely been shown. To the best of our knowledge, our assay is unique in the parallel detection 
of mRNA, miRNA, and lncRNA biomarkers from biological cells. 
 
 
Figure 6. Detection of diverse RNA biomarker species using prostate cancer cell line models. 
Fluorescence signals generated for detection of T1E4, miR-107, and SChLAP1 in (a)  DuCap 
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and (b) 22Rv1 cells within the 500-640 nm wavelength range. The different biomarker 
signature of both cell lines via fluorescence readout at 580 nm (c) is shown. Electrochemical 
signals generated for detection of T1E4, miR-107, and SChLAP1 in (d) DuCap and (e) 22Rv1 
cells. The different biomarker signature of both cell lines via electrochemical readout (f) is 
shown. Error bars represent standard deviation of three independent experiments. 
 
Non-invasive detection of RNA biomarkers in patient urinary samples  
To investigate the clinical application of our methodology, we challenged it with the more 
sensitive electrochemical analysis of T1E4 (Fig. 7(a)), miR-107 (Fig. 7(b)), and SChLAP1 
(Fig. 7(c)) RNA biomarkers from patient urinary samples (P1-P10 are from PCa patients, H1 
and H2 are from healthy males). The use of urinary samples provided a form of non-invasive 
liquid biopsy as compared to painful, costly, and infection-risky tissue biopsies. Towards this 
end, we firstly extracted cellular total RNA from patient urine samples using a 
commercialized spin-column technique (see Experimental section for more details).  
 
For the PCa patients, we generally observed higher expressions of the different target RNA 
biomarkers as compared to those of the healthy samples (Fig. 7). This is in good agreement 
with previous reports which stated T1E4 presence as well as miR-107 and SChLAP1 
overexpression in malignant PCa cases [25, 26, 29]. To demonstrate diagnostic application, 
we established cutoff values (Fig. 7) to predict abnormal expression levels for each target 
RNA biomarker based on the mean signals of the healthy samples and compared our 
outcomes with conventional qRT-PCR. Each cutoff value was determined from the mean 
signals of the healthy samples plus three standard deviations. A generated signal from a 
patient sample exceeding the cutoff value would then suggest that the particular RNA 
biomarker is of an abnormal level. Using this analysis, we profiled T1E4, miR107, and 
SChLAP1 biomarker signatures for each patient and found 100% concordance with 
conventional qRT-PCR validation (Table S2). This successful detection of multiple 
clinically-promising RNA biomarkers species underscored the clinical application potential 
of our assay potential in obtaining biomarker signatures from biological samples. As 
mutations in PCa (and other cancer types) differ amongst different patients, a more effective 
diagnosis would utilize the combined detection of several different biomarkers to generate 
biomarker signatures (i.e. cancer molecular characterization) [42, 43]. Thus, the versatile 
nature of our proposed assay for different RNA biomarker species analysis, allows a 
potentially powerful diagnostic tool for generating informative biomarker signatures to 
enable potent personalized cancer therapies. 
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Figure 7. Non-invasive RNA detection in clinical urinary samples. Electrochemical detection 
of (a) T1E4; (b) miR-107; and (c) SChLAP1 RNA biomarker species in urinary samples 
collected from twelve prostate cancer patients (P1-P10) and two healthy males (H1 and H2). 
Error bars represent standard deviation of three independent experiments. 
 
CONCLUSIONS 
In conclusion, amplification-free detection of three different RNA species by poly(A-T)-
templated CuNBs synthesis is reported for the first time. We have demonstrated a technique 
for versatile detection of different RNA biomarker species with high fM-level sensitivity and 
specificity via flexible fluorescence/electrochemical readout. The successful detection in 
urinary samples from PCa patients and subsequent result validation with conventional qRT-
PCR; demonstrated the clinical potential of our assay for non-invasive detection of RNA 
biomarker signatures during PCa diagnosis.  
 
Our proposed assay has demonstrated several benefits to mitigate conventional RNA 
detection challenges: (i) it does not require any enzymatic amplification to achieve a 
detectable readout signal, thus avoiding possible amplification bias/artifacts. (ii) it shows the 
versatile detection of different-length RNA species with a single technique (albeit a simple 
and convenient extension step for RNA species without natural polyA tails), and does not 
require any special assay designs such as stem-loop primers for detecting short-length 
miRNAs. (iii) it utilizes poly(A-T)-templated CuNBs for readouts in place of conventional 
fluorescence dye labels, therefore allowing for a more inexpensive and stable readout.    
 
With future cancer diagnosis most likely to combine different biomarker species for 
comprehensive disease molecular characterization, we envisage that our described 
methodology could serve as an attractive amplification- and fluorescent dye-free alternative 
for different RNA species detection. Moreover, our assay could easily be adapted for RNA 
disease biomarkers in other diseases through rational capture probe design.       
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SUPPLEMENTARY INFORMATION 
 
Table S1. Oligonucleotide sequences used in experiments 
Oligos 5'-Sequence-3' 
T1E4 Capture Probe  
CAACTGATAAGGCTTCCTGCCGCGCTCCAGG-
Biotin 
miR-107 Capture Probe TGATAGCCCTGTACAATGCTGCT-Biotin 
SChLap1 Capture Probe TGTGTCCAGAACTGGTGGGTTCTTGGTCTC-Biotin 
T1E4 RT-qRCR Forward 
Primer 
ATTTAGGTACAACTCTTTCCCTCGTC 
T1E4 RT-qRCR Reverse Primer TGTATAGGAATCCCACTGAATTTTTC 
miR-107 RT-qRCR Forward 
Primer  
AGCAGCATTGTACAG 
miR-107 RT-qRCR Reverse 
Primer 
TTTTTTTTTTTTTTTTTG 
SChLap1 RT-qRCR Forward 
Primer  
GAGACCAAGAACCCACCAGTTCTGGACACA 
SChLap1 RT-qRCR Reverse 
Primer 
CATCTGGCACTTCTTCCCCAGTCATTCCAT 
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Figure S1. Optimization of (a) polyA extension time; (b) CuSO4 concentration; and (c) 
sodium ascorbate concentration. 
 
 
Figure S2. Fluorescence signals (580 nm) generated using various concentrations of (a) 
T1E4, (b) miR-107, and (c) SChLAP1. Error bars represent standard deviation of three 
independent experiments.  
 
 
Figure S3. Electrochemical signals generated using various concentrations of (a) T1E4, (b) 
miR-107, and (c) SChLAP1. Error bars represent standard deviation of three independent 
experiments. 
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Table S2. qRT-PCR validation of urinary sample results.  
 Our Assay qRT-PCR 
Sample T1E4 
Status 
miR-107 
Status 
SChLap1 
Status 
T1E4 Ct 
(Cycle)   
miR-107 Ct 
(Cycle)   
SChLAP1 Ct 
(Cycle)   
P1 Normal Normal Abnormal 31.8 25.8 16.3 
P2 Abnormal Abnormal Abnormal 15.3 16.9 16.7 
P3 Abnormal Abnormal Normal 29.2 20.0 27.0 
P4 Abnormal Abnormal Abnormal 14.7 15.7 18.7 
P5 Normal Abnormal Abnormal 30.5 16.3 17.4 
P6 Normal Abnormal Abnormal 31.4 16.9 17.4 
P7 Abnormal Abnormal Abnormal 15.6 17.6 16.9 
P8 Normal Abnormal Normal 32.4 16.4 27.3 
P9 Abnormal Abnormal Abnormal 14.6 22.1 18.4 
P10 Abnormal Normal Abnormal 19.1 25.8 21.2 
H1 Normal Normal Normal 33.8 26.3 26.5 
H2 Normal Normal Normal 31.2 25.9 26.3 
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6 
Simultaneous Analysis of Multiple Biomarkers via Multiplexing/High-
Throughput Parallel Assays 
 
 
Introduction 
As true for the majority of cancer types, prostate cancer is a highly heterogeneous disease 
which shows a large degree of inter- and intra-tumor molecular variability in patients. This 
makes the classification of prostate cancer into indolent and aggressive disease subtypes for 
precision therapy an extremely challenging task. Hence, to more accurately understand an 
individual cancer patient’s disease subtype, molecular biomarker diagnostic needs to detect 
multiple biomarkers (instead of a single biomarker) to provide a more complete screening 
outcome for clinical decision-making. Specifically for prostate cancer, the concurrent 
screening of multiple next-generation urinary RNA biomarkers from a single patient sample 
could improve clinical diagnosis, prognosis, and treatment prediction. To achieve this, 
multiple targets could be detected i) within a single tube by using multiple target-specific 
detection labels (i.e. multiplexed screening) or ii) using a multi-array approach whereby 
different biomarkers from a single sample are analyzed simultaneously (i.e. high-throughput 
parallel screening). Using these two concepts, this chapter describes the development of 
novel bioassays which enable simultaneous detection of multiple biomarkers for a more 
comprehensive prostate cancer diagnosis. Chapter 6.1 demonstrates the use of surface-
enhanced Raman spectroscopy for rapid five-plexed detection of urinary biomarkers in 
prostate cancer subtyping. Chapter 6.2 showcases a novel technique which fuses multi-RNA 
target probe ligation and isothermal recombinase polymerase amplification for high-speed 
biosensing of different prostate cancer fusion gene variants. Chapter 6.3 describes a 
nanodevice that innovatively uses alternating current electrohydrodynamic (ac-EHD) fluidic 
manipulation to simultaneously profile the expression of three various types of next-
generation urinary RNA biomarkers in a cohort of prostate cancer patients. 
 
Chapter 6 is based on three published articles in Small (2016) [Chapter 6.1], Biosensors & 
Bioelectronics (2017) [Chapter 6.2], and Small (2018) [Chapter 6.3]. 
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Toward Precision Medicine: A Cancer Molecular Subtyping 
Nano-Strategy for RNA Biomarkers in Tumor and Urine  
 
Kevin M. Koo, Eugene J. H. Wee, Paul N. Mainwaring, Yuling Wang, Matt Trau 
 
 
ABSTRACT 
Cancer is a heterogeneous disease which manifests as different molecular subtypes. Due to 
the complex nature of tumor initiation, progression and metastatsis; cancer in different 
patients progresses at individual rates via various pathways. Currently, this cancer 
heterogeneity is largely unexploited, and the concept of precision medicine is to incorporate 
diagnostic technology to enable tailored treatments for different patients. To allow accurate 
cancer screening, early detection, therapy and monitoring; the characterization of multiple 
oncogenic biomarkers is required to characterize individualized cancer molecular subtypes. 
Despite the reliability of current multiplexed detection techniques; novel strategies are 
needed to resolve limitations such as long assay time, complex assay protocols, and difficulty 
in intepreting broad overlapping spectral peaks associated with conventional fluorescence 
readouts. Herein we present a rapid (80 min) multiplexed platform strategy for subtyping 
prostate cancer (PCa) tumor and urine samples based on their RNA biomarker profiles. This 
was achieved by combining rapid multiplexed isothermal reverse transcription-recombinase 
polymerase amplification (RT-RPA) of target RNA biomarkers with surface-enhanced 
Raman spectroscopy (SERS) nanotags for a “one-pot” assay. This is the first translational 
application of a RT-RPA/SERS-based platform for multiplexed cancer biomarker detection to 
address a clinical need. With excellent sensitivity of 200 zmol (100 copies) and specificity, 
we believe this platform methodology could be a useful tool for rapid multiplexed subtyping 
of cancers.      
 
INTRODUCTION 
In recent years, there is overwhelming evidence that cancer is not just a single disease, but 
rather a variety of intricate subtypes which requires different treatment strategies.
[1]
 For 
instance, prostate cancer (PCa) is a heterogeneous disease comprising of both clinically 
significant (aggressive and lethal) and insignificant (slow-growing and non-life threatening) 
Chapter 6.1 
 
223 
 
subtypes. These different PCa subtypes could be characterized by their genetic (DNA, 
epigenetic and RNA expression) profiles,
[2]
 and being able to stratify patients based on their 
profiles could potentially allow more effective personalized treatment decisions (i.e. precision 
medicine).
[3]
 Recently, the potential of detecting multiple biomarkers for PCa subtyping and 
personalized treatment has been demonstrated in several reports.
[4]
 The non-invasive use of 
urinary biomarkers is of particular interest due to the potential of eliminating financial, 
medical and psychological implications associated with biopsy procedures. Of note, novel 
urinary RNA biomarkers such as PCA3
[5]
 and TMPRSS2:ERG fusion genes
[6]
 were 
demonstrated to improve PCa diagnosis and risk stratification over the current use of a single 
prostate-specific antigen (PSA) biomarker. In these studies, the combination of both 
TMPRSS2:ERG and PCA3 was found to provide better risk prediction for high-grade PCa
[4a, 
7]
 Apart from diagnosis/prognosis, a splice variant of the androgen receptor (ARV7) has also 
been discovered recently to predict drug resistance response in advanced PCa patients,
[8]
 and 
thus, the use of ARV7 for directing clinical decisions could potentially save valuable 
treatment time and cost. Thereby, it is of great clinical interest to develop a screening 
methodology for these promising PCa biomarkers simultaneously in a rapid manner. To meet 
this need, we herein describe a novel nano-subtyping platform for rapid multiplexed detection 
of PCa biomarkers, whilst addressing the limitations of methodologies used in current 
practice.  
 
Existing technologies for multiplexed RNA biomarker detection and cancer molecular 
subtyping are generally dependent on established techniques such as quantitative real-time 
polymerase chain reaction (qRT-PCR);
[4a, 4e]
 direct hybridization;
[9]
 and next-generation 
sequencing (NGS).
[3b]
 While effective for multiplexing, these techniques are limited by 
tedious protocols, slow turn-around time, high instrument cost, and requirement for high 
starting sample amount. Additionally, the multiplexed fluorescence-based readouts of 
traditional techniques are limited by large spectral overlaps and thus, convolute the 
interpretation of multiplexed detection data. To allow for fast, convenient, and sensitive 
amplification of trace RNA biomarker levels in biological samples, reverse transcription-
recombinase polymerase amplification (RT-RPA) is a viable alternative to traditional RT-
PCR techniques. RT-RPA is an isothermal amplification technique
[10]
 which utilizes 
enzymatic strand separation during the amplification process instead of heat denaturation 
used in RT-PCR. This removal of thermal cycling steps has allowed rapid and cost-effective 
RT-RPA detection of a wide variety of human disease-related RNA targets in literature.
[11]
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However, to the best of our knowledge, there still exists a lack of highly-multiplexed RT-
RPA techniques which could be a potential solution for faster cancer molecular subtyping in 
patient samples.  
Surface-enhanced Raman spectroscopy (SERS) is an ideal candidate technique for detecting 
multiple target molecules (including RNA
[12]
) present in a single sample.  SERS is a method 
which involves the adsorption of molecules (or labels) onto metal nanoparticles (eg. gold or 
silver) surfaces
[13]
 to significantly amplify the Raman scattering effect through 
electromagnetic field amplification (via excitation of the localized surface plasmon of 
nanoparticles). Typically, target molecules are labelled with SERS labels (Raman probe 
molecules-coated metallic nanoparticles) for enhanced detection down to single-molecule 
level.
[14]
 The unique fingerprint spectra of each specific label and the narrow well-separated 
SERS spectral peaks allow for the detection of multiple target molecules concurrently with 
easy interpretation unlike multiplexed fluorescence detection. The magnetic isolation of DNA 
and protein targets for labelled SERS detection has been investigated,
[15]
 and shown to be 
highly sensitive as well as readily multiplexable. Yet, possibly due to the lack of a robust 
amplification techniques, similar applications for multiplexed RNA detection has rarely been 
demonstrated. Therefore, considering the advantages of SERS, an assay which integrates 
multiplexed RT-RPA of RNA biomarkers with “one-pot” SERS-based readout is a 
potentially attractive technique for PCa molecular subtyping.            
 
Herein, for the first time, we described a five-plexed assay for simultaneously detecting 
promising next-generation biomarkers in PCa. Our proposed assay offered distinct benefits: 
(i) multiplexed biomarker detection could be achieved within a short time-frame with rapid 
isothermal RT-RPA and “one-pot” SERS readout; (ii) easy interpretation of detection 
outcomes from well-resolved SERS spectral peaks without the need for further data 
processing; (iii) applicable to clinical samples such as tissue biopsy specimens, and urine 
samples. With high specificity and zmol-level sensitivity, the combination of RT-RPA and 
SERS shows great potential as a cancer screening platform for multiplexed molecular 
subtyping. 
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EXPERIMENTAL SECTION  
Reagents and Materials 
All reagents were of analytical grade and purchased commercially (Sigma Aldrich, 
Australia). UltraPureTM DNase/RNase-free distilled water (Invitrogen, Australia) was used 
throughout the experiments. Oligonucleotides were synthesized and purchased commercially 
(Integrated DNA Technologies, Singapore) and sequences are shown in Table S1. 
 
Synthesis of SERS Nanotags: SERS nanotags were synthesized by the coating of Raman 
reporters and DNA probes on the AuNPs surface.
[24]
 Briefly, AuNPs were synthesized by 
citrate reduction of HAuCl4
[25]
 and AuNPs (1 mL) was then mixed with TCEP-treated 
thiolated DNA oligonucleotides (10 μL, 50 μM) (IDT, Singapore) at room temperature (RT) 
for 12 hours. Then, Raman probe (100 μL, 1 mM): 4-mercaptobenzoic acid (MBA); 2,7-
mercapto-4-methylcoumarin (MMC); 2-mercapto-4-methyl-5-thiazoleacetic acid (MMTAA); 
4-mercapto-3-nitrobenzoic acid (MNBA); or 2,3,5,6-tetrafluoro-4-mercaptobenzoic acid 
(TFMBA) was added to the AuNPs for incubation at RT overnight. Afterwhich, NaCl (0.6 
M) in PBS (1 mM) was used to age the SERS nanotags at RT for 12 hours before 
centrifugation and resuspension of SERS nanotags into PBS buffer (10 mM) prior to use. The 
final concentration (0.5 nM) of the SERS nanotags mix was determined by the UV extinction 
spectra of AuNPs. 
 
Cell Culture and RNA Extraction 
DuCap, LnCap, and 22Rv1 cells were cultured in RPMI-1640 growth media (Life 
Technologies, Australia) supplemented with fetal bovine serum  (10%) (Life Technologies, 
Australia) in a humidified incubator containing CO2 (5%) at 37ºC. Total RNA was extracted 
using Direct-zol
TM
 RNA MiniPrep kit (Zymo Research, USA) according to manufacturer’s 
instructions. Cultured cells were lysed using TRIzol
®
 reagent (Life Technologies, Australia) 
before addition of ethanol. Then, the mixture was transferred into a supplied Zymo-Spin
TM
 
IIC Column in a collection tube for centrifugation. After several wash steps, the purified 
RNA was eluted with RNase-free water (50 µL). The RNA integrity and purity were checked 
using a NanoDrop Spectrophotometer (Thermo Fisher Scientific, Australia). 
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RNA Extraction from Patient Tumor and Urine Samples 
Ethics approval was obtained from The University of Queensland Institutional Human 
Research Ethics Committee (Approval No. 201400012) and informed consent was obtained 
from all subjects prior to sample collection. Methods pertaining to clinical samples were 
carried out in accordance with approved guidelines. Voided urinary and biopsy samples were 
collected from men patients undergoing treatment for prostate cancer.  
 
Total RNA was extracted from the urine samples using the commercially-available ZR Urine 
RNA Isolation Kit
TM
 (Zymo Research, USA). For each sample, urine (30 mL) was passed 
through the supplied ZRC GF
TM
 Filter to retain urinary cells. Then, supplied urine RNA 
buffer (700 µL) was passed through the filter and the filtered cells were collected in the flow-
through. Next, cells from the flow-through were lysed, and total RNA was washed and eluted 
in RNase-free water (10 µL). 
 
Total RNA was extracted from biopsy samples using Qiagen All-Prep according to 
manufacturer’s instructions. Briefly, tissue samples were disrupted and homogenized before 
being transferred to an AllPrep DNA spin column for centrifugation. The flow-through was 
used for total RNA purification by first transferring into an RNeasy spin column. After 
several steps of washing and centrifugation, the purified RNA was eluted in RNase-free water 
(30 µL).  
 
Multiplexed RT-RPA  
For multiplexed amplification of target biomarkers, the TwistAmp Basic RT kit (Twist-DX, 
UK) was used with slight modifications to manufacturer’s instructions. Each dried-freeze 
pellet was resuspended in buffer (29.5 µL) and DNase/RNase-free water (4.5 µL) before 
splitting into four equal aliqots. Then, each primer (375 nM) (Table S1) and purified RNA (1 
µL, 50 ng) were added to make a reaction volume (12.5 µL) prior to incubation at 41°C for 
20 min. 
 
Hybridization to SERS Nanotags and Magnetic Isolation 
After amplification, RPA amplicons (10 µL) were incubated with MBA- (1 µL), MMC- (2 
µL), MMTAA- (5 µL), MNBA- (5 µL), and TFMBA- (2 µL) SERS nanotags for 20 min at 
37 °C. It is essential to highlight that due to the non-identical SERS signal levels in the stock 
solutions, the various SERS nanotags were added in different amounts such that a 1:1:1:1:1 
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SERS signal was obtained for a 1:1:1:1:1 target mix. Before application to patient samples, 
we used cell line RNA to optimize the different amounts of added SERS nanotags (data not 
shown), and provide accurate quantification of target biomarkers. After incubation with 
SERS nanotags, streptavidin-magnetic beads (5 µL) (New England Biolabs, Australia) was 
added to the mixture for 10 min of incubation at room temperature. The amplicons-SERS 
nanotags complexes were then isolated on a magnetic plate with three consecutive washes of 
wash buffer (1 mM PBS buffer, 0.01% Tween20).  
 
One-Pot SERS Detection of Biomarkers  
After the final wash, the pellet was then resuspended in PBS buffer (60 µL, 1 mM) and 
transferred to a quartz cuvette for SERS measurements on the IM-52 portable Raman 
microscope (Snowy Range Instruments, USA). An average SERS spectrum was obtained for 
each sample from five acquisitions of 2 sec integration by a 785 nm excitation laser at 70 
mW. In all, this instantaneous SERS readout in combination with 20 min of RNA extraction; 
20 min of multiplexed RT-RPA; 30 min of SERS naonotag hybridization and magnetic 
isolation; and 10 min of overall sample preparation time, gave a sample-to-answer assay time 
of 80 min.  
 
Quantitative Comparison of Biomarker Levels 
To account for variations in starting sample RNA amounts, the Raman intensity of a target 
biomarker was normalized with respect to the stably-expressed housekeeping RN7SL1 RNA 
(i.e. loading control) of the same sample. The normalized Raman intensity which reflected 
the respective biomarker level (i.e. higher biomarker level led to higher Raman intensity), 
allowed for convenient biomarker level comparisons between samples: 
  
Normalized Raman Intensity = (iBiomarker / iRN7SL1)    (Equation 1) 
 
where iBiomarker is the average Raman intensity for target RNA (T1E4, RN7SL1, T1E5, 
ARV7, or PCA3), and iRN7SL1 is the average Raman intensity for RN7SL1 RNA 
loading control of the same sample. 
 
qRT-PCR Validation 
The KAPA SYBR
®
 FAST One-Step qRT-PCR kit (KAPA BIOSYSTEMS, Australia) was 
used to set up a single reaction volume (10 µL) for each sample. Each reaction volume 
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consist of KAPA SYBR
®
 FAST qPCR Master Mix (1X), each forward and reverse primer 
(200 nM) (Table 1), KAPA RT Mix (1X), ROX dye (50 nM) and cell line total RNA 
template (30 ng). RT-qPCR was performed using the Applied Biosystems® 7500 Real-Time 
PCR System (Thermo Fisher Scientific, Australia). The cycling protocol was: 42°C for 10 
min to synthesize cDNA, followed by 95°C for 5 min to deactivate RT before cycling 35 
times (95°C for 30 s, 50°C for 30 s and 72°C for 1 min) and finished with 72°C for 10 min. 
 
RESULTS AND DISCUSSION    
Working Principle 
The working principle of our five-plexed screening assay is illustrated in Figure 1. Firstly, 
the target RNA biomarkers in the sample are isothermally amplified concurrently by 
multiplexed RT-RPA using biomarker-specific primers. By use of modified primers, the 
generated amplicons are tagged with biotin molecules and target-specific 5’ overhang 
barcode sequences on either ends. Each 5’ barcode overhang sequence is achieved by 
inclusion of an internal carbon linker in the primer which prevents DNA extension on the 
complementary strand. Thus, this leaves the barcode sequence single-stranded to facilitate 
hybridization with complementary sequences on SERS nanotags. Next, all the amplicon-
SERS nanotag complexes are attached to streptavidin (SA)-coated magnetic beads via biotin 
tags. These attachments facilitate slight AuNPs aggregation (Figure S1, Supporting 
Information) on the magnetic beads for higher SERS enhancement
[16]
. Finally, the 
magnetically enriched SERS-labelled amplicons are interrogated by Raman spectrometer to 
both identify (unique spectral peak) and quantify (peak intensity) the targets present in the 
sample. 
 
In this study, we selected a panel of five RNA targets comprising of next-generation 
biomarkers which are exceptionally promising
[8, 17]
 for PCa subtyping and risk stratification. 
The targets include two most common TMPRSS2:ERG gene fusion variants: TMPRSS2 exon 
1-ERG exon 4 (T1E4) and TMPRSS2 exon 1-ERG exon 5 (T1E5); PCA3; ARV7; and a 
stably-expressed housekeeping RNA (RN7SL1)
[18]
. 
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Figure 1. Schematic representation of assay. Total RNA is firstly isolated from samples 
before target RNA biomarkers are simultaneously amplified using isothermal reverse 
transcription-recombinase polymerase amplification. During amplification, amplicons are 
tagged with biotin molecules and target-specific overhang hybridization sequences. The 
different biomarker-specific amplicons are then labelled with respective SERS nanotags 
through complementary sequence hybridization and magnetically-purified. Finally, the 
amplicons are detected by SERS concurrently and quantitative analysis of biomarker level is 
derived from spectral peak of each unique SERS nanotag. 
 
Characterization of SERS Nanotags 
Five different Raman probe molecules, namely MBA; MMC; MMTAA; MNBA; and 
TFMBA (see experimental section for the full chemical names), were used to synthesize the 
SERS nanotags in our experiments. These Raman probes were assembled along with 
respective oligonucleotide sequences (Table S1, Supporting Information) on surfaces of gold 
nanoparticles (AuNPs) to generate different SERS nanotags. To ensure successful synthesis 
and function of the five different SERS nanotags, we first used transmission electron 
microscopy (TEM) to image the SERS nanotags (Figure 2A). The SERS nanotags were 
generally uniform in size at ~70 nm diameter. Next, we characterized the different SERS 
nanotags by UV/Vis absorption spectroscopy (Figure 2B). Here, as consistent with a 
refractive index change due to surface functionalization,
[19]
 a spectral peak red shift for 
Raman probes/oligonucleotides-modified AuNPs was observed as compared to bare AuNPs, 
Finally, each SERS nanotag was analyzed both individually and as a mixture of all five 
nanotags. As shown in Figure 2C, the individual SERS signal for each nanotag was 
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successfully detected and found to be different from each other. Distinct peak of each 
different Raman probe was observed at 1075 cm
-1
 (MBA), 1175 cm
-1
 (MMC), 1285 cm
-1
 
(MMTAA), 1338 cm
-1
 (MNBA), 1380 cm
-1
 (TFMBA). These unique spectral peaks were 
distinct and easily-distinguished even during multiplexed detection of all five labels (Figure 
S2, Supporting Information). These characterization experiments thus demonstrated that our 
synthesized SERS nanotags were functional and able to generate distinctive SERS signals for 
multiplexed detection of target molecules. 
 
 
Figure 2. Characterization of SERS nanotags. (A) Typical TEM image of SERS nanotags. 
(B) UV/Vis absorption spectra of bare AuNPs and different SERS nanotags. (C) Unique 
SERS spectral peaks of individual SERS nanotags (Left). Molecular structures of Raman 
probes used for synthesis of each SERS nanotag (Right).  
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Assay Sensitivity 
A serial dilution of in vitro transcribed T1E4 RNA was first used to evaluate the sensitivity of 
our assay. SERS measurements were conducted following multiplexed RT-RPA 
amplification, SERS nanotag hybridization, and magnetic isolation. We observed that the 
Raman intensity associated with T1E4 (1075 cm
-1
) increased in a copy number-dependent 
manner, and the negative no-target control showed negligible background signal (Figure 
3A). The limit of detection (LOD) of our assay was determined to be 100 copies (200 zmol) 
with a linear range of log(1-10
6
) copies (Figure 3B). Moreover, the increase in Raman 
intensity with higher amount of input RNA also demonstrated the feasibility of the assay for 
quantitative biomarker detection. This could be useful for applications such as the monitoring 
of biomarker levels to assess drug response during therapy.    
 
In addition, multiplexed detection sensitivity in a biologically-complex sample (e.g. cell line-
derived RNA) was also evaluated. To this end, we titrated known amounts of in vitro 
transcribed ARV7 RNA into background of LnCAp cell line-isolated RNA. As ARV7 is 
absent in LnCap, we could readily observed Raman intensity changes due to different ARV7 
levels. Figure 3C & D showed that the ARV7 Raman intensity (1338 cm
-1
) increased 
proportionally with increasing ARV7 copies whilst signals from background LnCap-
endogenous RN7SL1 (1175 cm
-1
) and PCA3 (1375 cm
-1
) RNA remained constant. Similar to 
T1E4, the LOD for ARV7 in a complex system was maintained at approximately 100 copies 
with a linear range of log(1-10
6
) copies (Figure S3, Supporting Information). Together, the 
data suggested a sensitive and robust approach for targeted RNA detection.  
 
Our observed zmol-level LOD is generally less than the level of RNA material in a single 
cell,
[20]
 and therefore adequate and suitable for detection in real clinical samples. This LOD is 
also superior to existing multiplexed SERS label-based assays
[21]
 that reported higher LOD 
and/or required starting sample amount for disease detection. We reasoned that our higher 
assay sensitivity was due to dual signal amplification through isothermal amplification as 
well as SERS effect. It is also worthy to note that our assay could be performed in a much 
shorter assay timeframe (80 min) as compared to conventional techniques such as qRT-PCR, 
fluorescence in-situ hybridization (FISH), or NGS (at least 2.5 hours from sample-to-answer).  
 
As a 70 mW laser was used to enable SERS in our assay, we investigated if assay 
performance such as sensitivity could be affected by sample degradation via laser excitation. 
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To this end, samples were interrogated by laser and Raman intensities were recorded over 
multiple scans. Our findings indicated no significant sample degradation as the average 
Raman intensities remained constant with increasing number of signal acquisition (i.e. longer 
laser exposure) even at a low input amount of 100 ARV7 copies (Figure S4, Supporting 
Information). We reasoned that this was due to the small detection area that was being 
interrogated by a fixed laser beam in relation to the large body of sample volume; thus it was 
unlikely that freely-diffusing targets within the sample solution could be degraded by laser 
exposure during a single signal acquisition.   
 
 
Figure 3. Assay sensitivity. (A) Average SERS spectra corresponding to different copy 
numbers of input T1E4 RNA. (B) Analogous linear calibration plot for T1E4 copy number 
titration. (C) Average SERS spectra corresponding to different copy numbers of input ARV7 
RNA in background of LnCap RNA. (D) Corresponding normalized Raman intensities for 
ARV7 copy number titration. Error bars represent standard deviation of three independent 
experiments (n = 3). 
 
Assay Specificity 
To evaluate assay specificity, we used our full set of RT-RPA primers and SERS nanotags to 
detect target biomarkers in three different PCa cell lines individually. Each of the three 
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chosen cell lines carries different target biomarker(s) of interest: DuCap is positive for T1E4 
and T1E5; LnCap is positive for PCA3; and 22Rv1 cell line is positive for ARV7 and PCA3. 
Additionally, all three cell lines were tested for RN7SL1 housekeeping RNA as a positive 
loading control. We assigned the five different SERS nanotags for the detection of each 
target: T1E4 (MBA, 1075 cm
-1
); RN7SL1 (MMC, 1175 cm
-1
); PCA3 (MMTAA, 1285 cm
-1
); 
T1E5 (MNBA, 1338 cm
-1
); ARV7 (TFMBA, 1380 cm
-1
). Figure 4 showed the specific SERS 
detection of biomarkers associated with each particular cell line. Typically, DuCap was only 
positive for T1E4, T1E5, and RN7SL1, whilst spectral peaks for ARV7 and PCA3 were 
noticeably absent (Figure 4A1 & A2); LnCap was only positive for PCA3 and RN7SL1 
(Figure 4B1 & B2); and 22Rv1 was only positive for ARV7, PCA3, and RN7SL1 (Figure 
4C1 & C2). These results coupled with the low background signals of the negative no-target 
controls (Figure 4) confirmed the specificity of the RT-RPA primers during selective 
amplification of targets, as well as the effect of stringent wash steps to remove non-
specifically bound SERS nanotags on the magnetic bead surface. This high assay specificity 
was important for accurately discriminating target sequences in clinical blood or urine 
samples with large amounts of non-targets.  
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Figure 4. Assay specificity. Average SERS spectra of multiplexed biomarker profiling in 
(A1) DuCap, (B1) LnCap, and (C1) 22Rv1 cell lines. Corresponding normalized Raman 
intensities are shown in (A2), (B2), and (C2) respectively. Error bars represent standard 
deviation of three independent experiments (n = 3). 
 
Multiplexed Detection of PCa Biomarkers 
To demonstrate the multiplexing capability of our assay, we simultaneously detected the five 
PCa biomarkers by mixing purified total RNA from three different PCa cell lines. As shown 
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in Figure 5A, all five targets could be detected and identified by their unique SERS spectral 
peaks from the mixture of different cell lines. Additionally, the normalized Raman intensities 
(Equation 1) of the respective targets reflected the different biomarker levels quantitatively 
(Figure 5B). The biomarker level trend determined by our assay outcome was subsequently 
validated by qRT-PCR with good agreement (Figure S5, Supporting Information). This 
experiment thus exhibited the multiplexing capability of our assay in biologically-complex 
cell line samples. 
 
 
Figure 5. Multiplexed detection of biomarkers in prostate cancer cell lines. (A) Simultaneous 
SERS detection of five different biomarkers in a mixture of total RNA extracted from 
DuCap, LnCap, and 22Rv1 cells. (B) Corresponding normalized Raman intensities. Error 
bars represent standard deviation of three independent experiments (n = 3). 
 
Multiplexed Biomarker Detection in Patient Tumor and Urine Samples 
The central aim of our effort was to allow simultaneous interrogation of PCa biomarkers in 
patient samples with a rapid multiplexed SERS assay. To demonstrate clinical feasibility, we 
challenged our assay by profiling biomarker levels in samples from PCa patients. We 
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performed our five-plexed SERS assay on extracted total RNA from tumor (Figure 6A & B) 
and urine (Figure 6C-E) samples of different patients, and successfully measured different  
levels of four different PCa biomarkers (T1E4, T1E5, ARV7, and PCA3) in addition to the 
RN7SL1 loading controls for all patients. The normalized Raman intensities (Equation 1) of 
each biomarker allowed for easy quantitative comparisons of biomarker levels between 
samples. For instance, we observed that T1E4 level in U1 (Figure 6C2) was about 3-fold 
higher than in U2 (Figure 6C2) after normalizing T1E4 Raman intensities to the respective 
stably-expressed RN7SL1 housekeeping RNA Raman intensities (i.e. normalized biomarker 
levels to account for different starting sample RNA amounts). 
 
We also validated our results with current standard qRT-PCR approach with 100% 
concordance (Figure S6-10, Supporting Information). In comparison to existing SERS 
techniques for RNA detection
[12, 22]
, we found that our proposed assay: i) possessed superior 
detection sensitivity; ii) successfully showed multiplexed RNA detection for more than three 
targets for the first time; and most importantly iii) demonstrated clinical translation potential 
with real cancer patient samples.   
 
The biomarker profiles obtained for the different PCa patients reflected the heterogeneity of 
the disease as each patient exhibited a different profile from each other. The availability of 
such PCa molecular profiling based on multiple biomarker levels could pave the way for 
widespread personalized cancer treatment in the near future. Given that numerous cancer 
molecular subtypes exist amongst different patients, the multiplexed profiling of relevant 
oncogenic biomarkers by our proposed strategy could aid in providing more timely and 
effective tailored-made therapy plans for each individual cancer patient and/or aid in 
biomarker level monitoring during drug treatment. Additionally, this would be a significant 
improvement over the single PSA biomarker test used in current PCa screening. The low 
specificity of PSA has been associated with high number of false-positive and -negative PCa 
diagnoses, leading to unnecessary medical procedures such as biopsies and prostatectomies. 
The ability of our assay to simultaneously detect multiple PCa biomarkers could provide a 
more informative and accurate PCa diagnosis to spare patients from redundant medical 
expenses. Lastly, our assay produced the same detection accuracy and reliability as qRT-
PCR, making it attractive for facilitating rapid patient diagnosis in a clinical setting. 
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Figure 6. Clinical applications of assay. Average SERS spectra of multiplexed biomarker 
profiling in patient biopsy tissue (A1 & B1), and urine (C1, D1, E1) samples. Corresponding 
normalized Raman intensities are shown in (A2), (B2), (C2), (D2), and (E2) respectively. 
Error bars represent standard deviation of three independent experiments (n = 3). 
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CONCLUSION 
In summary, with an aim to better characterize PCa subtypes in a quick, sensitive, and 
quantitative fashion; we have developed a multiplexed assay that is capable of simultaneously 
detecting several biomarkers in patient samples quantitatively within a short timeframe of 80 
min. Our proposed assay involved the use of multiplexed isothermal RT-RPA to amplify 
RNA targets in the sample before labelling the amplicons with different synthesized SERS 
nanotags for rapid one-pot SERS detection. We demonstrated that our proposed assay was 
capable of highly sensitive (200 zmol) and specific PCa molecular profiling in clinical urine 
and tissue specimens.  
 
By combining the benefits of multiplexed isothermal amplification and one-pot SERS 
detection, our method firstly obviated the need for lengthy thermal cycling procedures 
associated with conventional amplification methods. Secondly, the multiplexed SERS 
readout offered speedy detection of target biomarkers with well-resolved spectral peaks to 
ensure easy interpretation of data. Thirdly, clinical application potential was demonstrated for 
use on real patient samples, with the detection of biomarkers in patient urine samples as an 
especially promising method for non-invasive PCa diagnostics.  
 
We envisioned that our assay offers considerable potential for further improvement. First, the 
assay throughput could be scaled up by synthesizing more types of SERS nanotags with 
different encoded Raman probes. In literature, the successful fabrication of 31 different 
SERS-encoded nanoparticles with unique vibrational fingerprint has been reported.
[23]
 Based 
on this, we could potentially create a similar number of SERS nanotags for detection of more 
cancer biomarkers. Second, besides the detection of RNA biomarkers, the proposed assay 
could be readily adopted for the detection of other oncogenic biomarkers such as single 
nucleotide variants (SNVs) or DNA methylation by changing RT-RPA primers. The analysis 
of different cancer mutations could allow a more explicit snapshot of tumor status. 
Furthermore, apart from cancer detection, our assay is applicable for biomarker detection in 
other human diseases as well. Third, with the emergence of portable handheld Raman 
spectrometers, the SERS readout could be made more convenient for on-site testing. Hence, 
we believe the present demonstration and promise of our proposed assay is a potential 
approach for PCa molecular subtyping and personalized therapy. 
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SUPPORTING INFORMATION 
 
Table S1. Oligonucleotide sequences used in experiments.  
Oligos 5'-Sequence-3' 
T1E4 RT-RPA Forward Primer  
TACACAGCAC(C3)CGCGGCAGGAAGCCTTAT   
 
T1E4 RT-RPA Reverse Primer 
Biotin-GTTACATTCCATTTTGAT 
 
RN7SL1 RT-RPA Forward Primer  
GCTACACGAT(C3)CCGATCGGGTGTCCGCAC 
 
RN7SL1 RT-RPA Reverse Primer 
Biotin-AGGCGCGATCCCACTACT 
 
T1E5 RT-RPA Forward Primer  
CAGATCGTCATGTTC(C3)AGCGCGGCAGGAACT
CTC 
 
T1E5 RT-RPA Reverse Primer 
Biotin -CTGCTGGCACGATAACTC 
 
ARV7 RT-RPA Forward Primer  TCTGCACCAATGTAC(C3)CACTATTGATAAATTC
CG 
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ARV7 RT-RPA Reverse Primer Biotin-TGAGGCAAGTCAGCCTTT 
PCA3 RT-RPA Forward Primer  
ACGATGCATG(C3)CCTGATGATACAGAGGTGAG 
 
PCA3 RT-RPA Reverse Primer 
Biotin-GCACAGGGCGAGGCTCATCG  
 
T1E4 qRT-PCR Forward Primer  CCTGGAGCGCGGCAGGAAGCCTTATCAGTTG 
T1E4 qRT-PCR Reverse Primer GCTAGGGTTACATTCCATTTTGATGGTGAC 
RN7SL1 qRT-PCR Forward 
Primer  CGCCGCCTGGAGCGCGGCAGGAACTCTCCT 
RN7SL1 qRT-PCR Reverse Primer CTGCTGGCACGATAACTCTGCGCTCGTTCG 
T1E5 qRT-PCR Forward Primer  GCTATGCCGATCGGGTGTCCGCACTAAGTT 
T1E5 qRT-PCR Reverse Primer GACGGGGTCTCGCTATGTTGCCCAGGCTGG 
ARV7 qRT-PCR Forward Primer  
TGATTGCACTATTGATAAATTCCGAAGGAA 
ARV7 qRT-PCR Reverse Primer 
TTTGAATGAGGCAAGTCAGCCTTTCTTCAG 
PCA3 qRT-PCR Forward Primer  
CCTGATGATACAGAGGTGAG 
PCA3 qRT-PCR Reverse Primer 
GCACAGGGCGAGGCTCATCG 
*Underlined bases are complementary to sequences on SERS nanotags. 
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Figure S1. Typical TEM image of the SERS nanotags on the magentic beads. Slight 
aggregation of SERS nanotags (indicated by arrows) was observed after hybridization to 
targets. 
 
 
Figure S2. Combined SERS spectra of different SERS nanotags. Each SERS nanotag was 
synthesized from a different Raman probe molecule (Structure shown on right).   
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Figure S3. Linear calibration plot for ARV7 copy number titration. 
 
 
Figure S4. Average SERS spectra of increasing number (5; 10; and 20) of signal acquisitions 
(2 sec laser integration). 
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Figure S5. Combined fluorescence spectra of qRT-PCR biomarker detection in mixture of 
isolated total RNA from 3 cell lines (DuCap, LnCap, 22Rv1). 
 
 
Figure S6. Combined fluorescence spectra of qRT-PCR biomarker detection in isolated total 
RNA from tumor tissue sample A. 
 
Chapter 6.1 
 
247 
 
 
Figure S7. Combined fluorescence spectra of qRT-PCR biomarker detection in isolated total 
RNA from tumor tissue sample B. 
 
Figure S8. Combined fluorescence spectra of qRT-PCR biomarker detection in isolated total 
RNA from urine sample C. 
 
Chapter 6.1 
 
248 
 
 
Figure S9. Combined fluorescence spectra of qRT-PCR biomarker detection in isolated total 
RNA from urine sample D. 
 
 
Figure S10. Combined fluorescence spectra of qRT-PCR biomarker detection in isolated 
total RNA from urine sample E.  
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High-Speed Biosensing Strategy for Non-Invasive Profiling of 
Multiple Cancer Fusion Genes in Urine 
 
Kevin M. Koo, Eugene J. H. Wee, Matt Trau
 
 
 
ABSTRACT 
Aberrant chromosal rearrangements, such as the multiple variants of TMPRSS2:ERG fusion 
gene mutations in prostate cancer (PCa), are promising diagnostic and prognostic biomarkers 
due to their specific expression in cancerous tissue only. Additionally, TMPRSS2:ERG 
variants are detectable in urine to provide non-invasive PCa diagnostic sampling as an 
attractive surrogate for needle biopsies. Therefore, rapid and simplistic assays for identifying 
multiple urinary TMPRSS2:ERG variants are potentially useful to aid in early cancer 
detection, immediate patient risk stratification, and prompt personalized treatment. However, 
current strategies for simultaneous detection of multiple gene fusions are limited by tedious 
and prolonged experimental protocols, thus limiting their use as  rapid clinical screening 
tools. Herein, we report a simple and rapid gene fusion strategy which expliots the specificity 
of DNA ligase and the speed of isothermal amplification to simultaneously detect multiple 
fusion gene RNAs within a short sample-to-answer timeframe of 60 min. The method has a 
low detection limit of 2 amol (1000 copies), and was successfully applied for non-invasive 
fusion gene profiling in patient urine samples with subsequent validation by a PCR-based 
gold standard approach.  
 
INTRODUCTION 
Fusion genes are a result of chromosomal rearrangements such as translocations, 
deletions, or inversions (Rabbitts 2009). This can result in abnormal gene expression 
and in turn, leads to tumour initiation and development (Edwards 2010; Mitelman et 
al. 2007; Prensner and Chinnaiyan 2009). With regards to cancer diagnosis and 
prognosis, fusion genes are emerging as biomarkers of immense value due to their 
specific presence in tumor tissue only. Additionally, it is now known that recurrent 
gene fusions are useful for characterizing specific subtypes of prostate, breast, and 
lung cancers for targeted treatments (Kumar-Sinha et al. 2015; Kumar-Sinha et al. 
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2008). The most prevalent group of gene fusions affecting approximately 50% of all 
prostate cancer (PCa) cases, is the fusion between TMPRSS2 and ERG genes (Soller 
et al. 2006; Tomlins et al. 2005). There are about 20 TMPRSS2:ERG variants with 
different fusion junctions (Clark et al. 2007; St. John et al. 2012), and the presence of 
certain variants in tumour cells has been associated with cancer aggressiveness and 
metastatic potential (Lapointe et al. 2007; Wang et al. 2006). Additionally, 
TMPRSS2:ERG mRNAs are also detectable in urine (Hessels et al. 2007), thus 
presenting as a convenient and non-invasive mean to detect and stratify PCa as 
compared to a tissue biopsy which is both painful and expensive. Therefore, 
TMPRSS2:ERG fusion genes are of increasing interest as diagnostic and prognostic 
biomarkers for early PCa detection, immediate patient risk stratification, and prompt 
personalized treatment (Tomlins et al. 2009). Herein, we describe a novel technique 
for rapid and non-invasive profiling of multiple TMPRSS2:ERG variants concurrently 
while achieving results within a considerably shorter timeframe as compared to 
current methodologies. 
 
Ligase-based strategies (Schouten et al. 2002) are currently used to detect multiple 
gene rearrangements (Cui et al. 2012; Lee et al. 2010) by enzymatically ligating 
adjacent barcoded probes that flank fusion junctions to effectively generate a library of 
PCR-amplifiable and identifiable fusion events for further downstream analysis. 
Despite being an effective research tool, this approach has drawbacks which we aimed 
to address in this report. Firstly, the use of DNA ligases (typically T4 DNA ligase) is 
inefficient and slow on RNA templates; hence requiring long ligation protocols, 
alternative costly ligases or high starting sample amount to achieve detectable signals 
(Bullard and Bowater 2006; Lohman et al. 2014; Nilsson et al. 2001; Wee and Trau 
2016).
 
Next, the subsequent PCR step (Kvastad et al. 2015; Roy et al. 2015; Zhang et 
al. 2014) is also usually time-consuming (typically 120 min); and requires expensive 
and bulky instrumentation such as capillary electrophoresis systems (Lee et al. 2010; 
Schouten et al. 2002; Zhang et al. 2014) to identify and quantify targets in the sample. 
These drawbacks limit the use of ligase-based assay for quick and simple clinical 
screening of fusion gene RNAs.  
 
The use of a quicker isothermal amplification method such as Recombinase 
Polymerase Amplification (RPA) (Piepenburg et al. 2006) after probe ligation may 
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allow for faster and simpler assays to be performed on cheaper and simpler equipment. 
Additionally, the high sensitivity of RPA (Euler et al. 2013; Kersting et al. 2014) 
could be useful in amplifying lower amount of ligation products (i.e. shorter ligation 
time). This could resolve the issue of lengthy ligation time associated with 
conventional ligation-based strategies (Lee et al. 2010; Roy et al. 2015; Zhang et al. 
2014), and also potentially improve ligation specificity (Kuhn and Frank-Kamenetskii 
2005) for better signal-to-noise ratio. Currently, to the best of our knowledge, a 
ligation-based RPA assay for detecting cancer fusion gene RNAs such as 
TMPRSS2:ERG variants in PCa remains unexplored. 
 
Herein we describe a rapid assay which first involved rapid T4 DNA ligase-based 
ligation of probes specific to the fusion junctions of different TMPRSS2:ERG mRNA 
variants in a single reaction. This was then followed by isothermal RPA in individual 
RPA assays for real-time fluorescence identification (via convenient DNA-
intercalating dye) of fusion variants present in the sample. The assay was readily 
completed within 60 min, possessed amol-level detection sensitivity and could 
successfully profile the status of two different TMPRSS2:ERG variants and a RNA 
loading control in PCa cell lines and patient urine samples. 
 
EXPERIMENTAL 
Reagents and materials 
All reagents were of analytical grade and purchased from Sigma Aldrich (Australia). 
UltraPureTM DNase/RNase-free distilled water (Invitrogen, Australia) was used throughout 
the experiments. Oligonucleotides were purchased from Integrated DNA Technologies 
(USA) and sequences are shown (Supporting Information, Table S1).  
 
RNA extraction from cell lines 
DuCap and LnCap cells were kindly donated by Matthias Nees (Vtt, Finland); Gregor Tevz 
(APCRC, Australia); and Michelle Hill (UQDI, Australia). The cells were cultured in RPMI-
1640 growth media (Life Technologies, Australia) supplemented with 10% fetal bovine 
serum (Life Technologies, Australia) in a humidified incubator containing 5% CO2 at 37 ºC. 
RNA was extracted using Trizol® reagent (Life Technologies, Australia). RNA purity and 
integrity were checked using a NanoDrop Spectrophotometer (Thermo Scientific, USA). 
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RNA extraction from patient urine samples 
Ethics approval was obtained from The University of Queensland Institutional Human 
Research Ethics Committee (Approval No. 201400012) and informed consent was obtained 
from all subjects prior to sample collection. Methods pertaining to clinical samples were 
carried out in accordance with approved guidelines. 
 
Total RNA was extracted from urine samples using the commercially-available ZR urine 
RNA isolation Kit
TM
 (Zymo Research, USA). For each sample, 30 mL of urine was passed 
through the supplied ZRC GF
TM
 Filter to retain urinary cells. Then, 700 µL of supplied urine 
RNA buffer was passed through the filter and the filtered cells were collected in the flow-
through. Next, as per manufacturer’s instructions, the cells from the flow-through were lysed, 
washed and eluted in 10 µL of RNase-free water. RNA purity and integrity were checked 
using a NanoDrop Spectrophotometer (Thermo Scientific, USA). 
 
Multiplexed hybridization and ligation of probes  
A 10 µL hybrization mixture containing 100 nM of each ligation probe and 30 ng of total 
RNA extract or various concentrations of synthetic target sequences was made. The 
hybridization mixture was heated to 85°C for 2 min and then cooled on ice to facilitate 
hybridization. Next, 1 µL of the hybridization mixture was added to a 10 µL ligation mixture 
containing 40 U T4 DNA Ligase (New England Biolabs, Australia) and 1x T4 DNA Ligase 
Buffer. The ligation mixture was heated at 37°C (unless otherwise stated) for 5 min to ligate 
the hybridized probes before 2 min at 95°C to stop enzyme activity. 
  
Quantitative RPA 
The TwistAmp Basic RPA kit (Twist-DX, UK) was used with slight modifications to 
manufacturer’s instructions. Each isothermal amplification reaction was carried out in 
individual tubes. In each reaction, 7.38 µL of RPA rehydration buffer, 250 nM of each primer 
(Supporting Information, Table S1), 2 nM of SYTO® 9 (SYTO9) fluorescent dye (Thermo 
Fisher, Australia), and 1 µL of ligation mixture (containing hybridized and ligated probe 
templates) were added to a final 12.5 µl reaction volume. RT-RPA was performed on the 
Applied Biosystems® 7500 Real-Time PCR System (Thermo Scientific, Australia) at 37°C 
for 15 min where fluorescence measurements were acquired every 30 seconds. The relative 
fluorescence intensity at assay endpoint was calculated as follows: 
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Relative Fluorescence Intensity = (iSample – iRPA Control) / iRPA Control    (1) 
 
where iSample and iRPA Control are fluorescence intensities for target sample and RPA NoT 
control at the 15 min timepoint respectively. 
 
Quantitative PCR (qPCR) validation  
For validation analysis of each target (T1E4, T1E5, or RN7SL1) in clinical urine samples, the 
KAPA SYBR
®
 FAST One-Step qRT-PCR kit (KAPA BIOSYSTEMS, Australia) was used to 
set up a single reaction volume of 10 µl. Each reaction volume consist of 1X KAPA SYBR
®
 
FAST qPCR Master Mix, 200 nM of each forward and reverse primer (Table 1), 1X KAPA 
RT Mix, 50 nM ROX dye and 30 ng of total RNA template. qPCR was performed using the 
Applied Biosystems® 7500 Real-Time PCR System (Thermo Fisher Scientific, Australia). 
The cycling protocol was: 42°C for 10 min to synthesize cDNA, followed by 95°C for 5 min 
to deactivate RT before cycling 35 times (95°C for 30 s, 50°C for 30 s and 72°C for 1 min) 
and finished with 72°C for 10 min. The cycle threshold (Ct) value (i.e. initial target amount) 
was determined for each qPCR reaction in order to cross-validate the data of our proposed 
assay.     
 
RESULTS AND DISCUSSION 
Assay principle  
The principle of our assay for detecting multiple TMPRSS2:ERG variants is shown in Fig. 1. 
Three pairs of ligation probes (Probes 1A/1B/2A/2B/3A/3B) are designed to contain 
complementary sequences (in blue/orange/green) to each target sequence. Each ligation probe 
pair also contains a unique primer recognition sequence (in black/grey/brown) for RPA 
amplification. All three ligation probe pairs are added to a single starting sample for 
hybridization to target sequences of interest within 5 min, and successfully hybridized probes 
are subsequently ligated with T4 DNA ligase. The T4 DNA ligase catalyzed a phosphodiester 
bond formation between the 5’ phosphate and 3’ hydroxyl blunt ends of each hybridized 
ligation probe pair; and this ligation process could discriminate single base mismatches which 
is useful for differentiating highly-similar TMPRSS2:ERG fusion variant junctions (Tang et 
al. 2008). Moreover, since the ligation probes were designed for specific hybridization to 
gene fusion mRNA targets, the possibility of non-specific ligation probe hybridization to 
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genomic DNA (with non-complementary sequences) and subsequent T4 DNA ligase-
mediated ligation is therefore eliminated. Following ligation, individual ligated probe 
pairings for each target sequence are amplified isothermally by RPA (via. unique primer 
sequences) in individual tubes within 15 min. As the unique primer set in each RPA reaction 
is specific for each target sequence (T1E4, T1E5 or RN7SL1), the generation of double-
stranded amplicons in each target-specific RPA reaction could be converted into a 
fluorescence signal using a double-stranded DNA-intercalating dye. The incorporation of 
SYTO9 fluorescent dye in each RPA reaction allowed for convenient and sensitive real-time 
detection of successful amplification in presence of a target sequence. SYTO9 is a double-
stranded DNA intercalating dye which has been shown to possess better dye stability and 
fluorescence reproducibility as compared to traditional SYBR Green dyes (Monis et al. 
2005). In all, the whole sample-to-answer time for detection of three targets concurrently is 
60 min.  
 
In our experiments, we used three different RNA sequences as model targets to 
evaluate our proposed assay for PCa screening. The three target sequences comprised 
of two closely-related TMPRSS2:ERG variants of different fusion junctions: 
TMPRSS2 exon 1 with ERG exon 4 (T1E4) and TMPRSS2 exon 1 with ERG exon 5 
(T1E5), and an endogenously-expressed mRNA housekeeping sequence (RN7SL1). 
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Fig. 1. Schematic representation of ligation-based recombinase polymerase amplification 
(RPA) assay. Ligation probe pairs (Probes 1A/1B/1C) are designed to contain complementary 
sequences (in blue/orange/green) to each target sequence, and unique RPA primer recognition 
sequences (in black/grey/brown). Ligation probe pairs hybridize to multiple target sequences 
in total RNA starting sample and are subsequently enzymatically ligated. The ligated probes 
are then amplified using target-specific RPA primers in separate reactions. The inclusion of 
intercalating fluorescence dye allowed the amplification to be monitored in real-time. 
 
Optimization of Ligation Temperature  
The ligation temperature plays an important role in assay specificity as the optimal 
ligation temperature could allow probes to hybridize specifically to target sequences 
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and minimize false-positive signals from non-specific ligation and subsequent 
amplification (Zhang et al. 2014). To this end, we used ligation temperatures of 35°C, 
37°C, and 39°C to investigate the optimal temperature for using T1E4 probes to 
discriminate between closely-related T1E4 and T1E5 target sequences. An optimal 
temperature of 37°C was found to achieve the largest difference in relative 
fluorescence intensity and thus, maximized discrimination between T1E4 and T1E5 
(Supporting Information, Fig. S1). Hence, 37°C was selected as the ligation 
temperature for all further experiments. 
 
Efficiency of downstream RPA 
To investigate the efficiency of using downstream isothermal RPA instead of traditional PCR 
in our ligase-based assay, we firstly tested the selectivity of RPA primers for ligated probes 
amplification. We omitted two out of three of our ligation probe pairs at a time and repeated 
our assay on a 3-target mixture (T1E4, T1E5, and RN7SL1) with the remaining ligation 
probe pair. We found that the absence of particular ligation probe pairs led to negligible 
fluorescence signal for the corresponding target sequences (Fig. 2 and Supporting 
Information Fig. S2). Thus, this demonstrated the efficiency of each RPA primer pairs for 
successful amplification of respective ligated probe pairs to generate detectable fluorescence 
signals. In addition, the selectivity of each RPA primer set for exclusive amplification of its 
assigned ligated probe pairs was also tested (Supporting Information, Fig. S3). It was found 
that no RPA amplicons were generated for non-specific targets (eg. T1E4 RPA primers 
generated amplicons only in presence of T1E4 mRNA targets, and no amplification were 
observed with a mix of both T1E5 and RN7SL1 mRNA targets). This high primer selectivity 
will be essential for accurately discriminating target sequences in biologically-complex 
samples such as blood or urine samples.  
 
Moreover, the five min ligation step in our assay was significantly faster as compared 
to the typical T4 ligation protocol (Nilsson et al. 2001) which required at least two 
hours. Although a smaller amount of ligation products is expected as a consequence of 
reduced ligation time, this highlighted the high sensitivity and efficiency of the 
downstream RPA step in amplifying low quantities of ligated products to detectable 
levels. It is worthy to note that the low quantity of ligated product for each RPA 
reaction may allow for a single patient sample to be split into several parallel RPA 
analyses of multiple fusion gene biomarkers. In comparison to traditional ligation-
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based assays (with lengthy PCR amplification procedures (Kvastad et al. 2015; Roy et 
al. 2015; Zhang et al. 2014) which required about five hours, our approach (60 min) 
showed a marked five-fold improvement in total assay time. We envisage that the 
rapid nature of our proposed assay will be greatly beneficial for parallel-processing of 
patient samples, thus enabling a more efficient workflow to process high amount of 
clinical samples as well as quicker cancer diagnosis/prognosis for each patient. 
 
 
Fig. 2. Evaluation of downstream RPA efficiency. Relative fluorescence intensities after 
target-specific ligation and RPA of T1E4, T1E5, or RN7SL1 target sequences. Error bars 
represent standard deviation of three independent experiments. 
 
Assay sensitivity 
To evaluate detection sensitivity, we analyzed a serial dilution of synthetic T1E4 RNA 
transcripts using all three ligation probe pairs in our assay. The resulting positive 
relationship between fluorescence signal and different T1E4 concentrations are shown 
in Fig. 3. The assay detection limit was determined to be 1000 copies (2 amol) with a 
linear range between 10
3
-10
7
 copies (Supporting Information, Fig. S4). This detection 
limit is superior to existing ligation-based assays (Arefian et al. 2011; Roy et al. 2015) 
as well as existing multiplexed gene fusion detection methodologies which required a 
higher amount of starting material (Frampton et al. 2013; Lee et al. 2010; Lira et al. 
2013; Peter et al. 2001). Furthermore, the low amol detection limit in our proposed 
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assay was achieved with the simplicity of DNA-intercalating fluorescent dye readout 
in individual reactions. This enabled quick and simultaneous detection of multiple 
fusion gene in real-time without any prior need for complicated sequence-specific 
labelling procedure, thus offering a powerful tool for sensitive, low-cost and accurate 
PCa screening. Moreover, the quantitative nature of our assay in measuring gene 
fusion mRNA levels may be helpful for quantifying tumor load during diagnosis or 
monitoring treatment response during therapy.  
 
Fig. 3. Assay sensitivity. Combined fluorescence spectra generated from 10
3
 – 107 copies of 
synthetic T1E4 target sequences. 
 
Detection of multiple RNA targets  
To demonstrate the capability of our assay for detecting multiple targets simultaneously, we 
challenged the assay to detect the three target sequences simultaneously from a single starting 
sample. It was observed that each target-specific downstream RPA reaction generated a 
positive fluorescence signal (Fig. 4), thus demonstrating successful multiplexed detection of 
all three different sequences. The low background signals in both ligation and RPA no-target 
(NoT) controls showed that resulting fluorescence signals were attributed to the presence of 
target sequences. 
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Fig. 4. Combined fluorescence spectra for simultaneous detection of T1E4, T1E5, and 
RN7SL1 synthetic target sequences. Ligation and RPA no-target (NoT) controls were 
included.   
 
Specific detection of fusion genes in PCa cell lines 
After establishing the assay’s capability using synthetic sequences, we sought to investigate 
the assay performance on biologically-complex samples. To this end, we first challenged our 
assay with total RNA extracts from PCa cell lines to detect T1E4 and T1E5 fusion mRNA 
variants. T1E4 is the predominant fusion variant in PCa, and accounts for ~90% of 
TMPRSS2:ERG variants identified in tumor samples (Tu et al. 2007; Wang et al. 2006). 
T1E5 is another common TMPRSS2:ERG variant which has been found to co-exist with 
T1E4 (Clark et al. 2007; Tu et al. 2007). Importantly, both variants are highly PCa-specific 
biomarkers which are absent in clinically benign cases (Tomlins et al. 2005). Therefore, it is 
of interest to detect these different fusion variants to aid in diagnosing PCa and predicting 
disease development. As an initial test, two PCa cell lines were tested with our assay: DuCap 
(T1E4 and T1E5 positive) and LnCap (T1E4 and T1E5 negative). The resulting fluorescence 
signals are shown (Supporting Information, Fig. S5); and as shown in Fig. 5, T1E4 and T1E5 
were successfully detected in DuCap whilst negligible fluorescence signals were generated 
for the detection of either fusion variants in LnCap. To control for sample loading, the 
detection of housekeeping RN7SL1 mRNA was also included in our assay. Additionally, the 
sole detection of the RN7SL1 target in LnCap further underscored the assay specificity 
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during multiplexed probe ligation and parallel RPA reactions. This high detection specificity 
is most likely conferred by the dual target recognition events (first by ligation probes, 
followed by RPA primers) within our assay. These detection outcomes for presence/absence 
of TMPRSS2:ERG variants in PCa are also in agreement with previous studies (Koo et al. 
2016; Tomlins et al. 2005; Yoshimoto et al. 2006), thus validating the accuracy of our assay. 
Lastly, the assay also showed good reproducibility with a CV of 8.9% (n = 3).  
  
 
Fig. 5. Profiling of multiple gene fusion biomarkers in cell lines and clinical urine samples. 
Two prostate cancer cell lines (DuCap and LnCap) and 11 clinical urine samples (P1- P9, H1 
and H2) were tested for T1E4 (yellow), T1E5 (green), and RN7SL1 (grey) presence. Shaded 
bar plots indicates positive presence of target sequence in sample. Error bars represent 
standard deviation of three independent experiments. 
 
Gene fusion profiling in clinical patient samples  
The eventual aim of our assay was to show clinical utility for rapid profiling fusion 
genes in patient urine samples. The non-invasive detection of fusion genes from urine 
offers evident benefits such as being pain-free, inexpensive, and without the risk of 
infections as compared to surgical biopsy sampling. After preliminary work on cell 
lines, we proceeded to test our assay on nine urine samples obtained from PCa patients 
as well as two urine samples from healthy individuals (Fig. 5 and Supporting 
Information, Fig. S6). T1E4 and T1E5 cutoff values were determined based on the 
mean signal of healthy controls plus three standard deviations. We conveniently 
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scored patient samples to be positive/negative for each target biomarker by noting if 
fluorescence signals are higher/lower than  the cutoff values. Using or assay, we found 
that three PCa samples (P1, P5, and P8) were positive for both T1E4 and T1E5, whilst 
five samples (P2, P3, P4, P7 and P9) were positive for T1E4 only. For P6 and healthy 
controls (H1 and H2), only loading control RN7SL1 signals were observed to indicate 
the presence of input RNA and absence of both T1E4 and T1E5.  
 
From our assay results, the variable fusion gene expressions of different PCa patients 
highlighted the promise of using fusion gene profiling to inform clinical diagnosis. 
Though large-scale population-based clinical studies are still ongoing, previous pilot 
studies have shown TMPRSS2:ERG fusion variants to be present in about half of all 
PCa cases (Soller et al. 2006; Tomlins et al. 2005) and linked to lethal PCa forms 
(Wang et al. 2006). Hence, the successful demonstration of our assay for 
TMPRSS2:ERG profiling in clinical samples may provide quick and accurate 
diagnosis for clinically-significant PCa and enable targeted therapies for 
TMPRSS2:ERG inhibition. Nonetheless, we are aware that our current assay format is 
a promising diagnostic demonstration, and application to a larger pool of patient 
samples is required to prove clinical utility. Our assay results were validated with 
qPCR (Supporting Information, Table S2) with excellent agreement, thus 
demonstrating analytical accuracy in clinical samples. In each assay run involving cell 
line and clinical patient samples, the total assay time was ~60 min and required only 
30 ng of total RNA starting sample. The successful detection of multiple 
TMPRSS2:ERG variants in urine samples suggested a possibility for future non-
invasive PCa screening as an alternative to current surgical tissue biopsies. Due to the 
ease of urine sampling and the release of PCa cancer cells into urine, urine is a 
promising substrate for developing non-invasive PCa diagnostics. Additionally, the 
readout of our assay only required a conventional fluorescence detector, and we 
envisaged that the use of portable fluorometers (Boyle et al. 2013; Clancy et al. 2015; 
Li et al. 2010) could allow our assay to be increasingly cost-efficient and amenable for 
clinical application in the future.  
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CONCLUSIONS 
In conclusion, we have developed a rapid ligation-based RPA assay for simultaneously 
detecting different TMPRSS2:ERG fusion variants in PCa patient samples with high 
amol-sensitivity and specificity. Our assay results on patient urine samples were in 
excellent agreement with the gold standard PCR-based approach, thereby underscoring 
the promise of an accurate and reliable clinical screening technique for non-invasive 
PCa diagnosis. Most crucially, our 60 min sample-to-answer assay time is a 
remarkable improvement on the current tedious and time-consuming detection of 
multiple fusion genes. For future work, the multiplexing capability of our proposed 
assay could be scaled up by the rational design and addition of more ligation probe 
pairs. This could be useful for the detection of other TMPRSS2:ERG variants during 
PCa screening to aid in better diagnosis and therapy. Moreover, by altering probe 
design, our assay could be modified for multiple gene fusion detection in other cancers 
or diseases.  
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SUPPORTING INFORMATION 
 
Table S1. Oligonucleotide sequences used in experiments. *Underlined and bold 
represent RPA primer sequences on ligation probes. 
Oligos 5'-Sequence-3' 
T1E4 Probe 1A  -PO-GCTTCCTGCCGACGAGGGAAAGAGTTGTACCTAAAT 
T1E4 Probe 1B TGTATAGGAATCCCACTGAATTTTTCCTCACAACTGATAAG 
T1E5 Probe 1A -PO-AGTTCCTGCCGATAAGGGAGATAATAAGAGTTGGGT 
T1E5 Probe 1B TAACTCATATTGTAGAAGAGTAGAAGCATTCATCAGGAG 
RN7SL1 Probe 1A 
-PO-
TAGTGCGGACACACAGGGAGCCGAAAGACGAAAGGCC 
RN7SL1 Probe 1B GGCTGTATACATTTCCCTCAGGACAGTGATGCCGAACT 
T1E4 RPA Fwd 
Primer 
ATTTAGGTACAACTCTTTCCCTCGTC 
T1E4 RPA Rev 
Primer 
TGTATAGGAATCCCACTGAATTTTTC 
T1E5 RPA Fwd 
Primer 
ACCCAACTCTTATTATCTCCCTTATC 
T1E5 RPA Rev 
Primer 
TAACTCATATTGTAGAAGAGTAGAAG 
RN7SL1 RPA Fwd 
Primer 
GGCCTTTCGTCTTTCGGCTCCCTGTG 
RN7SL1 RPA Rev 
Primer 
GGCTGTATACATTTCCCTCAGGACAG 
T1E4 RT-PCR Fwd 
Primer 
CCTGGAGCGCGGCAGGAAGCCTTATCAGTTG 
T1E4 RT-PCR Rev 
Primer 
GCTAGGGTTACATTCCATTTTGATGGTGAC 
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T1E5 RT-PCR Fwd 
Primer 
GCTATGCCGATCGGGTGTCCGCACTAAGTT 
T1E5 RT-PCR Rev 
Primer 
GACGGGGTCTCGCTATGTTGCCCAGGCTGG 
RN7SL1 RT-PCR 
Fwd Primer 
CGCCGCCTGGAGCGCGGCAGGAACTCTCCT 
RN7SL1 RT-PCR 
Rev Primer 
CTGCTGGCACGATAACTCTGCGCTCGTTCG 
 
 
Fig. S1. Effect of ligation temperature on assay specificity. 
 
 
Fig. S2. Combined fluorescence spectra for the detection of T1E4, T1E5, and RN7SL1 target 
sequences using only (A) T1E4 probes, (B) RN7SL1 probes, (C) T1E5 probes. 
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Fig. S3. Gel electrophoresis of RPA reactions with different primers and target combinations. 
 
Fig. S4. Linear calibration plot of the average florescence measurements
 
at different initial 
T1E4 input copies. Error bars represent standard deviation of three independent experiments.  
 
 
Fig. S5. Combined fluorescence spectra for the detection of T1E4, T1E5, and RN7SL1 in (A) 
DuCap, and (B) LnCap cell lines. 
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Fig. S6. Combined fluorescence spectra for the detection of T1E4, T1E5, and RN7SL1 in 
patient urine samples. 
 
 
 
 
 
 
 
Chapter 6.2 
 
269 
 
Table S2. qPCR validation of urine sample results. qPCR cycle threshold (Ct) values for 
the detection of T1E4, T1E5, and RN7SL1 in patient urine samples. Ct values in bold are 
targets which were tested negative using our assay. 
 qPCR  Our Assay 
Sample T1E4 T1E5 RN7SL1 T1E4 T1E5 RN7SL1 
P1 20.6 27.2 13.3 + + + 
P2 26.8 33.8 12.9 + - + 
P3 29.1 32.7 14.7 + - + 
P4 27.7 32.9 10.2 + - + 
P5 15.1 17.2 13.1 + + + 
P6 30.4 31.5 15.9 - - + 
P7 19.3 31.7 14.2 + - + 
P8 21.2 23.3 10.4 + + + 
P9 23.4 30.8 14.4 + - + 
H1 33.1 33.8 15.2 - - + 
H2 32.5 33.9 14.4 - - + 
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Amplification-Free Multi-RNA Type Profiling for Cancer Risk 
Stratification via Alternating Current Electrohydrodynamic 
Nanomixing  
 
Kevin M. Koo, Shuvashis Dey, and Matt Trau 
 
ABSTRACT 
Simultaneous analysis of messenger RNA (mRNA), microRNA (miRNA), and long non-
coding RNA (lncRNA) - multi-RNA type profiling - is increasingly crucial in cancer 
diagnostics. Yet, rapid multi-RNA type profiling is challenging due to enzymatic 
amplification reliance and RNA type-dependent characteristics. Here we report a nanodevice 
that uniquely uses alterable alternating current electrohydrodynamic (ac-EHD) forces to 
enhance probe-target hybridization prior to direct native RNA target detection, without target 
amplification or surface functionalization. To exemplify clinical applicability, we performed 
non-invasive screening of next-generation prostate cancer (PCa) RNA biomarkers (of 
different types) in patient urine samples. A strong correlation between multi-RNA type 
expression and aggressive PCa was found, and the nanodevice performance is statistically 
evaluated. We believe our miniaturized system exhibits potential for cancer risk stratification 
via multi-RNA type profiling. 
 
INTRODUCTION 
The combinational analysis of different RNA cancer biomarker types (multi-RNA type 
profiling) is becoming increasingly useful in personalized patient screening and monitoring. 
Taking prostate cancer (PCa) for example, multi-RNA type profiling could help identify 
aggressive PCa for personalized patient treatment, whilst sparing indolent cases from 
unnecessary treatments (i.e. risk stratification).[1] Lately, interest in non-invasive “liquid 
biopsies”[2] has uncovered various types of next-generation PCa RNA biomarkers[3] in 
urine. Such next-generation biomarkers include: highly PCa-specific gene fusion messenger 
RNA (mRNA) between TMPRSS2 and ERG genes (T2:ERG)[4] which rarely occurred in 
benign cases, and overexpression of miR-107[5]  microRNA (miRNA) and SChLAP1[6] 
long non-coding RNA (lncRNA) that are strongly related to  aggressive PCa. T2:ERG is 
present in about half of all clinically-detected PCa, and increased T2:ERG levels are linked to 
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higher tumor volume and worse clinical prognosis. miR-107 has been found to be a 
potentially useful circulating biomarker with significantly higher levels in PCa patients as 
compared to healthy controls. SChLAP1 was discovered as one of the top-ranked prognostic 
PCa urine biomarker candidates associated with metastatic PCa progression in over 1000 
patients. Hence, from a clinical standpoint, simultaneous profiling of these different types of 
urinary RNA biomarkers could be a valuable non-invasive diagnostic tool for differentiating 
aggressive forms of PCa to enable personalized treatment.   
 
Presently, the simultaneous detection of multiple RNA biomarkers, especially so for different 
RNA types, is a challenging task. Rapid multi-RNA type profiling from patient samples is 
generally performed by quantitative polymerase chain reaction (qPCR) which may cause 
amplification artifacts/bias. Moreover, qPCR has to be modified according to detect different 
RNA target types due to type-dependent characteristics.[7] Thus, we have recently developed 
amplification-free RNA assays that eliminated cumbersome surface functionalization, and 
used adenine-driven target adsorption to allow direct detection of RNA biomarkers without 
enzymatic modification of native RNA copies.[8] Yet, similar to existing amplification-free 
RNA detection systems like the prominent NanoString Technologies,[9] our methodology is 
impeded by (i) hours-long probe-target hybridization due to slow-diffusion kinetics, (ii) large 
sample amount requirement which is impractical for multiple target detection.  
 
To circumvent these issues, we hereby report a nanodevice which demonstrates adjustable 
alternating current electrohydrodynamic (ac-EHD) nanoscaled fluidic mixing (i.e. nano-
mixing) to enhance probe-target hybridization kinetics. This nano-mixing phenomenon arises 
from the application of an ac potential across a pair of asymmetrical microelectrode. This 
gives rise to fluidic movement within nanometres of the microelectrode surfaces to maneuver 
molecules in solution, driven primarily by a body force on the free charges within the two 
non-uniformly charged double layers on the microelectrode surfaces. Unlike most 
microfluidic manipulation with limited control, ac-EHD nano-mixing can be uniquely 
manipulated and “tuned” through deft selection of the ac frequency to alter the nanoscaled 
fluidic force strength.[10] Herein, we designed a new paired circular electrode design to 
generate an optimal ac-EHD nano-mixing effect. For the first time, we applied ac-EHD 
nanofluidics for fast concentration of probes and RNA targets from bulk solution, as well as 
enhanced hybridization to an extent whereby conventional molecular amplification (eg. PCR) 
is unnecessary and native RNA targets could be directly detected.   
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EXPERIMENTAL SECTION 
Materials 
All reagents (Sigma Aldrich) were of analytical grade and used without further purification 
unless otherwise stated. UltraPureTM DNase/RNase-free distilled water (Invitrogen) was 
used throughout the experiments. Oligonucleotides (Integrated DNA Technologies) 
sequences used in this work are shown in Table S1. 
 
Nanodevice design and fabrication 
Design and fabrication of the nanodevice were carried out at Australian National Fabrication 
Facility-Queensland Node. Nanodevice design was prepared using L-edit (MEMS-pro, v15) 
and then inscribed on to a 5-inches chrome mask using direct laser writer. Exposed masks 
were then developed using standard mask development procedure that included sequential 
treatment with Az726 solution (1 min), then chrome etching (1.5 min) followed by acetone 
cleaning and finally drying by nitrogen gas. This design contains three sets of two separate 
microwells, termed as “Mixing” and “Detection” microwells. Each “Mixing” and “Detection” 
microwell contains a circular working microelectrode (1000 µm and 800 µm in diameter 
respectively), that is surrounded by a 50 µm-thick ring microelectrode. Both circular and ring 
microelectrodes are connected separately to a pair of common connection pads for energizing 
the chip with external ac power source, and the inner circular and ring microelectrode are 
separated by 50 µm. To pattern the design on substrate, silicone wafers were water-cleaned 
and dried (5 min). After cleaning, a 200 nm-thick layer of AzNolF 2070 negative photoresist 
(Microchem) was coated on the clean wafer by spin coating (3000 rpm, 30 s). Following this, 
the polymer-coated wafers were then UV exposed to transfer the design. UV exposed wafers 
were then developed using PGMEA (propylene glycol methyl ether acetate) and dried with 
liquid nitrogen, and were transferred for gold deposition. This step is followed by overnight 
lift-off step to reveal gold structures on the nanodevice. 
 
To fabricate microwells, PDMS (polydimethylsiloxane) master mix was poured onto the flat 
silicon surface, degassed and cured at 65˚C for 1 h. After curing step, two holes were 
punched and the PDMS layer was plasma-bonded to the prepared nanodevice. 
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ac-EHD nano-mixing of probes and targets 
Total RNA extract from cell lines/urinary samples were adjusted (20 ng, 2.5 µL) using 
phosphate buffer saline (PBS) buffer (137 mM sodium chloride, 2 mM potassium chloride, 
pH 7.4), and added to each of the three “Mixing” microwell (one microwell for each RNA 
target type) on the nanodevice. Briefly, biotinylated capture probes (2.5 µL, 10 µM) for 
different RNA targets (T2:ERG, miR-107 and SChLAP1) was also added to the respective 
“Mixing” microwell. Then, ac-EHD nano-mixing of targets and probes was induced in each 
“Mixing” microwell through application of an ac field strength of f = 500 Hz and Vpp = 800 
mV for 10 min. The ac field parameters were optimized in this study for maximal 
enhancement of probe-target collisions and complementary hybridization. 
 
Magnetic isolation of hybridized targets  
For magnetic isolation of biotinylated probe-target molecules after ac-EHD nano-mixing, 
streptavidin-labeled Dynabeads
®
 MyOne
TM
 Streptavidin C1 (Invitrogen) magnetic beads (5 
µL) was added to each microwell, mixed thoroughly, and incubated for 15 min. Afterwhich, a 
permanent magnet was placed under the nanodevice, and the magnetic beads with bound 
RNA targets were separated from solution, washed twice with washing buffer (10 mM Tris-
HCl, pH 7.5; 1 mM EDTA ; 2 M NaCl) within the microwells, and resuspended in RNase-
free water (10 µL for T2:ERG mRNA or 7.5 µL for miR-107 miRNA and SChLAP1 lncRNA 
targets). 
 
Target adsorption via adenine-gold affinity interactions 
To promote the adsorption of RNA targets onto bare gold microelectrode surface for 
detection, 3’-polyA tails were extended on miRNA and lncRNA targets (without natural 
polyA tails) by mixing resuspended magnetic beads-miRNA/lncRNA targets (7.5 µL) with E. 
Coli Poly(A) polymerase reaction buffer (250 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 
pH 7.9), ATP (1 mM), and E. Coli Poly(A) polymerase (5 U) (New England BioLabs) to 
make up a reaction mixture (10 µL). Each reaction mixture was incubated at 37°C for 10 min 
by placing the nanodevice on a heating plate before Poly(A) polymerase was inactivated by 
addition of EDTA (10 mM). To remove leftover reagents, the magnetic beads with bound 
polyA-extended targets were washed twice as previously described, and resuspended in 
RNase-free water (10 µL). 
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Next, all targets were heat-released from probes by heating the solution in each microwell at 
95°C for 2 min. A magnet was immediately placed under the nanodevice, and the supernatant 
of each microwell containing different released RNA targets was collected, diluted in 5x 
saline-sodium citrate (SSC) buffer (20 µL, pH 7.0), and introduced into respective 
downstream “Detection” microwells. In the “Detection” microwells, the targets were allowed 
to adsorb onto the surface of the gold working microelectrode for 10 min through adenine-
gold affinity interactions. The microelectrodes were then washed with PBS (10 mM) before 
electrochemical measurements.  
 
Detection of adsorbed targets   
All electrochemical measurements were performed on a CH1040C potentiostat (CH 
Instruments). The electrolyte buffer consisted of PBS solution (10 mM, pH 7) containing 1:1 
[Fe(CN)6]
3-
/[Fe(CN)6]
4-
 (2.5 mM) and KCl (0.1 M). Differential pulse voltammetry (DPV) 
signals were recorded from -0.2 V- 0.15 V with a pulse amplitude of 50 mV and a pulse 
width of 50 ms. The % current response change (% i) was obtained by calculated as follows: 
 
(% i) = [(iBare – iAdsorbed) / iBare] x 100  
 
where iBare and iAdsorbed are current densities for bare microelectrode and microelectrode after 
sample adsorption respectively. 
 
Statistical analysis    
The Passing and Bablok regression analysis was used to compare between the patients’ RNA 
biomarker expression levels measured on our nanodevice, and the data generated by a 
reference qPCR technique. The analyses were performed using the XLSTAT software 
(Addinsoft). 
 
Cell culture   
PCa cells were cultured in RPMI-1640 growth media (Life Technologies) supplemented with 
fetal bovine serum (10%) (Life Technologies) in a humidified incubator containing  CO2 
(5%) at 37ºC. 
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Preparation of patient urine samples 
Ethics approval was obtained from The University of Queensland Institutional Human 
Research Ethics Committee (Approval No. 2004000047) and informed consent was obtained 
from all subjects prior to sample collection. Methods pertaining to clinical samples were 
carried out in accordance with approved guidelines. Voided urinary samples were collected 
from men undergoing treatment for PCa at the Royal Brisbane and Women’s Hospital.  
 
Total RNA was extracted from the urine samples using the commercially-available ZR urine 
RNA isolation Kit
TM
 (Zymo Research). Each urine sample (30 mL) was passed through the 
supplied ZRC GF
TM
 Filter to retain urinary cells. Then, supplied urine RNA buffer (700 µL) 
was passed through the filter and the filtered cells were collected in the flow-through. Next, 
as per manufacturer’s instructions, the cells from the flow-through were lysed, washed and 
eluted in RNase-free water (10 µL). Total RNA concentration for each sample was assayed 
using Qubit® RNA HS Assay Kit (Thermo Scientific) and total RNA input for each single 
assay run was standardized (20 ng) for non-biased comparisons of target biomarker 
expression levels. 
 
RESULTS AND DISCUSSION 
Nanodevice for Amplification-free Multi-RNA Type Profiling  
Our fabricated nanodevice enables parallel analysis of three RNA biomarkers, and consists of 
three sets of “Mixing” and “Detection” microwells. Each microwell contains asymmetric 
circular and ring microelectrode pairs (Figure 1a) for ac-EHD nano-mixing or adsorption-
based target detection.  
 
Upon ac potential difference application across the microelectrodes to generate a non-
uniform field (E), the asymmetrical microelectrode geometry engenders a lateral variation in 
number of accumulated double-layer charges with spatial charge distribution on the 
microelectrode surfaces (Figure 1b). These charges experience a force F (F = ρEt, where ρ = 
charge density and Et = tangential component of E). Due to the lateral force on the larger ring 
microelectrode (FL) being stronger than that of the smaller circular microelectrode (Fs), the 
resultant net fluid flows towards the larger microelectrode (i.e. FL > Fs). Consequently, this 
unidirectional fluid flow causes molecules in solution to be dragged by the fluidic flow
[11]
 and 
induces the necessary nano-mixing effect to enhance probe-target hybridization kinetics. To 
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visualize ac-EHD nano-mixing, we have utilized fluorescent beads to showcase the nano-
mixing motion (Video S1, Supporting Information). Notably, these resultant fluidic forces 
enable intensified concentration and collision frequency of probes and targets in bulk solution 
at nm-length from the microelectrode surface, thus speeding up hybridization in minuscule 
fluid volume within the “Mixing” microwells. 
 
Figure 1c depicts the assay workflow with total RNA extract from samples being firstly 
added to “Mixing” microwells on the device, with each containing a different target-specific 
probe. After enhanced probe-target hybridization via ac-EHD nano-mixing, streptavidin-
magnetic beads are added to magnetically-enrich captured targets. Prior to electrochemical 
target detection by adenine- gold adsorption,
[8]
 enzymatic 3’ polyA extensions are briefly 
performed on miRNA and lncRNA targets without endongenous polyA tails. RNA targets are 
subsequently heat-released from probes and transferred to “Detection” microwells for rapid 
adsorption onto gold microelectrode surfaces through their endogenous (for mRNA 
targets)/enzymatically-synthesized polyA tails. This transfer step to an unmodified bare gold 
electrode is to ensure minimal adsorption of non-target molecules and prevent false positive 
detection. Figure 1d shows the atomic force microscopy (AFM) characterization of the gold 
“Detection” microelectrode surface after rapid target adsorption. Lastly, to quantify the 
amount of adsorbed RNA biomarker targets, a [Fe(CN)6]
3-/4- 
redox system is used for 
generating a detectable Faradaic current signal. 
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Figure 1. a) Brightfield microscopic images showing the asymmetric microelectrode 
dimensions in the “Mixing” (left) and “Detection” (right) microwells. b) Mechanism of ac-
EHD nano-mixing effect. Under ac field (E) application, the asymmetrical microelectrodes 
result in a lateral quantity difference of double-layer charges nm above the microelectrode 
surface. This leads to a stronger lateral force on the larger microelectrode and a resultant net 
fluid flow towards it. c) Schematic of the analysis workflow. (i) ac-EHD nano-mixing to 
speed up probe-target hybridization; (ii) Addition of streptavidin-magnetic beads to bind 
biotinylated probe-target molecules for magnetic target purification, and subsequent polyA 
extensions of purified targets; (iii) Heat release of targets from capture probes; (iv) PolyA 
sequences facilitated rapid target adsorption onto bare gold microelectrode surface for 
electrochemical detection. d) Atomic force microscopy (AFM) images showing successful 
RNA target adsorption on the gold microelectrode surface. 
 
ac-EHD Nano-mixing for Enhanced Probe-Target Hybridization  
The main bottleneck of all hybridization-type assays is the long hybridization time required 
for freely-diffusing probes and targets to interact in solution. Microfluidic mixing can 
enhance the hybridization performance but mostly with little control over the mixing 
forces.
[12]
  We have thus employed ac-EHD nano-mixing to resolve the dilemma of sluggish 
hybridization kinetics. A unique feature of ac-EHD nano-mixing effect is that the frequency 
and amplitude of the applied ac-field could be flexibly tuned for absolute control over the 
generated fluidic forces. This thus allows for optimal enrichment and probe hybridization of 
RNA targets.  
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We first tested a frequency (f) range of 250-1000 Hz at constant amplitude (Vpp) of 800 mV 
to determine the optimal applied field strength for specific target detection in minimal time 
(Figure S1, Supporting Information). We found that hybridization at lower field strength of 
500 Hz is more effective than at higher field strengths at which the fluidic mixing is possibly 
too vigorous for efficient hybridization. Furthermore, as compared to a 100 min incubation 
control experiment which solely relies on Brownian motion diffusion for probe-target 
hybridization, a similar level of detectable signal was achieved in 10 min (10-fold decrease in 
assay time) via ac-EHD nano-mixing (500 Hz, 800 mV) (Figure S2, Supporting Information). 
This demonstrates that our optimized ac-EHD nano-mixing can effectively augment probe-
target hybridization, and significantly reduce total sample-to-answer duration to within 60 
min.        
 
Detection Limit for RNA Targets  
A high level of detection sensitivity is required to detect low levels of RNA targets present in 
clinical samples. To evaluate the detection limit of our nanodevice, we titrated different 
concentration of T2:ERG (500 aM - 500 fM) (Figure 2a), miR-107 (50 aM - 50fM) (Figure 
2b), and SChLAP1 (500 aM - 500 fM) (Figure 2c) target sequences and monitored the 
concentration-dependent changes in electrochemical signals during detection. We found that 
our biosensing platform generated signals that increased linearly with increasing target 
concentrations, and has a limit-of-detection of 500 aM (1.5 x 10
4
 copies); 50 aM (3 x 10
5
 
copies); 500 aM (1.6 x 10
4
 copies) for T2:ERG (Figure 2d), miR-107 (Figure 2e), and 
SChLAP1 (Figure 2f) respectively. With aM-level detection sensitivity without any prior 
enzymatic amplification step and a total assay time of 60 min, our nanodevice outperforms 
current amplification-free RNA detection methods
[8, 13]
 in sensitivity and speed. Particularly, 
with regards to short-length miRNA target detection which benefits the most from 
amplification-free biosensing strategies, we achieved an excellent miRNA detection limit 
similar to recent hybridization-based miRNA detection approaches
[14]
 but without any need 
for intricate nanoparticle synthesis and labeling. This series of titration experiments show that 
the nanodevice is viable for quantifying different types of RNA targets over a range of 
clinically-relevant levels in patient samples,
[15]
 and also avoids the caveats (eg, artifacts, bias) 
associated with enzymatic nucleic acid amplification. 
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Figure 2. Detection sensitivity of a) T2:ERG mRNA; b) miR-107 miRNA; and c) SChLAP1 
lncRNA targets. The average concentration-dependent % current response change and 
corresponding linear calibration plot (inset) for d) T2:ERG; e) miR-107; and f) SChLAP1 
respectively. NTC represents no-target controls. Error bars represent standard deviations of 
triplicate independent measurements. 
 
Specificity of Target Capture  
The specific capturing of intended targets is fundamental for developing accurate and reliable 
clinical assays. To ensure a high level of capture probe specificity is achieved for intended 
RNA targets, we investigated whether the capture probes used in our experiments are able to 
detect their respective target sequences from a heterogeneous mixture of non-target 
sequences. Within individual microwells on our miniaturized device, we challenged each of 
our designed capture probes with a mixture of different T2:ERG, miR-107, and 
SChLAP1synthetic RNA sequences and used the resultant electrochemical responses as a 
measure of successful probe-target hybridization and subsequent detection. Each of our three 
capture probe sequences showed high specificity towards its respective complementary 
target, and generated a measured signal only in the event of matched probe-target pairings 
(Figure S3a-c, Supporting Information). In quantitative terms, the electrochemical response 
change between capture probes and specific targets is about 7- to 9-fold higher than that of 
non-specific targets (Figure S3d, Supporting Information), and generated signals from non-
specific targets are not significantly different from no-target control background signals (t-
test P > 0.05).  
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Furthermore, the hybridization between probes and targets occurs in solution without 
immobilized surface-bound probes and thus removes the issue of non-specific surface fouling 
interactions. For eventual applications in patient sample testing, the high specificity of our 
proposed nanodevice is essential for discriminating low levels of RNA targets from a 
complex background of non-target biomolecules.  
 
 
Figure 3. Screening of T2:ERG, miR-107, and SChLAP1 biomarkers in a) DuCap, b) 22Rv1, 
and c) LnCap prostate cancer cell lines. The average % current response change and heat map 
representation d) of the multi-RNA type profiling data. NTC represents no-target controls 
Error bars represent standard deviations of triplicate independent measurements. 
 
RNA Expression Profiling in Cultured PCa Cells 
To further investigate capture probe specificity and test the feasibility of our nanodevice for 
use in biological samples, we challenged our nanodevice with the simultaneous detection of 
T2:ERG, miR-107, and SChLAP1 by titrating DuCap (Figure 3a), 22Rv1 (Figure 3b), and 
LnCap (Figure 3c) PCa cells into healthy donor urine. It was found that the three cell lines 
displayed different expression profiles for the three RNA biomarkers: DuCap showed high 
T2:ERG with low miR-107 and SChLAP1 expressions; 22Rv1 contrastingly showed low 
T2:ERG with high miR-107 and SChLAP1 expressions; whilst LnCap showed high SChLAP1 
with low T2:ERG and miR-107 expressions (Figure 3d). These findings were successfully 
validated with qPCR, and reports in literature.
[4a, 5a, 6a]
 These results exhibited the robustness 
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and practical utility of our nanodevice in detecting potential diagnostic PCa biomarkers from 
actual biological fluid samples, and underlined the unique ability of our nanodevice in 
detecting different RNA types simultaneously. 
 
Non-invasive Multi-RNA Type Profiling in Patient Urine Samples  
To demonstrate clinical feasibility, we attempted the non-invasive profiling of T2:ERG, miR-
107, and SChLAP1 biomarkers from PCa patient urine samples (Figure 4). In total, we tested 
pre-treatment urine samples from 18 PCa patients and three healthy controls. Overall, we 
found that the PCa samples displayed more frequent T2:ERG presence as well as higher miR-
107 and/or SChLAP1 expression as compared to healthy controls (Figure 4a). Amongst the 
PCa patients, eight samples (P2, P3, P5, P9, P11, P14, P15, and P17) which showed higher 
expression for all T2:ERG, miR-107 and SChLAP1 biomarkers,  were highly correlated with 
poorer biopsy outcomes (Table S2, Supporting Information) which indicated aggressive PCa 
forms. It is notable that the combined use of all three biomarkers outperformed a single 
biomarker’s ability in aggressive PCa discrimination. These results showcase the ability of 
our nanodevice in obtaining multi-RNA type biomarker signatures, and the possibility of 
using the resultant signature for personalized PCa risk stratification. 
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Figure 4. a) Multi-RNA type profiling of 18 prostate cancer urine samples and three healthy 
controls. (*) indicates patients with poor biopsy outcomes indicative of aggressive cancer. b) 
Monitoring of multi-RNA type expression changes in eight patient urine samples before and 
after treatment. Pre- (black bars) and post- (grey bars) treatment RNA biomarker levels are 
directly reflected by % current response changes, with corresponding heat map diagrams. 
Error bars represent standard deviations of duplicate independent measurements.  
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We performed qPCR to validate the patient sample results of our nanodevice (Table S3, 
Supporting Information), and used Passing and Boblok regression analysis
[16]
 for robust 
evaluation of the linear relationship between two analytical methods.
[17]
 Through this 
statistical test, we obtained linear regression plots which shows the degree of agreement 
between the two methods for T2:ERG, miR-107 and SChLAP1 detection (Figure S4, 
Supporting Information). The y-intercepts and slope values of the fitted regression line (in 
red) of our nanodevice data are close to “0” and “1” respectively within 95% confidence 
intervals (CI) of the reference line (in black), thus showing good agreement between both 
methods. Furthermore, Cusum linearity tests showed that both methods share a linear 
relationship with no significant differences (p > 0.05) for the detection of all three RNA 
target types (Figure S4, Supporting Information), and residual plots also presented narrow 
distribution of standard deviations around the fitted regression lines (Figure S5, Supporting 
Information). Therefore, we found that the qPCR data and our nanodevice data are consistent 
and highly correlated, and our nanodevice platform could be an ideal alternative to qPCR.   
 
We then examined our nanodevice’s potential for monitoring a patient’s RNA biomarker 
expression profile in post-treatment urine samples (Figure 4b). From the eight patients with 
aggressive PCa who subsequently underwent radical prostatectomy treatment, the post-
treatment urine samples of five patients (P2, P3, P9, P15, and P17) were detected with lower 
T2:ERG, miR-107 and SChLAP1 expression. These outcomes were correlated with no PCa 
recurrence for these patients whilst the three remaining patients (P5, P11, P14) who later 
developed post-treatment PCa recurrence were detected with no significant decrease in 
biomarker expression between their pre- and post-treatment urine samples. Besides 
displaying the potential of our nanodevice as a tool for PCa treatment monitoring, these 
results also underscore the usefulness of combining different RNA types for recurrence 
prediction in future clinical studies. 
 
CONCLUSION 
In summary, we reported the use of nanodevice-based ac-EHD nano-mixing for 
amplification-free multi-RNA type profiling, with enhancements in analytical speed and 
sensitivity over existing assays. Using our nanodevice on non-invasive PCa urine samples as 
surrogates for tumor biopsies, we displayed the potential of combining our nanodevice with 
multi-RNA type profiling for disease diagnosis, prognosis, and monitoring. Despite our 
multi-step assay protocol, it is noteworthy to highlight that the current short total assay 
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timeframe of 60 min may be further reduced through feasible automation of the heating and 
fluidic transfer steps. Moreover, our platform is amenable for further higher-throughput RNA 
analysis to provide a more comprehensive disease snapshot. We envision that our nanodevice 
could be a possible tool for early personalized risk stratification in individual cancer patients, 
thereby potentially allowing prompt therapeutic opportunities. 
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SUPPORTING INFORMATION 
 
Table S1. Oligonucleotide sequences used in experiments 
Oligos 5'-Sequence-3' 
TMPRSS2:ERG Capture Probe  
CAACTGATAAGGCTTCCTGCCGCGCTCCAGG-
Biotin 
miR-107 Capture Probe TGATAGCCCTGTACAATGCTGCT-Biotin 
SChLAP1 Capture Probe TGTGTCCAGAACTGGTGGGTTCTTGGTCTC-Biotin 
TMPRSS2:ERG qRCR Forward 
Primer 
ATTTAGGTACAACTCTTTCCCTCGTC 
TMPRSS2:ERG qRCR Reverse 
Primer 
TGTATAGGAATCCCACTGAATTTTTC 
miR-107 qRCR Forward Primer  AGCAGCATTGTACAG 
miR-107 qRCR Reverse Primer TTTTTTTTTTTTTTTTTG 
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SChLAP1 qRCR Forward Primer  GAGACCAAGAACCCACCAGTTCTGGACACA 
SChLAP1 qRCR Reverse Primer CATCTGGCACTTCTTCCCCAGTCATTCCAT 
 
Optimization of ac-EHD nano-mixing field strength 
 
Figure S1. Optimization of frequency (f) (250-1000 Hz) at constant amplitude (Vpp) of 800 
mV to determine the optimal applied field strength for ac-EHD nano-mixing. 
 
Enhanced probe-target hybridization 
 
Figure S2. ac-EHD nano-mixing to enhance probe-target collision frequency. Average % 
current response change at different time points over 100 min after using ac-EHD nano-
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mixing (black) or static incubation (red) for probe-target hybridization. Error bars represent 
standard deviations of triplicate independent measurements.  
 
Specificity of RNA target capture 
 
Figure S3. Electrochemical signals using a mixture of different RNA targets and a single a) 
T2:ERG mRNA; b) miR-107 miRNA; and c) SChLAP1 lncRNA target capture probe. The 
average % current response change d) for specific detection of T2:ERG, miR-107, and 
SChLAP1. NTC represents no-target controls Error bars represent standard deviations of 
triplicate independent measurements. 
 
Table S2. Tumor Gleason scores for patient biopsy samples. Highlighted in bold are patients 
with a Gleason score of >7 that is indicative of aggressive cancer. 
Sample no. Gleason Score Sample no. Gleason Score 
P1 7 P10 7 
P2 8 P11 8 
P3 9 P12 6 
P4 6 P13 6 
P5 8 P14 9 
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P6 6 P15 9 
P7 7 P16 6 
P8 7 P17 8 
P9 9 P18 7 
 
Table S3. qPCR validation of urinary sample results. (*) indicates patients with poor biopsy 
outcomes indicative of aggressive cancer. 
 qPCR Ct (Cycle)  Our Device Data (% i) 
Sample 
no. 
TMPRSS2:ERG miR1-
07 
SChLAP1  TMPRSS2:ERG miR1-
07 
SChLAP1 
P1 33.2 25.1 15.9  0 30 90 
P2* 17.5 17.7 16.5  80 80 85 
P3* 20.5 19.3 17.6  65 70 80 
P4 24.5 23.1 25.6  40 50 30 
P5* 17.7 15.4 17.9  80 95 80 
P6 28.3 22.9 24.8  20 60 40 
P7 30.3 23.6 25.5  10 45 30 
P8 29.8 25.5 23.6  10 30 45 
P9* 23.0 17.4 16.0  60 80 90 
P10 28.5 25.3 17.7  20 50 80 
P11* 16.3 17.3 20.1  90 80 70 
P12 25.8 22.2 17.0  30 60 75 
P13 29.7 24.1 24.8  10 40 40 
P14* 19.6 16.3 16.6  70 90 90 
P15* 17.1 17.3 17.0  80 80 80 
P16 25.4 24.7 28.2  30 40 20 
P17* 22.4 19.1 17.8  60 70 80 
P18 25.1 25.0 25.4  30 30 30 
H1 30.1 24.5 28.2  10 40 20 
H2 32.7 25.3 28.4  0 30 20 
H3 33.0 28.0 25.6  0 20 30 
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Regression plots of Passing-Boblok analyses 
 
Figure S4. Passing−Boblok regression analyses (n = 21) of our nanodevice-based assay and 
qPCR for the detection of a) T2:ERG, regression line equation: y =  0.89 x + 5.96 (95% CI, 
0.84-0.97 for slope and 3.23-8.84 for intercept); b) miR-107, regression line equation: y =  
0.98 x + 2.65 (95% CI, 0.88-1.07 for slope and -1.84-2.65 for intercept); and c) SChLAP1, 
regression line equation: y =  0.96 x + 3.02 (95% CI, 0.89-1.01 for slope and 0.40-8.86 for 
intercept) biomarkers. 
 
7. Residual plots of Passing-Boblok analyses 
 
 
Figure S5. Passing−Boblok residual plots showing standard deviation distribution around the 
fitted regression lines of our device-based assay and qPCR for the detection of a) T2:ERG; b) 
miR-107; c) SChLAP1 biomarkers. 
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7 
Clinical Evaluation of Non-Invasive Nanodiagnostics for Prostate Cancer 
Risk Stratification 
 
 
Introduction 
To facilitate the translation of novel nanodiagnostic approaches from research bench to the 
clinic, it is an essential requirement to perform a comprehensive clinical evaluation of the 
developed nanotechnologies with well-annotated patient sample cohorts. Explicitly, en-route 
to the eventual translation of academic nanotechnological innovations into clinical tools for 
improving patient care; clinical metrics such as clinical sensitivity and specificity, positive 
and negative predictive values, and the area-under-curve value of the receiver operator 
characteristic curve have to be assessed in order to demonstrate nanodiagnostic performance 
and utility in real human patients. This chapter discusses the clinical evaluation of a 
nanodiagnostic assay that has been previously introduced for non-invasive prostate cancer 
early detection and risk stratification in patient urine samples. Moreover, during the assay 
clinical evaluation process, the clinical value of a novel target biomarker panel for improving 
prostate cancer screening, is also being simultaneously investigated. Therefore, pilot clinical 
studies permitted combined clinical evaluation of both nanodiagnostic technologies and 
urinary RNA biomarkers. Chapter 7 reports the clinical performance of a flocculation-based 
TMPRSS2:ERG triage assay for non-invasive visual identification of significant prostate 
cancer in pre- and post-prostatectomy prostate cancer urine samples.  
 
Chapter 7 is based on one submitted research manuscript. 
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TMPRSS2:ERG Status in Pre- And Post-Prostatectomy Urine: A 
Novel First-Line Triage Nanoassay for Non-Invasive Visual 
Identification of Significant Prostate Cancer 
 
Kevin M. Koo, Eugene J. H. Wee, Renée S. Richards, Martin F. Lavin, Robert A. Gardiner, 
Paul N. Mainwaring, Matt Trau
 
 
 
ABSTRACT 
Background: Novel screening assays for identification of significant (Gleason score ≥7) 
prostate cancer (PCa) are needed to address the negative overtreatment impact on patients 
with insignificant PCa. The nanoscaled Single Drop Genomics (SDG) assay has been 
demonstrated for visual detection of urinary TMPRSS2:ERG (T2:ERG) transcripts with 
single cell-level sensitivity. By relating urinary T2:ERG status to pathology outcomes, we 
herein investigated SDG’s clinical potential as a first-line triage assay to impact clinical 
decision making. Methods: Pre- and post-prostatectomy urine samples were collected and 
urinary sediment RNA was extracted. T2:ERG status was determined using SDG which 
combines isothermal RNA amplification and visual evaluation. SDG/T2:ERG outcomes were 
correlated to clinical and pathological data, and compared against serum prostate-specific 
antigen (PSA) and Prostate Cancer Prevention Trial (PCPT) calculator risk prediction tools. 
SDG clinical evaluation was performed by receiver operating characteristic curve analysis. 
Results: In this cohort of 46 paired pre- and post-prostatectomy and 15 healthy volunteers/ 
PCa biopsy-negative control urine samples, positive and negative T2:ERG status by SDG 
were significantly correlated with significant and insignificant PCa respectively. The 
observed positive and negative predictive value for detecting significant PCa is 90.8%, and 
72.3% respectively. In our patient cohort, the area under curve (AUC) of SDG/T2:ERG is 
0.75 as compared to 0.54 by use of serum PSA test. Conclusions: In perspective, the 
T2:ERG detection outcomes of SDG are promising for significant PCa identification during 
early screening. 
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INTRODUCTION 
Despite being one of the most common solid tumor malignancy and leading cause of cancer-
related deaths in men, the current prostate-specific antigen (PSA)-based screening of prostate 
cancer (PCa) remains an imperfect test which results in significant over-diagnosis and -
treatment. The general conclusion of the recent findings of two major randomized PSA-based 
PCa screening trials [1, 2] has suggest that the net benefit of PSA testing is insufficient to risk 
the proven harms of unnecessary radical prostatectomy/radiation therapy [3]. Hence, there is 
a critical need for better screening strategies to accurately identify patients (Gleason score 
≥7) who actually require and can benefit from PCa treatments. 
 
We envisage that an improved PCa screening test in the clinic would encompass both the use 
of a more PC-specific biomarker, and an accompanying screening technology which could 
perform biomarker detection in a fast, affordable, and accurate fashion. T2:ERG (T2:ERG) 
gene fusions are the most common chromosomal rearrangement mutations in PCa, and have 
been shown to be highly specific for PCa [4], and only detectable in high-grade prostatic 
intraepithelial neoplasia (PIN) lesions in close proximity to T2:ERG-positive tumor foci [5]. 
There have been also several reports of an association between T2:ERG presence and 
clinically-significant aggressive PCa [6-8]. Additionally, T2:ERG RNA are detectable from 
patient urine [9], thus allowing for convenient non-invasive testing.  
 
Recently, we have demonstrated a novel miniaturized Single Drop Genomics (SDG) 
technique for visual detection of urine-isolated T2:ERG RNA within a minuscule fluid 
droplet [10]. In principle, SDG employed magnetic beads for DNA-mediated bridging 
flocculation to initiate a solution color change in T2:ERG presence. SDG displayed single-
cell detection sensitivity, and exploited the binary (presence/absence) nature of T2:ERG in 
PC for rapid naked-eye evaluation with minimal equipment. Importantly, the isothermal 
target amplification time of the SDG is adjustable to measure a certain threshold of T2:ERG 
level. Therefore, SDG could be an ideal triage assay for risk stratifying PCa non-invasively 
using urine samples.  
 
In this paper, we investigated the use of our developed technique as a first-line T2:ERG triage 
assay for non-invasive visual identification of significant prostate cancer. In a cohort of 46 
paired pre- and post-prostatectomy urine samples, we correlated SDG-detected T2:ERG 
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status to pathology outcomes, and investigated the potential of our SDG-T2:ERG approach in 
comparison to other current PCa predictive tools.   
 
METHODS 
Study Population 
This study consists of men who underwent radical prostatectomy treatment, due to suspicious 
DRE and/or PSA screening results during initial screening. Men were enrolled at the Royal 
Brisbane and Women’s Hospital. Ethics approval was obtained from The University of 
Queensland Institutional Human Research Ethics Committee (Approval No. 2004000047). 
All subjects provided informed consent prior to sample collection and methods pertaining to 
clinical samples were carried out in accordance with approved guidelines.  
 
Sample collection and processing 
Voided urine specimens were collected from men and assigned a study ID as per standard 
procedure. Samples were stored at -80 °C until sample processing. Total RNA was extracted 
from 1.5 mL of urine sample using the ZR urine RNA isolation Kit
TM
 (Zymo Research, USA) 
according to manufacturer’s instructions, and eluted in 15 µl of RNase-free water. 
 
SDG assay 
The SDG assay is performed in the following steps: isothermal biomarker amplification, 
magnetic amplicon purification, visual detection of biomarker presence. For isothermal 
amplification, the TwistAmp Basic RT-RPA kit (Twist-DX, UK) was used with slight 
modifications to manufacturer’s instructions. Briefly, 2 µl of extracted RNA and 500 nM of 
each primer (Table S1) were added to make a 12.5 µl reaction volume prior to incubation at 
41°C for 30 min. Next, amplicons were purifed using the Agencourt AMPure XP kit 
(Beckman Coulter, USA). Two volumes of magnetic beads were first incubated with one 
volume of amplicons for 10 minutes. The amplicon-bound magnetic beads were then 
separated using a magnet and washed once with 100% isopropanol and once with 80% 
ethanol. Finally, total RNA was eluted in 25 µl of RNase-free water. After purification, 5 µl 
of purified RPA amplicons was incubated with two volumes of magnetic beads for 5 min 
before bead separation by magnet. Then, 20 µL of flocculation buffer (200 mM acetate 
buffer, pH 4.4) was added to the beads. After 1 min of incubation, the mixture was gently 
agitated using a magnet and observed for colour change.   
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Statistical analysis 
All data processing and ROC curve generation were performed using the Origin software 
(OriginLab, USA).  
 
RESULTS  
Patient characteristics 
Non-DRE urine samples were collected from 61 men. Of the 61 men, 15 were healthy 
volunteers/PCa biopsy-negative controls. For the remaining 46 men, pre- and post-
prostatectomy urine samples were collected for T2:ERG expression analysis. For each 
sample, RNA was extracted and presence/absence of T2:ERG and RN7SL1 internal control 
transcripts were determined using the nanotechnological-based SDG assay. 
  
The median age of the men is 62.5 years and median pre-prostatectomy serum PSA is 7.5 
ng/mL (Table 1). All 61 men were of Cucasian descent, and the tumor-positive rate was 
75.4% with 97.8% having a Gleason score (GS) ≥7 (69.9% GS 3+4, 45.7% GS 4+3)    
 
SDG screening outcomes for PCa prediction 
For each sample, positive T2:ERG status was visually evaluated by a change in solution color 
[10]. An evaluation for RN7SL1 internal control was also being performed to ensure 
successful RNA extraction from each urine sample. In our cohort of pre- urine samples, SDG 
exhibited good clinical performance in the specific detection of PCa. As compared to the use 
of PSA, the SDG-detected T2:ERG status demonstrated greater positive predictive value 
(PPV) (90.8% vs 60.2% ), negative predictive value (NPV) (72.3% vs 59.4%), and AUC 
(0.90 vs 0.54) for tumor-positive samples (Figure 1a). The SDG assay generated a positive 
T2:ERG status in all tumor-positive samples and displayed negative outcomes in all the 
control samples.    
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Table 1. Patient clinical characteristics and SDG-T2:ERG status of pre-prostatectomy urine 
samples.  
      
Pre-Op 
T2:ERG (+) 
Pre-Op 
T2:ERG (-) 
PSA (>4 
ng/mL) 
Patients, n (%) 
46 
(100)   25 (54.3) 21 (45.7) 34 (76.1 %) 
Control cohort 15         
Age (years) 62.5         
Median serum PSA level 
(ng/mL) 7.5         
            
Gleason Score           
GS<7 1 (2.2)   0 (0.0) 1 (4.8) 3 (2.1) 
GS (3+4) 
17 
(36.9)   1 (4.0) 16 (76.2) 13 (37.1) 
GS (4+3) 
21 
(45.7)   18 (72.0) 3 (14.2) 10 (28.6) 
GS>7 
7 
(15.2)   6 (24.0) 1 (4.8) 9 (25.7) 
            
Pathologic Stage           
T1, T2 
27 
(58.7)         
>T2 
19 
(41.3)         
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Figure 1. ROC curves of SDG-T2:ERG and PSA for tumor-positive diagnoses (a), and SDG-
T2:ERG and PCPT for high-grade PCA detection (b).  
 
Detection of high grade prostate cancer 
The Gleason scoring of prostate tissue is presently the most powerful predictor of PCa 
prognosis. The predictive ability of the SDG-T2:ERG assay was further evaluated in the 
prediction of pathological GS associated with significant PCa (GS ≥7 and pathologic tumor 
>2). From pre-prostatectomy samples, positive SDG-T2:ERG assay outcomes were 
associated with significant PCa (AUC = 0.75). As compared to Prostate Cancer Prevention 
Trial (PCPT) risk calculator (AUC = 0.58) that incorporates PSA and other clinical factors in 
an attempt to provide an individual risk estimate, the SDG-T2:ERG assay showed better 
predictive ability for significant PCa (Figure 1b). 
 
As studies have shown GS≥4+3 to have a worse prognosis as compared to GS 3+4 PCa [11, 
12], we investigated SDG-T2:ERG’s accuracy in improving prognostic prediction for 
pathologic GS 4+3/3+4 status. Among 45 samples (97.8%) with GS ≥7, the SDG-T2:ERG 
assay correctly discriminated 72% GS  4+3/>7 vs 4% GS 3+4 samples (AUC = 0.88) (Table 
1).  
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Monitoring of biochemical recurrence  
Using post-prostatectomy urine samples, we also investigated the SDG-T2:ERG assay’s 
utility as a PCa monitoring tool for predicting biochemical recurrence. Amongst the 42 post-
prostatectomy samples, 58.7% developed biochemical recurrence as indicated by a raising 
PSA level. The SDG assay detected positive T2:ERG status in 79.2% of these samples, thus 
suggesting that SDG-T2:ERG is a viable alternative post-treatment urinary assay for 
monitoring of PCa biochemical recurrence (Table 2).    
 
Table 2. Patient biochemical recurrences and SDG-T2:ERG status of post-prostatectomy 
urine samples.  
      
Post-Op Fusion 
(+) 
Post-Op Fusion  
(-) 
Patients, n (%) 46 (100)   24 (34.8) 22 (65.2) 
          
Biochemical Recurrence 27 (58.7)   19 (79.2) 8 (36.4) 
No Biochemical Recurrence 19 (41.3)   5 (20.8) 14 63.6) 
 
DISCUSSION  
We have described a novel nanotechnological SDG assay which evaluates urinary T2:ERG 
status for diagnosing men with high-grade (GS≥7) PCa at early screening. The T2:ERG 
biomarker is one of the most PCa-specific diagnostic biomarkers, and Laxman et al. first 
reported detection of T2:ERG in patient urine samples as an attractive and non-invasive assay 
for PCa early detection [9]. Notably, it was reported that the quantity of urinary T2:ERG 
transcripts strongly correlated with tumour burden [7, 8]. Furthermore, several research 
groups have also demonstrated the potential prognostic utility of urinary T1E4 detection 
through association with aggressive PCa [6, 13]. While T2:ERG has routinely been detected 
in urine samples by conventional research-based RT-PCR techniques [13, 14], we identified 
that the use of a nanotechnological-based assay may enable a faster T2:ERG screening 
approach with a simplified readout that is amenable for use as a clinical PCa triage assay. 
SDG has previously been shown to possess single-cell detection sensitivity [10], and could 
potentially be useful for non-invasive T2:ERG detection in urine without prior digital rectal 
exam (DRE) as demonstrated in this work.  
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In our cohort of samples, SDG-T2:ERG specifically detects PCa (AUC = 0.90, NPV = 
72.3%) (Figure 1a) and also accurately predicts significant (GS≥7) PCa (AUC = 0.75) 
(Figure 1b). Furthermore, among the high-grade PCa, SDG-T2:ERG is able to accurately 
discriminate a larger portion of higher-grade GS 4+3 tumors (AUC = 0.88) (Table 1). These 
results highlighted the PCa-specificity of the T2:ERG biomarker over serum PSA and its 
association with clinically significant PCa. It also demonstrated the robustness of the SDG 
assay in T2:ERG detection from urine samples. Our use of T2:ERG to detect significant PCa 
is consistent with a clinical-grade, transcription-mediated amplification assay which found 
urine T2:ERG expression to be associated with clinically significant cancer at biopsy and 
prostatectomy [8], thereby supporting a role for T2:ERG as a potential PCa detection and risk 
stratification biomarker. Additionally, we also utilized the SDG-T2:ERG assay on post-
prostatectomy urine samples to predict for biochemical recurrence and the obtained results 
reflected that our assay may be of use for disease recurrence monitoring purpose after radical 
prostatectomy treatment (Table 2). 
 
Despite the highly promising initial results, there are some limitations to this study. Firstly, 
the statistical power of this study is limited by a relatively small cohort. However, it is 
noteworthy that our cohort is well-represented with men of GS≥7 (including both 4+3 and 
3+4) pathology findings in order to study the high grade disease discriminating ability of our 
SDG-T2:ERG assay. Our initial data herein is encouraging, and we are progressing with 
expansion of our clinical sample cohort by collecting and longitudinal monitoring of clinical 
data and samples. Another point of concern is that our SDG assay is unable to quantify 
T2:ERG levels. However, we will like to highlight that an optimal SDG cut-off point for 
T2:ERG detection could be easily set by adjusting the isothermal target amplification time. 
 
CONCLUSION 
This study highlights the use of SDG, a novel nanotechnological assay which targets the 
urinary T2:ERG biomarker for discriminating significant PCa in men presented for early 
screening.  
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SUPPORTING INFORMATION 
 
Table S1 Primer sequences 
Primer Sequence (5’ to 3’) 
RT-RPA Forward CCTGGAGCGCGGCAGGAAGCCTTATCAGTTG 
RT-RPA Reverse GCTAGGGTTACATTCCATTTTGATGGTGAC 
Oligonucleotides were purchased from Integrated DNA Technologies, USA 
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8 
Conclusions & Future Work 
 
 
8.1 Conclusions 
In conclusion, with the goal to improve PCa early detection for better disease risk 
stratification in the clinic, this thesis has advanced both the fields of clinical PCa screening 
methodologies and accurate non-invasive identification of aggressive PCa subtypes from 
urine samples. The core research work being showcased throughout this dissertation on the 
design of novel nanodiagnostics for next-generation PCa biomarker detection has 
successfully met the stated thesis objectives under Section 1.2.    
 
The first research objective is the development of gene fusion (TMPRSS2:ERG) diagnostics 
towards non-invasive clinical use. This thesis has described various TMPRSS2:ERG 
nanobiosensing methods which innovatively unified isothermal recombinase polymerase 
amplification with a variety of detection readouts to enable different applications. These 
include a bridging flocculation-based assay for simple naked-eye detection (Chapter 3.2); an 
enzyme-catalyzed assay with flexible visual and quantitative detection (Chapter 3.3); two 
different label-free approaches with direct SERS detection (Chapter 4). Depending on the 
need for visual, quantitative, or molecular analysis of TMPRSS2:ERG status in PCa urinary 
specimens, each of these nanodiagnostic tools could be employed suitably for the intended 
purpose.       
 
The second research objective is the design of amplification-free nanobiosensors for 
universal detection of various RNA biomarker species. By using nucleic acid target-magnetic 
enrichment and facile adsorption-based electrochemical target detection (Chapter 5), this 
thesis has reported a suite of enzymatic amplification-free techniques for all major species of 
next-generation PCa urinary RNA biomarkers. These techniques have allowed direct RNA 
detection without the related shortcomings of nucleic acid amplification, cumbersome 
sensing surface modification, and detection label hybridization chemistry.   
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The third research objective is the expansion into simultaneous detection of multiple 
biomarkers. This thesis has achieved this objective through two different strategies, namely 
by multiplexed screening or high-throughput parallel screening. For multiplexed screening, 
the first-ever “one-pot” five-plexed urinary RNA biosensor by use of various self-synthesized 
SERS nanotags (Chapter 6.1) is shown. For high-throughput parallel screening, rapid real-
time fluorescence detection of different PCa gene fusion variants is demonstrated through a 
novel merger of multiple concurrent DNA probe-RNA target ligation and rapid real-time 
recombinase polymerase amplification (Chapter 6.2); and a nanofluidic manipulation 
technique for rapid amplification-free multi-RNA type profiling in pre- and post-treatment 
patient urinary samples (Chapter 6.3). These assays have enabled quick simultaneous 
detection of different next-generation PCa biomarkers for potentially more specific and 
informative screening. 
 
The fourth and fifth research objectives are the clinical evaluation of developed 
nanotechnological assays, and the investigation of biomarker value via pilot clinical studies. 
These two objectives are intricately linked because the clinical performance of both the 
nanodiagnostic assay and target biomarker panel were jointly analyzed when being applied to 
a broad cohort of patient samples. Chapter 7 presents the clinical evaluation of a nanoscaled 
assay developed during the course of this thesis for TMPRSS2:ERG detection in pre- and 
post-prostatectomy urine samples. By relating urinary TMPRSS2:ERG status to pathology 
outcomes, we investigated the combination of nanotechnological assay and TMPRSS2:ERG 
biomarker as a first-line triage assay to impact clinical decision making. The “blueprint” for 
clinical assay evaluation and biomarker value investigation in this chapter could subsequently 
be adapted for other nanotechnologies to translate academic-laboratory diagnostic 
innovations for patient care efficiently. 
 
8.2 Future work 
As concluded above, the work described in this thesis has significantly contributed towards 
advancements in a new era of more accurate and personalized PCa screening. Consequently, 
the research outcomes which were established within this thesis will serve as a basis for 
future studies. 
 
From an analytical standpoint, the target detection limit for most techniques may still be 
further improved upon through nanoscaled innovations. There are two approaches to increase 
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the detection sensitivity, namely, amplification of target copies and/or readout signals. For 
target amplification, it is worth investigating the utility of other isothermal nucleic acid 
amplification techniques besides recombinase polymerase amplification. This would allow 
side-by-side evaluations of the benefits and shortcomings of integrating different isothermal 
amplification techniques into the various nanodiagnostic platforms being described in this 
thesis. For readout signal amplification, a promising direction would research into using more 
sophisticated surface-enhanced Raman scattering readout labels. These readout labels may 
possess distinctive morphologies or surface nanostructures which aid in producing greater 
Raman enhancement effects. Thus, it would be interesting to pursue the incorporation of 
these advanced labels into our multiplexed biosensing technique (Chapter 6.1) to potentially 
achieve greater detection sensitivity. 
 
For all nanodiagnostic approaches showcased throughout this thesis, the sample preparation 
step to extract cellular nucleic acid has primarily been achieved through commercial 
magnetic bead purification or spin-column kits. Whilst efficient and straightforward to 
perform, these methodologies are currently the most time-consuming step in the entire 
sample-to-answer workflow. A more ideal preparation protocol would be a direct sampling 
methodology whereby tumor cells are lyzed in its native biological medium (i.e. blood or 
urine), and the released nucleic acid targets could then be promptly used for enzymatic 
amplification or capture probe hybridization via the developed nanotechnological techniques 
of this thesis work. Hence, further work is to be done with regards to rapid and simplified 
target extraction from clinical samples. Specifically, this requires research into ways to keep 
cellular nucleic acids stable and protected from degradation once being released, as well as 
methodologies to collect the released nucleic acid targets for transfer to downstream 
processing.      
 
From a clinical point of view, extensive clinical evaluation of newly-developed 
nanodiagnostic technologies and novel biomarker panel is essential to ensure adequate 
performance for patient use. In this regard, the described work in Chapter 7 has attempted to 
address this need for clinical evaluation, and has resulted in promising initial outcomes. 
However, these pilot clinical studies are still preliminary; and future work in testing with a 
higher number of patient samples to further evaluate clinical metrics, blinded studies, cross-
institutional technological validation, will be necessary to demonstrate improved PCa 
screening benefits. Furthermore, during these further studies, discoveries of more next-
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generation PCa biomarkers may be uncovered. These new promising biomarkers may be 
readily incorporated for assessment of significant gain in area-under-curve value of the 
receiver operator characteristic curve. Finally, it would be worthy to utilize the clinical 
studies to answer some current pressing biological issues about urinary PCa screening. For 
instance, the feasibility of using urine as an ideal surrogate for blood/biopsy tissue could be 
thoroughly examined by using nanodiagnostics to test the biomarker correlation in the urine, 
blood, and biopsy tissue specimens of the same patient. Another potential longitudinal study 
could also be performed by using nanodiagnostics to investigate urinary biomarker 
expression (i.e. tumorigenesis) changes at different time points during PCa progression.       
 
This thesis has yielded several nanodiagnostic platforms for RNA biosensing. While PCa 
cancer gene fusion detection is primarily used as the biological/clinical model in this thesis, 
further extension of these platform applications for gene fusion screening in other cancers 
(eg. BCR-ABL1in leukemia; BRAF fusions in melanoma; EML4-ALK in lung cancer) as well 
as RNA biomarker detection in other diseases (eg. oncogenic, pathogenic or viral) would be 
worth pursuing.  
  
 
 
 
 
 
